Activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N CD28|NN|N/N surface|NN|N/N receptor|NN|N provides|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N major|JJ|N/N costimulatory|JJ|N/N signal|NN|N for|IN|(NP\NP)/NP T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N resulting|VBG|(S[ng]\NP)/PP in|IN|PP/NP enhanced|VBN|N/N production|NN|N of|IN|(NP\NP)/NP interleukin-2|NN|N (|LRB|(N\N)/N IL-2|NN|N )|RRB|RRB and|CC|conj cell|NN|N/N proliferation|NN|N .|.|.
In|IN|(S/S)/NP primary|JJ|N/N T|NN|N/N lymphocytes|NNS|N we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] CD28|NN|N/N ligation|NN|N leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N rapid|JJ|N/N intracellular|JJ|N/N formation|NN|N of|IN|(NP\NP)/NP reactive|JJ|N/N oxygen|NN|N/N intermediates|NNS|N (|LRB|(NP\NP)/NP ROIs|NNS|N )|RRB|RRB which|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP CD28-mediated|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-kappa|NN|N/N B/CD28-responsive|JJ|N/N complex|NN|N and|CC|conj IL-2|NN|N/N expression|NN|N .|.|.
Delineation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N CD28|NN|N/N signaling|NN|N/N cascade|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) involve|VB|(S[b]\NP)/NP protein|NN|N/N tyrosine|NN|N/N kinase|NN|N/N activity|NN|N ,|,|, followed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP phospholipase|NN|N/N A2|NN|N and|CC|conj 5-lipoxygenase|NN|N .|.|.
Our|PRP$|NP[nb]/N data|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] lipoxygenase|NN|N/N metabolites|NNS|N activate|VBP|(S[dcl]\NP)/NP ROI|NN|N/N formation|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) then|RB|(S\NP)/(S\NP) induce|VBP|(S[dcl]\NP)/NP IL-2|NN|N/N expression|NN|N via|IN|((S\NP)\(S\NP))/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N .|.|.
These|DT|NP[nb]/N findings|NNS|N should|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) useful|JJ|(S[adj]\NP)/PP for|IN|PP/NP therapeutic|JJ|N/N strategies|NNS|N and|CC|conj the|DT|NP[nb]/N development|NN|N of|IN|(NP\NP)/NP immunosuppressants|NNS|N targeting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N CD28|NN|N/N costimulatory|NN|N/N pathway|NN|N .|.|.
Human|JJ|N/N immunodeficiency|NN|N/N virus|NN|N type|NN|N\N 2|CD|(N\N)\(N\N) (|LRB|(N\N)/N HIV-2|NN|N )|RRB|RRB ,|,|, like|IN|((S\NP)/(S\NP))/NP HIV-1|NN|N ,|,|, causes|VBZ|(S[dcl]\NP)/NP AIDS|NN|N and|CC|conj is|VBZ|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP AIDS|NN|N/N cases|NNS|N primarily|RB|(NP\NP)/(NP\NP) in|IN|(NP\NP)/NP West|NNP|N/N Africa|NNP|N .|.|.
HIV-1|NN|N and|CC|conj HIV-2|NN|N display|VBP|(S[dcl]\NP)/NP significant|JJ|N/N differences|NNS|N in|IN|(NP\NP)/NP nucleic|JJ|(N/N)/(N/N) acid|NN|N/N sequence|NN|N and|CC|conj in|IN|(NP\NP)/NP the|DT|NP[nb]/N natural|JJ|N/N history|NN|N of|IN|(NP\NP)/NP clinical|JJ|N/N disease|NN|N .|.|.
Consistent|JJ|(S/S)/PP with|IN|PP/NP these|DT|NP[nb]/N differences|NNS|N ,|,|, we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) previously|RB|(S\NP)\(S\NP) demonstrated|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N enhancer/promoter|NN|N/N region|NN|N of|IN|(NP\NP)/NP HIV-2|NN|N functions|VBZ|S[dcl]\NP quite|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) differently|RB|((S\NP)\(S\NP))/PP from|IN|PP/NP that|DT|NP of|IN|(NP\NP)/NP HIV-1|NN|N .|.|.
Whereas|IN|(S/S)/S[dcl] activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV-1|NN|N/N enhancer|NN|N following|VBG|(NP\NP)/NP T-cell|NN|N/N stimulation|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP largely|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) through|IN|((S\NP)\(S\NP))/NP binding|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N factor|NN|N NF-kappa|NN|N/N B|NN|N to|TO|(NP\NP)/NP two|CD|N/N adjacent|JJ|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N sites|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV-1|NN|N/N long|JJ|N/N terminal|JJ|N/N repeat|NN|N ,|,|, activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV-2|NN|N/N enhancer|NN|N in|IN|(NP\NP)/NP monocytes|NNS|N and|CC|conj T|NN|N/N cells|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) dependent|JJ|(S[adj]\NP)/PP on|IN|PP/NP four|CD|N/N cis-acting|JJ|N/N elements|NNS|N :|:|(NP\NP)/NP a|DT|NP[nb]/N single|JJ|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N site|NN|N ,|,|, two|CD|N/N purine-rich|JJ|N/N binding|VBG|N/N sites|NNS|N ,|,|, PuB1|NN|N and|CC|conj PuB2|NN|N ,|,|, and|CC|conj a|DT|NP[nb]/N pets|NN|N/N site|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) now|RB|(S\NP)\(S\NP) identified|VBN|(S[pt]\NP)/NP a|DT|NP[nb]/N novel|JJ|N/N cis-acting|JJ|N/N element|NN|N within|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV-2|NN|N/N enhancer|NN|N ,|,|, immediately|RB|(S[adj]\NP)/(S[adj]\NP) upstream|JJ|(S[adj]\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N kappa|NN|(N/N)/(N/N) B|NN|N/N site|NN|N ,|,|, designated|VBN|(S[pss]\NP)/NP peri-kappa|NN|N/N B|NN|N .|.|.
This|DT|NP[nb]/N site|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) conserved|VBN|S[pss]\NP among|IN|((S\NP)\(S\NP))/NP isolates|NNS|N of|IN|(NP\NP)/NP HIV-2|NN|N and|CC|conj the|DT|NP[nb]/N closely|RB|(N/N)/(N/N) related|JJ|N/N simian|JJ|N/N immunodeficiency|NN|N/N virus|NN|N ,|,|, and|CC|conj transfection|NN|N/N assays|NNS|N show|VBP|((S[dcl]\NP)/(S[to]\NP))/NP this|DT|NP[nb]/N site|NN|N to|TO|(S[to]\NP)/(S[b]\NP) mediate|VB|(S[b]\NP)/NP HIV-2|NN|N/N enhancer|NN|N/N activation|NN|N following|VBG|((S\NP)\(S\NP))/NP stimulation|NN|N of|IN|(NP\NP)/NP monocytic|JJ|N/N but|CC|conj not|RB|(N/N)/(N/N) T-cell|NN|N/N lines|NNS|N .|.|.
This|DT|NP is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N first|JJ|N/N description|NN|N of|IN|(NP\NP)/NP an|DT|NP[nb]/N HIV-2|NN|N/N enhancer|NN|N/N element|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) displays|VBZ|(S[dcl]\NP)/NP such|JJ|NP/NP monocyte|NN|N/N specificity|NN|N ,|,|, and|CC|conj no|DT|NP[nb]/N comparable|JJ|N/N enhancer|NN|N/N element|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) clearly|RB|(S\NP)/(S\NP) defined|VBN|(S[pss]\NP)/PP for|IN|PP/NP HIV-1|NN|N .|.|.
While|IN|(S/S)/S[dcl] a|DT|NP[nb]/N nuclear|JJ|N/N factor|NN|N (|LRB|(NP\NP)/NP s|NNS|N )|RRB|RRB from|IN|(NP\NP)/NP both|CC|NP/NP peripheral|JJ|N/N blood|NN|N/N monocytes|NNS|N and|CC|conj T|NN|N/N cells|NNS|N binds|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N peri-kappa|NN|(N/N)/(N/N) B|NN|N/N site|NN|N ,|,|, electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] either|CC|S[dcl]/S[dcl] a|DT|NP[nb]/N different|JJ|N/N protein|NN|N binds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP this|DT|NP[nb]/N site|NN|N in|IN|((S\NP)\(S\NP))/NP monocytes|NNS|N versus|CC|conj T|NN|N/N cells|NNS|N or|CC|conj that|IN|S[em]/S[dcl] the|DT|NP[nb]/N protein|NN|N recognizing|VBG|(S[ng]\NP)/NP this|DT|NP[nb]/N enhancer|NN|N/N element|NN|N undergoes|VBZ|(S[dcl]\NP)/NP differential|JJ|N/N modification|NN|N in|IN|(NP\NP)/NP monocytes|NNS|N and|CC|conj T|NN|N/N cells|NNS|N ,|,|, thus|RB|(S\NP)/(S\NP) supporting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N transfection|NN|N/N data|NNS|N .|.|.
Further|RB|S/S ,|,|, while|IN|(S/S)/S[dcl] specific|JJ|N/N constitutive|JJ|N/N binding|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N peri-kappa|NN|(N/N)/(N/N) B|NN|N/N site|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) seen|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP monocytes|NNS|N ,|,|, stimulation|NN|N with|IN|(NP\NP)/NP phorbol|NN|N/N esters|NNS|N induces|VBZ|(S[dcl]\NP)/NP additional|JJ|N/N ,|,|, specific|JJ|N/N binding|NN|N .|.|.
Understanding|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N monocyte-specific|JJ|N/N function|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N peri-kappa|NN|(N/N)/(N/N) B|NN|N/N factor|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) ultimately|RB|(S\NP)\(S\NP) provide|VB|((S[b]\NP)/PP)/NP insight|NN|N into|IN|PP/NP the|DT|NP[nb]/N different|JJ|N/N role|NN|N monocytes|NNS|N and|CC|conj T|NN|N/N cells|NNS|N play|VBP|(S[dcl]\NP)/NP in|IN|((S\NP)\(S\NP))/NP HIV|NN|N/N pathogenesis|NN|N .|.|.
Adenovirus|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) Ad|NN|N/N )|RRB|RRB infection|NN|N and|CC|conj E1A|NN|N/N transfection|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) model|VB|(S[b]\NP)/NP changes|NNS|N in|IN|(NP\NP)/NP susceptibility|NN|N to|TO|(NP\NP)/NP NK|NN|N/N cell|NN|N/N killing|NN|N caused|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP transient|JJ|N/N vs|CC|conj stable|JJ|N/N E1A|NN|N/N expression|NN|N in|IN|(NP\NP)/NP human|JJ|N/N cells|NNS|N .|.|.
Only|RB|N/N stably|RB|(N/N)/(N/N) transfected|VBN|N/N target|NN|N/N cells|NNS|N exhibited|VBD|(S[dcl]\NP)/NP cytolytic|JJ|N/N susceptibility|NN|N ,|,|, despite|IN|((S\NP)\(S\NP))/NP expression|NN|N of|IN|(NP\NP)/NP equivalent|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP E1A|NN|N/N proteins|NNS|N in|IN|(NP\NP)/NP Ad-infected|JJ|N/N targets|NNS|N .|.|.
The|DT|NP[nb]/N inability|NN|N of|IN|(NP\NP)/NP E1A|NN|N/N gene|NN|N/N products|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP cytolytic|JJ|N/N susceptibility|NN|N during|IN|((S\NP)\(S\NP))/NP infection|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) explained|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N inhibitory|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP viral|JJ|N/N infection|NN|N on|IN|(NP\NP)/NP otherwise|RB|(N/N)/(N/N) susceptible|JJ|N/N target|NN|N/N cells|NNS|N or|CC|conj by|IN|((S\NP)\(S\NP))/NP viral|JJ|N/N gene|NN|N/N effects|NNS|N on|IN|(NP\NP)/NP class|NN|N/N I|CD|(N/N)\(N/N) MHC|NN|N/N antigen|NN|N/N expression|NN|N on|IN|(NP\NP)/NP target|NN|N/N cells|NNS|N .|.|.
This|DT|NP[nb]/N differential|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP E1A|NN|N/N expression|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N cytolytic|JJ|N/N phenotypes|NNS|N of|IN|(NP\NP)/NP infected|JJ|N/N and|CC|conj stably|RB|(N/N)/(N/N) transfected|VBN|N/N human|JJ|N/N cells|NNS|N suggests|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] human|JJ|N/N NK|NN|N/N cells|NNS|N provide|VBP|(S[dcl]\NP)/NP an|DT|NP[nb]/N effective|JJ|N/N immunologic|JJ|N/N barrier|NN|N against|IN|(NP\NP)/NP the|DT|NP[nb]/N in|FW|(N/N)/(N/N) vivo|FW|N/N survival|NN|N and|CC|conj neoplastic|JJ|N/N progression|NN|N of|IN|(NP\NP)/NP E1A-immortalized|JJ|N/N cells|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) may|MD|(S[dcl]\NP)/(S[b]\NP) emerge|VB|S[b]\NP from|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N reservoir|NN|N of|IN|(NP\NP)/NP persistently|RB|(N/N)/(N/N) infected|JJ|N/N cells|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N host|NN|N .|.|.
The|DT|NP[nb]/N CD4|NN|N/N coreceptor|NN|N interacts|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP non-polymorphic|JJ|N/N regions|NNS|N of|IN|(NP\NP)/NP major|JJ|N/N histocompatibility|NN|N/N complex|NN|N/N class|NN|N/N II|CD|(N/N)\(N/N) molecules|NNS|N on|IN|(NP\NP)/NP antigen-presenting|JJ|N/N cells|NNS|N and|CC|conj contributes|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) investigated|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP CD4|NN|N/N triggering|NN|N on|IN|(NP\NP)/NP T|NN|(N/N)/(N/N) cell|NN|N/N activating|NN|N/N signals|NNS|N in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N lymphoma|NN|N/N model|NN|N using|VBG|(S[ng]\NP)/NP monoclonal|JJ|N/N antibodies|NNS|N (|LRB|(NP\NP)/NP mAb|NN|N )|RRB|RRB which|WDT|(NP\NP)/(S[dcl]\NP) recognize|VBP|(S[dcl]\NP)/NP different|JJ|N/N CD4|NN|N/N epitopes|NNS|N .|.|.
We|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] CD4|NN|N/N triggering|NN|N delivers|VBZ|(S[dcl]\NP)/NP signals|NNS|N capable|JJ|(S[adj]\NP)/PP of|IN|PP/(S[ng]\NP) activating|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N NF-AT|NN|N/N transcription|NN|N/N factor|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP interleukin-2|NN|N/N gene|NN|N/N expression|NN|N .|.|.
Whereas|IN|(S/S)/S[dcl] different|JJ|N/N anti-CD4|JJ|N/N mAb|NN|N or|CC|conj HIV-1|NN|N/N gp120|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) all|DT|(S\NP)\(S\NP) trigger|VB|(S[b]\NP)/NP activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N protein|NN|N/N tyrosine|NN|N/N kinases|NNS|N p56lck|NN|N and|CC|conj p59fyn|NN|N and|CC|conj phosphorylation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Shc|NN|N/N adaptor|NN|N/N protein|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) mediates|VBZ|(S[dcl]\NP)/NP signals|NNS|N to|TO|(NP\NP)/NP Ras|NN|N ,|,|, they|PRP|NP differed|VBD|S[dcl]\NP significantly|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP their|PRP$|NP[nb]/N ability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP NF-AT|NN|N .|.|.
Lack|NN|N of|IN|(NP\NP)/NP full|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP NF-AT|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) correlated|VBN|(S[pss]\NP)/PP to|TO|PP/NP a|DT|NP[nb]/N dramatically|RB|(N/N)/(N/N) reduced|VBN|N/N capacity|NN|N to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP calcium|NN|N/N flux|NN|N and|CC|conj could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) complemented|VBN|(S[pss]\NP)/PP with|IN|PP/NP a|DT|NP[nb]/N calcium|NN|N/N ionophore|NN|N .|.|.
The|DT|NP[nb]/N results|NNS|N identify|VBP|(S[dcl]\NP)/NP functionally|RB|(N/N)/(N/N) distinct|JJ|N/N epitopes|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N CD4|NN|N/N coreceptor|NN|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Ras/protein|NN|N/N kinase|NN|N/N C|NN|N/N and|CC|conj calcium|NN|N/N pathways|NNS|N .|.|.
High-dose|JJ|N/N estrogen|NN|N/N administration|NN|N induces|VBZ|(S[dcl]\NP)/NP anemia|NN|N in|IN|((S\NP)\(S\NP))/NP mammals|NNS|N .|.|.
In|IN|(S/S)/NP chickens|NNS|N ,|,|, estrogens|NNS|N stimulate|VBP|(S[dcl]\NP)/NP outgrowth|NN|N of|IN|(NP\NP)/NP bone|NN|N/N marrow-derived|JJ|N/N erythroid|JJ|N/N progenitor|NN|N/N cells|NNS|N and|CC|conj delay|VBP|(S[dcl]\NP)/NP their|PRP$|NP[nb]/N maturation|NN|N .|.|.
This|DT|NP[nb]/N delay|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP down-regulation|NN|N of|IN|(NP\NP)/NP many|JJ|N/N erythroid|JJ|N/N cell-specific|JJ|N/N genes|NNS|N ,|,|, including|VBG|(NP\NP)/NP alpha-|NN|N and|CC|conj beta-globin|NN|N ,|,|, band|NN|N 3|CD|N\N ,|,|, band|NN|N 4.1|CD|N\N ,|,|, and|CC|conj the|DT|NP[nb]/N erythroid|JJ|N/N cell-specific|JJ|N/N histone|NN|N H5|NN|N .|.|.
We|PRP|NP show|VBP|(S[dcl]\NP)/S[em] here|RB|(S\NP)\(S\NP) that|IN|S[em]/S[dcl] estrogens|NNS|N also|RB|(S\NP)/(S\NP) reduce|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP erythroid|JJ|N/N progenitor|NN|N/N cells|NNS|N in|IN|(NP\NP)/NP primary|JJ|N/N human|JJ|N/N bone|NN|(N/N)/(N/N) marrow|NN|N/N cultures|NNS|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) address|VB|(S[b]\NP)/NP potential|JJ|N/N mechanisms|NNS|N by|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) estrogens|NNS|N suppress|VBP|(S[dcl]\NP)/NP erythropoiesis|NN|N ,|,|, we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) examined|VBN|(S[pt]\NP)/NP their|PRP$|NP[nb]/N effects|NNS|N on|IN|(NP\NP)/NP GATA-1|NN|N ,|,|, an|DT|NP[nb]/N erythroid|JJ|N/N transcription|NN|N/N factor|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) participates|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N majority|NN|N of|IN|(NP\NP)/NP erythroid|JJ|N/N cell-specific|JJ|N/N genes|NNS|N and|CC|conj is|VBZ|(S[dcl]\NP)/(S[adj]\NP) necessary|JJ|(S[adj]\NP)/PP for|IN|PP/NP full|JJ|N/N maturation|NN|N of|IN|(NP\NP)/NP erythrocytes|NNS|N .|.|.
We|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N transcriptional|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP GATA-1|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) strongly|RB|(S\NP)/(S\NP) repressed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N estrogen|NN|N/N receptor|NN|N (|LRB|(NP\NP)/NP ER|NN|N )|RRB|RRB in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N ligand-dependent|JJ|N/N manner|NN|N and|CC|conj that|IN|S[em]/S[dcl] this|DT|NP[nb]/N repression|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) reversible|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP 4-hydroxytamoxifen|NN|N .|.|.
ER-mediated|JJ|N/N repression|NN|N of|IN|(NP\NP)/NP GATA-1|NN|N/N activity|NN|N occurs|VBZ|S[dcl]\NP on|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N artificial|JJ|N/N promoter|NN|N containing|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N single|JJ|N/N GATA-binding|JJ|N/N site|NN|N ,|,|, as|RB|conj/conj well|RB|conj/conj as|IN|conj in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N context|NN|N of|IN|(NP\NP)/NP an|DT|NP[nb]/N intact|JJ|N/N promoter|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) normally|RB|(S\NP)\(S\NP) regulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP GATA-1|NN|N .|.|.
GATA-1|NN|N and|CC|conj ER|NN|N bind|VBP|(S[dcl]\NP)/PP to|TO|PP/NP each|DT|NP[nb]/N other|JJ|N in|FW|((S\NP)\(S\NP))/NP vitro|FW|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N absence|NN|N of|IN|(NP\NP)/NP DNA|NN|N .|.|.
In|IN|(S/S)/NP coimmunoprecipitation|NN|N/N experiments|NNS|N using|VBG|(S[ng]\NP)/NP transfected|VBN|N/N COS|NN|N/N cells|NNS|N ,|,|, GATA-1|NN|N and|CC|conj ER|NN|N associate|VBP|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N ligand-dependent|JJ|N/N manner|NN|N .|.|.
Mapping|NN|N/N experiments|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] GATA-1|NN|N and|CC|conj the|DT|NP[nb]/N ER|NN|N form|VBP|(S[dcl]\NP)/NP at|IN|((N/N)/(N/N))/(S[asup]\NP) least|JJS|S[asup]\NP two|CD|N/N contacts|NNS|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) involve|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N finger|NN|N/N region|NN|N and|CC|conj the|DT|NP[nb]/N N-terminal|JJ|N/N activation|NN|N/N domain|NN|N of|IN|(NP\NP)/NP GATA-1|NN|N .|.|.
We|PRP|NP speculate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] estrogens|NNS|N exert|VBP|(S[dcl]\NP)/NP effects|NNS|N on|IN|(NP\NP)/NP erythropoiesis|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) modulating|VBG|(S[ng]\NP)/NP GATA-1|NN|N/N activity|NN|N through|IN|((S\NP)\(S\NP))/NP protein-protein|JJ|N/N interaction|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N ER|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] interleukin-1|NN|N (|LRB|(N\N)/N IL-1|NN|N )|RRB|RRB and|CC|conj IL-2|NN|N control|VBP|(S[dcl]\NP)/NP IL-2|NN|N/N receptor|NN|N/N alpha|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL-2R|NN|N/N alpha|NN|N/N )|RRB|RRB gene|NN|N/N transcription|NN|N in|IN|((S\NP)\(S\NP))/NP CD4-CD8-murine|JJ|N/N T|NN|N/N lymphocyte|NN|N/N precursors|NNS|N .|.|.
Here|RB|S/S we|PRP|NP map|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N cis-acting|JJ|N/N elements|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) mediate|VBP|(S[dcl]\NP)/NP interleukin|NN|N/N responsiveness|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N mouse|NN|N/N IL-2R|NN|N/N alpha|NN|N/N gene|NN|N using|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N thymic|JJ|N/N lymphoma-derived|JJ|N/N hybridoma|NN|N (|LRB|(N\N)/N PC60|NN|N )|RRB|RRB .|.|.
The|DT|NP[nb]/N transcriptional|JJ|N/N response|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2R|NN|N/N alpha|NN|N/N gene|NN|N to|TO|(NP\NP)/NP stimulation|NN|N by|IN|(NP\NP)/NP IL-1|NN|N +|CC|conj IL-2|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) biphasic|JJ|S[adj]\NP .|.|.
IL-1|NN|N induces|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N rapid|JJ|N/N ,|,|, protein|NN|N/N synthesis-independent|JJ|N/N appearance|NN|N of|IN|(NP\NP)/NP IL-2R|NN|N/N alpha|NN|N/N mRNA|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) blocked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP inhibitors|NNS|N of|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N .|.|.
It|PRP|NP also|RB|(S\NP)/(S\NP) primes|VBZ|((S[dcl]\NP)/(S[to]\NP))/NP cells|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) become|VB|(S[b]\NP)/(S[adj]\NP) IL-2|NN|(S[adj]\NP)/(S[adj]\NP) responsive|JJ|S[adj]\NP and|CC|conj thereby|RB|(S\NP)/(S\NP) prepares|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N second|JJ|N/N phase|NN|N ,|,|, in|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) IL-2|NN|N induces|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N 100-fold|RB|N/N further|JJ|N/N increase|NN|N in|IN|(NP\NP)/NP IL-2R|NN|N/N alpha|NN|N/N transcripts|NNS|N .|.|.
Transient|JJ|N/N transfection|NN|N/N experiments|NNS|N show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] several|JJ|N/N elements|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N promoter-proximal|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2R|NN|N/N alpha|NN|N/N gene|NN|N contribute|VBP|(S[dcl]\NP)/PP to|TO|PP/NP IL-1|NN|N/N responsiveness|NN|N ,|,|, most|RBS|(NP/NP)/(NP/NP) importantly|RB|NP/NP an|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N site|NN|N conserved|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N human|JJ|N/N and|CC|conj mouse|NN|N/N gene|NN|N .|.|.
IL-2|NN|N/N responsiveness|NN|N ,|,|, on|IN|((S\NP)/(S\NP))/NP the|DT|NP[nb]/N other|JJ|N/N hand|NN|N ,|,|, depends|VBZ|(S[dcl]\NP)/PP on|IN|PP/NP a|DT|NP[nb]/N 78-nucleotide|JJ|N/N segment|NN|N 1.3|CD|N/N kilobases|NNS|N upstream|RB|((NP\NP)\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N major|JJ|N/N transcription|NN|N/N start|NN|N/N site|NN|N .|.|.
This|DT|NP[nb]/N segment|NN|N functions|VBZ|(S[dcl]\NP)/PP as|IN|PP/NP an|DT|NP[nb]/N IL-2-inducible|JJ|N/N enhancer|NN|N and|CC|conj lies|VBZ|S[dcl]\NP within|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N region|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) becomes|VBZ|(S[dcl]\NP)/(S[adj]\NP) DNase|NN|(S[adj]\NP)/(S[adj]\NP) I|CD|((S[adj]\NP)/(S[adj]\NP))\((S[adj]\NP)/(S[adj]\NP)) hypersensitive|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N T|NN|N/N cells|NNS|N in|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) IL-2R|NN|N/N alpha|NN|N/N expression|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP .|.|.
IL-2|NN|N/N responsiveness|NN|N requires|VBZ|(S[dcl]\NP)/NP three|CD|N/N distinct|JJ|N/N elements|NNS|N within|IN|(NP\NP)/NP the|DT|NP[nb]/N enhancer|NN|N .|.|.
Two|CD|N of|IN|(NP\NP)/NP these|DT|NP are|VBP|(S[dcl]\NP)/NP potential|JJ|N/N binding|VBG|N/N sites|NNS|N for|IN|(NP\NP)/NP STAT|NN|N/N proteins|NNS|N .|.|.
This|DT|NP[nb]/N review|NN|N focuses|VBZ|(S[dcl]\NP)/PP on|IN|PP/NP the|DT|NP[nb]/N roles|NNS|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N in|IN|(NP\NP)/NP hematopoietic|JJ|N/N lineage|NN|N/N commitment|NN|N .|.|.
A|DT|NP[nb]/N brief|JJ|N/N introduction|NN|N to|TO|(NP\NP)/NP lineage|NN|N/N commitment|NN|N and|CC|conj asymmetric|JJ|N/N cell|NN|N/N division|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) followed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N discussion|NN|N of|IN|(NP\NP)/NP several|JJ|N/N methods|NNS|N used|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) identify|VB|(S[b]\NP)/NP transcription|NN|N/N factors|NNS|N important|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/(S[ng]\NP) specifying|VBG|(S[ng]\NP)/NP hematopoietic|JJ|N/N cell|NN|N/N types|NNS|N .|.|.
Next|RB|(S/NP)/(S/NP) is|VBZ|(S[inv]/NP)/(S[pss]\NP) presented|VBN|S[pss]\NP a|DT|NP[nb]/N discussion|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N use|NN|N of|IN|(NP\NP)/NP embryonic|JJ|N/N stem|NN|N/N cells|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N analysis|NN|N of|IN|(NP\NP)/NP hematopoietic|JJ|N/N gene|NN|N/N expression|NN|N and|CC|conj the|DT|NP[nb]/N use|NN|N of|IN|(NP\NP)/NP targeted|VBN|N/N gene|NN|N/N disruption|NN|N to|TO|(S[to]\NP)/(S[b]\NP) analyze|VB|(S[b]\NP)/NP the|DT|NP[nb]/N role|NN|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N in|IN|(NP\NP)/NP hematopoiesis|NN|N .|.|.
Finally|RB|S/S ,|,|, the|DT|NP[nb]/N status|NN|N of|IN|(NP\NP)/NP our|PRP$|NP[nb]/N current|JJ|N/N knowledge|NN|N concerning|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N roles|NNS|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N commitment|NN|N to|TO|(NP\NP)/NP erythroid|JJ|N/N ,|,|, myeloid|JJ|N/N and|CC|conj lymphoid|JJ|N/N cell|NN|N/N types|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) summarized|VBN|S[pss]\NP .|.|.
Epstein-Barr|JJ|N/N virus|NN|N (|LRB|(N\N)/N EBV|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/(S[pss]\NP) known|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) infect|VB|(S[b]\NP)/NP B|NN|N/N cells|NNS|N and|CC|conj epithelial|JJ|N/N cells|NNS|N .|.|.
We|PRP|NP and|CC|conj others|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] EBV|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) also|RB|(S\NP)\(S\NP) infect|VB|(S[b]\NP)/NP a|DT|NP[nb]/N subset|NN|N of|IN|(NP\NP)/NP thymocytes|NNS|N .|.|.
Infection|NN|N of|IN|(NP\NP)/NP thymocytes|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) accompanied|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N appearance|NN|N of|IN|(NP\NP)/NP linear|JJ|N/N EBV|NN|N/N genome|NN|N within|IN|(NP\NP)/NP 8|CD|N/N hr|NN|N of|IN|(NP\NP)/NP infection|NN|N .|.|.
Circularization|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N EBV|NN|N/N genome|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) detected|VBN|S[pss]\NP .|.|.
This|DT|NP is|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP contrast|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N infection|NN|N in|IN|(NP\NP)/NP B|NN|N/N cells|NNS|N where|WRB|(NP\NP)/S[dcl] the|DT|NP[nb]/N genome|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) circularize|VB|S[b]\NP within|IN|((S\NP)\(S\NP))/NP 24|CD|N/N hr|NN|N of|IN|(NP\NP)/NP infection|NN|N .|.|.
The|DT|NP[nb]/N appearance|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N BamHI|NN|N/N ZLF-1|NN|N/N gene|NN|N/N product|NN|N ,|,|, ZEBRA|NN|N ,|,|, by|IN|(NP\NP)/NP RT-PCR|NN|N ,|,|, was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP within|IN|((S\NP)\(S\NP))/NP 8|CD|N/N hr|NN|N of|IN|(NP\NP)/NP infection|NN|N .|.|.
The|DT|NP[nb]/N appearance|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N novel|JJ|N/N fusion|NN|N/N transcript|NN|N (|LRB|(NP\NP)/NP RAZ|NN|N )|RRB|RRB ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) comprised|VBD|(S[dcl]\NP)/NP regions|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N BZLF-1|NN|N/N locus|NN|N and|CC|conj the|DT|NP[nb]/N adjacent|JJ|N/N BRLF-1|NN|N/N locus|NN|N ,|,|, was|VBD|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP RT-PCR|NN|N .|.|.
ZEBRA|NN|N/N protein|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) identified|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP infected|JJ|N/N thymocytes|NNS|N by|IN|((S\NP)\(S\NP))/NP immunoprecipitation|NN|N .|.|.
In|IN|(S/S)/NP addition|NN|N ,|,|, we|PRP|NP demonstrated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N EBNA-1|NN|N/N gene|NN|N in|IN|(NP\NP)/NP infected|JJ|N/N thymocytes|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) transcribed|VBN|(S[pss]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N Fp|NN|N/N promoter|NN|N ,|,|, rather|RB|conj/conj than|IN|conj from|IN|PP/NP the|DT|NP[nb]/N Cp/Wp|NN|N/N promoter|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) used|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP latently|RB|(N/N)/(N/N) infected|JJ|N/N B|NN|N/N cells|NNS|N .|.|.
Transcripts|NNS|N encoding|VBG|(S[ng]\NP)/NP gp350/220|NN|N ,|,|, the|DT|NP[nb]/N major|JJ|N/N coat|NN|N/N protein|NN|N of|IN|(NP\NP)/NP EBV|NN|N ,|,|, were|VBD|(S[dcl]\NP)/(S[pss]\NP) identified|VBN|S[pss]\NP ,|,|, but|CC|conj we|PRP|NP did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) find|VB|(S[b]\NP)/NP any|DT|NP[nb]/N evidence|NN|N of|IN|(NP\NP)/NP transcription|NN|N from|IN|(NP\NP)/NP the|DT|NP[nb]/N LMP-2A|NN|N/N or|CC|conj EBER-1|NN|N/N loci|NNS|N in|IN|(NP\NP)/NP infected|JJ|N/N thymocytes|NNS|N .|.|.
These|DT|NP[nb]/N observations|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] de|FW|(N/N)/(N/N) novo|FW|N/N EBV|NN|N/N infection|NN|N of|IN|(NP\NP)/NP thymocytes|NNS|N differs|VBZ|(S[dcl]\NP)/PP from|IN|PP/NP infection|NN|N of|IN|(NP\NP)/NP B|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N main|JJ|N/N difference|NN|N is|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] with|IN|(S/S)/NP thymocytes|NNS|N ,|,|, no|DT|NP[nb]/N evidence|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP that|IN|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N virus|NN|N ever|RB|(S\NP)/(S\NP) circularizes|VBZ|S[dcl]\NP .|.|.
Rather|RB|S/S ,|,|, EBV|NN|N remains|VBZ|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N linear|JJ|N/N configuration|NN|N from|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) replicative|JJ|N/N genes|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) transcribed|VBN|S[pss]\NP .|.|.
A|DT|NP[nb]/N key|JJ|N/N cytokine|NN|N induced|VBN|S[pss]\NP during|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N immune|JJ|N/N response|NN|N is|VBZ|(S[dcl]\NP)/NP IL-2|NN|N .|.|.
Following|VBG|(S/S)/NP T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N ,|,|, the|DT|NP[nb]/N genes|NNS|N encoding|VBG|(S[ng]\NP)/NP IL-2|NN|N and|CC|conj the|DT|NP[nb]/N various|JJ|N/N chains|NNS|N of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N receptor|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) transcriptionally|RB|(S\NP)\(S\NP) induced|VBN|S[pss]\NP .|.|.
In|IN|(S/S)/NP turn|NN|N ,|,|, secreted|VBN|N/N IL-2|NN|N serves|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) stimulate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N proliferation|NN|N and|CC|conj differentiation|NN|N of|IN|(NP\NP)/NP T|NN|N/N lymphocytes|NNS|N .|.|.
Several|JJ|N/N recent|JJ|N/N studies|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) implicated|VBN|((S[pt]\NP)/PP)/NP Jak|NN|N/N kinases|NNS|N in|IN|PP/NP the|DT|NP[nb]/N signaling|NN|N/N pathway|NN|N induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP IL-2|NN|N .|.|.
Following|VBG|(S/S)/NP this|DT|NP[nb]/N lead|NN|N ,|,|, we|PRP|NP set|VBD|(S[dcl]\NP)/(S[to]\NP) out|RP|(S\NP)\(S\NP) to|TO|(S[to]\NP)/(S[b]\NP) identify|VB|(S[b]\NP)/NP transcription|NN|N/N factors|NNS|N induced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP IL-2|NN|N .|.|.
Human|JJ|N/N peripheral|JJ|N/N blood|NN|N/N lymphocytes|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) contain|VB|(S[b]\NP)/NP several|JJ|N/N IL-2-inducible|JJ|N/N DNA|NN|N/N binding|NN|N/N activities|NNS|N .|.|.
Similar|JJ|N/N activities|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N transformed|VBN|N/N human|JJ|N/N lymphocyte|NN|N/N line|NN|N ,|,|, termed|VBN|(S[pss]\NP)/NP YT|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) purified|VBN|(S[pt]\NP)/NP these|DT|NP[nb]/N activities|NNS|N and|CC|conj found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N principal|JJ|N/N IL-2-inducible|JJ|N/N component|NN|N bears|VBZ|(S[dcl]\NP)/NP significant|JJ|N/N relatedness|NN|N to|TO|(NP\NP)/NP a|DT|NP[nb]/N prolactin-induced|JJ|N/N transcription|NN|N/N factor|NN|N first|RB|(S\NP)/(S\NP) identified|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP sheep|NN|N/N mammary|JJ|(N/N)/(N/N) gland|NN|N/N tissue|NN|N .|.|.
We|PRP|NP hypothesize|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] activation|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N protein|NN|N ,|,|, designated|VBN|(S[pss]\NP)/NP hStat5|NN|N ,|,|, helps|VBZ|(S[dcl]\NP)/(S[b]\NP) govern|VB|(S[b]\NP)/NP the|DT|NP[nb]/N biological|JJ|N/N effects|NNS|N of|IN|(NP\NP)/NP IL-2|NN|N during|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N immune|JJ|N/N response|NN|N .|.|.
The|DT|NP[nb]/N cell|NN|N/N cycle-dependent|JJ|N/N transcription|NN|N/N factor|NN|N ,|,|, E2F-1|NN|N ,|,|, regulates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N cyclin-like|JJ|N/N species|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DNA|NN|N/N repair|NN|N/N enzyme|NN|N uracil-DNA|NN|N/N glycosylase|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) UDG|NN|N/N )|RRB|RRB gene|NN|N in|IN|(NP\NP)/NP human|JJ|N/N osteosarcoma|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) Saos-2|NN|N/N )|RRB|RRB cells|NNS|N .|.|.
We|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] ,|,|, through|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N deletion|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N UDG|NN|N/N promoter|NN|N/N sequences|NNS|N ,|,|, that|IN|S[em]/S[dcl] expression|NN|N of|IN|(NP\NP)/NP E2F-1|NN|N activates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N UDG|NN|N/N promoter|NN|N through|IN|((S\NP)\(S\NP))/NP several|JJ|N/N E2F|NN|N/N sites|NNS|N .|.|.
The|DT|NP[nb]/N major|JJ|N/N putative|JJ|N/N downstream|JJ|N/N site|NN|N for|IN|(NP\NP)/NP E2F|NN|N ,|,|, located|JJ|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N first|JJ|N/N exon|NN|N ,|,|, serves|VBZ|(S[dcl]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N target|NN|N for|IN|(NP\NP)/NP E2F-1/DP1|NN|N/N complex|NN|N/N binding|NN|N in|FW|(NP\NP)/NP vitro|FW|N .|.|.
We|PRP|NP also|RB|(S\NP)/(S\NP) provide|VBP|(S[dcl]\NP)/NP evidence|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N functional|JJ|N/N relationship|NN|N between|IN|(NP\NP)/NP the|DT|NP[nb]/N cyclin-like|JJ|N/N UDG|NN|N/N gene|NN|N/N product|NN|N and|CC|conj E2F|NN|N .|.|.
High|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP UDG|NN|N/N expression|NN|N in|IN|(NP\NP)/NP a|DT|NP[nb]/N transient|JJ|N/N transfection|NN|N/N assay|NN|N result|VBP|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N down-regulation|NN|N of|IN|(NP\NP)/NP transcriptional|JJ|N/N activity|NN|N through|IN|(NP\NP)/NP elements|NNS|N specific|JJ|(S[adj]\NP)/PP for|IN|PP/NP E2F-mediated|JJ|N/N transcription|NN|N .|.|.
Overexpression|NN|N of|IN|(NP\NP)/NP UDG|NN|N in|IN|(NP\NP)/NP Saos|NN|N/N 2|CD|(N/N)\(N/N) cells|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) delay|VB|(S[b]\NP)/NP growth|NN|N late|RB|((S\NP)\(S\NP))/PP in|IN|PP/NP G1|NN|N/N phase|NN|N and|CC|conj transiently|RB|(S\NP)/(S\NP) arrest|VB|((S[b]\NP)/PP)/NP these|DT|NP[nb]/N cells|NNS|N from|IN|PP/(S[ng]\NP) progressing|VBG|(S[ng]\NP)/PP into|IN|PP/NP the|DT|NP[nb]/N S|NN|N/N phase|NN|N .|.|.
This|DT|NP[nb]/N hypothetical|JJ|N/N model|NN|N integrates|VBZ|((S[dcl]\NP)/PP)/NP one|CD|N/N mechanism|NN|N of|IN|(NP\NP)/NP DNA|NN|N/N repair|NN|N with|IN|PP/NP the|DT|NP[nb]/N cell|NN|N/N cycle|NN|N/N control|NN|N of|IN|(NP\NP)/NP gene|NN|N/N transcription|NN|N ,|,|, likely|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) through|IN|((S\NP)\(S\NP))/NP E2F|NN|N .|.|.
This|DT|NP implicates|VBZ|((S[dcl]\NP)/PP)/NP E2F|NN|N as|IN|PP/NP a|DT|NP[nb]/N multifunctional|JJ|N/N target|NN|N for|IN|(NP\NP)/NP proteins|NNS|N and|CC|conj enzymes|NNS|N ,|,|, possibly|RB|(S[adj]\NP)/(S[adj]\NP) ,|,|, responsive|JJ|(S[adj]\NP)/PP to|TO|PP/NP DNA|NN|N/N damage|NN|N through|IN|(NP\NP)/NP the|DT|NP[nb]/N negative|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP UDG|NN|N on|IN|(NP\NP)/NP E2F-mediated|JJ|N/N transcriptional|JJ|N/N activity|NN|N .|.|.
Interferon-gamma|NN|N (|LRB|(N\N)/N IFN-gamma|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N immunoregulatory|JJ|N/N protein|NN|N produced|VBN|S[pss]\NP predominantly|RB|(S\NP)\(S\NP) by|IN|((S\NP)\(S\NP))/NP T|NN|N/N cells|NNS|N and|CC|conj large|JJ|N/N granular|JJ|N/N lymphocytes|NNS|N (|LRB|(NP\NP)/NP LGL|NN|N )|RRB|RRB in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP different|JJ|N/N extracellular|JJ|N/N signals|NNS|N .|.|.
In|IN|(S/S)/(S[adj]\NP) particular|JJ|S[adj]\NP ,|,|, two|CD|N/N interleukins|NNS|N (|LRB|(NP\NP)/NP ILs|NNS|N )|RRB|RRB ,|,|, IL-2|NN|N and|CC|conj IL-12|NN|N ,|,|, have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP potent|JJ|N/N inducers|NNS|N of|IN|(NP\NP)/NP IFN-gamma|NN|N/N gene|NN|N/N expression|NN|N in|IN|(NP\NP)/NP both|CC|NP/NP T|NN|N/N cells|NNS|N and|CC|conj LGL|NN|N .|.|.
Although|IN|(S/S)/S[dcl] it|PRP|NP has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) reported|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] there|EX|NP[thr] are|VBP|(S[dcl]\NP[thr])/NP some|DT|NP[nb]/N T|NN|(N/N)/(N/N) cell|NN|N/N lines|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) produce|VBP|(S[dcl]\NP)/NP IFN-gamma|NN|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP IL-2|NN|N/N and|CC|conj IL-12|NN|N/N stimulation|NN|N ,|,|, there|EX|NP[thr] has|VBZ|(S[dcl]\NP[thr])/(S[pt]\NP) as|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) yet|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/NP no|DT|NP[nb]/N report|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N natural|JJ|N/N killer|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) NK|NN|N/N )|RRB|RRB cell|NN|N/N line|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) responds|VBZ|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N similar|JJ|N/N manner|NN|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N report|NN|N we|PRP|NP present|VBP|(S[dcl]\NP)/NP evidence|NN|N/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N cell|NN|N/N line|NN|N NK3.3|NN|N derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP human|JJ|N/N NK|NN|N/N cells|NNS|N ,|,|, responds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP both|CC|NP/NP IL-2|NN|N and|CC|conj IL-12|NN|N ,|,|, as|IN|((S\NP)\(S\NP))/(S[pss]\NP) measured|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP increases|NNS|N in|IN|(NP\NP)/NP IFN-gamma|NN|N/N and|CC|conj granulocyte-macrophage|JJ|N/N colony-stimulating|JJ|N/N factor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) GM-CSF|NN|N/N )|RRB|RRB cytoplasmic|JJ|N/N mRNA|NN|N/N and|CC|conj protein|NN|N/N expression|NN|N .|.|.
In|IN|(S/S)/NP addition|NN|N ,|,|, when|WRB|(S/S)/(S[pss]\NP) used|VBN|S[pss]\NP together|RB|(S\NP)\(S\NP) IL-2|NN|N and|CC|conj IL-12|NN|N synergized|VBD|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP IFN-gamma|NN|N and|CC|conj GM-CSF|NN|N and|CC|conj this|DT|NP[nb]/N synergy|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) attributed|VBN|(S[pss]\NP)/PP to|TO|PP/NP an|DT|NP[nb]/N increased|VBN|N/N accumulation|NN|N and|CC|conj stability|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IFN-gamma|NN|N/N and|CC|conj GM-CSF|NN|N/N mRNAs|NNS|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) investigate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N signaling|NN|N/N pathways|NNS|N involved|VBN|(S[adj]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N gene|NN|N/N induction|NN|N ,|,|, five|CD|N/N inhibitors|NNS|N ,|,|, cyclosporin|NN|N/N A|NN|N (|LRB|(NP\NP)/NP CsA|NN|N )|RRB|RRB ,|,|, transforming|VBG|N/N growth|NN|N/N factor-beta|NN|N ,|,|, cycloheximide|NN|N ,|,|, genistein|NN|N ,|,|, and|CC|conj staurosporine|NN|N/N A|NN|N ,|,|, were|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|(S[pss]\NP)/PP in|IN|PP/(S[ng]\NP) analyzing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP IL-2|NN|N and|CC|conj IL-12|NN|N on|IN|(NP\NP)/NP NK3.3|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] activation|NN|N of|IN|(NP\NP)/NP protein|NN|N/N kinase|NN|N/N C|NN|N ,|,|, but|CC|conj not|RB|NP/NP new|JJ|N/N protein|NN|N/N synthesis|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP IL-2|NN|N/N induction|NN|N of|IN|(NP\NP)/NP IFN-gamma|NN|N/N and|CC|conj GM-CSF|NN|N/N cytoplasmic|JJ|N/N mRNA|NN|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, IL-12|NN|N/N induction|NN|N of|IN|(NP\NP)/NP IFN-gamma|NN|N/N cytoplasmic|JJ|N/N mRNA|NN|N appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) only|RB|((S\NP)/(S\NP))/((S\NP)/(S\NP)) partially|RB|(S\NP)/(S\NP) depend|VB|(S[b]\NP)/PP on|IN|PP/NP activation|NN|N of|IN|(NP\NP)/NP protein|NN|N/N kinase|NN|N/N C|NN|N .|.|.
Furthermore|RB|S/S ,|,|, both|CC|NP/NP transforming|VBG|N/N growth|NN|N/N factor-beta|NN|N and|CC|conj genistein|NN|N ,|,|, a|DT|NP[nb]/N tyrosine|NN|N/N kinase|NN|N/N inhibitor|NN|N ,|,|, could|MD|(S[dcl]\NP)/(S[b]\NP) suppress|VB|(S[b]\NP)/NP IL-2|NN|N/N and|CC|conj IL-12|NN|N/N signaling|NN|N but|CC|conj CsA|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) generally|RB|(S[adj]\NP)/(S[adj]\NP) inactive|JJ|S[adj]\NP .|.|.
It|PRP|NP also|RB|(S\NP)/(S\NP) was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] suppression|NN|N of|IN|(NP\NP)/NP cytokine|NN|N/N gene|NN|N/N expression|NN|N by|IN|(NP\NP)/NP these|DT|NP[nb]/N agents|NNS|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) independent|JJ|(S[adj]\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N inhibition|NN|N of|IN|(NP\NP)/NP proliferation|NN|N .|.|.
In|IN|(S/S)/NP addition|NN|N ,|,|, IL-2|NN|N but|CC|conj not|RB|NP/NP IL-12|NN|N induced|VBD|(S[dcl]\NP)/NP nuclear|JJ|N/N factors|NNS|N NF-kappa|NN|N/N B|NN|N and|CC|conj AP1|NN|N ,|,|, and|CC|conj regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N nuclear|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N two|CD|N/N DNA|NN|N/N binding|NN|N/N protein|NN|N/N complexes|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) correlated|VBN|(S[pss]\NP)/PP with|IN|PP/NP IFN-gamma|NN|N/N and|CC|conj GM-CSF|NN|N/N gene|NN|N/N expression|NN|N .|.|.
These|DT|NP[nb]/N data|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-2|NN|N and|CC|conj IL-12|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) have|VB|(S[b]\NP)/NP distinct|JJ|N/N signaling|NN|N/N pathways|NNS|N leading|VBG|(S[ng]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP IFN-gamma|NN|N/N and|CC|conj GM-CSF|NN|N/N gene|NN|N/N expression|NN|N ,|,|, and|CC|conj that|IN|S[em]/S[dcl] the|DT|NP[nb]/N NK3.3|NN|N/N cell|NN|N/N line|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) serve|VB|(S[b]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N novel|JJ|N/N model|NN|N for|IN|(NP\NP)/(S[ng]\NP) dissecting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N biochemical|JJ|N/N and|CC|conj molecular|JJ|N/N events|NNS|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP these|DT|NP[nb]/N pathways|NNS|N .|.|.
Stimulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N T-cell|NN|N/N antigen|NN|N/N receptor|NN|N (|LRB|(NP\NP)/NP TCR|NN|N )|RRB|RRB induces|VBZ|(S[dcl]\NP)/NP activation|NN|N of|IN|(NP\NP)/NP multiple|JJ|N/N tyrosine|NN|N/N kinases|NNS|N ,|,|, resulting|VBG|(S[ng]\NP)/PP in|IN|PP/NP phosphorylation|NN|N of|IN|(NP\NP)/NP numerous|JJ|N/N intracellular|JJ|N/N substrates|NNS|N .|.|.
One|CD|N/N substrate|NN|N is|VBZ|(S[dcl]\NP)/NP p95vav|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP exclusively|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP hematopoietic|JJ|N/N and|CC|conj trophoblast|NN|N/N cells|NNS|N .|.|.
It|PRP|NP contains|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP structural|JJ|N/N motifs|NNS|N ,|,|, including|VBG|(NP\NP)/NP Src|NN|N/N homology|NN|N/N 2|CD|(N/N)\(N/N) ,|,|, Src|NN|N/N homology|NN|N/N 3|CD|(N/N)\(N/N) ,|,|, and|CC|conj pleckstrin|NN|N/N homology|NN|N/N domains|NNS|N and|CC|conj a|DT|NP[nb]/N putative|JJ|N/N guanine|NN|N/N nucleotide|NN|N/N exchange|NN|N/N domain|NN|N .|.|.
The|DT|NP[nb]/N role|NN|N of|IN|(NP\NP)/NP p95vav|NN|N in|IN|(NP\NP)/NP TCR-mediated|JJ|N/N signaling|NN|N/N processes|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) unclear|JJ|S[adj]\NP .|.|.
Here|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] overexpression|NN|N of|IN|(NP\NP)/NP p95vav|NN|N alone|RB|NP\NP in|IN|(NP\NP)/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N nuclear|JJ|N/N factors|NNS|N ,|,|, including|VBG|(NP\NP)/NP NFAT|NN|N ,|,|, involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP interleukin-2|NN|N/N expression|NN|N .|.|.
Furthermore|RB|S/S ,|,|, p95vav|NN|N synergizes|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP TCR|NN|N/N stimulation|NN|N in|IN|((S\NP)\(S\NP))/(S[ng]\NP) inducing|VBG|(S[ng]\NP)/NP NFAT-|NN|N/N and|CC|conj interleukin-2-dependent|JJ|N/N transcription|NN|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, NFAT|NN|N/N activation|NN|N by|IN|(NP\NP)/NP a|DT|NP[nb]/N G-protein-coupled|JJ|N/N receptor|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) modulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP p95vav|NN|N/N overexpression|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N effect|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) specific|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N TCR|NN|N/N signaling|NN|N/N pathways|NNS|N .|.|.
Although|IN|(S/S)/S[dcl] removal|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N first|JJ|(N/N)/(N/N) 67|CD|N/N amino|NN|N/N acids|NNS|N of|IN|(NP\NP)/NP p95vav|NN|N activates|VBZ|(S[dcl]\NP)/NP its|PRP$|NP[nb]/N transforming|NN|N/N potential|NN|N in|IN|((S\NP)\(S\NP))/NP NIH|NN|N/N 3T3|NN|N/N cells|NNS|N ,|,|, this|DT|NP[nb]/N region|NN|N appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP its|PRP$|NP[nb]/N function|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N .|.|.
We|PRP|NP further|RB|(S\NP)/(S\NP) demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N p95vav-induced|JJ|N/N NFAT|NN|N/N activation|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) mimicked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP Ras|NN|N/N activation|NN|N ,|,|, though|IN|((S\NP)\(S\NP))/S[dcl] its|PRP$|NP[nb]/N function|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) dependent|JJ|S[adj]\NP upon|IN|((S[adj]\NP)\(S[adj]\NP))/NP Ras|NN|N and|CC|conj Raf|NN|N .|.|.
Furthermore|RB|S/S ,|,|, the|DT|NP[nb]/N activating|NN|N/N function|NN|N of|IN|(NP\NP)/NP p95vav|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) blocked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP FK506|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] its|PRP$|NP[nb]/N activity|NN|N also|RB|(S\NP)/(S\NP) depends|VBZ|(S[dcl]\NP)/PP on|IN|PP/NP calcineurin|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) further|RB|(S\NP)/(S\NP) dissect|VB|(S[b]\NP)/NP p95vav|NN|N/N involvement|NN|N in|IN|(NP\NP)/NP TCR|NN|N/N signaling|NN|N ,|,|, we|PRP|NP analyzed|VBD|(S[dcl]\NP)/NP various|JJ|N/N Jurkat|NN|N/N mutants|NNS|N deficient|JJ|(S[adj]\NP)/PP in|IN|PP/NP TCR|NN|N/N signaling|NN|N/N function|NN|N or|CC|conj TCR|NN|N/N expression|NN|N and|CC|conj showed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] an|DT|NP[nb]/N intact|JJ|N/N TCR|NN|N/N signaling|NN|N/N pathway|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|S[pss]\NP for|IN|(((S\NP)\(S\NP))/(S[to]\NP))/NP p95vav|NN|N to|TO|(S[to]\NP)/(S[b]\NP) function|VB|S[b]\NP .|.|.
However|RB|S/S ,|,|, overexpression|NN|N of|IN|(NP\NP)/NP p95vav|NN|N does|VBZ|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) appear|VB|(S[b]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) influence|VB|(S[b]\NP)/NP TCR-induced|JJ|N/N protein|NN|N/N tyrosine|NN|N/N phosphorylation|NN|N or|CC|conj increases|NNS|N in|IN|(NP\NP)/NP cytoplasmic|JJ|N/N free|JJ|N/N calcium|NN|N .|.|.
Taken|VBN|S[pss]\NP together|RB|(S\NP)\(S\NP) ,|,|, our|PRP$|NP[nb]/N data|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] p95vav|NN|N plays|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N at|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N yet|RB|(N/N)/(N/N) unidentified|JJ|N/N proximal|JJ|N/N position|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N TCR|NN|N/N signaling|NN|N/N cascade|NN|N .|.|.
The|DT|NP[nb]/N granulocyte-macrophage|JJ|N/N colony-stimulating|JJ|N/N factor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) GM-CSF|NN|N/N )|RRB|RRB gene|NN|N/N promoter|NN|N contains|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N consensus|NN|N/N sequence|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N polyomavirus|NN|N/N enhancer|NN|N/N binding-protein|NN|N/N 2|CD|(N/N)\(N/N) (|LRB|((N/N)\(N/N))/(N/N) PEBP2|NN|N/N )|RRB|RRB transcription|NN|N/N factor|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) consists|VBZ|(S[dcl]\NP)/PP of|IN|PP/NP alpha|NN|N/N and|CC|conj beta|NN|N/N subunits|NNS|N .|.|.
There|EX|NP[thr] are|VBP|(S[dcl]\NP[thr])/NP at|IN|((N/N)/(N/N))/(S[asup]\NP) least|JJS|S[asup]\NP two|CD|N/N genes|NNS|N ,|,|, alpha|NN|N/N A|NN|N and|CC|conj alpha|NN|N/N B|NN|N ,|,|, encoding|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N alpha|NN|N/N subunit|NN|N .|.|.
alpha|NN|N/N B|NN|N is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N mouse|NN|N/N homologue|NN|N of|IN|(NP\NP)/NP human|JJ|N/N AML1|NN|N/N gene|NN|N detected|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N breakpoints|NNS|N of|IN|(NP\NP)/NP t|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) 8|CD|N/N ;|:|; 21|CD|N/N )|RRB|RRB and|CC|conj t|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) 3|CD|N/N ;|:|; 21|CD|N/N )|RRB|RRB myeloid|JJ|N/N leukemias|NNS|N .|.|.
We|PRP|NP examined|VBD|(S[dcl]\NP)/NP alpha|NN|N/N A1|NN|N (|LRB|(NP\NP)/NP an|DT|NP[nb]/N alpha|NN|N/N A-gene|JJ|N/N product|NN|N )|RRB|RRB and|CC|conj alpha|NN|N/N B1|NN|N and|CC|conj alpha|NN|N/N B2|NN|N (|LRB|(NP\NP)/NP two|CD|N/N alpha|NN|N/N B-encoded|JJ|N/N isomers|NNS|N )|RRB|RRB for|IN|((S\NP)\(S\NP))/NP their|PRP$|NP[nb]/N effects|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N GM-CSF|NN|N/N promoter|NN|N .|.|.
PEBP2|NN|N/N alpha|NN|N/N A1|NN|N/N ,|,|, alpha|NN|N/N B1|NN|N/N ,|,|, and|CC|conj alpha|NN|N/N B2|NN|N/N proteins|NNS|N bound|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N PEBP2|NN|N/N site|NN|N within|IN|(NP\NP)/NP the|DT|NP[nb]/N mouse|NN|N/N GM-CSF|NN|N/N promoter|NN|N .|.|.
PEBP2|NN|N/N alpha|NN|N/N A1|NN|N and|CC|conj alpha|NN|N/N B1|NN|N enhanced|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N GM-CSF|NN|N/N promoter-driven|JJ|N/N reporter|NN|N/N plasmid|NN|N in|IN|(NP\NP)/NP unstimulated|JJ|N/N and|CC|conj 12-O-tetradecanoylphorbol|NN|(N/N)/(N/N) 13-acetate/phytohemagglutinin-stimulated|JJ|N/N human|JJ|N/N Jurkat|NN|N/N T|NN|N/N cells|NNS|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, the|DT|NP[nb]/N promoter|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) suppressed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP alpha|NN|N/N B2|NN|N .|.|.
Coexpression|NN|N of|IN|(NP\NP)/NP alpha|NN|N/N B1|NN|N and|CC|conj alpha|NN|N/N B2|NN|N showed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N promoter|NN|N/N activity|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) determined|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N alpha|NN|N/N B1/alpha|NN|N/N B2|NN|N/N ratio|NN|N .|.|.
Jurkat|NN|N/N cell|NN|N/N extract|NN|N contained|VBD|(S[dcl]\NP)/NP PEBP2|NN|N/N site-binding|JJ|N/N protein|NN|N (|LRB|(NP\NP)/NP s|NNS|N )|RRB|RRB that|WDT|(NP\NP)/(S[dcl]\NP) cross-reacted|VBD|(S[dcl]\NP)/PP with|IN|PP/NP antimouse|JJ|N/N alpha|NN|N/N A1|NN|N/N antibodies|NNS|N .|.|.
Northern|NN|(N/N)/(N/N) blot|NN|N/N analysis|NN|N indicated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP human|JJ|N/N PEBP2|NN|N/N alpha|NN|N/N A|NN|N/N ,|,|, alpha|NN|N/N B|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) AML1|NN|N/N )|RRB|RRB ,|,|, and|CC|conj beta|NN|N/N genes|NNS|N in|IN|(NP\NP)/NP Jurkat|NN|N/N cells|NNS|N .|.|.
Although|IN|(S/S)/S[dcl] further|JJ|N/N studies|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) determine|VB|(S[b]\NP)/NP the|DT|NP[nb]/N precise|JJ|N/N role|NN|N of|IN|(NP\NP)/NP PEBP2|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N GM-CSF|NN|N/N promoter|NN|N/N activity|NN|N ,|,|, the|DT|NP[nb]/N present|JJ|N/N findings|NNS|N suggested|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N importance|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N relative|JJ|N/N ratio|NN|N of|IN|(NP\NP)/NP different|JJ|N/N PEBP2|NN|N/N isoforms|NNS|N in|IN|(NP\NP)/(S[ng]\NP) regulating|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N levels|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N promoter|NN|N/N activity|NN|N .|.|.
The|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP cytokine|NN|N/N expression|NN|N in|IN|(NP\NP)/NP monocytes|NNS|N/N /macrophages|NNS|N by|IN|(NP\NP)/NP bacterial|JJ|N/N endotoxin|NN|N or|CC|conj lipopolysaccharide|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N critical|JJ|N/N ,|,|, highly|RB|(N/N)/(N/N) regulated|VBN|N/N host|NN|N/N defence|NN|N/N response|NN|N .|.|.
The|DT|NP[nb]/N augmentation|NN|N of|IN|(NP\NP)/NP LPS|NN|N/N responses|NNS|N by|IN|(NP\NP)/NP interferon|NN|N/N gamma|NN|N (|LRB|(NP\NP)/NP IFN-gamma|NN|N )|RRB|RRB ,|,|, referred|VBN|((S[pss]\NP)/PP)/(PP/NP) to|TO|PP/NP as|IN|PP/NP priming|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[adj]\NP) well|RB|(S[adj]\NP)/(S[adj]\NP) established|VBN|S[adj]\NP .|.|.
However|RB|S/S ,|,|, the|DT|NP[nb]/N mechanism|NN|N (|LRB|(NP\NP)/NP s|NNS|N )|RRB|RRB by|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) priming|NN|N occurs|VBZ|S[dcl]\NP is|VBZ|(S[dcl]\NP)/(S[pss]\NP) poorly|RB|(S\NP)/(S\NP) defined|VBN|S[pss]\NP .|.|.
Using|VBG|(S[ng]\NP)/NP tumour|NN|N/N necrosis|NN|N/N factor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) TNF|NN|N/N )|RRB|RRB induction|NN|N as|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N model|NN|N ,|,|, experiments|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) designed|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) analyse|VB|(S[b]\NP)/NP in|IN|((S\NP)\(S\NP))/NP detail|NN|N the|DT|NP[nb]/N priming|NN|N/N effect|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N LPS|NN|N/N response|NN|N in|IN|(NP\NP)/NP human|JJ|N/N monocytes|NNS|N .|.|.
Priming|NN|N by|IN|(NP\NP)/NP IFN-gamma|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) primarily|RB|(S\NP)/(S\NP) manifested|VBN|(S[pss]\NP)/PP at|IN|PP/NP the|DT|NP[nb]/N level|NN|N of|IN|(NP\NP)/NP TNF|NN|N/N mRNA|NN|N/N accumulation|NN|N .|.|.
IFN-gamma|NN|N/N pre-treatment|NN|N affected|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N magnitude|NN|N rather|RB|conj/conj than|IN|conj the|DT|NP[nb]/N sensitivity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N LPS|NN|N/N response|NN|N .|.|.
Priming|NN|N occurred|VBD|S[dcl]\NP after|IN|((S\NP)\(S\NP))/NP several|JJ|N/N hours|NNS|N of|IN|(NP\NP)/NP treatment|NN|N ,|,|, and|CC|conj the|DT|NP[nb]/N primed|JJ|N/N state|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP either|CC|NP/NP IFN-gamma|NN|N or|CC|conj GM-CSF|NN|N ,|,|, but|CC|conj not|RB|NP/NP M-CSF|NN|N .|.|.
Primed|VBN|N/N monocytes|NNS|N transcribed|VBD|(S[dcl]\NP)/NP TNF|NN|N/N mRNA|NN|N at|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N higher|JJR|N/N rate|NN|N than|IN|(NP\NP)/NP freshly|RB|(N/N)/(N/N) isolated|VBN|N/N monocytes|NNS|N upon|IN|((S\NP)\(S\NP))/NP activation|NN|N with|IN|(NP\NP)/NP LPS|NN|N .|.|.
The|DT|NP[nb]/N increased|VBN|N/N transcriptional|JJ|N/N rate|NN|N correlated|VBD|(S[dcl]\NP)/PP with|IN|PP/NP a|DT|NP[nb]/N marked|JJ|N/N increase|NN|N in|IN|(NP\NP)/NP nuclear|JJ|N/N factor-kappa|NN|N/N B|NN|N/N activity|NN|N in|IN|(NP\NP)/NP these|DT|NP[nb]/N cells|NNS|N as|IN|(NP\NP)/(S[pss]\NP) determined|VBN|(S[pss]\NP)/PP by|IN|PP/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N using|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N consensus|NN|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N oligonucleotide|NN|N .|.|.
An|DT|NP[nb]/N additional|JJ|N/N significant|JJ|N/N finding|NN|N was|VBD|(S[dcl]\NP)/S[em] than|IN|S[em]/S[dcl] TNF|NN|N/N mRNA|NN|N induced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP primed|VBN|N/N cells|NNS|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) much|RB|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) more|RBR|(S[adj]\NP)/(S[adj]\NP) stable|JJ|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/PP in|IN|PP/NP unprimed|JJ|N/N cells|NNS|N (|LRB|(S\S)/S[dcl] T1/2|NN|N increased|VBN|S[dcl]\NP 6-8-fold|RB|(S\NP)\(S\NP) )|RRB|RRB .|.|.
Consistent|JJ|(S/S)/PP with|IN|PP/NP the|DT|NP[nb]/N increased|VBN|N/N mRNA|NN|N/N stability|NN|N ,|,|, the|DT|NP[nb]/N duration|NN|N of|IN|(NP\NP)/NP mRNA|NN|N/N accumulation|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) longer|RBR|S[adj]\NP following|VBG|((S\NP)\(S\NP))/NP LPS|NN|N/N stimulation|NN|N in|IN|(NP\NP)/NP primed|VBN|N/N monocytes|NNS|N ,|,|, in|IN|(NP\NP)/NP addition|NN|N to|TO|(NP\NP)/(S[ng]\NP) being|VBG|(S[ng]\NP)/PP of|IN|PP/NP greater|JJR|N/N magnitude|NN|N .|.|.
Finally|RB|S/S ,|,|, primed|VBN|N/N and|CC|conj unprimed|JJ|N/N cells|NNS|N possessed|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N differential|JJ|N/N sensitivity|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N kinase|NN|N/N inhibitor|NN|N H-89|NN|N .|.|.
H-89|NN|N substantially|RB|(S\NP)/(S\NP) suppressed|VBD|(S[dcl]\NP)/NP LPS-induced|JJ|N/N TNF|NN|N/N mRNA|NN|N/N accumulation|NN|N in|IN|(NP\NP)/NP unprimed|JJ|N/N cells|NNS|N ,|,|, but|CC|conj had|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N effect|NN|N on|IN|(NP\NP)/NP primed|VBN|N/N monocytes|NNS|N following|VBG|((S\NP)\(S\NP))/NP LPS|NN|N/N stimulation|NN|N .|.|.
The|DT|NP[nb]/N CD4|NN|N/N promoter|NN|N plays|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N developmental|JJ|N/N control|NN|N of|IN|(NP\NP)/NP CD4|NN|N/N transcription|NN|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N report|NN|N ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N minimal|JJ|N/N CD4|NN|N/N promoter|NN|N has|VBZ|(S[dcl]\NP)/NP four|CD|N/N factor|NN|N/N binding|NN|N/N sites|NNS|N ,|,|, each|DT|NP of|IN|(NP\NP)/NP which|WDT|((NP\NP)/(S[dcl]\NP))\(NP/NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP full|JJ|N/N function|NN|N .|.|.
Using|VBG|(S[ng]\NP)/NP biochemical|JJ|N/N and|CC|conj mutagenesis|NN|N/N analyses|NNS|N ,|,|, we|PRP|NP determined|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] multiple|JJ|N/N nuclear|JJ|N/N factors|NNS|N bind|VBP|(S[dcl]\NP)/PP to|TO|PP/NP these|DT|NP[nb]/N independent|JJ|N/N sites|NNS|N .|.|.
We|PRP|NP determined|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] an|DT|NP[nb]/N initiator-like|JJ|N/N sequence|NN|N present|JJ|S[adj]\NP at|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N cap|NN|N/N site|NN|N and|CC|conj an|DT|NP[nb]/N Ets|NN|N/N consensus|NN|N/N sequence|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP full|JJ|N/N promoter|NN|N/N function|NN|N .|.|.
We|PRP|NP also|RB|(S\NP)/(S\NP) demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N Myc-associated|JJ|N/N zinc|NN|N/N finger|NN|N/N protein|NN|N (|LRB|(NP\NP)/NP MAZ|NN|N )|RRB|RRB appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP the|DT|NP[nb]/N predominant|JJ|N/N factor|NN|N binding|VBG|S[ng]\NP to|TO|((S\NP)\(S\NP))/NP one|CD|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N sites|NNS|N .|.|.
This|DT|NP[nb]/N last|JJ|N/N site|NN|N closely|RB|(S\NP)/(S\NP) resembles|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N ME1a1|NN|N/N G3AG4AG3|NN|N/N motif|NN|N previously|RB|(S\NP)/(S\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP a|DT|NP[nb]/N critical|JJ|N/N element|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N P2|NN|N/N promoter|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N c-myc|NN|N/N gene|NN|N .|.|.
We|PRP|NP therefore|RB|(S\NP)/(S\NP) believe|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N MAZ|NN|N/N transcription|NN|N/N factor|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) also|RB|(S\NP)\(S\NP) likely|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) play|VB|(S[b]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N control|NN|N of|IN|(NP\NP)/NP developmental|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N CD4|NN|N/N gene|NN|N .|.|.
Activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TAL1|NN|N/N (|LRB|LRB or|CC|conj SCL|NN|N/N )|RRB|RRB gene|NN|N ,|,|, originally|RB|(S\NP)/(S\NP) identified|VBN|(S[pss]\NP)/PP through|IN|PP/NP its|PRP$|NP[nb]/N involvement|NN|N by|IN|(NP\NP)/NP a|DT|NP[nb]/N recurrent|JJ|N/N chromosomal|JJ|N/N translocation|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N most|RBS|(N/N)/(N/N) frequent|JJ|N/N molecular|JJ|N/N lesion|NN|N recognized|VBN|(S[pss]\NP)/PP in|IN|PP/NP T-cell|NN|N/N acute|JJ|N/N lymphoblastic|JJ|N/N leukemia|NN|N .|.|.
The|DT|NP[nb]/N protein|NN|N/N products|NNS|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N gene|NN|N contain|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N basic-helix-loop-helix|JJ|N/N motif|NN|N characteristic|JJ|(S[adj]\NP)/PP of|IN|PP/NP a|DT|NP[nb]/N large|JJ|N/N family|NN|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) bind|VBP|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N canonical|JJ|N/N DNA|NN|N/N sequence|NN|N CANNTG|NN|N as|IN|((S\NP)\(S\NP))/NP protein|NN|N/N heterodimers|NNS|N .|.|.
TAL1|NN|N/N expression|NN|N by|IN|(NP\NP)/NP erythroid|JJ|N/N cells|NNS|N in|FW|(NP\NP)/NP vivo|FW|N and|CC|conj in|IN|(NP\NP)/NP chemical-induced|JJ|N/N erythroleukemia|NN|N/N cell|NN|N/N lines|NNS|N in|FW|(NP\NP)/NP vivo|FW|N suggested|VBD|(S[dcl]\NP)/S[dcl] the|DT|NP[nb]/N gene|NN|N might|MD|(S[dcl]\NP)/(S[b]\NP) regulate|VB|(S[b]\NP)/NP aspects|NNS|N of|IN|(NP\NP)/NP erythroid|JJ|N/N differentiation|NN|N .|.|.
Since|IN|(S/S)/S[dcl] the|DT|NP[nb]/N terminal|JJ|N/N events|NNS|N of|IN|(NP\NP)/NP erythropoiesis|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) controlled|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N glycoprotein|NN|N/N hormone|NN|N erythropoietin|NN|N (|LRB|(NP\NP)/NP Epo|NN|N )|RRB|RRB ,|,|, we|PRP|NP investigated|VBD|(S[dcl]\NP)/S[qem] whether|IN|S[qem]/S[dcl] the|DT|NP[nb]/N expression|NN|N or|CC|conj activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TAL1|NN|N/N gene|NN|N and|CC|conj its|PRP$|NP[nb]/N protein|NN|N/N products|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) affected|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP Epo|NN|N in|IN|(NP\NP)/NP splenic|JJ|N/N erythroblasts|NNS|N from|IN|(NP\NP)/NP mice|NNS|N infected|VBN|(S[pss]\NP)/PP with|IN|PP/NP an|DT|NP[nb]/N anemia-inducing|JJ|N/N strain|NN|N of|IN|(NP\NP)/NP Friend|NN|N/N virus|NN|N (|LRB|(NP\NP)/NP FVA|NN|N/N cells|NNS|N )|RRB|RRB .|.|.
Epo|NN|N elicited|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N rapid|JJ|N/N ,|,|, dose-related|JJ|N/N increase|NN|N in|IN|(NP\NP)/NP TAL1|NN|N/N mRNA|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) increasing|VBG|(S[ng]\NP)/NP transcription|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N gene|NN|N and|CC|conj stabilizing|VBG|(S[ng]\NP)/NP one|CD|N of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N mRNAs|NNS|N .|.|.
An|DT|NP[nb]/N Epo-inducible|JJ|N/N TAL1|NN|N/N DNA|NN|N/N binding|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) identified|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP FVA|NN|N/N cell|NN|N/N nuclear|JJ|N/N extracts|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) subsequently|RB|(S\NP)/(S\NP) decayed|VBD|S[dcl]\NP despite|IN|((S\NP)\(S\NP))/(S[ng]\NP) accumulating|VBG|(S[ng]\NP)/NP mRNA|NN|N and|CC|conj protein|NN|N .|.|.
Induction|NN|N of|IN|(NP\NP)/NP DNA|NN|N/N binding|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP temporally|RB|(S\NP)\(S\NP) with|IN|PP/NP Epo-induced|JJ|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP nuclear|JJ|N/N TAL1|NN|N/N protein|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] Epo|NN|N acts|VBZ|(S[dcl]\NP)/PP at|IN|PP/NP both|CC|NP/NP transcriptional|JJ|N/N and|CC|conj posttranscriptional|JJ|N/N levels|NNS|N on|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N TAL1|NN|N/N locus|NN|N in|IN|(NP\NP)/NP Friend|NN|N/N virus-induced|JJ|N/N erythroblasts|NNS|N and|CC|conj establish|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N link|NN|N between|IN|(NP\NP)/NP Epo|NN|N/N signaling|NN|N/N mechanisms|NNS|N and|CC|conj a|DT|NP[nb]/N member|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N family|NN|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N involved|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N differentiation|NN|N of|IN|(NP\NP)/NP diverse|JJ|N/N cell|NN|N/N lineages|NNS|N .|.|.
We|PRP|NP describe|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N method|NN|N for|IN|(NP\NP)/NP relative|JJ|N/N quantification|NN|N of|IN|(NP\NP)/NP specific|JJ|N/N mRNA|NN|N using|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N nonradioactive|JJ|N/N assay|NN|N based|VBN|(S[pss]\NP)/PP on|IN|PP/NP DNA|NN|N/N strand|NN|N/N competition|NN|N between|IN|(NP\NP)/NP identical|JJ|N/N sequences|NNS|N of|IN|(NP\NP)/NP biotin-|NN|N/N and|CC|conj fluorescein-labeled|JJ|N/N amplicon|NN|N (|LRB|(NP\NP)/NP probe|NN|N )|RRB|RRB and|CC|conj unlabeled|JJ|N/N amplicon|NN|N (|LRB|(N\N)/N target|NN|N )|RRB|RRB during|IN|(NP\NP)/NP hybridization|NN|N .|.|.
As|IN|(S/S)/S[dcl] the|DT|NP[nb]/N target|NN|N/N quantity|NN|N increased|VBD|S[dcl]\NP ,|,|, that|DT|NP of|IN|(NP\NP)/NP the|DT|NP[nb]/N double-labeled|JJ|N/N probe|NN|N decreased|VBD|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP accordance|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N mass|NN|N/N action|NN|N/N law|NN|N .|.|.
This|DT|NP[nb]/N technique|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) successfully|RB|(S\NP)/(S\NP) applied|VBN|S[pss]\NP to|TO|(S[to]\NP)/(S[b]\NP) evaluate|VB|(S[b]\NP)/NP differences|NNS|N in|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptor|NN|N/N expression|NN|N in|IN|(NP\NP)/NP U937|NN|N/N cells|NNS|N before|IN|((S\NP)\(S\NP))/NP and|CC|conj after|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N addition|NN|N of|IN|(NP\NP)/NP potent|JJ|N/N differentiation|NN|N/N inducers|NNS|N :|:|(NP\NP)/NP 12-O-tetradecanoylphorbol|NN|N/N 13-acetate|NN|N (|LRB|(NP\NP)/NP TPA|NN|N )|RRB|RRB and|CC|conj a|DT|NP[nb]/N combination|NN|N of|IN|(NP\NP)/NP all-trans|JJ|N/N retinoic|JJ|N/N acid|NN|N (|LRB|(N\N)/N RA|NN|N )|RRB|RRB and|CC|conj 1,25-dihydroxyvitamin|NN|N/N D2|NN|N (|LRB|(NP\NP)/NP VD|NN|N )|RRB|RRB .|.|.
We|PRP|NP observed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] TPA|NN|N/N treatment|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP an|DT|NP[nb]/N increase|NN|N in|IN|(NP\NP)/NP specific|JJ|N/N binding|NN|N of|IN|(NP\NP)/NP [3H]dexamethasone|NN|N and|CC|conj up-regulation|NN|N of|IN|(NP\NP)/NP GR|NN|N/N mRNA|NN|N while|IN|(S\S)/S[dcl] no|DT|NP[nb]/N enhanced|VBN|N/N GR|NN|N/N expression|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) perceived|VBN|(S[pss]\NP)/PP with|IN|PP/NP RA|NN|N/N /VD|NN|N/N treatment|NN|N .|.|.
In|IN|(S/S)/NP contrast|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N purely|RB|(N/N)/(N/N) enhancer-dependent|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP cytokines|NNS|N such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP TNF|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV|NN|N/N regulatory|JJ|N/N region|NN|N (|LRB|(N\N)/N LTR|NN|N )|RRB|RRB ,|,|, we|PRP|NP observed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] okadaic|JJ|N/N acid|NN|N (|LRB|(N\N)/N OKA|NN|N )|RRB|RRB activates|VBZ|(S[dcl]\NP)/NP HIV|NN|N/N transcription|NN|N through|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP the|DT|NP[nb]/N enhancer|NN|N ,|,|, responding|VBG|(S[ng]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N factor|NN|N NF-kappa|NN|N/N B|NN|N ,|,|, and|CC|conj the|DT|NP[nb]/N promoter|NN|N/N domain|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N LTR|NN|N .|.|.
The|DT|NP[nb]/N inducibility|NN|N of|IN|(NP\NP)/NP HIV|NN|N/N LTR-driven|JJ|N/N luciferase|NN|N/N expression|NN|N/N constructs|NNS|N in|IN|(NP\NP)/NP lymphoblastoid|JJ|N/N cells|NNS|N stimulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP OKA|NN|N depended|VBD|(S[dcl]\NP)/PP on|IN|PP/NP both|CC|NP/NP functional|JJ|N/N Sp1|NN|N/N binding|NN|N/N elements|NNS|N and|CC|conj the|DT|NP[nb]/N ability|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TATA|NN|N/N box|NN|N to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/NP the|DT|NP[nb]/N protein|NN|N TBP|NN|NP .|.|.
In|IN|(S/S)/NP both|CC|NP/NP transformed|VBN|N/N and|CC|conj normal|JJ|N/N lymphocytes|NNS|N ,|,|, OKA|NN|N/N stimulation|NN|N induced|VBD|(S[dcl]\NP)/NP intense|JJ|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP the|DT|NP constitutively|RB|(N/N)/(N/N) expressed|VBN|N/N Sp1|NN|N/N protein|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N nucleus|NN|N ,|,|, a|DT|NP[nb]/N property|NN|N of|IN|(NP\NP)/NP OKA|NN|N not|RB|(S\NP)/(S\NP) shared|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP TNF|NN|N ,|,|, phorbol|NN|N/N ester|NN|N ,|,|, or|CC|conj PHA|NN|N and|CC|conj interleukin|NN|N 2|CD|N\N .|.|.
Responsiveness|NN|N of|IN|(NP\NP)/NP LTR|NN|N/N constructs|NNS|N deleted|VBN|(S[pss]\NP)/PP of|IN|PP/NP kappa|NN|(N/N)/(N/N) B|NN|N/N elements|NNS|N to|TO|(NP\NP)/NP HIV|NN|N/N Tat|NN|N/N expression|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) increased|VBN|S[pss]\NP upon|IN|((S\NP)\(S\NP))/NP OKA|NN|N/N but|CC|conj not|RB|(N/N)/(N/N) TNF|NN|N/N stimulation|NN|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] SP1|NN|N/N phosphorylation|NN|N induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP OKA|NN|N ,|,|, a|DT|NP[nb]/N selective|JJ|N/N inhibitor|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N serine-threonine|JJ|N/N phosphatase|NN|N PP2A|NN|N ,|,|, facilitates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N formation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N transcription|NN|N/N complex|NN|N involving|VBG|(S[ng]\NP)/NP general|JJ|N/N transcription|NN|N/N factors|NNS|N ,|,|, HIV|NN|N/N Tat|NN|N ,|,|, and|CC|conj Sp1|NN|N/N proteins|NNS|N .|.|.
The|DT|NP[nb]/N formation|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N complex|NN|N would|MD|(S[dcl]\NP)/(S[b]\NP) increase|VB|S[b]\NP ,|,|, independently|RB|((S\NP)\(S\NP))/PP of|IN|PP/NP an|DT|conj in|NN|(((S\NP)\(S\NP))/(NP\NP))/NP synergy|NN|N with|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N ,|,|, the|DT|NP[nb]/N low|JJ|N/N basal|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV|NN|N/N LTR|NN|N observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N T|NN|N/N lymphocytes|NNS|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) understand|VB|(S[b]\NP)/NP the|DT|NP[nb]/N molecular|JJ|N/N bases|NNS|N for|IN|(NP\NP)/NP cytokine|NN|N/N redundancy|NN|N and|CC|conj pleiotropy|NN|N ,|,|, we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) compared|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N Stat|NN|N/N proteins|NNS|N activated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP peripheral|JJ|N/N blood|NN|N/N lymphocytes|NNS|N (|LRB|(NP\NP)/NP PBLs|NNS|N )|RRB|RRB by|IN|((S\NP)\(S\NP))/NP cytokines|NNS|N with|IN|((S\NP)\(S\NP))/NP shared|JJ|N/N and|CC|conj distinct|JJ|N/N actions|NNS|N .|.|.
Interleukin-2|NN|N (|LRB|(N\N)/N IL-2|NN|N )|RRB|RRB rapidly|RB|(S\NP)/(S\NP) activated|VBD|(S[dcl]\NP)/NP Stat5|NN|N in|IN|(NP\NP)/NP fresh|JJ|N/N PBL|NN|N ,|,|, and|CC|conj Stat3|NN|N and|CC|conj Stat5|NN|N in|IN|(NP\NP)/NP preactivated|JJ|N/N PBL|NN|N .|.|.
IL-7|NN|N and|CC|conj IL-15|NN|N induced|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N same|JJ|N/N complexes|NNS|N as|IN|(NP\NP)/NP IL-2|NN|N ,|,|, a|DT|NP[nb]/N feature|NN|N explained|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N existence|NN|N of|IN|(NP\NP)/NP similar|JJ|N/N tyrosine-phosphorylated|JJ|N/N motifs|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N cytoplasmic|JJ|N/N domains|NNS|N of|IN|(NP\NP)/NP IL-2R|NN|N/N beta|NN|N and|CC|conj IL-7R|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) can|MD|(S[dcl]\NP)/(S[b]\NP) serve|VB|(S[b]\NP)/PP as|IN|PP/NP docking|NN|N/N sites|NNS|N for|IN|(NP\NP)/NP Stat|NN|N/N proteins|NNS|N .|.|.
IL-13|NN|N Induced|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N same|JJ|N/N complexes|NNS|N as|IN|(NP\NP)/NP IL-4|NN|N ,|,|, a|DT|NP[nb]/N finding|NN|N explained|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP our|PRP$|NP[nb]/N studies|NNS|N implicating|VBG|((S[ng]\NP)/PP)/NP IL-4R|NN|N as|IN|PP/NP a|DT|NP[nb]/N shared|JJ|N/N component|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N receptors|NNS|N .|.|.
These|DT|NP[nb]/N studies|NNS|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] a|DT|NP[nb]/N single|JJ|N/N cytokine|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP different|JJ|N/N combinations|NNS|N of|IN|(NP\NP)/NP Stat|NN|N/N proteins|NNS|N under|IN|((S\NP)\(S\NP))/NP different|JJ|N/N physiological|JJ|N/N conditions|NNS|N ,|,|, and|CC|conj also|RB|(S\NP)/(S\NP) indicate|VBP|(S[dcl]\NP)/NP two|CD|N/N mechanisms|NNS|N by|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) distinct|JJ|N/N cytokines|NNS|N can|MD|(S[dcl]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N same|JJ|N/N Stat|NN|N/N protein|NN|N .|.|.
I|NN|N/N kappa|NN|N/N B-alpha|NN|N inhibits|VBZ|(S[dcl]\NP)/NP transcription|NN|N/N factor|NN|N NF-kappa|NN|N/N B|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) retaining|VBG|(S[ng]\NP)/NP it|PRP|NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cytoplasm|NN|N .|.|.
Various|JJ|N/N stimuli|NNS|N ,|,|, typically|RB|NP/NP those|DT|NP associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP stress|NN|N or|CC|conj pathogens|NNS|N ,|,|, rapidly|RB|(S\NP)/(S\NP) inactivate|VBP|(S[dcl]\NP)/NP I|NN|N/N kappa|NN|N/N B-alpha|NN|N .|.|.
This|DT|NP liberates|VBZ|(S[dcl]\NP)/NP NF-kappa|NN|N/N B|NN|N to|TO|(S[to]\NP)/(S[b]\NP) translocate|VB|(S[b]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N nucleus|NN|N and|CC|conj initiate|VB|(S[b]\NP)/NP transcription|NN|N of|IN|(NP\NP)/NP genes|NNS|N important|JJ|(S[adj]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N defense|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N organism|NN|N .|.|.
Activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N correlates|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP phosphorylation|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|N/N B-alpha|NN|N and|CC|conj requires|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N proteolysis|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N inhibitor|NN|N .|.|.
When|WRB|(S/S)/S[dcl] either|CC|NP/NP serine-32|NN|N or|CC|conj serine-36|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|N/N B-alpha|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) mutated|VBN|S[pss]\NP ,|,|, the|DT|NP[nb]/N protein|NN|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) undergo|VB|(S[b]\NP)/NP signal-induced|JJ|N/N phosphorylation|NN|N or|CC|conj degradation|NN|N ,|,|, and|CC|conj NF-kappa|NN|N/N B|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) be|VB|(S[b]\NP)/(S[pss]\NP) activated|VBN|S[pss]\NP .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] phosphorylation|NN|N at|IN|(NP\NP)/NP one|CD|N or|CC|conj both|DT|NP of|IN|(NP\NP)/NP these|DT|NP[nb]/N residues|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) critical|JJ|(S[adj]\NP)/PP for|IN|PP/NP activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N .|.|.
Erythropoietin|NN|N (|LRB|(NP\NP)/NP Epo|NN|N )|RRB|RRB ,|,|, the|DT|NP[nb]/N primary|JJ|N/N regulator|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N production|NN|N of|IN|(NP\NP)/NP erythroid|JJ|N/N cells|NNS|N ,|,|, acts|VBZ|S[dcl]\NP by|IN|((S\NP)\(S\NP))/(S[ng]\NP) binding|VBG|(S[ng]\NP)/PP to|TO|PP/NP a|DT|NP[nb]/N cell|NN|N/N surface|NN|N/N receptor|NN|N (|LRB|(NP\NP)/NP EpoR|NN|N )|RRB|RRB on|IN|(NP\NP)/NP erythroid|JJ|N/N progenitors|NNS|N .|.|.
We|PRP|NP used|VBD|((S[dcl]\NP)/(S[to]\NP))/NP deletion|NN|N/N analysis|NN|N and|CC|conj transfection|NN|N/N assays|NNS|N with|IN|(NP\NP)/NP reporter|NN|N/N gene|NN|N/N constructs|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) examine|VB|(S[b]\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N control|NN|N/N elements|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N 5'|JJ|N/N flanking|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N EpoR|NN|N/N gene|NN|N .|.|.
In|IN|(S/S)/NP erythroid|JJ|N/N cells|NNS|N most|JJS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) contained|VBN|(S[pss]\NP)/PP in|IN|PP/NP a|DT|NP[nb]/N 150|CD|(N/N)/(N/N) bp|NN|N/N promoter|NN|N/N fragment|NN|N with|IN|(NP\NP)/NP binding|VBG|N/N sites|NNS|N for|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N AP2|NN|N ,|,|, Sp1|NN|N and|CC|conj the|DT|NP[nb]/N erythroid-specific|JJ|N/N GATA-1|NN|N .|.|.
The|DT|NP[nb]/N 150|CD|N/N bp|NN|N/N hEpoR|NN|N/N promoter|NN|N exhibited|VBD|(S[dcl]\NP)/NP high|JJ|N/N and|CC|conj low|JJ|N/N activity|NN|N in|IN|(NP\NP)/NP erythroid|JJ|N/N OCIM1|NN|N and|CC|conj K562|NN|N/N cells|NNS|N ,|,|, respectively|RB|NP\NP ,|,|, reflecting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N high|JJ|N/N and|CC|conj low|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP constitutive|JJ|N/N hEpoR|NN|N/N expression|NN|N .|.|.
The|DT|NP[nb]/N GATA-1|NN|N/N and|CC|conj Sp1|NN|N/N binding|NN|N/N sites|NNS|N in|IN|(NP\NP)/NP this|DT|NP[nb]/N promoter|NN|N lacking|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N TATA|NN|N/N sequence|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) necessary|JJ|(S[adj]\NP)/PP for|IN|PP/NP a|DT|NP[nb]/N high|JJ|N/N level|NN|N of|IN|(NP\NP)/NP transcription|NN|N/N activation|NN|N .|.|.
Protein-DNA|JJ|N/N binding|NN|N/N studies|NNS|N suggested|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] Sp1|NN|N and|CC|conj two|CD|N/N other|JJ|N/N CCGCCC|NN|N/N binding|NN|N/N proteins|NNS|N from|IN|(NP\NP)/NP erythroid|JJ|N/N and|CC|conj non-erythroid|JJ|N/N cells|NNS|N could|MD|(S[dcl]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N Sp1|NN|N/N binding|NN|N/N motif|NN|N .|.|.
By|IN|(S/S)/(S[ng]\NP) increasing|VBG|(S[ng]\NP)/NP GATA-1|NN|N/N levels|NNS|N via|IN|((S\NP)\(S\NP))/NP co-transfection|NN|N ,|,|, we|PRP|NP were|VBD|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) transactivate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N hEpoR|NN|N/N promoter|NN|N in|IN|(NP\NP)/NP K562|NN|N/N cells|NNS|N and|CC|conj non-erythroid|JJ|N/N cells|NNS|N ,|,|, but|CC|conj not|RB|(NP\NP)/(NP\NP) in|IN|(NP\NP)/NP the|DT|NP[nb]/N highly|RB|(N/N)/(N/N) active|JJ|N/N OCIM1|NN|N/N cells|NNS|N ,|,|, although|IN|((S\NP)\(S\NP))/S[dcl] GATA-1|NN|N/N mRNA|NN|N/N levels|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) comparable|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP OCIM1|NN|N and|CC|conj K562|NN|N .|.|.
Interestingly|RB|S/S ,|,|, when|WRB|(S/S)/S[dcl] we|PRP|NP mutated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N Sp1|NN|N/N site|NN|N ,|,|, resulting|VBG|(S[ng]\NP)/PP in|IN|PP/NP a|DT|NP[nb]/N marked|JJ|N/N decrease|NN|N in|IN|(NP\NP)/NP hEpoR|NN|N/N promoter|NN|N/N activity|NN|N ,|,|, we|PRP|NP could|MD|(S[dcl]\NP)/(S[b]\NP) restore|VB|(S[b]\NP)/NP transactivation|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) increasing|VBG|(S[ng]\NP)/NP GATA-1|NN|N/N levels|NNS|N in|IN|(NP\NP)/NP OCIM1|NN|N/N cells|NNS|N .|.|.
These|DT|NP[nb]/N data|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] while|IN|(S/S)/S[dcl] GATA-1|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) transactivate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N EpoR|NN|N/N promoter|NN|N ,|,|, the|DT|NP[nb]/N level|NN|N of|IN|(NP\NP)/NP hEpoR|NN|N/N gene|NN|N/N expression|NN|N does|VBZ|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) depend|VB|(S[b]\NP)/PP on|IN|PP/NP GATA-1|NN|N alone|RB|NP\NP .|.|.
Rather|RB|S/S ,|,|, hEpoR|NN|N/N transcription|NN|N/N activity|NN|N depends|VBZ|(S[dcl]\NP)/PP on|IN|PP/NP coordination|NN|N between|IN|(NP\NP)/NP Sp1|NN|N and|CC|conj GATA-1|NN|N with|IN|(NP\NP)/NP other|JJ|N/N cell-specific|JJ|N/N factors|NNS|N ,|,|, including|VBG|(NP\NP)/NP possibly|RB|(N/N)/(N/N) other|JJ|N/N Sp1-like|JJ|N/N binding|NN|N/N proteins|NNS|N ,|,|, to|TO|(S[to]\NP)/(S[b]\NP) provide|VB|(S[b]\NP)/NP high|JJ|(N/N)/N level|NN|N ,|,|, tissue-specific|JJ|N/N expression|NN|N .|.|.
Chronic|JJ|N/N myelogenous|JJ|N/N leukemia|NN|N evolves|VBZ|(S[dcl]\NP)/NP in|IN|((S\NP)\(S\NP))/NP two|CD|N/N clinically|RB|(N/N)/(N/N) distinct|JJ|N/N stages|NNS|N :|:|: a|DT|NP[nb]/N chronic|JJ|N/N and|CC|conj a|DT|NP[nb]/N blast|NN|N/N crisis|NN|N/N phase|NN|N .|.|.
The|DT|NP[nb]/N molecular|JJ|N/N changes|NNS|N associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP chronic|JJ|N/N phase|NN|N to|TO|(NP\NP)/NP blast|NN|N/N crisis|NN|N/N transition|NN|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) largely|RB|(S[adj]\NP)/(S[adj]\NP) unknown|JJ|S[adj]\NP .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) identified|VBN|(S[pt]\NP)/NP a|DT|NP[nb]/N cDNA|NN|N/N clone|NN|N ,|,|, DR-nm23|NN|N ,|,|, differentially|RB|(S\NP)/(S\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N blast-crisis|JJ|N/N cDNA|NN|N/N library|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) has|VBZ|(S[dcl]\NP)/NP approximately|RB|(N/N)/(N/N) 70|CD|(N/N)/(N/N) %|NN|N/N sequence|NN|N/N similarity|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N putative|JJ|N/N metastatic|JJ|N/N suppressor|NN|N/N genes|NNS|N ,|,|, nm23-H1|NN|N and|CC|conj nm23-H2|NN|N .|.|.
The|DT|NP[nb]/N deduced|VBN|N/N amino|NN|(N/N)/(N/N) acid|NN|N/N sequence|NN|N/N similarity|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N proteins|NNS|N encoded|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP these|DT|NP[nb]/N two|CD|N/N latter|JJ|N/N genes|NNS|N is|VBZ|(S[dcl]\NP)/NP approximately|RB|(N/N)/(N/N) 65|CD|N/N %|NN|N and|CC|conj includes|VBZ|(S[dcl]\NP)/NP domains|NNS|N and|CC|conj amino|NN|(N/N)/(N/N) acid|NN|N/N residues|NNS|N (|LRB|(NP\NP)/NP the|DT|NP[nb]/N leucine|NN|N/N zipper-like|JJ|N/N and|CC|conj the|DT|NP[nb]/N RGD|NN|N/N domain|NN|N ,|,|, a|DT|NP[nb]/N serine|NN|N/N and|CC|conj a|DT|NP[nb]/N histidine|NN|N/N residue|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N NH2-|NN|N and|CC|conj in|IN|(NP\NP)/NP the|DT|NP[nb]/N COOH-terminal|JJ|N/N portion|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N protein|NN|N ,|,|, respectively|RB|NP\NP )|RRB|RRB postulated|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) important|JJ|(S[adj]\NP)/PP for|IN|PP/NP nm23|NN|N/N function|NN|N .|.|.
DR-nm23|NN|N/N mRNA|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) preferentially|RB|(S\NP)\(S\NP) expressed|VBN|(S[pss]\NP)/PP at|IN|PP/NP early|JJ|N/N stages|NNS|N of|IN|(NP\NP)/NP myeloid|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP highly|RB|(N/N)/(N/N) purified|VBN|N/N CD34+|JJ|N/N cells|NNS|N .|.|.
Its|PRP$|NP[nb]/N constitutive|JJ|N/N expression|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N myeloid|JJ|N/N precursor|NN|N/N 32Dc13|NN|N/N cell|NN|N/N line|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) growth-factor|NN|(S[adj]\NP)/(S[adj]\NP) dependent|JJ|S[adj]\NP for|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP proliferation|NN|N and|CC|conj differentiation|NN|N ,|,|, results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP inhibition|NN|N of|IN|(NP\NP)/NP granulocytic|JJ|N/N differentiation|NN|N induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP granulocyte|NN|N/N colony-stimulating|JJ|N/N factor|NN|N and|CC|conj causes|VBZ|(S[dcl]\NP)/NP apoptotic|JJ|N/N cell|NN|N/N death|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) consistent|JJ|(S[adj]\NP)/PP with|IN|PP/NP a|DT|NP[nb]/N role|NN|N for|IN|(NP\NP)/NP DR-nm23|NN|N in|IN|(NP\NP)/NP normal|JJ|N/N hematopoiesis|NN|N and|CC|conj raise|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N possibility|NN|N/S[em] that|IN|S[em]/S[dcl] its|PRP$|NP[nb]/N overexpression|NN|N contributes|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP differentiation|NN|N/N arrest|NN|N ,|,|, a|DT|NP[nb]/N feature|NN|N of|IN|(NP\NP)/NP blastic|JJ|N/N transformation|NN|N in|IN|(NP\NP)/NP chronic|JJ|N/N myelogenous|JJ|N/N leukemia|NN|N .|.|.
Expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IgG|NN|N/N Fc|NN|N/N receptor|NN|N type|NN|N\N I|CD|(N\N)\(N\N) (|LRB|(NP\NP)/NP Fc|NN|N/N gamma|NN|N/N RI|NN|N )|RRB|RRB on|IN|(NP\NP)/NP myeloid|JJ|N/N cells|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) dramatically|RB|(S\NP)\(S\NP) increased|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP treatment|NN|N with|IN|(NP\NP)/NP interferon-gamma|NN|N (|LRB|(N\N)/N IFN-gamma|NN|N )|RRB|RRB .|.|.
We|PRP|NP observed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] Fc|NN|N/N gamma|NN|N/N RI|NN|N/N transcript|NN|N/N levels|NNS|N in|IN|(NP\NP)/NP monoblast-like|JJ|N/N U937|NN|N/N cells|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) elevated|VBN|S[pss]\NP within|IN|((S\NP)\(S\NP))/NP 3|CD|N/N hr|NN|N and|CC|conj peaked|VBD|S[dcl]\NP 12|CD|(((S\NP)\(S\NP))/((S\NP)\(S\NP)))/(((S\NP)\(S\NP))/((S\NP)\(S\NP))) hr|NN|((S\NP)\(S\NP))/((S\NP)\(S\NP)) after|IN|((S\NP)\(S\NP))/NP exposure|NN|N to|TO|(NP\NP)/NP IFN-gamma|NN|N .|.|.
Treatment|NN|N of|IN|(NP\NP)/NP U937|NN|N with|IN|(NP\NP)/NP IFN-gamma|NN|N for|IN|(NP\NP)/NP 9|CD|N/N hr|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP cycloheximide|NN|N led|VBD|(S[dcl]\NP)/PP to|TO|PP/NP super-induction|NN|N of|IN|(NP\NP)/NP Fc|NN|N/N gamma|NN|N/N RI|NN|N/N expression|NN|N .|.|.
Nuclear|JJ|N/N run-on|JJ|N/N analysis|NN|N revealed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N rate|NN|N of|IN|(NP\NP)/NP Fc|NN|N/N gamma|NN|N/N RI|NN|N/N transcription|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) increased|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP IFN-gamma|NN|N .|.|.
Genomic|JJ|N/N sequence|NN|N upstream|JJ|(S[adj]\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N Fc|NN|N/N gamma|NN|N/N RIC|NN|N/N gene|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) cloned|VBN|S[pss]\NP and|CC|conj subjected|VBN|(S[pss]\NP)/PP to|TO|PP/NP primer|NN|N/N extension|NN|N/N analysis|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) demonstrated|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N single|JJ|N/N transcription|NN|N/N initiation|NN|N/N site|NN|N without|IN|(NP\NP)/NP a|DT|NP[nb]/N TATA|NN|N/N box|NN|N .|.|.
Transient|JJ|N/N transfections|NNS|N of|IN|(NP\NP)/NP CAT|NN|N/N reporter|NN|N/N gene|NN|N/N constructs|NNS|N containing|VBG|(S[ng]\NP)/NP various|JJ|N/N Fc|NN|N/N gamma|NN|N/N RIC|NN|N/N promoter|NN|N/N sequences|NNS|N into|IN|(NP\NP)/NP U937|NN|N/N cells|NNS|N revealed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] a|DT|NP[nb]/N 20-bp|JJ|N/N region|NN|N surrounding|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N start|NN|N/N site|NN|N (|LRB|(NP\NP)/NP -7|CD|N to|TO|(NP\NP)/NP +13|CD|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[adj]\NP) capable|JJ|(S[adj]\NP)/PP of|IN|PP/(S[ng]\NP) mediating|VBG|(S[ng]\NP)/NP transcription|NN|N/N initiation|NN|N and|CC|conj that|IN|S[em]/S[dcl] an|DT|NP[nb]/N IFN-gamma|NN|N/N responsive|JJ|N/N element|NN|N (|LRB|(N\N)/N GIRE|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[adj]\NP) present|JJ|S[adj]\NP within|IN|((S\NP)\(S\NP))/NP 74|CD|N/N bp|NN|N upstream|JJ|(S[adj]\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N transcription|NN|N/N initiation|NN|N/N site|NN|N .|.|.
A|DT|NP[nb]/N 17-bp|JJ|N/N sequence|NN|N between|IN|(NP\NP)/NP positions|NNS|N -51|CD|N and|CC|conj -35|CD|N conferred|VBD|(S[dcl]\NP)/NP IFN-gamma|NN|N/N responsiveness|NN|N on|IN|(NP\NP)/NP a|DT|NP[nb]/N heterologous|JJ|N/N promoter|NN|N .|.|.
Double-stranded|JJ|N/N GIRE|NN|N/N sequence|NN|N ,|,|, but|CC|conj not|RB|NP/NP a|DT|NP[nb]/N scrambled|VBN|N/N sequence|NN|N ,|,|, was|VBD|(S[dcl]\NP)/(S[pss]\NP) specifically|RB|(S\NP)\(S\NP) bound|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP nuclear|JJ|N/N proteins|NNS|N from|IN|(NP\NP)/NP IFN-gamma|NN|N/N treated|JJ|N/N U937|NN|N/N cells|NNS|N .|.|.
Gel|NN|N/N shift|NN|N/N experiments|NNS|N further|RB|(S\NP)/(S\NP) showed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N STAT1|NN|N/N alpha|NN|N/N protein|NN|N bound|VBD|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N Fc|NN|N/N gamma|NN|N/N RIC|NN|N/N GIRE|NN|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP IFN-gamma|NN|N/N treatment|NN|N of|IN|(NP\NP)/NP U937|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N Fc|NN|N/N gamma|NN|N/N RIC|NN|N/N GIRE|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) homologous|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N IFN-gamma|NN|N/N activation|NN|N/N sequence|NN|N (|LRB|(NP\NP)/NP GAS|NN|N )|RRB|RRB of|IN|(NP\NP)/NP the|DT|NP[nb]/N guanylate|NN|N/N binding|NN|N/N protein|NN|N and|CC|conj to|TO|PP/NP X|NN|N/N box|NN|N/N elements|NNS|N of|IN|(NP\NP)/NP class|NN|N/N II|CD|(N/N)\(N/N) MHC|NN|N/N genes|NNS|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] transcriptional|JJ|N/N regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Fc|NN|N/N gamma|NN|N/N RIC|NN|N/N gene|NN|N by|IN|(NP\NP)/NP IFN-gamma|NN|N involves|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N binding|NN|N of|IN|(NP\NP)/NP STAT1|NN|N/N alpha|NN|N to|TO|(NP\NP)/NP a|DT|NP[nb]/N 17-bp|JJ|N/N GAS|NN|N/N homology|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N proximal|JJ|N/N promoter|NN|N .|.|.
Human|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N lymphotropic|JJ|N/N virus|NN|N I|NN|N\N (|LRB|(NP\NP)/NP HTLV-I|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N etiological|JJ|N/N agent|NN|N for|IN|(NP\NP)/NP adult|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N leukemia|NN|N and|CC|conj tropical|JJ|N/N spastic|JJ|N/N paraparesis|NN|N (|LRB|(NP\NP)/(S[pss]\NP) also|RB|(S\NP)/(S\NP) termed|VBN|(S[pss]\NP)/NP HTLV-I-associated|JJ|N/N myelopathy|NN|N )|RRB|RRB .|.|.
HTLV-I-infected|JJ|N/N peripheral|JJ|N/N blood|NN|N/N T|NN|N/N cells|NNS|N exhibit|VBP|(S[dcl]\NP)/NP an|DT|NP[nb]/N initial|JJ|N/N phase|NN|N of|IN|(NP\NP)/NP interleukin-2|NN|(N/N)/(N/N) (|LRB|(((N/N)/(N/N))\((N/N)/(N/N)))/N IL-2|NN|N )|RRB|RRB -dependent|JJ|N/N growth|NN|N ;|:|; over|IN|(S/S)/NP time|NN|N ,|,|, by|IN|(S/S)/NP an|DT|NP[nb]/N unknown|JJ|N/N mechanism|NN|N ,|,|, the|DT|NP[nb]/N cells|NNS|N become|VBP|(S[dcl]\NP)/(S[adj]\NP) IL-2-independent|JJ|S[adj]\NP .|.|.
Whereas|IN|(S/S)/S[dcl] the|DT|NP[nb]/N Jak|NN|N/N kinases|NNS|N Jak1|NN|N and|CC|conj Jak3|NN|N and|CC|conj the|DT|NP[nb]/N signal|NN|N/N transducer|NN|N and|CC|conj activator|NN|N of|IN|(NP\NP)/NP transcription|NN|N/N proteins|NNS|N Stat3|NN|N and|CC|conj Stat5|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) activated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N T|NN|N/N cells|NNS|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP IL-2|NN|N ,|,|, this|DT|NP[nb]/N signaling|NN|N/N pathway|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) constitutively|RB|(S\NP)\(S\NP) activated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP HTLV-I-transformed|JJ|N/N cells|NNS|N .|.|.
In|IN|(S/S)/NP HTLV-I-infected|JJ|N/N cord|NN|N/N blood|NN|N/N lymphocytes|NNS|N ,|,|, the|DT|NP[nb]/N transition|NN|N from|IN|(NP\NP)/NP IL-2-dependent|JJ|N/N to|TO|((N/N)\(N/N))/(N/N) IL-2-independent|JJ|N/N growth|NN|N correlated|VBD|(S[dcl]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N acquisition|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N constitutively|RB|(N/N)/(N/N) activated|JJ|N/N Jak-STAT|JJ|N/N pathway|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) suggests|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] this|DT|NP[nb]/N pathway|NN|N participates|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP HTLV-I-mediated|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N transformation|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) test|VB|(S[b]\NP)/NP the|DT|NP[nb]/N hypothesis|NN|N/S[em] that|IN|S[em]/S[dcl] nitric|JJ|N/N oxide|NN|N (|LRB|(N\N)/N NO|NN|N )|RRB|RRB limits|VBZ|(S[dcl]\NP)/NP endothelial|JJ|N/N activation|NN|N ,|,|, we|PRP|NP treated|VBD|(S[dcl]\NP)/NP cytokine-stimulated|JJ|N/N human|JJ|N/N saphenous|JJ|N/N vein|NN|N/N endothelial|JJ|N/N cells|NNS|N with|IN|(NP\NP)/NP several|JJ|N/N NO|NN|N/N donors|NNS|N and|CC|conj assessed|VBD|(S[dcl]\NP)/NP their|PRP$|NP[nb]/N effects|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N inducible|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP vascular|JJ|N/N cell|NN|N/N adhesion|NN|N/N molecule-1|NN|N (|LRB|(NP\NP)/NP VCAM-1|NN|N )|RRB|RRB .|.|.
In|IN|(S/S)/NP a|DT|NP[nb]/N concentration-dependent|JJ|N/N manner|NN|N ,|,|, NO|NN|N inhibited|VBD|(S[dcl]\NP)/NP interleukin|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL|NN|N/N )|RRB|RRB -1|CD|(N/N)\(N/N) alpha-stimulated|JJ|N/N VCAM-1|NN|N/N expression|NN|N by|IN|((S\NP)\(S\NP))/NP 35-55|CD|N/N %|NN|N as|IN|(NP\NP)/(S[pss]\NP) determined|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP cell|NN|N/N surface|NN|N/N enzyme|NN|N/N immunoassays|NNS|N and|CC|conj flow|NN|N/N cytometry|NN|N .|.|.
This|DT|NP[nb]/N inhibition|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) paralleled|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP reduced|VBN|N/N monocyte|NN|N/N adhesion|NN|N to|TO|(NP\NP)/NP endothelial|JJ|N/N monolayers|NNS|N in|IN|(NP\NP)/NP nonstatic|JJ|N/N assays|NNS|N ,|,|, was|VBD|(S[dcl]\NP)/(S[adj]\NP) unaffected|JJ|(S[adj]\NP)/PP by|IN|PP/NP cGMP|NN|N/N analogues|NNS|N ,|,|, and|CC|conj was|VBD|(S[dcl]\NP)/(S[adj]\NP) quantitatively|RB|(S[adj]\NP)/(S[adj]\NP) similar|JJ|S[adj]\NP after|IN|((S\NP)\(S\NP))/NP stimulation|NN|N by|IN|((S\NP)\(S\NP))/NP either|CC|NP/NP IL-1|NN|N/N alpha|NN|N ,|,|, IL-1|NN|N/N beta|NN|N ,|,|, IL-4|NN|N ,|,|, tumor|NN|N/N necrosis|NN|N/N factor|NN|N (|LRB|(NP\NP)/NP TNF|NN|N/N alpha|NN|N )|RRB|RRB ,|,|, or|CC|conj bacterial|JJ|N/N lipopolysaccharide|NN|N .|.|.
NO|NN|N also|RB|(S\NP)/(S\NP) decreased|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N endothelial|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP other|JJ|N/N leukocyte|NN|N/N adhesion|NN|N/N molecules|NNS|N (|LRB|(NP\NP)/NP E-selectin|NN|N and|CC|conj to|TO|(NP\NP)/NP a|DT|NP[nb]/N lesser|JJR|N/N extent|NN|N ,|,|, intercellular|JJ|N/N adhesion|NN|N/N molecule-1|NN|N )|RRB|RRB and|CC|conj secretable|JJ|N/N cytokines|NNS|N (|LRB|(NP\NP)/NP IL-6|NN|N and|CC|conj IL-8|NN|N )|RRB|RRB .|.|.
Inhibition|NN|N of|IN|(NP\NP)/NP endogenous|JJ|N/N NO|NN|N/N production|NN|N by|IN|(NP\NP)/NP L-N-monomethyl-arginine|NN|N also|RB|(S\NP)/(S\NP) induced|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP VCAM-1|NN|N ,|,|, but|CC|conj did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) augment|VB|(S[b]\NP)/NP cytokine-induced|JJ|N/N VCAM-1|NN|N/N expression|NN|N .|.|.
Nuclear|JJ|N/N run-on|JJ|N/N assays|NNS|N ,|,|, transfection|NN|N/N studies|NNS|N using|VBG|(S[ng]\NP)/NP various|JJ|N/N VCAM-1|NN|N/N promoter|NN|N/N reporter|NN|N/N gene|NN|N/N constructs|NNS|N ,|,|, and|CC|conj electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] NO|NN|N represses|VBZ|(S[dcl]\NP)/NP VCAM-1|NN|N/N gene|NN|N/N transcription|NN|N ,|,|, in|IN|((S\NP)\(S\NP))/NP part|NN|N ,|,|, by|IN|((S\NP)\(S\NP))/(S[ng]\NP) inhibiting|VBG|(S[ng]\NP)/NP NF-kappa|NN|N/N B|NN|N .|.|.
We|PRP|NP propose|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] NO|NN|N 's|POS|(NP[nb]/N)\NP ability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) limit|VB|(S[b]\NP)/NP endothelial|JJ|N/N activation|NN|N and|CC|conj inhibit|VB|(S[b]\NP)/NP monocyte|NN|N/N adhesion|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) contribute|VB|(S[b]\NP)/PP to|TO|PP/NP some|DT|NP of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N antiatherogenic|JJ|N/N and|CC|conj antiinflammatory|JJ|N/N properties|NNS|N within|IN|(NP\NP)/NP the|DT|NP[nb]/N vessel|NN|N/N wall|NN|N .|.|.
Murine|JJ|N/N macrophage|NN|N/N inflammatory|JJ|N/N protein|NN|N/N 1|CD|N/N alpha|NN|N (|LRB|(N\N)/N MIP-1|NN|N/N alpha|NN|N )|RRB|RRB and|CC|conj its|PRP$|NP[nb]/N human|JJ|N/N equivalent|NN|N (|LRB|(NP\NP)/NP GOS19|NN|N ,|,|, LD78|NN|N ,|,|, or|CC|conj AT464|NN|N )|RRB|RRB are|VBP|(S[dcl]\NP)/NP members|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N -C-C|NN|N/N family|NN|N of|IN|(NP\NP)/NP low-molecular-weight|JJ|N/N chemokines|NNS|N .|.|.
Secreted|VBN|(S[pss]\NP)/PP from|IN|PP/NP activated|VBN|N/N T|NN|N/N cells|NNS|N and|CC|conj macrophages|NNS|N ,|,|, bone|NN|N/N marrow-derived|JJ|N/N MIP-1|NN|N/N alpha/GOS19|NN|N inhibits|VBZ|(S[dcl]\NP)/NP primitive|JJ|N/N hematopoietic|JJ|N/N stem|NN|N/N cells|NNS|N and|CC|conj appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N homeostatic|JJ|N/N control|NN|N of|IN|(NP\NP)/NP stem|NN|(N/N)/(N/N) cell|NN|N/N proliferation|NN|N .|.|.
It|PRP|NP also|RB|(S\NP)/(S\NP) induces|VBZ|(S[dcl]\NP)/NP chemotaxis|NN|N and|CC|conj inflammatory|JJ|N/N responses|NNS|N in|IN|(NP\NP)/NP mature|JJ|N/N cell|NN|N/N types|NNS|N .|.|.
Therefore|RB|S/S ,|,|, it|PRP|NP[expl] is|VBZ|(S[dcl]\NP[expl])/(S[adj]\NP) important|JJ|S[adj]\NP to|TO|(S[to]\NP)/(S[b]\NP) understand|VB|(S[b]\NP)/NP the|DT|NP[nb]/N mechanisms|NNS|N which|WDT|(NP\NP)/(S[dcl]\NP) control|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP MIP-1|NN|N/N alpha/GOS19|NN|N .|.|.
Previous|JJ|N/N work|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] in|IN|(S/S)/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N ,|,|, a|DT|NP[nb]/N set|NN|N of|IN|(NP\NP)/NP widely|RB|(N/N)/(N/N) expressed|VBN|N/N transcription|NN|N/N factors|NNS|N (|LRB|(NP\NP)/NP the|DT|NP[nb]/N ICK-1|NN|N/N family|NN|N )|RRB|RRB affect|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N GOS19|NN|N/N promoter|NN|N .|.|.
One|CD|N/N member|NN|N ,|,|, ICK-1A|NN|N ,|,|, behaves|VBZ|(S[dcl]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N strong|JJ|N/N negative|JJ|N/N regulator|NN|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N communication|NN|N ,|,|, we|PRP|NP provide|VBP|(S[dcl]\NP)/NP evidence|NN|N/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N pathway|NN|N of|IN|(NP\NP)/NP induction|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N macrophage|NN|N/N cell|NN|N/N line|NN|N U937|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) different|JJ|(S[adj]\NP)/PP from|IN|PP/NP that|DT|NP in|IN|(NP\NP)/NP Jurkat|NN|N/N cells|NNS|N .|.|.
Furthermore|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N ICK-1|NN|N/N binding|NN|N/N site|NN|N does|VBZ|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) confer|VB|(S[b]\NP)/NP negative|JJ|N/N regulation|NN|N in|IN|(NP\NP)/NP U937|NN|N/N cells|NNS|N .|.|.
We|PRP|NP provide|VBP|(S[dcl]\NP)/NP evidence|NN|N for|IN|(NP\NP)/NP an|DT|NP[nb]/N additional|JJ|N/N binding|VBG|N/N site|NN|N ,|,|, the|DT|NP[nb]/N MIP-1|NN|N/N alpha|NN|N/N nuclear|JJ|N/N protein|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) MNP|NN|N/N )|RRB|RRB site|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) overlaps|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N ICK-1|NN|N/N site|NN|N .|.|.
Interaction|NN|N of|IN|(NP\NP)/NP nuclear|JJ|N/N extracts|NNS|N from|IN|(NP\NP)/NP various|JJ|N/N cell|NN|N/N lines|NNS|N and|CC|conj tissue|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N MNP|NN|N/N site|NN|N leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N formation|NN|N of|IN|(NP\NP)/NP fast-migrating|JJ|N/N protein-DNA|JJ|N/N complexes|NNS|N with|IN|(NP\NP)/NP similar|JJ|N/N but|CC|conj distinct|JJ|N/N electrophoretic|JJ|N/N mobilities|NNS|N .|.|.
A|DT|NP[nb]/N mutation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N MNP|NN|N/N site|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) does|VBZ|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) abrogate|VB|(S[b]\NP)/NP ICK-1|NN|N/N binding|NN|N inactivates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N GOS19.1|NN|N/N promoter|NN|N in|IN|(NP\NP)/NP U937|NN|N/N cells|NNS|N and|CC|conj reduces|VBZ|(S[dcl]\NP)/NP its|PRP$|NP[nb]/N activity|NN|N by|IN|((S\NP)\(S\NP))/(S[adj]\NP) fourfold|RB|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP Jurkat|NN|N/N cells|NNS|N .|.|.
We|PRP|NP propose|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N MNP|NN|N/N protein|NN|N (|LRB|(NP\NP)/NP s|NNS|N )|RRB|RRB binding|VBG|S[ng]\NP at|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N MNP|NN|N/N site|NN|N constitutes|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N novel|JJ|N/N transcription|NN|N/N factor|NN|N (|LRB|(NP\NP)/NP s|NNS|N )|RRB|RRB expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP hematopoietic|JJ|N/N cells|NNS|N .|.|.
Toremifene|NN|N exerts|VBZ|(S[dcl]\NP)/NP multiple|JJ|N/N and|CC|conj varied|JJ|N/N effects|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N gene|NN|N/N expression|NN|N of|IN|(NP\NP)/NP human|JJ|N/N peripheral|JJ|N/N mononuclear|JJ|N/N cells|NNS|N .|.|.
After|IN|(S/S)/NP short-term|JJ|N/N ,|,|, in|FW|(N/N)/(N/N) vitro|FW|N/N exposure|NN|N to|TO|(NP\NP)/NP therapeutical|JJ|N/N levels|NNS|N ,|,|, distinct|JJ|N/N changes|NNS|N in|IN|(NP\NP)/NP P-glycoprotein|NN|N ,|,|, steroid|NN|N/N receptors|NNS|N ,|,|, p53|NN|N and|CC|conj Bcl-2|NN|N/N expression|NN|N take|VBP|(S[dcl]\NP)/NP place|NN|N .|.|.
In|IN|(S/S)/NP view|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N increasing|VBG|N/N use|NN|N of|IN|(NP\NP)/NP antiestrogens|NNS|N in|IN|(NP\NP)/NP cancer|NN|N/N therapy|NN|N and|CC|conj prevention|NN|N ,|,|, there|EX|NP[thr] is|VBZ|(S[dcl]\NP[thr])/NP obvious|JJ|N/N merit|NN|N in|IN|(NP\NP)/NP long-term|JJ|N/N in|FW|(N/N)/(N/N) vivo|FW|N/N studies|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) conducted|VBN|S[pss]\NP .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N interaction|NN|N of|IN|(NP\NP)/NP interleukin|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL|NN|N/N )|RRB|RRB -5|CD|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N receptor|NN|N activates|VBZ|(S[dcl]\NP)/NP Lyn|NN|N/N tyrosine|NN|N/N kinase|NN|N within|IN|((S\NP)\(S\NP))/NP 1|CD|N/N min|NN|N and|CC|conj Jak2|NN|N/N tyrosine|NN|N/N kinase|NN|N within|IN|((S\NP)\(S\NP))/NP 1-3|CD|N/N min|NN|N .|.|.
IL-5|NN|N also|RB|(S\NP)/(S\NP) stimulates|VBZ|(S[dcl]\NP)/NP GTP|NN|N binding|VBG|(S[ng]\NP)/PP to|TO|PP/NP p21ras|NN|N .|.|.
The|DT|NP[nb]/N signal|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) subsequently|RB|(S\NP)\(S\NP) propagated|VBN|(S[pss]\NP)/PP through|IN|PP/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP Raf-1|NN|N/N ,|,|, MEK|NN|N/N ,|,|, and|CC|conj MAP|NN|N/N kinases|NNS|N as|IN|((S\NP)\(S\NP))/(S[pss]\NP) shown|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP their|PRP$|NP[nb]/N increased|VBN|N/N autophosphorylation|NN|N in|FW|(NP\NP)/NP vitro|FW|N and|CC|conj phosphorylation|NN|N in|FW|(NP\NP)/NP situ|FW|N .|.|.
Jak2|NN|N/N kinase|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) phosphorylate|VB|(S[b]\NP)/NP STAT|NN|N/N nuclear|JJ|N/N proteins|NNS|N .|.|.
The|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP STAT|NN|N/N nuclear|JJ|N/N factors|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) studied|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N using|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N gamma|NN|N/N activation|NN|N/N site|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) GAS|NN|N/N )|RRB|RRB probe|NN|N .|.|.
We|PRP|NP found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-5|NN|N induces|VBZ|(S[dcl]\NP)/NP two|CD|N/N GAS-binding|JJ|N/N proteins|NNS|N in|IN|((S\NP)\(S\NP))/NP eosinophils|NNS|N ,|,|, one|CD|NP of|IN|(NP\NP)/NP which|WDT|((NP\NP)/(S[dcl]\NP))\(NP/NP) is|VBZ|(S[dcl]\NP)/NP STAT1|NN|N .|.|.
We|PRP|NP conclude|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-5|NN|(N/N)/(N/N) induced|JJ|N/N signals|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) propagated|VBN|(S[pss]\NP)/PP through|IN|PP/NP two|CD|N/N distinct|JJ|N/N pathways|NNS|N :|:|: (|LRB|(N\N)/N 1|LS|N )|RRB|RRB Lyn|NN|N -->|TO|(NP\NP)/NP Ras|NN|N -->|TO|(NP\NP)/NP Raf-1|NN|N -->|TO|(NP\NP)/NP MEK|NN|N -->|TO|(NP\NP)/NP MAP|NN|N/N kinase|NN|N and|CC|conj (|LRB|(N\N)/N 2|LS|N )|RRB|RRB Jak2|NN|N -->|TO|(NP\NP)/NP STAT1|NN|N .|.|.
The|DT|NP[nb]/N IE2|NN|N/N gene|NN|N/N product|NN|N of|IN|(NP\NP)/NP human|JJ|N/N cytomegalovirus|NN|N (|LRB|(N\N)/N HCMV|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/NP one|CD|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N few|JJ|N/N viral|JJ|N/N regulatory|JJ|N/N proteins|NNS|N expressed|VBN|S[pss]\NP immediately|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) upon|IN|((S\NP)\(S\NP))/NP infection|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N host|NN|N/N cell|NN|N .|.|.
It|PRP|NP is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N potent|JJ|N/N transcriptional|JJ|N/N activator|NN|N of|IN|(NP\NP)/NP many|JJ|N/N viral|JJ|N/N and|CC|conj cellular|JJ|N/N promoters|NNS|N .|.|.
We|PRP|NP found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N retinoblastoma|NN|N/N susceptibility|NN|N/N gene|NN|N/N product|NN|N (|LRB|(NP\NP)/NP Rb|NN|N )|RRB|RRB dramatically|RB|(S\NP)/(S\NP) suppressed|VBD|(S[dcl]\NP)/NP this|DT|NP[nb]/N IE2|NN|N/N transactivation|NN|N of|IN|(NP\NP)/NP various|JJ|N/N promoters|NNS|N .|.|.
However|RB|S/S ,|,|, unlike|IN|(S/S)/NP another|DT|NP[nb]/N tumor|NN|N/N suppressor|NN|N/N protein|NN|N ,|,|, p53|NN|N ,|,|, Rb|NN|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) have|VB|(S[b]\NP)/NP any|DT|NP[nb]/N significant|JJ|N/N effect|NN|N on|IN|(NP\NP)/NP basal|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP transcription|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] Rb|NN|N specifically|RB|(S\NP)/(S\NP) interacts|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP IE2|NN|N rather|RB|conj/conj than|IN|conj other|JJ|N/N cellular|JJ|N/N factors|NNS|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N general|JJ|N/N transcription|NN|N/N machinery|NN|N .|.|.
We|PRP|NP found|VBD|(S[dcl]\NP)/S[em] by|IN|((S\NP)\(S\NP))/NP protein-affinity|JJ|N/N chromatography|NN|N that|IN|S[em]/S[dcl] Rb|NN|N in|IN|(NP\NP)/NP nuclear|JJ|N/N extracts|NNS|N or|CC|conj produced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP in|FW|(N/N)/(N/N) vitro|FW|N/N translation|NN|N directly|RB|(S\NP)/(S\NP) bound|VBD|(S[dcl]\NP)/PP to|TO|PP/NP IE2|NN|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] Rb|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) regulate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N life|NN|N/N cycle|NN|N of|IN|(NP\NP)/NP HCMV|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) endemic|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N human|JJ|N/N population|NN|N .|.|.
Furthermore|RB|S/S ,|,|, these|DT|NP[nb]/N data|NNS|N may|MD|(S[dcl]\NP)/(S[b]\NP) provide|VB|(S[b]\NP)/NP new|JJ|N/N insights|NNS|N into|IN|(NP\NP)/NP the|DT|NP[nb]/N slow|JJ|N/N rate|NN|N of|IN|(NP\NP)/NP HCMV|NN|N/N DNA|NN|N/N replication|NN|N in|IN|(NP\NP)/NP cells|NNS|N and|CC|conj the|DT|NP[nb]/N possible|JJ|N/N involvement|NN|N of|IN|(NP\NP)/NP HCMV|NN|N in|IN|(NP\NP)/NP tumorigenesis|NN|N .|.|.
Expression|NN|N of|IN|(NP\NP)/NP nucleoside|NN|N/N diphosphate|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) NDP|NN|N/N )|RRB|RRB kinase|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) homologous|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N nm23|NN|N/N gene|NN|N/N product|NN|N in|IN|(NP\NP)/NP a|DT|NP[nb]/N variety|NN|N of|IN|(NP\NP)/NP species|NNS|N ,|,|, has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) found|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) inversely|RB|(S\NP)/(S\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP metastatic|JJ|N/N potential|NN|N .|.|.
However|RB|S/S ,|,|, the|DT|NP[nb]/N relationship|NN|N remains|VBZ|(S[dcl]\NP)/(S[adj]\NP) controversial|JJ|S[adj]\NP according|VBG|((S\NP)\(S\NP))/PP to|TO|PP/NP the|DT|NP[nb]/N tumor|NN|N/N cell|NN|N/N types|NNS|N and|CC|conj experimental|JJ|N/N system|NN|N ,|,|, with|IN|((S\NP)\(S\NP))/NP conflicting|VBG|N/N results|NNS|N from|IN|(NP\NP)/NP different|JJ|N/N research|NN|N/N groups|NNS|N .|.|.
In|IN|((S/S)/(S[to]\NP))/NP order|NN|N to|TO|(S[to]\NP)/(S[b]\NP) determine|VB|(S[b]\NP)/S[qem] whether|IN|S[qem]/S[dcl] NDP|NN|N/N kinase|NN|N/N expression|NN|N serves|VBZ|(S[dcl]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N marker|NN|N for|IN|(NP\NP)/NP metastatic|JJ|N/N potential|NN|N in|IN|(NP\NP)/NP human|JJ|N/N skin|NN|N/N cancer|NN|N ,|,|, we|PRP|NP assessed|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N levels|NNS|N of|IN|(NP\NP)/NP NDP|NN|N/N kinase|NN|N/N expression|NN|N in|IN|(NP\NP)/NP 9|CD|N/N keratoacanthomas|NNS|N (|LRB|(NP\NP)/NP KAs|NNS|N )|RRB|RRB ,|,|, 26|CD|N/N squamous|JJ|N/N cell|NN|N/N carcinomas|NNS|N (|LRB|(NP\NP)/NP SCCs|NNS|N )|RRB|RRB ,|,|, and|CC|conj 25|CD|N/N basal|JJ|N/N cell|NN|N/N carcinomas|NNS|N (|LRB|(NP\NP)/NP BCCs|NNS|N )|RRB|RRB using|VBG|(S[ng]\NP)/NP immunohistochemistry|NN|N .|.|.
The|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP NDP|NN|N/N kinase|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) intense|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP KA|NN|N and|CC|conj SCC|NN|N compared|VBN|((S\NP)\(S\NP))/PP with|IN|PP/NP BCC|NN|N .|.|.
However|RB|S/S ,|,|, the|DT|NP[nb]/N difference|NN|N of|IN|(NP\NP)/NP NDP|NN|N/N kinase|NN|N/N expression|NN|N between|IN|(NP\NP)/NP KA|NN|N and|CC|conj SCC|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) statistically|RB|(S[adj]\NP)/(S[adj]\NP) significant|JJ|S[adj]\NP .|.|.
And|CC|S/S there|EX|NP[thr] was|VBD|(S[dcl]\NP[thr])/NP no|DT|NP[nb]/N statistically|RB|(N/N)/(N/N) significant|JJ|N/N difference|NN|N in|IN|(NP\NP)/NP NDP|NN|N/N kinase|NN|N/N expression|NN|N between|IN|(NP\NP)/NP SCC|NN|N with|IN|(NP\NP)/NP metastasis|NN|N and|CC|conj SCC|NN|N without|IN|(NP\NP)/NP metastasis|NN|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N contradict|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N hypothesis|NN|N concerning|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N possible|JJ|N/N role|NN|N of|IN|(NP\NP)/NP nm23|NN|N/N gene|NN|N as|IN|(NP\NP)/NP a|DT|NP[nb]/N metastatic|JJ|N/N suppressor|NN|N/N gene|NN|N in|IN|(NP\NP)/NP human|JJ|N/N skin|NN|N/N cancer|NN|N .|.|.
The|DT|NP[nb]/N mechanism|NN|N of|IN|(NP\NP)/NP overexpression|NN|N in|IN|(NP\NP)/NP various|JJ|N/N tumor|NN|N/N cell|NN|N/N types|NNS|N and|CC|conj its|PRP$|NP[nb]/N biological|JJ|N/N significance|NN|N in|IN|(NP\NP)/NP cutaneous|JJ|N/N carcinogenesis|NN|N remain|VB|S[b]\NP to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) determined|VBN|S[pss]\NP .|.|.
The|DT|NP[nb]/N major|JJ|N/N histocompatibility|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) MHC|NN|N/N )|RRB|RRB class|NN|N/N II|CD|(N/N)\(N/N) genes|NNS|N encode|VBP|(S[dcl]\NP)/NP cell|NN|N/N surface|NN|N/N proteins|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) bind|VBP|(S[dcl]\NP)/NP antigenic|JJ|N/N peptide|NN|N for|IN|((S\NP)\(S\NP))/NP presentation|NN|N to|TO|(NP\NP)/NP T-cells|NNS|N .|.|.
The|DT|NP[nb]/N class|NN|N/N II|CD|(N/N)\(N/N) proteins|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|(S[pss]\NP)/PP constitutively|RB|(S\NP)\(S\NP) on|IN|PP/NP B-cells|NNS|N and|CC|conj EBV-|NN|N/N transformed|JJ|N/N B-cells|NNS|N ,|,|, and|CC|conj are|VBP|(S[dcl]\NP)/(S[adj]\NP) inducible|JJ|S[adj]\NP by|IN|((S[adj]\NP)\(S[adj]\NP))/NP IFN-gamma|NN|N on|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N wide|JJ|N/N variety|NN|N of|IN|(NP\NP)/NP cell|NN|N/N types|NNS|N .|.|.
Retinoblastoma|NN|N/N protein|NN|N (|LRB|(NP\NP)/NP RB|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N tumor|NN|N/N suppressor|NN|N and|CC|conj functions|VBZ|(S[dcl]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N transcriptional|JJ|N/N repressor|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) binding|VBG|(S[ng]\NP)/NP and|CC|conj inactivating|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N transactivator|NN|N E2F-I|NN|N .|.|.
RB-defective|JJ|N/N tumor|NN|N/N lines|NNS|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) non-inducible|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP MHC|NN|N class|NN|N\N II|CD|(N\N)\(N\N) by|IN|((S[adj]\NP)\(S[adj]\NP))/NP IFN-gamma|NN|N ,|,|, or|CC|conj very|RB|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) weakly|RB|(S[adj]\NP)/(S[adj]\NP) inducible|JJ|S[adj]\NP ,|,|, but|CC|conj transfection|NN|N of|IN|(NP\NP)/NP 2|CD|N/N different|JJ|N/N lines|NNS|N with|IN|(NP\NP)/NP RB|NN|N/N expression|NN|N/N vectors|NNS|N re-establishes|VBZ|(S[dcl]\NP)/NP or|CC|conj substantially|RB|(S\NP)/(S\NP) enhances|VBZ|(S[dcl]\NP)/NP class|NN|N/N II|CD|(N/N)\(N/N) inducibility|NN|N .|.|.
Therefore|RB|S/S ,|,|, we|PRP|NP examined|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N RB|NN|N/N status|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N series|NN|N of|IN|(NP\NP)/NP B-cell|NN|N/N mutants|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[adj]\NP) defective|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP class|NN|N/N II|CD|(N/N)\(N/N) expression|NN|N ,|,|, generated|VBN|S[pss]\NP either|CC|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|FW|((S\NP)\(S\NP))/NP vitro|FW|N or|CC|conj derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP Bare|NN|N/N Lymphocyte|NN|N/N Syndrome|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) BLS|NN|N/N )|RRB|RRB patients|NNS|N .|.|.
Nuclear|JJ|N/N matrix-bound|JJ|N/N RB|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) detectable|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP all|DT|NP[nb]/N cases|NNS|N ,|,|, indicating|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] loss|NN|N of|IN|(NP\NP)/NP RB|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) responsible|JJ|(S[adj]\NP)/PP for|IN|PP/NP decreased|VBN|N/N class|NN|N/N II|CD|(N/N)\(N/N) expression|NN|N in|IN|(NP\NP)/NP these|DT|NP[nb]/N lines|NNS|N .|.|.
A|DT|NP[nb]/N second|JJ|N/N E2F-I|NN|N/N binding|NN|N/N protein|NN|N ,|,|, most|RBS|(N/N)/(N/N) likely|RB|N/N DP-I|NN|N ,|,|, was|VBD|(S[dcl]\NP)/(S[adj]\NP) also|RB|(S\NP)\(S\NP) apparently|RB|(S[adj]\NP)/(S[adj]\NP) normal|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP class|NN|N/N II-positive|JJ|N/N and|CC|conj -negative|JJ|N/N B-cell|NN|N/N lines|NNS|N .|.|.
We|PRP|NP also|RB|(S\NP)/(S\NP) examined|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N IFN-gamma|NN|N/N induction|NN|N of|IN|(NP\NP)/NP CIITA|NN|N in|IN|(NP\NP)/NP RB-defective|JJ|N/N lines|NNS|N .|.|.
CIITA|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N class|NN|N/N II|CD|(N/N)\(N/N) gene|NN|N/N transactivator|NN|N known|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) defective|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP one|CD|N/N form|NN|N of|IN|(NP\NP)/NP BLS|NN|N and|CC|conj to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP MHC|NN|N class|NN|N\N II|CD|(N\N)\(N\N) by|IN|(NP\NP)/NP IFN-gamma|NN|N .|.|.
CIITA|NN|N/N mRNA|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) normally|RB|(S\NP)\(S\NP) inducible|JJ|S[adj]\NP by|IN|((S[adj]\NP)\(S[adj]\NP))/NP IFN-gamma|NN|N in|IN|((S\NP)\(S\NP))/NP class|NN|N/N II|CD|(N/N)\(N/N) non-inducible|JJ|N/N ,|,|, RB-defective|JJ|N/N lines|NNS|N ,|,|, and|CC|conj in|IN|(S/S)/NP one|CD|N/N line|NN|N ,|,|, re-expression|NN|N of|IN|(NP\NP)/NP RB|NN|N has|VBZ|(S[dcl]\NP)/NP no|DT|NP[nb]/N effect|NN|N on|IN|(NP\NP)/NP CIITA|NN|N/N mRNA|NN|N/N induction|NN|N/N levels|NNS|N .|.|.
Thus|RB|S/S ,|,|, the|DT|NP[nb]/N block|NN|N in|IN|(NP\NP)/NP MHC|NN|N/N class|NN|N/N II|CD|(N/N)\(N/N) inducibility|NN|N in|IN|(NP\NP)/NP RB-defective|JJ|N/N cells|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) due|JJ|(S[adj]\NP)/PP to|TO|PP/NP a|DT|NP[nb]/N block|NN|N in|IN|(NP\NP)/NP CIITA|NN|N/N inducibility|NN|N .|.|.
Interleukin|NN|N 12|CD|N\N (|LRB|(N\N)/N IL-12|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N immunoregulatory|JJ|N/N cytokine|NN|N whose|WP$|((NP\NP)/(S[dcl]\NP))/N receptor|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N member|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N hematopoietin|NN|N/N receptor|NN|N/N superfamily|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) recently|RB|(S\NP)\(S\NP) demonstrated|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] stimulation|NN|N of|IN|(NP\NP)/NP human|JJ|N/N T|NN|N/N and|CC|conj natural|JJ|N/N killer|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP IL-12|NN|N induces|VBZ|(S[dcl]\NP)/NP tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Janus|NN|N/N family|NN|N/N tyrosine|NN|N/N kinase|NN|N/N JAK2|NN|N and|CC|conj Tyk2|NN|N ,|,|, implicating|VBG|(S[ng]\NP)/NP these|DT|NP[nb]/N kinases|NNS|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N immediate|JJ|N/N biochemical|JJ|N/N response|NN|N to|TO|(NP\NP)/NP IL-12|NN|N .|.|.
Recently|RB|S/S ,|,|, transcription|NN|N/N factors|NNS|N known|VBN|(S[pss]\NP)/PP as|IN|PP/NP STATs|NNS|N (|LRB|(NP\NP)/NP signal|NN|N/N transducers|NNS|N and|CC|conj activators|NNS|N of|IN|(NP\NP)/NP transcription|NN|N )|RRB|RRB have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) tyrosine|NN|(S[adj]\NP)/(S[adj]\NP) phosphorylated|JJ|S[adj]\NP and|CC|conj activated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP a|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP cytokines|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) bind|VBP|(S[dcl]\NP)/NP hematopoietin|NN|N/N receptors|NNS|N and|CC|conj activate|VBP|(S[dcl]\NP)/NP JAK|NN|N/N kinases|NNS|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N report|NN|N we|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-12|NN|N induces|VBZ|(S[dcl]\NP)/NP tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N recently|RB|(N/N)/(N/N) identified|VBN|N/N STAT|NN|(N/N)/(N/N) family|NN|N/N member|NN|N ,|,|, STAT4|NN|N ,|,|, and|CC|conj show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] STAT4|NN|N/N expression|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) regulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP T-cell|NN|N/N activation|NN|N .|.|.
Furthermore|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-12|NN|N stimulates|VBZ|(S[dcl]\NP)/NP formation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N DNA-binding|JJ|N/N complex|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) recognizes|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N DNA|NN|N/N sequence|NN|N previously|RB|(S\NP)/(S\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/NP STAT|NN|N/N proteins|NNS|N and|CC|conj that|IN|S[em]/S[dcl] this|DT|NP[nb]/N complex|NN|N contains|VBZ|(S[dcl]\NP)/NP STAT4|NN|N .|.|.
These|DT|NP[nb]/N data|NNS|N ,|,|, and|CC|conj the|DT|NP[nb]/N recent|JJ|N/N demonstration|NN|N of|IN|(NP\NP)/NP JAK|NN|N/N phosphorylation|NN|N by|IN|(NP\NP)/NP IL-12|NN|N ,|,|, identify|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N rapid|JJ|N/N signal-transduction|JJ|N/N pathway|NN|N likely|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) mediate|VB|(S[b]\NP)/NP IL-12-induced|JJ|N/N gene|NN|N/N expression|NN|N .|.|.
OBJECTIVE|NN|S/S :|:|: Activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N hypothalamic-pituitary-adrenal|JJ|N/N axis|NN|N is|VBZ|(S[dcl]\NP)/PP of|IN|PP/NP vital|JJ|N/N importance|NN|N during|IN|(NP\NP)/NP critical|JJ|N/N illness|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) studied|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N adaptive|JJ|N/N mechanisms|NNS|N which|WDT|(NP\NP)/(S[dcl]\NP) occur|VBP|S[dcl]\NP at|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N level|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N in|IN|((S\NP)\(S\NP))/NP glucocorticoid|NN|N/N target|NN|N/N tissues|NNS|N in|IN|(NP\NP)/NP patients|NNS|N with|IN|(NP\NP)/NP sepsis|NN|N or|CC|conj septic|JJ|N/N shock|NN|N .|.|.
DESIGN|NN|S/S :|:|: The|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP hypercortisolaemia|NN|N ,|,|, hyperthermia|NN|N and|CC|conj cellular|JJ|N/N composition|NN|N on|IN|(NP\NP)/NP number|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptors|NNS|N per|IN|(NP\NP)/NP cell|NN|N and|CC|conj their|PRP$|NP[nb]/N affinity|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) evaluated|VBN|S[pss]\NP ,|,|, both|CC|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|FW|((S\NP)\(S\NP))/NP vitro|FW|N and|CC|conj in|FW|((S\NP)\(S\NP))/NP vivo|FW|N ,|,|, in|IN|((S\NP)\(S\NP))/NP peripheral|JJ|N/N blood|NN|N/N mononuclear|JJ|N/N leucocytes|NNS|N of|IN|(NP\NP)/NP control|JJ|N/N subjects|NNS|N and|CC|conj in|IN|((S\NP)\(S\NP))/NP patients|NNS|N with|IN|(NP\NP)/NP sepsis|NN|N or|CC|conj septic|JJ|N/N shock|NN|N .|.|.
SUBJECTS|NNS|S/S :|:|: Fifteen|CD|N/N patients|NNS|N (|LRB|(N\N)/N age|NN|N 25-79|CD|N\N )|RRB|RRB with|IN|(NP\NP)/NP sepsis|NN|N or|CC|conj septic|JJ|N/N shock|NN|N who|WP|(NP\NP)/(S[dcl]\NP) were|VBD|(S[dcl]\NP)/(S[pss]\NP) admitted|VBN|S[pss]\NP to|TO|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N intensive|JJ|(N/N)/(N/N) care|NN|N/N unit|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) studied|VBN|S[pss]\NP .|.|.
The|DT|NP[nb]/N control|JJ|N/N group|NN|N consisted|VBD|(S[dcl]\NP)/PP of|IN|PP/NP 24|CD|N/N healthy|JJ|N/N laboratory|NN|N/N employees|NNS|N .|.|.
MEASUREMENTS|NNS|S/S :|:|: The|DT|NP[nb]/N binding|NN|N/N capacity|NN|N and|CC|conj affinity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptors|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) measured|VBN|S[pss]\NP and|CC|conj compared|VBN|(S[pss]\NP)/PP to|TO|PP/NP clinical|JJ|N/N data|NNS|N and|CC|conj the|DT|NP[nb]/N plasma|NN|N/N cortisol|NN|N/N concentrations|NNS|N .|.|.
RESULTS|NNS|S/S :|:|: Hypercortisolaemia|NN|N ,|,|, in|FW|(NP\NP)/NP vitro|FW|N ,|,|, resulted|VBD|(S[dcl]\NP)/PP in|IN|PP/NP a|DT|NP[nb]/N decreased|VBN|N/N affinity|NN|N and|CC|conj a|DT|NP[nb]/N decreased|VBN|N/N binding|NN|N/N capacity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N .|.|.
In|FW|(S/S)/NP vitro|FW|N ,|,|, hyperthermia|NN|N as|RB|conj/conj well|RB|conj/conj as|IN|conj variations|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N cellular|JJ|N/N composition|NN|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) influence|VB|(S[b]\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N .|.|.
In|FW|(S/S)/NP vivo|FW|N ,|,|, there|EX|NP[thr] was|VBD|(S[dcl]\NP[thr])/NP no|DT|NP[nb]/N change|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP receptors|NNS|N per|IN|(NP\NP)/NP cell|NN|N in|IN|(NP\NP)/NP patients|NNS|N with|IN|(NP\NP)/NP sepsis|NN|N or|CC|conj septic|JJ|N/N shock|NN|N as|IN|((S\NP)\(S\NP))/(S[pss]\NP) compared|VBN|(S[pss]\NP)/PP to|TO|PP/NP healthy|JJ|N/N controls|NNS|N .|.|.
However|RB|S/S ,|,|, a|DT|NP[nb]/N decreased|VBN|N/N affinity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP .|.|.
There|EX|NP[thr] was|VBD|(S[dcl]\NP[thr])/NP a|DT|NP[nb]/N weak|JJ|N/N but|CC|conj significant|JJ|N/N negative|JJ|N/N correlation|NN|N between|IN|(NP\NP)/NP body|NN|N/N temperature|NN|N and|CC|conj the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptors|NNS|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N patient|NN|N/N group|NN|N .|.|.
There|EX|NP[thr] was|VBD|(S[dcl]\NP[thr])/NP no|DT|NP[nb]/N relation|NN|N between|IN|(NP\NP)/NP circulating|VBG|N/N cortisol|NN|N/N concentrations|NNS|N and|CC|conj glucocorticoid|NN|N/N receptor|NN|N/N affinity|NN|N and|CC|conj number|NN|N .|.|.
CONCLUSIONS|NNS|S/S :|:|: There|EX|NP[thr] is|VBZ|(S[dcl]\NP[thr])/NP no|DT|NP[nb]/N obvious|JJ|N/N regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptors|NNS|N by|IN|(NP\NP)/NP plasma|NN|N/N cortisol|NN|N/N concentrations|NNS|N in|FW|(NP\NP)/NP vivo|FW|N .|.|.
The|DT|NP[nb]/N decreased|VBN|N/N affinity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N together|RB|(NP\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N negative|JJ|N/N correlation|NN|N between|IN|(NP\NP)/NP hyperthermia|NN|N and|CC|conj the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptors|NNS|N in|IN|(NP\NP)/NP patients|NNS|N with|IN|(NP\NP)/NP sepsis|NN|N or|CC|conj septic|JJ|N/N shock|NN|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] hypothalamic-pituitary-adrenal|JJ|N/N axis|NN|N/N activation|NN|N during|IN|(NP\NP)/NP critical|JJ|N/N illness|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) accompanied|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP peripheral|JJ|N/N adaptation|NN|N in|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptor|NN|N/N number|NN|N and|CC|conj affinity|NN|N .|.|.
Activation|NN|N of|IN|(NP\NP)/NP cytoplasmic|JJ|N/N tyrosine|NN|N/N kinases|NNS|N is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N aspect|NN|N of|IN|(NP\NP)/NP signal|NN|N/N transduction|NN|N mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP integrins|NNS|N .|.|.
In|IN|(S/S)/NP the|DT|NP[nb]/N human|JJ|N/N monocytic|JJ|N/N cell|NN|N/N line|NN|N THP-1|NN|N ,|,|, either|CC|NP/NP integrin-dependent|JJ|N/N cell|NN|N/N adhesion|NN|N to|TO|(NP\NP)/NP fibronectin|NN|N or|CC|conj ligation|NN|N of|IN|(NP\NP)/NP beta|NN|N/N 1|CD|(N/N)\(N/N) integrins|NNS|N with|IN|(NP\NP)/NP antibodies|NNS|N causes|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N rapid|JJ|N/N and|CC|conj intense|JJ|N/N tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP two|CD|N/N sets|NNS|N of|IN|(NP\NP)/NP proteins|NNS|N of|IN|(NP\NP)/NP about|RB|(N/N)/(N/N) 65-75|CD|N/N and|CC|conj 120-125|CD|N/N kDa|NN|N .|.|.
In|IN|(S/S)/NP addition|NN|N ,|,|, integrin|NN|N/N ligation|NN|N leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP nuclear|JJ|N/N translocation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N p50|NN|N/N and|CC|conj p65|NN|N/N subunits|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N transcription|NN|N/N factor|NN|N ,|,|, to|TO|((S\NP)\(S\NP))/NP activation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N reporter|NN|N/N gene|NN|N driven|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N promoter|NN|N containing|VBG|(S[ng]\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N sites|NNS|N ,|,|, and|CC|conj to|TO|((S\NP)\(S\NP))/NP increased|VBN|N/N levels|NNS|N of|IN|(NP\NP)/NP mRNAs|NNS|N for|IN|(NP\NP)/NP immediate-early|JJ|N/N genes|NNS|N ,|,|, including|VBG|(NP\NP)/NP the|DT|NP[nb]/N cytokine|NN|N/N interleukin|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL|NN|N/N )|RRB|RRB -1|CD|(N/N)\(N/N) beta|NN|N .|.|.
The|DT|NP[nb]/N tyrosine|NN|N/N kinase|NN|N/N inhibitors|NNS|N genistein|NN|N and|CC|conj herbimycin|NN|N/N A|NN|N block|VBP|(S[dcl]\NP)/NP both|CC|NP/NP integrin-mediated|JJ|N/N tyrosine|NN|N/N phosphorylation|NN|N and|CC|conj increases|NNS|N in|IN|(NP\NP)/NP IL-1|NN|N/N beta|NN|N/N message|NN|N/N levels|NNS|N ,|,|, indicating|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N causal|JJ|N/N relationship|NN|N between|IN|(NP\NP)/NP the|DT|NP[nb]/N two|CD|N/N events|NNS|N .|.|.
The|DT|NP[nb]/N components|NNS|N tyrosine|NN|(S\NP)/(S\NP) phosphorylated|VBN|S[pss]\NP subsequent|JJ|((S\NP)\(S\NP))/PP to|TO|PP/NP cell|NN|N/N adhesion|NN|N include|VBP|(S[dcl]\NP)/NP paxillin|NN|N ,|,|, pp125FAK|NN|N ,|,|, and|CC|conj the|DT|NP[nb]/N SH2|NN|N/N domain|NN|N containing|VBG|(S[ng]\NP)/NP tyrosine|NN|N/N kinase|NN|N/N Syk|NN|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, integrin|NN|N/N ligation|NN|N with|IN|(NP\NP)/NP antibodies|NNS|N induces|VBZ|(S[dcl]\NP)/NP tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP Syk|NN|N but|CC|conj not|RB|(NP\NP)/(NP\NP) of|IN|(NP\NP)/NP FAK|NN|N or|CC|conj paxillin|NN|N .|.|.
In|IN|(S/S)/NP adhering|JJ|N/N cells|NNS|N ,|,|, pre-treatment|NN|N with|IN|(NP\NP)/NP cytochalasin|NN|N/N D|NN|N suppresses|VBZ|(S[dcl]\NP)/NP tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP FAK|NN|N and|CC|conj paxillin|NN|N but|CC|conj not|RB|(NP\NP)/(NP\NP) of|IN|(NP\NP)/NP Syk|NN|N ,|,|, while|IN|((S\NP)\(S\NP))/S[dcl] IL-1|NN|N/N beta|NN|N/N message|NN|N/N induction|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) unaffected|JJ|S[adj]\NP .|.|.
These|DT|NP[nb]/N observations|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N Syk|NN|N/N tyrosine|NN|N/N kinase|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N component|NN|N of|IN|(NP\NP)/NP an|DT|NP[nb]/N integrin|NN|N/N signaling|NN|N/N pathway|NN|N in|IN|(NP\NP)/NP monocytic|JJ|N/N cells|NNS|N ,|,|, leading|VBG|S[ng]\NP to|TO|((S\NP)\(S\NP))/NP activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N and|CC|conj to|TO|((S\NP)\(S\NP))/NP increased|VBN|N/N levels|NNS|N of|IN|(NP\NP)/NP cytokine|NN|N/N messages|NNS|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) determine|VB|(S[b]\NP)/S[qem] if|IN|S[qem]/S[dcl] New|NN|(N/N)/(N/N) World|NN|N/N primates|NNS|N express|VBP|(S[dcl]\NP)/NP an|DT|NP[nb]/N inhibitor|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) influences|VBZ|(S[dcl]\NP)/NP glucocorticoid|NN|N/N receptor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) GR|NN|N/N )|RRB|RRB binding|NN|N/N characteristics|NNS|N ,|,|, we|PRP|NP examined|VBD|(S[dcl]\NP)/NP [3H]dexamethasone|NN|N/N binding|NN|N in|IN|(NP\NP)/NP cytosol|NN|N prepared|VBN|(S[pss]\NP)/PP from|IN|PP/NP B95-8|NN|N/N lymphoid|JJ|N/N cells|NNS|N ,|,|, derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N cotton|NN|N/N top|NN|N/N tamarin|NN|N (|LRB|(N\N)/N Saguinus|FW|N/N oedipus|FW|N )|RRB|RRB ,|,|, in|IN|((S\NP)\(S\NP))/NP combination|NN|N with|IN|(NP\NP)/NP cytosol|NN|N prepared|VBN|(S[pss]\NP)/PP from|IN|PP/NP human|JJ|N/N or|CC|conj rat|NN|N/N tissues|NNS|N .|.|.
B95-8|NN|N/N cytosol|NN|N inhibited|VBD|(S[dcl]\NP)/NP specific|JJ|N/N binding|NN|N of|IN|(NP\NP)/NP [3H]dexamethasone|NN|N (|LRB|(N\N)/N P|NN|N <|JJR|(N\N)/N 0.01|CD|N )|RRB|RRB when|WRB|((S\NP)\(S\NP))/(S[pss]\NP) mixed|VBN|(S[pss]\NP)/PP with|IN|PP/NP cytosol|NN|N prepared|VBN|(S[pss]\NP)/PP from|IN|PP/NP either|CC|NP/NP a|DT|NP[nb]/N human|JJ|N/N lymphoid|JJ|N/N cell|NN|N/N line|NN|N (|LRB|(NP\NP)/NP HL|NN|N )|RRB|RRB or|CC|conj rat|NN|N/N thymus|NN|N .|.|.
The|DT|NP[nb]/N inhibitory|JJ|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) heat|NN|(S[adj]\NP)/(S[adj]\NP) labile|JJ|S[adj]\NP and|CC|conj trypsin|NN|(S[adj]\NP)/(S[adj]\NP) sensitive|JJ|S[adj]\NP .|.|.
Peak|JJ|N/N inhibitory|JJ|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N 150-200|CD|(N/N)/(N/N) kd|NN|N/N fractions|NNS|N after|IN|((S\NP)\(S\NP))/NP Sephacryl|NN|N/N G-200|NN|N/N ultrafiltration|NN|N .|.|.
Scatchard|NN|N/N analysis|NN|N of|IN|(NP\NP)/NP [3H]dexamethasone|NN|N/N binding|NN|N using|VBG|(S[ng]\NP)/NP mixed|JJ|N/N cytosol|NN|N showed|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N diminished|VBN|N/N GR|NN|N/N apparent|JJ|N/N binding|NN|N/N affinity|NN|N when|WRB|((S\NP)\(S\NP))/(S[pss]\NP) compared|VBN|(S[pss]\NP)/PP to|TO|PP/NP HL|NN|N/N cytosol|NN|N .|.|.
Kinetic|JJ|N/N studies|NNS|N using|VBG|(S[ng]\NP)/NP mixed|JJ|N/N cytosol|NN|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] B95-8|NN|N/N cytosol|NN|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) affect|VB|(S[b]\NP)/NP the|DT|NP[nb]/N apparent|JJ|N/N dissociation|NN|N/N rate|NN|N of|IN|(NP\NP)/NP [3H]dexamethasone|NN|N .|.|.
These|DT|NP[nb]/N data|NNS|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] B95-8|NN|N/N cells|NNS|N contain|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N competitive|JJ|N/N inhibitor|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) prevents|VBZ|(S[dcl]\NP)/NP binding|NN|N of|IN|(NP\NP)/NP dexamethasone|NN|N to|TO|(NP\NP)/NP its|PRP$|NP[nb]/N cognate|JJ|N/N receptor|NN|N .|.|.
The|DT|NP[nb]/N mRNA|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N Duffy|NN|N/N blood|NN|N/N group|NN|N/N antigen|NN|N ,|,|, the|DT|NP[nb]/N erythrocyte|NN|N/N receptor|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N Plasmodium|NN|N/N vivax|NN|N/N malaria|NN|N/N parasite|NN|N ,|,|, has|VBZ|(S[dcl]\NP)/(S[pt]\NP) recently|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) cloned|VBN|S[pss]\NP and|CC|conj shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) encode|VB|(S[b]\NP)/NP a|DT|NP widely|RB|(N/N)/(N/N) expressed|VBN|N/N chemokine|NN|N/N receptor|NN|N .|.|.
Here|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N Duffy|NN|N/N antigen/chemokine|NN|N/N receptor|NN|N/N gene|NN|N (|LRB|(NP\NP)/NP DARC|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/(S[adj]\NP) composed|VBN|(S[adj]\NP)/PP of|IN|PP/NP a|DT|NP[nb]/N single|JJ|N/N exon|NN|N and|CC|conj that|IN|S[em]/S[dcl] most|JJS|N/N Duffy-negative|JJ|N/N blacks|NNS|N carry|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N silent|JJ|N/N FY*B|NN|N/N allele|NN|N with|IN|(NP\NP)/NP a|DT|NP[nb]/N single|JJ|N/N T|NN|N/N to|TO|((N/N)\(N/N))/(N/N) C|NN|N/N substitution|NN|N at|IN|(NP\NP)/NP nucleotide|NN|N -46|CD|N\N .|.|.
This|DT|NP[nb]/N mutation|NN|N impairs|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP erythroid|JJ|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) disrupting|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N binding|VBG|N/N site|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N GATA1|NN|N/N erythroid|JJ|N/N transcription|NN|N/N factor|NN|N .|.|.
With|IN|(S/S)/NP the|DT|NP[nb]/N recent|JJ|N/N characterization|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N FY*A|NN|N/N and|CC|conj FY*B|NN|N/N alleles|NNS|N ,|,|, these|DT|NP[nb]/N findings|NNS|N provide|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N molecular|JJ|N/N basis|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Duffy|NN|N/N blood|NN|N/N group|NN|N/N system|NN|N and|CC|conj an|DT|NP[nb]/N explanation|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N erythroid-specific|JJ|N/N repression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DARC|NN|N/N gene|NN|N in|IN|(NP\NP)/NP Duffy-negative|JJ|N/N individuals|NNS|N .|.|.
The|DT|NP[nb]/N present|JJ|N/N studies|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) examined|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP pokeweed|NN|N/N mitogen|NN|N (|LRB|(NP\NP)/NP PWM|NN|N )|RRB|RRB on|IN|(NP\NP)/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP early|JJ|N/N growth|NN|N/N response-1|NN|N/N gene|NN|N (|LRB|(NP\NP)/NP EGR-1|NN|N )|RRB|RRB in|IN|(NP\NP)/NP normal|JJ|N/N human|JJ|N/N B|NN|N/N cells|NNS|N .|.|.
PWM|NN|N regulates|VBZ|(S[dcl]\NP)/NP EGR-1|NN|N/N gene|NN|N/N expression|NN|N by|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP transcriptional|JJ|N/N and|CC|conj post-transcriptional|JJ|N/N mechanisms|NNS|N .|.|.
Transient|JJ|N/N transfection|NN|N/N assays|NNS|N with|IN|(NP\NP)/NP EGR-1|NN|N/N promoter|NN|N/N fragments|NNS|N linked|VBN|(S[pss]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N chloramphenicol|NN|N/N acetyltransferase|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) CAT|NN|N/N )|RRB|RRB gene|NN|N demonstrated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] PWM|NN|N/N induced|JJ|N/N EGR-1|NN|N/N transcription|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) conferred|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N CArG|NN|N/N motif|NN|N (|LRB|(NP\NP)/NP C|NN|N/N C[AT]6GG|NN|N )|RRB|RRB in|IN|(NP\NP)/NP the|DT|NP[nb]/N EGR-1|NN|N/N promoter|NN|N .|.|.
The|DT|NP[nb]/N results|NNS|N further|RB|(S\NP)/(S\NP) demonstrated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP S6|NN|N/N kinase|NN|N (|LRB|(NP\NP)/NP pp90rsk|NN|N )|RRB|RRB ,|,|, evidenced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP phosphorylation|NN|N of|IN|(NP\NP)/NP S6|NN|N and|CC|conj serum|NN|N/N response|NN|N/N factor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) SRF|NN|N/N )|RRB|RRB peptides|NNS|N ,|,|, in|IN|(NP\NP)/NP PWM|NN|(N/N)/(N/N) treated|JJ|N/N B|NN|N/N cells|NNS|N .|.|.
Taken|VBN|S[pss]\NP together|RB|(S\NP)\(S\NP) ,|,|, these|DT|NP[nb]/N findings|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] PWM|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) initiate|VB|(S[b]\NP)/NP an|DT|NP[nb]/N intracytoplasmic|JJ|N/N signalling|NN|N/N cascade|NN|N and|CC|conj EGR-1|NN|N/N induction|NN|N in|IN|(NP\NP)/NP normal|JJ|N/N human|JJ|N/N B|NN|N/N cells|NNS|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) recently|RB|(S\NP)\(S\NP) found|VBN|(S[pt]\NP)/NP a|DT|NP[nb]/N novel|JJ|N/N conserved|VBN|N/N motif|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N promoters|NNS|N of|IN|(NP\NP)/NP several|JJ|N/N T-cell-expressed|JJ|N/N cytokines|NNS|N [|LRB|(NP\NP)/NP human|JJ|N/N interleukin-2|NN|N ,|,|, -4|CD|N ,|,|, -5|CD|N and|CC|conj -13|CD|N and|CC|conj human|JJ|N/N and|CC|conj mouse|NN|N/N granulocyte/macrophage-colony|NN|N/N stimulating|JJ|N/N factor|NN|N (|LRB|(N\N)/N GM-CSF|NN|N )|RRB|RRB ]|RRB|RRB .|.|.
It|PRP|NP contains|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N core|NN|N/N sequence|NN|N CTTGG|NN|N ...|:|: CCAAG|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) present|JJ|S[adj]\NP as|IN|((S\NP)\(S\NP))/NP part|NN|N of|IN|(NP\NP)/NP larger|JJR|N/N palindromic|JJ|N/N sequences|NNS|N in|IN|(NP\NP)/NP each|DT|NP[nb]/N gene|NN|N .|.|.
This|DT|NP suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] they|PRP|NP may|MD|(S[dcl]\NP)/(S[b]\NP) interact|VB|(S[b]\NP)/PP with|IN|PP/NP a|DT|NP[nb]/N new|JJ|N/N family|NN|N of|IN|(NP\NP)/NP trans-acting|JJ|N/N factors|NNS|N .|.|.
In|IN|(S/S)/NP transfection|NN|N/N assays|NNS|N ,|,|, the|DT|NP[nb]/N human|JJ|N/N GM-CSF|NN|N/N element|NN|N has|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N strong|JJ|N/N positive|JJ|N/N effect|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N reporter|NN|N/N gene|NN|N by|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N line|NN|N Jurkat|NN|N/N J6|NN|N upon|IN|(NP\NP)/NP stimulation|NN|N .|.|.
In|IN|(S/S)/NP DNA|NN|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N ,|,|, this|DT|NP[nb]/N sequence|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) give|VB|(S[b]\NP)/NP either|CC|NP/NP six|CD|N/N different|JJ|N/N specific|JJ|N/N bands|NNS|N which|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[pss]\NP) competed|VBN|S[pss]\NP out|RP|(S\NP)\(S\NP) by|IN|((S\NP)\(S\NP))/NP different|JJ|N/N parts|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N sequence|NN|N or|CC|conj one|CD|N/N specific|JJ|N/N band|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) competed|VBN|S[pss]\NP out|RP|(S\NP)\(S\NP) by|IN|((S\NP)\(S\NP))/NP each|DT|NP of|IN|(NP\NP)/NP the|DT|NP[nb]/N inverted|VBN|N/N repeats|NNS|N ,|,|, depending|VBG|((S\NP)\(S\NP))/PP on|IN|PP/NP the|DT|NP[nb]/N reconstitution|NN|N/N conditions|NNS|N .|.|.
In|IN|(S/S)/NP different|JJ|N/N genes|NNS|N ,|,|, the|DT|NP[nb]/N core|NN|N/N sequences|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) separated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP integer|NN|N/N numbers|NNS|N of|IN|(NP\NP)/NP helical|JJ|N/N turns|NNS|N .|.|.
Considering|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N strong|JJ|N/N positive|JJ|N/N regulatory|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N element|NN|N and|CC|conj its|PRP$|NP[nb]/N presence|NN|N in|IN|(NP\NP)/NP several|JJ|N/N T-cell-expressed|JJ|N/N cytokine|NN|N/N genes|NNS|N ,|,|, it|PRP|NP may|MD|(S[dcl]\NP[expl])/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) crucial|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N coordinated|VBN|N/N expression|NN|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N cytokines|NNS|N in|IN|(NP\NP)/NP T|NN|N/N helper|NN|N/N cells|NNS|N .|.|.
A|DT|NP[nb]/N human|JJ|N/N T|NN|N/N lymphoid|JJ|N/N cell|NN|N/N line|NN|N ,|,|, PEER|NN|N ,|,|, dies|VBZ|S[dcl]\NP by|IN|((S\NP)\(S\NP))/NP apoptosis|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP PMA|NN|N and|CC|conj calcium|NN|N/N ionophore|NN|N .|.|.
A|DT|NP[nb]/N new|JJ|N/N gene|NN|N ,|,|, TINUR|NN|N ,|,|, was|VBD|(S[dcl]\NP)/(S[pss]\NP) cloned|VBN|(S[pss]\NP)/PP from|IN|PP/NP apoptotic|JJ|N/N PEER|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TINUR|NN|N/N gene|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP within|IN|((S\NP)\(S\NP))/NP 1|CD|N/N h|NN|N after|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cross-linking|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N T|NN|(N/N)/(N/N) cell|NN|N/N Ag|NN|N/N receptor|NN|N/N complex|NN|N .|.|.
TINUR|NN|N belongs|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N NGFI-B/nur77|NN|N/N family|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N steroid|NN|N/N receptor|NN|N/N superfamily|NN|N and|CC|conj is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N orphan|NN|N/N receptor|NN|N .|.|.
TINUR|NN|N binds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N same|JJ|N/N DNA|NN|N/N sequence|NN|N as|IN|(NP\NP)/NP NGFI-B/nur77|NN|N .|.|.
We|PRP|NP also|RB|(S\NP)/(S\NP) propose|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N NGFI-B/nur77|NN|N/N family|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) classified|VBN|(S[pss]\NP)/PP into|IN|PP/NP two|CD|N/N subtypes|NNS|N .|.|.
BACKGROUND|NN|N :|:|(NP\NP)/S[dcl] The|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP vascular|JJ|N/N cell|NN|N/N adhesion|NN|N/N molecule-1|NN|N (|LRB|(NP\NP)/NP VCAM-1|NN|N )|RRB|RRB and|CC|conj E-selectin|NN|N by|IN|(NP\NP)/NP tumor|NN|N/N necrosis|NN|N/N factor-alpha|NN|N (|LRB|(N\N)/N TNF|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP mobilization|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N factor|NN|N nuclear|JJ|N/N factor-kappa|NN|N/N B|NN|N (|LRB|LRB NF-kappa|NN|N/N B|NN|N )|RRB|RRB .|.|.
Since|IN|(S/S)/S[dcl] salicylates|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) reported|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) inhibit|VB|(S[b]\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) preventing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N degradation|NN|N of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N inhibitor|NN|N I|NN|N/N kappa|NN|N/N B|NN|N ,|,|, we|PRP|NP studied|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N potential|JJ|N/N inhibition|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N pathway|NN|N by|IN|(NP\NP)/NP acetylsalicylate|NN|N (|LRB|(N\N)/N aspirin|NN|N )|RRB|RRB in|IN|((S\NP)\(S\NP))/NP human|JJ|N/N umbilical|JJ|N/N vein|NN|N/N endothelial|JJ|N/N cells|NNS|N (|LRB|(NP\NP)/NP HUVECs|NNS|N )|RRB|RRB .|.|.
METHODS|NNS|N AND|CC|conj RESULTS|NNS|N :|:|(NP\NP)/S[dcl] Gel-shift|JJ|N/N analyses|NNS|N demonstrated|VBD|(S[dcl]\NP)/NP dose-dependent|JJ|N/N inhibition|NN|N of|IN|(NP\NP)/NP TNF-induced|JJ|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N mobilization|NN|N by|IN|(NP\NP)/NP aspirin|NN|N at|IN|(NP\NP)/NP concentrations|NNS|N ranging|VBG|(S[ng]\NP)/PP from|IN|PP/NP 1|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 10|CD|N/N mmol/L|NN|N .|.|.
Induction|NN|N of|IN|(NP\NP)/NP VCAM-1|NN|N and|CC|conj E-selectin|NN|N/N surface|NN|N/N expression|NN|N by|IN|(NP\NP)/NP TNF|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) dose-dependently|RB|(S\NP)\(S\NP) reduced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP aspirin|NN|N over|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N same|JJ|N/N range|NN|N ,|,|, while|IN|(S\S)/S[dcl] induction|NN|N of|IN|(NP\NP)/NP intercellular|JJ|N/N adhesion|NN|N/N molecule-1|NN|N (|LRB|(NP\NP)/NP ICAM-1|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[pss]\NP) hardly|RB|(S\NP)/(S\NP) affected|VBN|S[pss]\NP .|.|.
Aspirin|NN|N appeared|VBD|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) prevent|VB|(S[b]\NP)/NP VCAM-1|NN|N/N transcription|NN|N ,|,|, since|IN|((S\NP)\(S\NP))/S[dcl] it|PRP|NP dose-dependently|RB|(S\NP)/(S\NP) inhibited|VBD|(S[dcl]\NP)/NP induction|NN|N of|IN|(NP\NP)/NP VCAM-1|NN|N/N mRNA|NN|N by|IN|((S\NP)\(S\NP))/NP TNF|NN|N .|.|.
As|IN|(S/S)/NP a|DT|NP[nb]/N functional|JJ|N/N consequence|NN|N ,|,|, adhesion|NN|N of|IN|(NP\NP)/NP U937|NN|N/N monocytes|NNS|N to|TO|(NP\NP)/NP TNF-stimulated|JJ|N/N HUVECs|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) markedly|RB|(S\NP)\(S\NP) reduced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP aspirin|NN|N due|JJ|((S\NP)\(S\NP))/PP to|TO|PP/NP suppression|NN|N of|IN|(NP\NP)/NP VCAM-1|NN|N and|CC|conj E-selectin|NN|N/N upregulation|NN|N .|.|.
These|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP aspirin|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) related|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N inhibition|NN|N of|IN|(NP\NP)/NP cyclooxygenase|NN|N/N activity|NN|N ,|,|, since|IN|((S\NP)\(S\NP))/S[dcl] indomethacin|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) ineffective|JJ|S[adj]\NP .|.|.
CONCLUSIONS|NNS|N :|:|(NP\NP)/S[dcl] Our|PRP$|NP[nb]/N data|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] aspirin|NN|N inhibits|VBZ|(S[dcl]\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N mobilization|NN|N ,|,|, induction|NN|N of|IN|(NP\NP)/NP VCAM-1|NN|N and|CC|conj E-selectin|NN|N ,|,|, and|CC|conj subsequent|JJ|N/N monocyte|NN|N/N adhesion|NN|N in|IN|(NP\NP)/NP endothelial|JJ|N/N cells|NNS|N stimulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP TNF|NN|N ,|,|, thereby|RB|(S\NP)/(S\NP) providing|VBG|(S[ng]\NP)/NP an|DT|NP[nb]/N additional|JJ|N/N mechanism|NN|N for|IN|(NP\NP)/NP therapeutic|JJ|N/N effects|NNS|N of|IN|(NP\NP)/NP aspirin|NN|N .|.|.
Activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N by|IN|(NP\NP)/NP various|JJ|N/N cellular|JJ|N/N stimuli|NNS|N involves|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N phosphorylation|NN|N and|CC|conj subsequent|JJ|N/N degradation|NN|N of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N inhibitor|NN|N ,|,|, I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N ,|,|, although|IN|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N underlying|VBG|N/N mechanism|NN|N remains|VBZ|(S[dcl]\NP)/(S[adj]\NP) unclear|JJ|S[adj]\NP .|.|.
In|IN|(S/S)/NP the|DT|NP[nb]/N present|JJ|N/N study|NN|N ,|,|, the|DT|NP[nb]/N role|NN|N of|IN|(NP\NP)/NP serine/threonine|NN|N/N phosphatases|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N/N phosphorylation|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) investigated|VBN|S[pss]\NP .|.|.
Our|PRP$|NP[nb]/N studies|NNS|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] incubation|NN|N of|IN|(NP\NP)/NP human|JJ|N/N T|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP low|JJ|N/N concentrations|NNS|N (|LRB|(NP\NP)/NP approximately|RB|(N/N)/(N/N) 1-5|CD|N/N nM|NN|N )|RRB|RRB of|IN|(NP\NP)/NP calyculin|NN|N/N A|NN|N or|CC|conj okadaic|JJ|N/N acid|NN|N ,|,|, potent|JJ|N/N inhibitors|NNS|N of|IN|(NP\NP)/NP protein|NN|N/N phosphatase|NN|N type|NN|N\N 1|CD|(N\N)\(N\N) (|LRB|(N\N)/N PP-1|NN|N )|RRB|RRB and|CC|conj type|NN|N 2A|NN|N\N (|LRB|(NP\NP)/NP PP-2A|NN|N )|RRB|RRB ,|,|, induces|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N phosphorylation|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N even|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N absence|NN|N of|IN|(NP\NP)/NP any|DT|NP[nb]/N cellular|JJ|N/N stimulus|NN|N .|.|.
This|DT|NP[nb]/N action|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N phosphatase|NN|N/N inhibitors|NNS|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N RelA.p50|NN|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N heterodimer|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) affected|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP agents|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) block|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N/N phosphorylation|NN|N by|IN|((S\NP)\(S\NP))/NP tumor|NN|N/N necrosis|NN|N/N factor|NN|N/N alpha|NN|N (|LRB|(NP\NP)/NP TNF-alpha|NN|N )|RRB|RRB .|.|.
Furthermore|RB|S/S ,|,|, the|DT|NP[nb]/N phosphorylated|VBN|N/N I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N from|IN|(NP\NP)/NP calyculin|NN|N/N A-treated|JJ|N/N cells|NNS|N ,|,|, but|CC|conj not|RB|NP/NP that|DT|NP from|IN|(NP\NP)/NP TNF-alpha-stimulated|JJ|N/N cells|NNS|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[adj]\NP) sensitive|JJ|(S[adj]\NP)/PP to|TO|PP/NP PP-2A|NN|N in|FW|(NP\NP)/NP vitro|FW|N ,|,|, suggesting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N existence|NN|N of|IN|(NP\NP)/NP fundamental|JJ|N/N differences|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N phosphorylation|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N two|CD|N/N different|JJ|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N inducers|NNS|N .|.|.
However|RB|S/S ,|,|, induction|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N/N phosphorylation|NN|N by|IN|(NP\NP)/NP both|CC|NP/NP TNF-alpha|NN|N and|CC|conj the|DT|NP[nb]/N phosphatase|NN|N/N inhibitors|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N subsequent|JJ|N/N degradation|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N .|.|.
We|PRP|NP further|RB|(S\NP)/(S\NP) demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] TNF-alpha-|NN|N and|CC|conj calyculin|NN|N/N A-induced|JJ|N/N I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N/N degradation|NN|N exhibits|VBZ|(S[dcl]\NP)/NP similar|JJ|N/N but|CC|conj not|RB|(N/N)/(N/N) identical|JJ|N/N sensitivities|NNS|N to|TO|(NP\NP)/NP a|DT|NP[nb]/N proteasome|JJ|N/N inhibitor|NN|N .|.|.
Together|RB|S/S ,|,|, these|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] phosphorylation|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N ,|,|, mediated|VBN|S[pss]\NP through|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP the|DT|NP[nb]/N TNF-alpha-inducible|JJ|N/N and|CC|conj the|DT|NP[nb]/N PP-2A-opposing|JJ|N/N kinases|NNS|N ,|,|, may|MD|(S[dcl]\NP)/(S[b]\NP) serve|VB|(S[b]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) target|NN|(S[b]\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N for|IN|((S\NP)\(S\NP))/NP proteasome-mediated|JJ|N/N degradation|NN|N .|.|.
The|DT|NP[nb]/N 5'|JJ|N/N flanking|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N alpha-globin|NN|N/N gene|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) highly|RB|(S[adj]\NP)/(S[adj]\NP) G+C|NN|(S[adj]\NP)/(S[adj]\NP) rich|JJ|S[adj]\NP and|CC|conj contains|VBZ|(S[dcl]\NP)/NP multiple|JJ|N/N copies|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N consensus|NN|N/N sequence|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N Sp1|NN|N/N binding|NN|N/N site|NN|N .|.|.
We|PRP|NP investigated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N role|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N G+C-rich|JJ|N/N region|NN|N in|IN|(NP\NP)/(S[ng]\NP) augmenting|VBG|(S[ng]\NP)/NP alpha-globin|NN|N/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N far-upstream|JJ|N/N alpha-globin|NN|N/N enhancer|NN|N ,|,|, HS-40|NN|N .|.|.
We|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] in|IN|(S/S)/NP transiently|RB|(N/N)/(N/N) transfected|VBN|N/N erythroid|JJ|N/N cells|NNS|N ,|,|, deletion|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N alpha-globin|NN|N/N G+C-rich|JJ|N/N 5'|JJ|N/N flanking|JJ|N/N region|NN|N has|VBZ|(S[dcl]\NP)/NP no|DT|NP[nb]/N effect|NN|N on|IN|(NP\NP)/NP alpha-globin|NN|N/N promoter|NN|N/N activity|NN|N .|.|.
However|RB|S/S ,|,|, upon|IN|(S/S)/NP stable|JJ|N/N integration|NN|N into|IN|(NP\NP)/NP chromatin|NN|N ,|,|, deletion|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N region|NN|N causes|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N nearly|RB|((N/N)/(N/N))/((N/N)/(N/N)) 90|CD|(N/N)/(N/N) %|NN|N/N decrease|NN|N in|IN|(NP\NP)/NP promoter|NN|N/N activity|NN|N compared|VBN|(NP\NP)/PP with|IN|PP/NP expression|NN|N from|IN|(NP\NP)/NP an|DT|NP[nb]/N alpha-globin|NN|N/N promoter|NN|N retaining|VBG|(S[ng]\NP)/NP this|DT|NP[nb]/N region|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N alpha-globin|NN|N/N G+C-rich|JJ|N/N 5'|JJ|N/N flanking|JJ|N/N region|NN|N augments|VBZ|(S[dcl]\NP)/NP alpha-globin|NN|N/N promoter|NN|N/N activity|NN|N in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N chromatin-dependent|JJ|N/N manner|NN|N .|.|.
We|PRP|NP further|RB|(S\NP)/(S\NP) show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] this|DT|NP[nb]/N G+C-rich|JJ|N/N region|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP alpha-globin|NN|N/N gene|NN|N/N expression|NN|N during|IN|((S\NP)\(S\NP))/NP erythroid|JJ|N/N differentiation|NN|N .|.|.
Finally|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] by|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP footprint|NN|N/N analysis|NN|N and|CC|conj functional|JJ|N/N assays|NNS|N that|IN|S[em]/S[dcl] the|DT|NP[nb]/N ability|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N G+C-rich|JJ|N/N region|NN|N to|TO|(S[to]\NP)/(S[b]\NP) increase|VB|(S[b]\NP)/NP alpha-globin|NN|N/N promoter|NN|N/N activity|NN|N from|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N stably|RB|(N/N)/(N/N) integrated|VBN|N/N alpha-globin|NN|N/N gene|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP its|PRP$|NP[nb]/N multiple|JJ|N/N binding|VBG|N/N sites|NNS|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N factor|NN|N Sp1|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) earlier|RBR|(S\NP)\(S\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] stimulation|NN|N of|IN|(NP\NP)/NP human|JJ|N/N CD4+|JJ|N/N T|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP SEA|NN|N presented|VBN|S[pss]\NP on|IN|((S\NP)\(S\NP))/NP Chinese|JJ|N/N hamster|NN|N/N ovary|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) CHO|NN|N/N )|RRB|RRB -DR|NN|N/N transfectants|NNS|N coexpressing|VBG|(S[ng]\NP)/NP either|CC|NP/NP B7|NN|N or|CC|conj LFA-3|NN|N resulted|VBD|(S[dcl]\NP)/PP in|IN|PP/NP distinct|JJ|N/N cytokine|NN|N/N profiles|NNS|N .|.|.
We|PRP|NP now|RB|(S\NP)/(S\NP) demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] B7|NN|N ,|,|, but|CC|conj not|RB|NP/NP LFA-3|NN|N ,|,|, strongly|RB|(S\NP)/(S\NP) costimulated|VBD|(S[dcl]\NP)/NP IL-2|NN|N/N transcription|NN|N and|CC|conj mRNA|NN|N/N expression|NN|N in|IN|((S\NP)\(S\NP))/NP CD4+|JJ|N/N T|NN|N/N cells|NNS|N .|.|.
Maximal|JJ|N/N increase|NN|N in|IN|(NP\NP)/NP IL-2|NN|N/N transcription|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) recorded|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP CHO-DR/B7/LFA-3|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N cooperative|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP B7|NN|N and|CC|conj LFA-3|NN|N at|IN|(NP\NP)/NP the|DT|NP[nb]/N transcriptional|JJ|N/N level|NN|N .|.|.
Gel-shift|JJ|N/N analysis|NN|N demonstrated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] stimulation|NN|N of|IN|(NP\NP)/NP CD4+|JJ|N/N T|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP CHO-DR|NN|N and|CC|conj staphylococcal|JJ|N/N enterotoxin|NN|N/N A|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) sufficient|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP significant|JJ|N/N amounts|NNS|N of|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N proteins|NNS|N ,|,|, whereas|IN|((S\NP)\(S\NP))/S[dcl] induction|NN|N of|IN|(NP\NP)/NP AP-1|NN|N/N binding|NN|N/N proteins|NNS|N required|VBD|(S[dcl]\NP)/NP costimulation|NN|N .|.|.
LFA-3|NN|N induced|VBD|(S[dcl]\NP)/NP moderate|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP AP-1|NN|N ,|,|, but|CC|conj did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) influence|VB|(S[b]\NP)/NP the|DT|NP[nb]/N levels|NNS|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N ,|,|, while|IN|((S\NP)\(S\NP))/S[dcl] B7|NN|N/N costimulation|NN|N strongly|RB|(S\NP)/(S\NP) induced|VBD|(S[dcl]\NP)/NP both|CC|NP/NP AP-1|NN|N and|CC|conj substantially|RB|(N/N)/(N/N) enhanced|VBN|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N proteins|NNS|N .|.|.
The|DT|NP[nb]/N CHO-DR/B7/LFA-3triple|JJ|N/N transfectant|NN|N induced|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N further|JJ|N/N increase|NN|N in|IN|(NP\NP)/NP AP-1|NN|N and|CC|conj NF-kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N proteins|NNS|N compared|VBN|(NP\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N double|JJ|N/N transfectants|NNS|N .|.|.
The|DT|NP[nb]/N level|NN|N of|IN|(NP\NP)/NP Oct-1|NN|N/N binding|NN|N/N proteins|NNS|N remained|VBD|(S[dcl]\NP)/(S[adj]\NP) similar|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP all|DT|NP[nb]/N samples|NNS|N .|.|.
Super-shift|JJ|N/N analysis|NN|N revealed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N complex|NN|N of|IN|(NP\NP)/NP costimulated|VBN|N/N CD4+|JJ|N/N T|NN|N/N cells|NNS|N contained|VBD|(S[dcl]\NP)/NP large|JJ|N/N amounts|NNS|N of|IN|(NP\NP)/NP p50|NN|N ,|,|, substantial|JJ|N/N amounts|NNS|N of|IN|(NP\NP)/NP p65|NN|N ,|,|, and|CC|conj marginal|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP c-Rel|NN|N/N proteins|NNS|N .|.|.
The|DT|NP[nb]/N AP-1|NN|N/N binding|NN|N/N proteins|NNS|N contained|VBD|(S[dcl]\NP)/NP c-Jun|NN|N ,|,|, Jun-D|NN|N ,|,|, and|CC|conj Fra-1|NN|N ,|,|, but|CC|conj marginal|JJ|N/N amounts|NNS|N of|IN|(NP\NP)/NP Jun-B|NN|N and|CC|conj c-Fos|NN|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N indicate|VBP|(S[dcl]\NP)/NP distinct|JJ|N/N effects|NNS|N of|IN|(NP\NP)/NP B7|NN|N and|CC|conj LFA-3|NN|N/N costimulation|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP AP-1|NN|N and|CC|conj NF-kappa|NN|N/N B|NN|N .|.|.
These|DT|NP may|MD|(S[dcl]\NP)/(S[b]\NP) partly|RB|(S\NP)\(S\NP) account|VB|(S[b]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N differential|JJ|N/N effects|NNS|N of|IN|(NP\NP)/NP B7|NN|N/N and|CC|conj LFA-3|NN|N/N costimulation|NN|N on|IN|(NP\NP)/NP IL-2|NN|N/N expression|NN|N .|.|.
2,3,7,8-tetrachlorodibenzo-p-dioxin|NN|N (|LRB|(N\N)/N TCDD|NN|N )|RRB|RRB inhibits|VBZ|(S[dcl]\NP)/NP murine|JJ|N/N and|CC|conj human|JJ|N/N B|NN|N/N lymphocyte|NN|N/N immunoglobulin|NN|N/N production|NN|N through|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N unknown|JJ|N/N mechanism|NN|N .|.|.
This|DT|NP[nb]/N study|NN|N investigated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP TCDD|NN|N on|IN|(NP\NP)/NP expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N CD19|NN|N/N gene|NN|N in|IN|(NP\NP)/NP a|DT|NP[nb]/N human|JJ|N/N B|NN|N/N lymphocyte|NN|N/N cell|NN|N/N line|NN|N .|.|.
Northern|NN|(N/N)/(N/N) blot|NN|N/N analysis|NN|N showed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] TCDD|NN|N/N treatment|NN|N decreased|VBD|(S[dcl]\NP)/NP steady|JJ|(N/N)/(N/N) state|NN|N/N levels|NNS|N of|IN|(NP\NP)/NP CD19|NN|N/N mRNA|NN|N by|IN|((S\NP)\(S\NP))/NP 67|CD|N/N %|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N IM-9|NN|N/N cell|NN|N/N line|NN|N .|.|.
Using|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N gel|NN|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N ,|,|, we|PRP|NP identified|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N DNA-binding|NN|N/N complex|NN|N in|IN|(NP\NP)/NP IM-9|NN|N/N nuclear|JJ|N/N extracts|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) by|IN|((S\NP)/(S\NP))/NP several|JJ|N/N criteria|NNS|N appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP the|DT|NP[nb]/N Ah|NN|N/N receptor|NN|N .|.|.
In|IN|(S/S)/NP addition|NN|N ,|,|, the|DT|NP[nb]/N Ah|NN|N/N receptor|NN|N/N complex|NN|N recognized|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N DNA|NN|N/N binding|NN|N/N site|NN|N for|IN|(NP\NP)/NP B|NN|N/N cell|NN|N/N lineage-specific|JJ|N/N activator|NN|N/N protein|NN|N (|LRB|(NP\NP)/NP BSAP|NN|N )|RRB|RRB in|IN|(NP\NP)/NP the|DT|NP[nb]/N promoter|NN|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N CD19|NN|N/N gene|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) similar|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N consensus|NN|N/N Ah|NN|N/N receptor|NN|N/N DNA|NN|N/N binding|NN|N/N site|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N AhR|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) interfere|VB|(S[b]\NP)/PP with|IN|PP/NP BSAP-stimulated|JJ|N/N CD19|NN|N/N gene|NN|N/N transcription|NN|N by|IN|((S\NP)\(S\NP))/NP competition|NN|N for|IN|(NP\NP)/NP a|DT|NP[nb]/N common|JJ|N/N DNA|NN|N/N binding|NN|N/N site|NN|N .|.|.
We|PRP|NP recently|RB|(S\NP)/(S\NP) identified|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N differentiation|NN|N/N inhibitory|JJ|N/N factor|NN|N (|LRB|(N\N)/N I-factor|NN|N )|RRB|RRB in|IN|((S\NP)\(S\NP))/NP mouse|NN|N/N myeloid|JJ|N/N leukemia|NN|N/N M1|NN|N/N cells|NNS|N as|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N murine|JJ|N/N homolog|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N nm23-H2|NN|N/N gene|NN|N/N product|NN|N .|.|.
nm23|NN|N/N genes|NNS|N encode|VBP|(S[dcl]\NP)/NP proteins|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) participate|VBP|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP tumor|NN|N/N metastasis|NN|N/N regulation|NN|N and|CC|conj in|IN|((S\NP)\(S\NP))/NP various|JJ|N/N fundamental|JJ|N/N cellular|JJ|N/N processes|NNS|N ,|,|, although|IN|((S\NP)\(S\NP))/S[dcl] their|PRP$|NP[nb]/N mechanisms|NNS|N of|IN|(NP\NP)/NP action|NN|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) still|RB|(S\NP)\(S\NP) unknown|JJ|S[adj]\NP .|.|.
Although|IN|(S/S)/S[dcl] all|DT|NP[nb]/N nm23|NN|N/N proteins|NNS|N contain|VBP|(S[dcl]\NP)/NP nucleoside|NN|N/N diphosphate|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) NDP|NN|N/N )|RRB|RRB kinase|NN|N/N activity|NN|N ,|,|, it|PRP|NP has|VBZ|(S[dcl]\NP)/(S[pt]\NP) not|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) established|VBN|S[pss]\NP that|IN|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N enzyme|NN|N/N activity|NN|N mediated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N various|JJ|N/N functions|NNS|N of|IN|(NP\NP)/NP nm23|NN|N/N proteins|NNS|N .|.|.
In|IN|(S/S)/NP the|DT|NP[nb]/N present|JJ|N/N experiment|NN|N ,|,|, we|PRP|NP examined|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP nm23|NN|N/N proteins|NNS|N on|IN|(NP\NP)/NP various|JJ|N/N differentiation|NN|N/N induction|NN|N/N systems|NNS|N of|IN|(NP\NP)/NP human|JJ|N/N leukemic|JJ|N/N cells|NNS|N including|VBG|(NP\NP)/NP HL-60|NN|N/N ,|,|, U937|NN|N/N ,|,|, HEL/S|NN|N/N ,|,|, KU812F|NN|N/N ,|,|, K562|NN|N/N ,|,|, and|CC|conj HEL|NN|N/N cells|NNS|N .|.|.
Native|JJ|N/N human|JJ|N/N erythrocyte|NN|N/N NDP|NN|N/N kinase|NN|N/N protein|NN|N inhibited|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP erythroid|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP HEL|NN|N/N ,|,|, KU812|NN|N/N and|CC|conj K562|NN|N/N cells|NNS|N ,|,|, but|CC|conj not|RB|NP/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP monocytic|JJ|N/N or|CC|conj granulocytic|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP HL-60|NN|N/N ,|,|, U937|NN|N/N and|CC|conj HEL/S|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N erythroid|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP HEL|NN|N/N cells|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) inhibited|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP recombinant|JJ|N/N human|JJ|(N/N)/(N/N) nm23-H1|NN|N/N ,|,|, -H2|NN|N/N ,|,|, mouse|NN|(N/N)/(N/N) nm23-M1|NN|N/N ,|,|, and|CC|conj -M2|NN|N/N proteins|NNS|N .|.|.
Moreover|RB|S/S ,|,|, both|CC|NP/NP the|DT|NP[nb]/N mutant|JJ|N/N nm23-H2His|NN|N/N protein|NN|N and|CC|conj truncated|VBN|N/N nm23-H2|NN|N/N protein|NN|N containing|VBG|(S[ng]\NP)/NP N-terminal|JJ|N/N (|LRB|((N/N)\(N/N))/(N/N) 1-60|CD|N/N )|RRB|RRB peptide|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) do|VBP|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) have|VB|(S[b]\NP)/NP NDP|NN|N/N kinase|NN|N/N activity|NN|N ,|,|, also|RB|(S\NP)/(S\NP) inhibited|VBD|(S[dcl]\NP)/NP erythroid|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP HEL|NN|N/N cells|NNS|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] (|LRB|LRB 1|LS|S/S )|RRB|RRB the|DT|NP[nb]/N differentiation|NN|N/N inhibitory|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP I-factor/nm23|NN|N/N protein|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) restricted|JJ|S[adj]\NP to|TO|((S[adj]\NP)\(S[adj]\NP))/NP monocytic|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP M1|NN|N/N cells|NNS|N ,|,|, (|LRB|LRB 2|LS|S/S )|RRB|RRB the|DT|NP[nb]/N inhibitory|JJ|N/N activity|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) exhibited|VBN|S[pss]\NP without|IN|((S\NP)\(S\NP))/NP species|NNS|N/N specificity|NN|N ,|,|, and|CC|conj (|LRB|LRB 3|LS|S/S )|RRB|RRB the|DT|NP[nb]/N differentiation|NN|N/N inhibitory|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N nm23/NDP|NN|N/N kinase|NN|N/N protein|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) independent|JJ|(S[adj]\NP)/PP of|IN|PP/NP its|PRP$|NP[nb]/N enzyme|NN|N/N activity|NN|N and|CC|conj requires|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP N-terminal|JJ|N/N peptides|NNS|N .|.|.
Endothelial|JJ|N/N cells|NNS|N stimulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP LPS|NN|N express|VBP|(S[dcl]\NP)/NP E-selectin|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) plays|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/(S[ng]\NP) mediating|VBG|(S[ng]\NP)/NP neutrophil|NN|N/N adhesion|NN|N during|IN|((S\NP)\(S\NP))/NP inflammation|NN|N .|.|.
E-selectin|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP within|IN|((S\NP)\(S\NP))/NP 1-2|CD|N/N h|NN|N ,|,|, peaks|VBZ|(S[dcl]\NP)/PP at|IN|PP/NP 4-6|CD|N/N h|NN|N ,|,|, and|CC|conj gradually|RB|(S\NP)/(S\NP) returns|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP basal|JJ|N/N level|NN|N by|IN|((S\NP)\(S\NP))/NP 24|CD|N/N h|NN|N .|.|.
rBPI21|NN|N ,|,|, a|DT|NP[nb]/N recombinant|JJ|N/N N-terminal|JJ|N/N fragment|NN|N of|IN|(NP\NP)/NP human|JJ|N/N bactericidal/permeability-increasing|JJ|N/N protein|NN|N (|LRB|(N\N)/N BPI|NN|N )|RRB|RRB ,|,|, inhibited|VBD|(S[dcl]\NP)/NP LPS-induced|JJ|N/N E-selectin|NN|N/N expression|NN|N when|WRB|((S\NP)\(S\NP))/(S[pss]\NP) added|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N same|JJ|N/N time|NN|N as|IN|(NP\NP)/NP ,|,|, and|CC|conj up|IN|(NP\NP)/PP to|TO|PP/NP 6|CD|N/N h|NN|N after|IN|(NP\NP)/NP ,|,|, LPS|NN|N .|.|.
Delayed|VBN|N/N administration|NN|N of|IN|(NP\NP)/NP rBPI21|NN|N also|RB|(S\NP)/(S\NP) affected|VBD|(S[dcl]\NP)/NP LPS-mediated|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N nuclear|JJ|N/N factor|NN|N ,|,|, NF-kappa|NN|N/N B|NN|N .|.|.
Two|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 4|CD|N/N h|NN|N following|VBG|(NP\NP)/NP LPS|NN|N/N addition|NN|N to|TO|(NP\NP)/NP endothelial|JJ|N/N cells|NNS|N ,|,|, when|WRB|(S/S)/S[dcl] NF-kappa|NN|N/N B|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) already|RB|(S\NP)\(S\NP) activated|VBN|S[adj]\NP ,|,|, addition|NN|N of|IN|(NP\NP)/NP rBPI21|NN|N resulted|VBD|(S[dcl]\NP)/PP in|IN|PP/NP marked|JJ|N/N reduction|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N detectable|JJ|S[adj]\NP at|IN|((S[adj]\NP)\(S[adj]\NP))/NP 4|CD|N/N or|CC|conj 6|CD|N/N h|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] endothelial|JJ|N/N activation|NN|N requires|VBZ|(S[dcl]\NP)/NP continuous|JJ|N/N presence|NN|N of|IN|(NP\NP)/NP LPS|NN|N ,|,|, and|CC|conj rBPI21|NN|N acts|VBZ|S[dcl]\NP to|TO|((S\NP)\(S\NP))/(S[b]\NP) reverse|VB|(S[b]\NP)/NP LPS-mediated|JJ|N/N endothelial|JJ|N/N activation|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) interrupting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N on-going|JJ|N/N LPS|NN|N/N signal|NN|N .|.|.
Antigen|NN|N complexed|VBN|(S[pss]\NP)/PP with|IN|PP/NP major|JJ|N/N histocompatibility|NN|N/N complex|NN|N/N class|NN|N/N I|CD|(N/N)\(N/N) or|CC|conj II|CD|(N/N)\(N/N) molecules|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N surface|NN|N of|IN|(NP\NP)/NP antigen|NN|N/N presenting|NN|N/N cells|NNS|N interacts|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N T|NN|(N/N)/(N/N) cell|NN|N/N receptor|NN|N (|LRB|(NP\NP)/NP TCR|NN|N )|RRB|RRB on|IN|(NP\NP)/NP the|DT|NP[nb]/N surface|NN|N of|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N and|CC|conj initiates|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N activation|NN|N/N cascade|NN|N .|.|.
So|RB|(N/N)/(N/N) called|VBN|N/N costimulatory|JJ|N/N signals|NNS|N ,|,|, mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP other|JJ|N/N cell|NN|N/N surface|NN|N/N interactions|NNS|N or|CC|conj soluble|JJ|N/N cytokines|NNS|N produced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP antigen|NN|N/N presenting|NN|N/N cells|NNS|N ,|,|, are|VBP|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP complete|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N .|.|.
High|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP cytokine|NN|N/N gene|NN|N/N expression|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N also|RB|(S\NP)/(S\NP) required|VBD|(S[dcl]\NP)/NP both|CC|NP/NP TCR|NN|N/N and|CC|conj costimulatory|JJ|N/N signals|NNS|N .|.|.
The|DT|NP[nb]/N granulocyte-macrophage|JJ|N/N colony-stimulating|JJ|N/N factor|NN|N requires|VBZ|((S[dcl]\NP)/(S[to]\NP))/NP sequences|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N promoter|NN|N as|RB|conj/conj well|RB|conj/conj as|IN|conj a|DT|NP[nb]/N powerful|JJ|N/N enhancer|NN|N located|JJ|(S[pss]\NP)/(S[adj]\NP) 3kb|RB|(S[adj]\NP)/(S[adj]\NP) upstream|RB|S[adj]\NP to|TO|(S[to]\NP)/(S[b]\NP) respond|VB|(S[b]\NP)/PP to|TO|PP/NP TCR-like|JJ|N/N signals|NNS|N .|.|.
These|DT|NP[nb]/N promoter|NN|N/N and|CC|conj enhancer|NN|N/N regions|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) mainly|RB|(S\NP)/(S\NP) activated|VBN|(S[pss]\NP)/PP by|IN|PP/NP the|DT|NP[nb]/N transcription|NN|N/N factor|NN|N/N nuclear|JJ|N/N factor|NN|N of|IN|(NP\NP)/NP activated|VBN|N/N T|NN|N/N cells|NNS|N/N (|LRB|LRB NFAT|NN|N )|RRB|RRB .|.|.
The|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP NFAT|NN|N by|IN|(NP\NP)/NP TCR|NN|N/N signals|NNS|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) well|RB|(S\NP)/(S\NP) described|VBN|(S[pss]\NP)/PP for|IN|PP/NP interleukin-2|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL-2|NN|N/N )|RRB|RRB and|CC|conj IL-4|NN|N/N gene|NN|N/N transcription|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N .|.|.
Costimulatory|JJ|N/N signals|NNS|N ,|,|, such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N CD28|NN|N/N cell|NN|N/N surface|NN|N/N molecule|NN|N on|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N ,|,|, lead|VBP|(S[dcl]\NP)/PP to|TO|PP/NP activation|NN|N through|IN|(NP\NP)/NP a|DT|NP[nb]/N distinct|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N granulocyte-macrophage|JJ|N/N colony-stimulating|JJ|N/N factor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) GM-CSF|NN|N/N )|RRB|RRB promoter|NN|N .|.|.
This|DT|NP[nb]/N region|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) termed|VBN|(S[pss]\NP)/NP the|DT|NP[nb]/N CK-1|NN|N or|CC|conj CD28RE|NN|N and|CC|conj appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/NP specific|JJ|N/N members|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N family|NN|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N .|.|.
Human|JJ|N/N T|NN|N/N leukemia|NN|N/N virus|NN|N type|NN|N\N 1|CD|(N\N)\(N\N) (|LRB|(N\N)/N HTLV-1|NN|N )|RRB|RRB infects|VBZ|(S[dcl]\NP)/NP T|NN|N/N cells|NNS|N and|CC|conj can|MD|(S[dcl]\NP)/(S[b]\NP) lead|VB|S[b]\NP to|TO|(S[to]\NP)/(S[b]\NP) increase|VB|(S[b]\NP)/NP GM-CSF|NN|N/N expression|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) found|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N HTLV-1|NN|N/N transactivator|NN|N/N protein|NN|N ,|,|, tax|NN|N ,|,|, acts|VBZ|(S[dcl]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N costimulatory|JJ|N/N signal|NN|N for|IN|(NP\NP)/NP GM-CSF|NN|N/N and|CC|conj IL-2|NN|N/N gene|NN|N/N transcription|NN|N ,|,|, in|IN|(S\S)/(S\S) that|IN|(S\S)/S[dcl] it|PRP|NP can|MD|(S[dcl]\NP)/(S[b]\NP) cooperate|VB|(S[b]\NP)/PP with|IN|PP/NP TCR|NN|N/N signals|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) mediate|VB|(S[b]\NP)/NP high|JJ|(N/N)/(N/N) level|NN|N/N gene|NN|N/N expression|NN|N .|.|.
Tax|NN|N activates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N GM-CSF|NN|N/N promoter|NN|N through|IN|((S\NP)/(S\NP))/NP the|DT|NP[nb]/N CK-1/CD28RE|NN|N/N region|NN|N and|CC|conj also|RB|(S\NP)/(S\NP) activates|VBZ|((S[dcl]\NP)/(S[ng]\NP))/NP nuclear|JJ|N/N factor-kappa|NN|N/N B|NN|N binding|VBG|(S[ng]\NP)/PP to|TO|PP/NP this|DT|NP[nb]/N region|NN|N .|.|.
However|RB|S/S ,|,|, other|JJ|N/N transcription|NN|N/N factors|NNS|N or|CC|conj coactivators|NNS|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP tax|NN|N/N activation|NN|N but|CC|conj these|DT|NP remain|VBP|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) identified|VBN|S[pss]\NP .|.|.
The|DT|NP[nb]/N CK-1/CD28RE|NN|N of|IN|(NP\NP)/NP GM-CSF|NN|N shows|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N high|JJ|N/N degree|NN|N of|IN|(NP\NP)/NP similarity|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N CD28RE|NN|N and|CC|conj the|DT|NP[nb]/N IL-3|NN|N/N gene|NN|N also|RB|(S\NP)/(S\NP) contains|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N related|JJ|N/N region|NN|N .|.|.
This|DT|NP[nb]/N observation|NN|N ,|,|, together|RB|(NP\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N fact|NN|N/S[em] that|IN|S[em]/S[dcl] both|CC|NP/NP GM-CSF|NN|N and|CC|conj IL-2|NN|N respond|VBP|(S[dcl]\NP)/PP to|TO|PP/NP TCR|NN|N/N signals|NNS|N via|IN|((S\NP)\(S\NP))/NP NFAT|NN|N ,|,|, implies|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N high|JJ|N/N degree|NN|N of|IN|(NP\NP)/NP conservation|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP cytokine|NN|N/N gene|NN|N/N expression|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N .|.|.
1.|LS|S/S Administration|NN|N of|IN|(NP\NP)/NP danazol|NN|N for|IN|(NP\NP)/NP over|IN|(N/N)/(N/N) one|CD|N/N month|NN|N reduced|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N levels|NNS|N of|IN|(NP\NP)/NP estrogen|NN|N/N receptor|NN|N (|LRB|(NP\NP)/NP ER|NN|N )|RRB|RRB and|CC|conj its|PRP$|NP[nb]/N mRNA|NN|N to|TO|((S\NP)\(S\NP))/NP approximately|RB|(N/N)/(N/N) 50|CD|N/N and|CC|conj 20|CD|N/N %|NN|N ,|,|, respectively|RB|NP\NP in|IN|(NP\NP)/NP monocytes|NNS|N .|.|.
2.|LS|S/S Danazol|NN|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) alter|VB|(S[b]\NP)/NP the|DT|NP[nb]/N degradation|NN|N/N rate|NN|N of|IN|(NP\NP)/NP ER|NN|N/N mRNA|NN|N in|IN|(NP\NP)/NP monocytes|NNS|N .|.|.
3.|LS|S/S Danazol|NN|N decreased|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N rate|NN|N of|IN|(NP\NP)/NP ER|NN|N/N gene|NN|N to|TO|((S\NP)\(S\NP))/NP approximately|RB|(N/N)/(N/N) 50|CD|N/N %|NN|N in|IN|((S\NP)\(S\NP))/NP monocytes|NNS|N in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N run-on|JJ|N/N assay|NN|N .|.|.
4.|LS|S/S Danazol|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) release|VB|(S[b]\NP)/NP estrogen|NN|N/N predominance|NN|N via|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N reduction|NN|N of|IN|(NP\NP)/NP transcription|NN|N for|IN|(NP\NP)/NP ER|NN|N/N gene|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N reduction|NN|N of|IN|(NP\NP)/NP ER|NN|N/N mRNA|NN|N and|CC|conj ER|NN|N/N expressions|NNS|N in|IN|(NP\NP)/NP monocytes|NNS|N .|.|.
IL-2-mediated|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N proliferation|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N critical|JJ|N/N early|JJ|N/N event|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N inflammatory|JJ|N/N process|NN|N .|.|.
Formation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N NFAT-1|NN|N/N transcriptional|JJ|N/N complex|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N promoter|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) essential|JJ|(S[adj]\NP)/PP for|IN|PP/NP IL-2|NN|N/N transcription|NN|N .|.|.
Using|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N cell|NN|N/N line|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) stably|RB|(S\NP)\(S\NP) transfected|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N trimer|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N NFAT-1|NN|N/N regulatory|JJ|N/N element|NN|N linked|VBN|(S[pss]\NP)/PP to|TO|PP/NP a|DT|NP[nb]/N lac-Z|NN|N/N reporter|NN|N/N gene|NN|N ,|,|, we|PRP|NP screened|VBD|(S[dcl]\NP)/PP for|IN|PP/NP inhibitors|NNS|N of|IN|(NP\NP)/NP NFAT-1-mediated|JJ|N/N beta-galactosidase|NN|N/N activity|NN|N .|.|.
WIN|NN|N 61058|CD|N\N and|CC|conj WIN|NN|N 53071|CD|N\N were|VBD|(S[dcl]\NP)/(S[pss]\NP) identified|VBN|(S[pss]\NP)/PP as|IN|PP/NP microM|NN|N/N inhibitors|NNS|N .|.|.
These|DT|NP[nb]/N compounds|NNS|N also|RB|(S\NP)/(S\NP) inhibited|VBD|(S[dcl]\NP)/NP beta-galactosidase|NN|N/N mRNA|NN|N/N levels|NNS|N .|.|.
Similar|JJ|N/N inhibition|NN|N of|IN|(NP\NP)/NP NFAT-1-mediated|JJ|N/N gene|NN|N/N expression|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N second|JJ|N/N cell|NN|N/N line|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) stably|RB|(S\NP)\(S\NP) transfected|VBN|(S[pss]\NP)/PP with|IN|PP/NP NFAT-1|NN|N/N regulatory|JJ|N/N elements|NNS|N linked|VBN|(S[pss]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N reporter|NN|N/N gene|NN|N for|IN|(NP\NP)/NP sCD8|NN|N .|.|.
At|IN|(S/S)/NP 10|CD|N/N microM|NN|N ,|,|, both|DT|NP[nb]/N compounds|NNS|N inhibited|VBD|(S[dcl]\NP)/NP IL-2|NN|N/N mRNA|NN|N and|CC|conj protein|NN|N/N levels|NNS|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N NFAT-1-linked|JJ|N/N lac-Z|NN|N/N transfectants|NNS|N ,|,|, and|CC|conj in|IN|((S\NP)\(S\NP))/NP human|JJ|N/N lymphocytes|NNS|N .|.|.
Both|DT|NP[nb]/N compounds|NNS|N inhibited|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N mixed|JJ|N/N lymphocyte|NN|N/N reaction|NN|N ,|,|, and|CC|conj this|DT|NP[nb]/N inhibition|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) reversed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP exogenous|JJ|N/N IL-2|NN|N .|.|.
WIN|NN|N 53071|CD|N\N inhibited|VBD|(S[dcl]\NP)/NP IL-2|NN|N/N production|NN|N induced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N calcium-dependent|JJ|N/N PMA|NN|N and|CC|conj ionomycin|NN|N/N pathway|NN|N .|.|.
Conversely|RB|S/S ,|,|, calcium-independent|JJ|N/N anti-CD28|JJ|N/N Ab|NN|N and|CC|conj PMA-induced|JJ|N/N IL-2|NN|N/N production|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) resistant|JJ|S[adj]\NP .|.|.
Both|DT|NP[nb]/N compounds|NNS|N altered|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N NFAT-1|NN|N/N transcriptional|JJ|N/N complex|NN|N ,|,|, causing|VBG|(S[ng]\NP)/NP its|PRP$|NP[nb]/N retarded|VBN|N/N mobility|NN|N on|IN|(NP\NP)/NP gels|NNS|N .|.|.
By|IN|(S/S)/NP these|DT|NP[nb]/N functional|JJ|N/N criteria|NNS|N ,|,|, we|PRP|NP believe|VBP|(S[dcl]\NP)/S[dcl] we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) identified|VBN|(S[pt]\NP)/NP two|CD|N/N structurally|RB|(N/N)/(N/N) distinct|JJ|N/N ,|,|, novel|JJ|N/N inhibitors|NNS|N of|IN|(NP\NP)/NP NFAT-1-mediated|JJ|N/N transcription|NN|N .|.|.
Monocyte-macrophage|JJ|N/N differentiation|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|(S[pss]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N model|NN|N/N system|NN|N for|IN|(NP\NP)/(S[ng]\NP) studying|VBG|(S[ng]\NP)/NP gene|NN|N/N regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N vacuolar|NN|N/N H(+)-ATPase|NN|N (|LRB|(NP\NP)/NP V-ATPase|NN|N )|RRB|RRB .|.|.
We|PRP|NP examined|VBD|(S[dcl]\NP)/NP mRNA|NN|N/N levels|NNS|N of|IN|(NP\NP)/NP various|JJ|N/N V-ATPase|NN|N/N subunits|NNS|N during|IN|((S\NP)\(S\NP))/NP differentiation|NN|N of|IN|(NP\NP)/NP both|CC|NP/NP native|JJ|N/N monocytes|NNS|N and|CC|conj the|DT|NP[nb]/N cell|NN|N/N line|NN|N THP-1|NN|N ,|,|, and|CC|conj found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] transcriptional|JJ|N/N and|CC|conj post-transcriptional|JJ|N/N mechanisms|NNS|N could|MD|(S[dcl]\NP)/(S[b]\NP) account|VB|(S[b]\NP)/PP for|IN|PP/NP increases|NNS|N in|IN|(NP\NP)/NP cell|NN|N/N V-ATPase|NN|N/N content|NN|N .|.|.
From|IN|(S/S)/NP nuclear|JJ|N/N runoff|JJ|N/N experiments|NNS|N ,|,|, we|PRP|NP found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] one|CD|N/N subunit|NN|N in|IN|(NP\NP)/(S[adj]\NP) particular|JJ|S[adj]\NP ,|,|, the|DT|NP[nb]/N B2|NN|N/N isoform|NN|N (|LRB|(NP\NP)/NP Mr|NN|N =|JJ|(N\N)/N 56,000|CD|N )|RRB|RRB ,|,|, was|VBD|(S[dcl]\NP)/(S[pss]\NP) amplified|VBN|S[pss]\NP primarily|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) by|IN|((S\NP)\(S\NP))/NP transcriptional|JJ|N/N means|NNS|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) begun|VBN|(S[pt]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) examine|VB|(S[b]\NP)/NP the|DT|NP[nb]/N structure|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N B2|NN|N/N subunit|NN|N/N promoter|NN|N/N region|NN|N .|.|.
Isolation|NN|N and|CC|conj sequencing|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N first|JJ|N/N exon|NN|N and|CC|conj 5'-flanking|JJ|N/N region|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N gene|NN|N reveal|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N TATA-less|JJ|N/N promoter|NN|N with|IN|(NP\NP)/NP a|DT|NP[nb]/N high|JJ|N/N G|NN|N/N +|CC|conj C|NN|N/N content|NN|N .|.|.
Primer|NN|N/N extension|NN|N and|CC|conj ribonuclease|NN|N/N protection|NN|N/N analyses|NNS|N indicate|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N single|JJ|N/N major|JJ|N/N transcriptional|JJ|N/N start|NN|N/N site|NN|N .|.|.
We|PRP|NP transfected|VBD|(S[dcl]\NP)/NP promoter-luciferase|NN|N/N reporter|NN|N/N plasmids|NNS|N into|IN|((S\NP)\(S\NP))/NP THP-1|NN|N/N cells|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) define|VB|(S[b]\NP)/NP sequences|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) mediate|VBP|(S[dcl]\NP)/NP transcriptional|JJ|N/N control|NN|N during|IN|((S\NP)\(S\NP))/NP monocyte|NN|N/N differentiation|NN|N .|.|.
We|PRP|NP found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] sequences|NNS|N downstream|RB|(S[adj]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N transcriptional|JJ|N/N start|NN|N/N site|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) sufficient|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) confer|VB|(S[b]\NP)/NP increased|VBN|N/N expression|NN|N during|IN|(NP\NP)/NP THP-1|NN|N/N differentiation|NN|N .|.|.
DNase|NN|N/N I|CD|(N/N)\(N/N) footprinting|NN|N and|CC|conj sequence|NN|N/N analysis|NN|N revealed|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N existence|NN|N of|IN|(NP\NP)/NP multiple|JJ|N/N AP2|NN|N/N and|CC|conj Sp1|NN|N/N binding|NN|N/N sites|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N 5'-untranslated|JJ|N/N and|CC|conj proximal|JJ|N/N coding|VBG|N/N regions|NNS|N .|.|.
Expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N protooncogene|NN|N c-fos|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) controlled|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP three|CD|N/N main|JJ|N/N regulatory|JJ|N/N pathways|NNS|N involving|VBG|(S[ng]\NP)/NP kinase|NN|N/N C|NN|N ,|,|, cAMP|NN|N ,|,|, and|CC|conj calcium|NN|N .|.|.
Kinase|NN|N/N C|NN|N mediates|VBZ|(S[dcl]\NP)/NP its|PRP$|NP[nb]/N effects|NNS|N via|IN|((S\NP)\(S\NP))/NP phosphorylation|NN|N of|IN|(NP\NP)/NP serum|NN|N/N response|NN|N/N factor|NN|N (|LRB|(NP\NP)/NP SRF|NN|N )|RRB|RRB which|WDT|(NP\NP)/(S[dcl]\NP) interacts|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N serum|NN|N/N response|NN|N/N element|NN|N (|LRB|(NP\NP)/NP SRE|NN|N )|RRB|RRB ;|:|; cAMP|NN|N and|CC|conj calcium|NN|N mediate|VBP|(S[dcl]\NP)/NP their|PRP$|NP[nb]/N effects|NNS|N via|IN|((S\NP)\(S\NP))/NP phosphorylation|NN|N of|IN|(NP\NP)/NP CREB|NN|N (|LRB|(N\N)/N cAMP|NN|N/N regulatory|JJ|N/N element|NN|N/N binding|NN|N/N protein|NN|N )|RRB|RRB presumably|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) by|IN|((S\NP)\(S\NP))/NP activation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N protein|NN|N/N kinase|NN|N/N A|NN|N or|CC|conj calmodulin-regulated|JJ|N/N kinase|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) examined|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N function|NN|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N elements|NNS|N in|IN|(NP\NP)/NP Burkitt|NN|N 's|POS|(NP[nb]/N)\NP lymphoma|NN|N/N cells|NNS|N (|LRB|(NP\NP)/NP Ramos|NN|N and|CC|conj Daudi|NN|N )|RRB|RRB as|RB|conj/conj well|RB|conj/conj as|IN|conj a|DT|NP[nb]/N T|NN|N/N lymphocytic|JJ|N/N cell|NN|N/N line|NN|N (|LRB|(NP\NP)/NP Jurkat|NN|N )|RRB|RRB .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) found|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] stimulation|NN|N of|IN|(NP\NP)/NP any|DT|NP[nb]/N one|CD|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N pathways|NNS|N alone|RB|NP\NP has|VBZ|(S[dcl]\NP)/NP little|JJ|N/N or|CC|conj no|DT|N/N effect|NN|N on|IN|(NP\NP)/NP c-fos|NN|N/N induction|NN|N .|.|.
However|RB|S/S ,|,|, kinase|NN|N/N C|NN|N/N activation|NN|N (|LRB|(NP\NP)/NP PMA|NN|N/N stimulation|NN|N )|RRB|RRB combined|VBN|(S[pss]\NP)/PP with|IN|PP/NP either|CC|NP/NP cAMP|NN|N (|LRB|(N\N)/N forskolin|NN|N plus|CC|conj MIX|NN|N )|RRB|RRB or|CC|conj calcium|NN|N/N stimulation|NN|N (|LRB|(NP\NP)/NP ionophore|NN|N )|RRB|RRB leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP greatly|RB|(N/N)/(N/N) enhanced|VBN|N/N c-fos|NN|N/N induction|NN|N .|.|.
By|IN|(S/S)/NP contrast|NN|N ,|,|, cAMP|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP calcium|NN|N shows|VBZ|(S[dcl]\NP)/NP no|DT|NP[nb]/N synergy|NN|N in|IN|(NP\NP)/NP c-fos|NN|N/N induction|NN|N .|.|.
Okadaic|JJ|N/N acid|NN|N augments|VBZ|(S[dcl]\NP)/NP PMA-|NN|N as|RB|conj/conj well|RB|conj/conj as|IN|conj calcium-mediated|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP c-fos|NN|N ,|,|, and|CC|conj has|VBZ|(S[dcl]\NP)/NP little|JJ|N/N or|CC|conj no|DT|N/N effect|NN|N when|WRB|((S\NP)\(S\NP))/(S[pss]\NP) combined|VBN|(S[pss]\NP)/PP with|IN|PP/NP cAMP|NN|N .|.|.
The|DT|NP[nb]/N main|JJ|N/N difference|NN|N between|IN|(NP\NP)/NP Ramos|NN|N (|LRB|(NP\NP)/NP B|NN|N/N cells|NNS|N )|RRB|RRB and|CC|conj Jurkat|NN|N (|LRB|(NP\NP)/NP T|NN|N/N cells|NNS|N )|RRB|RRB in|IN|(NP\NP)/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP c-fos|NN|N is|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] cAMP|NN|N plus|CC|conj calcium|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) strongly|RB|(S[adj]\NP)/(S[adj]\NP) synergistic|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP Jurkat|NN|N and|CC|conj is|VBZ|(S[dcl]\NP)/PP without|IN|PP/NP effect|NN|N in|IN|((S\NP)\(S\NP))/NP Ramos|NN|N .|.|.
Analysis|NN|N of|IN|(NP\NP)/NP AP-1|NN|N/N activity|NN|N using|VBG|(S[ng]\NP)/NP gel|NN|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N confirms|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N requirements|NNS|N for|IN|(NP\NP)/NP synergy|NN|N in|IN|(NP\NP)/NP c-fos|NN|N/N mRNA|NN|N/N induction|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) paralleled|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP requirements|NNS|N for|IN|(NP\NP)/NP synergy|NN|N in|IN|(NP\NP)/NP induction|NN|N of|IN|(NP\NP)/NP AP-1|NN|N/N activity|NN|N .|.|.
Signaling|NN|N in|IN|(NP\NP)/NP B|NN|N/N cells|NNS|N due|JJ|(S[adj]\NP)/PP to|TO|PP/NP anti-Ig|JJ|N/N stimulation|NN|N involves|VBZ|(S[dcl]\NP)/NP both|CC|NP/NP kinase|NN|N/N C|NN|N/N activation|NN|N and|CC|conj release|NN|N of|IN|(NP\NP)/NP intracellular|JJ|N/N calcium|NN|N ,|,|, and|CC|conj results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP c-fos|NN|N/N mRNA|NN|N/N induction|NN|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] synergy|NN|N between|IN|(NP\NP)/NP the|DT|NP[nb]/N kinase|NN|N/N C|NN|N/N activation|NN|N and|CC|conj calcium|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) needed|VBN|S[pss]\NP for|IN|((S\NP)\(S\NP))/NP efficient|JJ|N/N c-fos|NN|N/N induction|NN|N since|IN|((S\NP)\(S\NP))/S[dcl] neither|DT|NP of|IN|(NP\NP)/NP these|DT|NP[nb]/N two|CD|N alone|RB|N\N induces|VBZ|(S[dcl]\NP)/NP c-fos|NN|N well|RB|(S\NP)\(S\NP) .|.|.
That|IN|N/S[dcl] synergy|NN|N of|IN|(NP\NP)/NP signaling|NN|N/N pathways|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) relevant|JJ|(S[adj]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N anti-Ig|JJ|N/N induction|NN|N of|IN|(NP\NP)/NP c-fos|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) supported|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N fact|NN|N/S[em] that|IN|S[em]/S[dcl] cAMP-inducing|JJ|N/N agents|NNS|N and|CC|conj okadaic|JJ|N/N acid|NN|N further|RB|(S\NP)/(S\NP) enhance|VBP|(S[dcl]\NP)/NP anti-Ig|JJ|N/N induction|NN|N of|IN|(NP\NP)/NP c-fos|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] cell-specific|JJ|N/N patterns|NNS|N of|IN|(NP\NP)/NP synergy|NN|N are|VBP|(S[dcl]\NP)/NP an|DT|NP[nb]/N essential|JJ|N/N feature|NN|N for|IN|(NP\NP)/NP c-fos|NN|N/N induction|NN|N and|CC|conj may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) relevant|JJ|(S[adj]\NP)/PP for|IN|PP/NP c-fos|NN|N/N control|NN|N through|IN|((S\NP)\(S\NP))/NP B|NN|N/N and|CC|conj T|NN|(N/N)/(N/N) cell|NN|N/N antigen|NN|N/N receptors|NNS|N .|.|.
The|DT|NP[nb]/N human|JJ|N/N granulocyte-macrophage|JJ|N/N CSF|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) GM-CSF|NN|N/N )|RRB|RRB gene|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP T|NN|N/N cells|NNS|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP TCR|NN|N/N activation|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) can|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) mimicked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP treatment|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N cells|NNS|N with|IN|((S\NP)\(S\NP))/NP PMA|NN|N and|CC|conj Ca2+|NN|N/N ionophore|NN|N .|.|.
The|DT|NP[nb]/N gene|NN|N contains|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N proximal|JJ|N/N functional|JJ|N/N promoter|NN|N/N region|NN|N (|LRB|(NP\NP)/NP -620|CD|N to|TO|(NP\NP)/NP +34|CD|N )|RRB|RRB ,|,|, as|RB|conj/conj well|RB|conj/conj as|IN|conj a|DT|NP[nb]/N powerful|JJ|N/N enhancer|NN|N located|JJ|(S[pss]\NP)/(S[adj]\NP) 3|CD|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) kb|NN|(S[adj]\NP)/(S[adj]\NP) upstream|RB|S[adj]\NP ,|,|, both|DT|NP of|IN|(NP\NP)/NP which|WDT|((NP\NP)/(S[dcl]\NP))\(NP/NP) are|VBP|(S[dcl]\NP)/(S[pss]\NP) involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N response|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N gene|NN|N to|TO|(NP\NP)/NP TCR|NN|N/N activation|NN|N .|.|.
The|DT|NP[nb]/N proximal|JJ|N/N promoter|NN|N contains|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N region|NN|N termed|VBN|(S[pss]\NP)/NP CLEO|NN|N (|LRB|(NP\NP)/NP -54|CD|N to|TO|(NP\NP)/NP -31|CD|N )|RRB|RRB that|WDT|(NP\NP)/(S[dcl]\NP) consists|VBZ|(S[dcl]\NP)/PP of|IN|PP/NP a|DT|NP[nb]/N purine-rich|JJ|N/N element|NN|N abutting|VBG|(S[ng]\NP)/NP an|DT|NP[nb]/N activator|NN|N/N protein-1|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) AP-1|NN|N/N )|RRB|RRB -like|JJ|N/N site|NN|N ,|,|, as|RB|conj/conj well|RB|conj/conj as|IN|conj an|DT|NP[nb]/N upstream|JJ|N/N nuclear|JJ|N/N factor-kappa|NN|N/N B|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) NF-kappa|NN|(N/N)/(N/N) B|NN|N/N )|RRB|RRB site|NN|N (|LRB|(NP\NP)/NP -85|CD|N to|TO|(NP\NP)/NP -76|CD|N )|RRB|RRB and|CC|conj a|DT|NP[nb]/N CK-1|NN|N/N element|NN|N (|LRB|(NP\NP)/NP -101|CD|N to|TO|(NP\NP)/NP -92|CD|N )|RRB|RRB .|.|.
We|PRP|NP show|VBP|(S[dcl]\NP)/S[em] in|IN|((S\NP)\(S\NP))/NP this|DT|NP[nb]/N work|NN|N that|IN|S[em]/S[dcl] mutations|NNS|N in|IN|(NP\NP)/NP either|CC|NP/NP the|DT|NP[nb]/N purine-rich|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N CLEO|NN|N/N element|NN|N or|CC|conj the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N site|NN|N result|VBP|(S[dcl]\NP)/PP in|IN|PP/NP reduced|VBN|N/N PMA/Ca2+|NN|N/N activation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N 620-bp|JJ|N/N human|JJ|N/N GM-CSF|NN|N/N promoter-|NN|N/N luciferase|NN|N/N reporter|NN|N/N construct|NN|N in|IN|(NP\NP)/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/NP 65|CD|N/N %|NN|N and|CC|conj 50|CD|N/N %|NN|N ,|,|, respectively|RB|NP\NP .|.|.
The|DT|NP[nb]/N major|JJ|N/N inducible|JJ|N/N protein|NN|N/N complex|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) binds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N human|JJ|N/N CLEO|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) hCLEO|NN|N/N )|RRB|RRB element|NN|N is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N AP-1-like|JJ|N/N complex|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) inducible|JJ|(S[adj]\NP)/PP by|IN|PP/NP PMA|NN|N alone|RB|NP\NP ,|,|, but|CC|conj shows|VBZ|(S[dcl]\NP)/NP increased|VBN|N/N binding|NN|N in|IN|(NP\NP)/NP response|NN|N to|TO|(NP\NP)/NP PMA|NN|N together|RB|(NP\NP)/(NP\NP) with|IN|(NP\NP)/NP Ca2+|NN|N/N ionophore|NN|N .|.|.
Although|IN|(S/S)/S[dcl] the|DT|NP[nb]/N binding|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N complex|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) cyclosporin-sensitive|JJ|S[adj]\NP ,|,|, promoter|NN|N/N induction|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) inhibited|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP cyclosporin|NN|N/N treatment|NN|N .|.|.
A|DT|NP[nb]/N second|JJ|N/N weak|JJ|N/N inducible|JJ|N/N complex|NN|N resembling|VBG|(S[ng]\NP)/NP nuclear|JJ|N/N factor|NN|N of|IN|(NP\NP)/NP activated|VBN|N/N T|NN|N/N cells|NNS|N (|LRB|(NP\NP)/NP NF-AT|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) observed|VBN|(S[pss]\NP)/(S[ng]\NP) binding|VBG|(S[ng]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N hCLEO|NN|N/N region|NN|N .|.|.
By|IN|(S/S)/(S[ng]\NP) using|VBG|(S[ng]\NP)/NP recombinant|JJ|N/N proteins|NNS|N ,|,|, we|PRP|NP confirmed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] AP-1|NN|N ,|,|, NF-ATp|NN|N ,|,|, and|CC|conj a|DT|NP[nb]/N higher|JJR|(N/N)/(N/N) order|NN|N/N NF-ATp|NN|N/N /AP-1|NN|N/N complex|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) all|DT|(S\NP)\(S\NP) form|VB|(S[b]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N hCLEO|NN|N/N element|NN|N ,|,|, and|CC|conj we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) also|RB|(S\NP)\(S\NP) defined|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N sequence|NN|N/N requirements|NNS|N for|IN|(NP\NP)/NP binding|NN|N of|IN|(NP\NP)/NP each|DT|NP of|IN|(NP\NP)/NP these|DT|NP[nb]/N complexes|NNS|N .|.|.
We|PRP|NP found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] expression|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N constitutively|RB|(N/N)/(N/N) active|JJ|N/N form|NN|N of|IN|(NP\NP)/NP calcineurin|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) substitute|VB|(S[b]\NP)/PP for|IN|PP/NP Ca2+|NN|N/N ionophore|NN|N and|CC|conj synergize|VB|(S[b]\NP)/PP with|IN|PP/NP PMA|NN|N to|TO|(S[to]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N GM-CSF|NN|N/N promoter|NN|N ,|,|, and|CC|conj conversely|RB|S/S that|IN|S[em]/S[dcl] mutant-activated|JJ|N/N Ras|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) substitute|VB|(S[b]\NP)/PP for|IN|PP/NP PMA|NN|N and|CC|conj cooperate|VB|(S[b]\NP)/PP with|IN|PP/NP Ca2+|NN|N/N ionophore|NN|N .|.|.
Co-expression|NN|N of|IN|(NP\NP)/NP Ras|NN|N and|CC|conj calcineurin|NN|N ,|,|, however|RB|(S\NP)/(S\NP) ,|,|, did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) activate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N GM-CSF|NN|N/N promoter|NN|N ,|,|, but|CC|conj required|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N additional|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N p65|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N imply|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] at|IN|((N/N)/(N/N))/(S[asup]\NP) least|JJS|S[asup]\NP three|CD|N/N signals|NNS|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) required|VBN|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N GM-CSF|NN|N/N proximal|JJ|N/N promoter|NN|N ,|,|, and|CC|conj that|IN|S[em]/S[dcl] the|DT|NP[nb]/N signals|NNS|N impinge|VBP|(S[dcl]\NP)/PP on|IN|PP/NP distinct|JJ|N/N transcription|NN|N/N factors|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) bind|VBP|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N hCLEO|NN|N/N and|CC|conj NF-kappa|NN|(N/N)/(N/N) B|NN|N/N regions|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N promoter|NN|N .|.|.
IL-10|NN|N affects|VBZ|(S[dcl]\NP)/NP monocytes|NNS|N and|CC|conj T|NN|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) driving|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N progression|NN|N of|IN|(NP\NP)/NP immune|JJ|N/N responsiveness|NN|N such|IN|((S\NP)\(S\NP))/S[em] that|IN|S[em]/S[dcl] Th2|NN|N/N lymphocyte-mediated|JJ|N/N effects|NNS|N predominate|VBP|S[dcl]\NP .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N report|NN|N ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] in|IN|(S/S)/NP monocytes|NNS|N and|CC|conj T|NN|N/N cells|NNS|N IL-10|NN|N stimulates|VBZ|(S[dcl]\NP)/NP tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N signal|NN|N/N transducers|NNS|N and|CC|conj activators|NNS|N of|IN|(NP\NP)/NP transcription|NN|N ,|,|, STAT1|NN|N/N alpha|NN|N and|CC|conj STAT3|NN|N ,|,|, in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N differential|JJ|N/N manner|NN|N such|IN|((S\NP)\(S\NP))/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N relative|JJ|N/N formation|NN|N of|IN|(NP\NP)/NP homo-|JJ|N and|CC|conj heterodimers|NNS|N varies|VBZ|S[dcl]\NP between|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N two|CD|N/N cell|NN|N/N types|NNS|N .|.|.
Moreover|RB|S/S ,|,|, monocytes|NNS|N express|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N novel|JJ|N/N IL-10-stimulated|JJ|N/N STAT|NN|N/N protein|NN|N with|IN|(NP\NP)/NP an|DT|NP[nb]/N M(r)|NN|N of|IN|(NP\NP)/NP 70|CD|N/N kDa|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) recognized|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N anti-STAT3|JJ|N/N Ab|NN|N but|CC|conj is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP T|NN|N/N cells|NNS|N .|.|.
IL-10|NN|N/N treatment|NN|N of|IN|(NP\NP)/NP both|CC|NP/NP T|NN|N/N cells|NNS|N and|CC|conj monocytes|NNS|N results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N ligand-induced|JJ|N/N tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP tyk2|NN|N and|CC|conj Jak1|NN|N ,|,|, but|CC|conj not|RB|NP/NP Jak2|NN|N or|CC|conj Jak3|NN|N .|.|.
Selective|JJ|N/N modulation|NN|N of|IN|(NP\NP)/NP immune|JJ|N/N responsiveness|NN|N by|IN|(NP\NP)/NP IL-10|NN|N in|IN|(NP\NP)/NP cells|NNS|N such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP monocytes|NNS|N and|CC|conj T|NN|N/N cells|NNS|N may|MD|(S[dcl]\NP)/(S[b]\NP) result|VB|(S[b]\NP)/PP in|IN|((S\NP)\(S\NP))/NP part|NN|N from|IN|PP/NP the|DT|NP[nb]/N differential|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP STAT|NN|N/N protein|NN|N/N pairs|NNS|N .|.|.
Biological|JJ|N/N markers|NNS|N of|IN|(NP\NP)/NP ovulation|NN|N ,|,|, after|IN|((S\NP)/(S\NP))/NP a|DT|NP[nb]/N great|JJ|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N past|NN|N ,|,|, have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) fallen|VBN|(S[pss]\NP)/PP into|IN|PP/NP disuse|NN|N for|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N large|JJ|N/N diffusion|NN|N of|IN|(NP\NP)/NP biochemical|JJ|N/N and|CC|conj biophysical|JJ|N/N ones|NNS|N .|.|.
However|RB|S/S ,|,|, the|DT|NP[nb]/N real|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP hormones|NNS|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP ovulation|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP biological|JJ|N/N modifications|NNS|N on|IN|(NP\NP)/NP target|NN|N/N tissues|NNS|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) explore|VB|(S[b]\NP)/NP the|DT|NP[nb]/N modifications|NNS|N of|IN|(NP\NP)/NP not|RB|(N/N)/(N/N) reproductive|JJ|N/N target|NN|N/N tissues|NNS|N as|IN|(NP\NP)/NP ovulation|NN|N/N markers|NNS|N we|PRP|NP studied|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N behaviour|NN|N of|IN|(NP\NP)/NP Albuminemia|NN|N ,|,|, Platelet|NN|N/N Factor|NN|N IV|CD|N\N (|LRB|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP indicator|NN|N of|IN|(NP\NP)/NP Platelet|NN|N/N Aggregation|NN|N )|RRB|RRB ,|,|, Type|NN|N/N II|CD|(N/N)\(N/N) estrogenic|JJ|N/N receptors|NNS|N in|IN|(NP\NP)/NP 42|CD|N/N ovulation|NN|N/N induced|JJ|N/N women|NNS|N ,|,|, undergoing|VBG|(S[ng]\NP)/NP our|PRP$|NP[nb]/N observation|NN|N .|.|.
33|CD|N of|IN|(NP\NP)/NP them|PRP|NP had|VBD|(S[dcl]\NP)/NP ovulation|NN|N and|CC|conj 9|CD|N developed|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N LUF|NN|N/N syndrome|NN|N ,|,|, constituting|VBG|(S[ng]\NP)/NP two|CD|N/N biological|JJ|N/N models|NNS|N of|IN|(NP\NP)/NP an|DT|NP[nb]/N opposite|JJ|N/N situation|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N three|CD|N/N markers|NNS|N observed|VBN|S[pss]\NP .|.|.
All|PDT|NP/NP the|DT|NP[nb]/N markers|NNS|N considered|VBN|S[pss]\NP were|VBD|(S[dcl]\NP)/(S[adj]\NP) sufficiently|RB|(S[adj]\NP)/(S[adj]\NP) sensitive|JJ|S[adj]\NP ,|,|, but|CC|conj among|IN|(S/S)/NP them|PRP|NP ,|,|, Platelet|NN|N/N Factor|NN|N IV|CD|N\N was|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N most|RBS|N/N reliable|JJ|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N hormonal|JJ|N/N ovulatory|JJ|N/N situation|NN|N .|.|.
The|DT|NP[nb]/N inert|JJ|N/N quality|NN|N of|IN|(NP\NP)/NP MRL-Ipr/Ipr|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) Ipr|NN|N/N )|RRB|RRB peripheral|JJ|N/N CD4-CD8-|JJ|N/N (|LRB|((N/N)\(N/N))/(N/N) CD4-8-|NN|N/N )|RRB|RRB T|NN|N/N cells|NNS|N manifests|VBZ|(S[dcl]\NP)/PP primarily|RB|(S\NP)\(S\NP) as|IN|PP/NP an|DT|NP[nb]/N inability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) proliferate|VB|S[b]\NP or|CC|conj produce|VB|(S[b]\NP)/NP IL-2|NN|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP TCR|NN|N or|CC|conj mitogenic|JJ|N/N stimulation|NN|N .|.|.
Yet|RB|S/S these|DT|NP[nb]/N same|JJ|N/N cells|NNS|N do|VBP|(S[dcl]\NP)/(S[b]\NP) initiate|VB|(S[b]\NP)/NP early|JJ|N/N TCR-mediated|JJ|N/N signaling|NN|N/N events|NNS|N ,|,|, such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP generation|NN|N of|IN|(NP\NP)/NP inositol|JJ|N/N phosphates|NNS|N and|CC|conj increased|VBN|N/N intracellular|JJ|N/N calcium|NN|N .|.|.
They|PRP|NP also|RB|(S\NP)/(S\NP) display|VBP|(S[dcl]\NP)/NP constitutively|RB|(N/N)/(N/N) high|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP p59fyn|NN|N and|CC|conj CD3|NN|N/N zeta|NN|N/N tyrosine|NN|N/N phosphorylation|NN|N .|.|.
The|DT|NP[nb]/N generation|NN|N of|IN|(NP\NP)/NP second|JJ|N/N messengers|NNS|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N normally|RB|(S\NP)/(S\NP) leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP downstream|JJ|N/N signaling|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP transcriptional|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N gene|NN|N .|.|.
We|PRP|NP ,|,|, therefore|RB|(S\NP)/(S\NP) ,|,|, compared|VBD|((S[dcl]\NP)/PP)/NP the|DT|NP[nb]/N activation|NN|N/N state|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N gene|NN|N/N promoter|NN|N/N region|NN|N in|IN|(NP\NP)/NP freshly|RB|(N/N)/(N/N) isolated|VBN|N/N and|CC|conj stimulated|VBN|N/N Ipr|NN|N/N CD4-8-T|NN|N/N cells|NNS|N with|IN|PP/NP that|DT|NP of|IN|(NP\NP)/NP normal|JJ|N/N T|NN|N/N lymphocytes|NNS|N .|.|.
Levels|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N octamer|NN|N/N ,|,|, NF-kappa|NN|(N/N)/(N/N) B|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) p50-p65|NN|N/N heterodimer|NN|N/N )|RRB|RRB ,|,|, and|CC|conj AP-1|NN|N/N transcriptional|JJ|N/N factors|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) constitutively|RB|(S\NP)\(S\NP) elevated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP freshly|RB|(N/N)/(N/N) isolated|VBN|N/N Ipr|NN|N/N CD4-8-T|NN|N/N cells|NNS|N ,|,|, consistent|JJ|(S[adj]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N activated|VBN|N/N phenotype|NN|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N cells|NNS|N .|.|.
Upon|IN|(S/S)/NP stimulation|NN|N with|IN|(NP\NP)/NP mitogens|NNS|N ,|,|, formation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N transactivating|VBG|N/N complex|NN|N ,|,|, nuclear|JJ|N/N factor|NN|N of|IN|(NP\NP)/NP activated|VBN|N/N T|NN|N/N cells|NNS|N (|LRB|(NP\NP)/NP NF-AT|NN|N )|RRB|RRB ,|,|, occurs|VBZ|S[dcl]\NP with|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N kinetics|NNS|N in|IN|((S\NP)\(S\NP))/NP Ipr|NN|N/N CD4-8-T|NN|N/N cells|NNS|N .|.|.
Yet|RB|S/S ,|,|, the|DT|NP[nb]/N levels|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N activating|VBG|N/N NF-AT|NN|N/N complex|NN|N never|RB|(S\NP)/(S\NP) reach|VBP|(S[dcl]\NP)/NP those|DT|NP observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP similarly|RB|(N/N)/(N/N) stimulated|VBN|N/N normal|JJ|N/N T|NN|N/N cells|NNS|N .|.|.
Furthermore|RB|S/S ,|,|, nuclear|JJ|N/N extracts|NNS|N from|IN|(NP\NP)/NP Ipr|NN|N/N CD4-8-T|NN|N/N cells|NNS|N display|VBP|(S[dcl]\NP)/NP high|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N novel|JJ|N/N specific|JJ|N/N binding|NN|N/N activity|NN|N at|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-AT|NN|N/N site|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) present|JJ|S[adj]\NP at|IN|((S[adj]\NP)\(S[adj]\NP))/NP much|JJ|(N/N)/(N/N) lower|JJR|N/N levels|NNS|N in|IN|((S[adj]\NP)\(S[adj]\NP))/NP freshly|RB|(N/N)/(N/N) isolated|VBN|N/N normal|JJ|N/N T|NN|N/N lymphocytes|NNS|N .|.|.
Upon|IN|(S/S)/NP mitogenic|JJ|N/N stimulation|NN|N ,|,|, the|DT|NP[nb]/N binding|NN|N/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N novel|JJ|N/N NF-AT-binding|JJ|N/N factor|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) rapidly|RB|(S\NP)\(S\NP) down-regulated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N T|NN|N/N cells|NNS|N ,|,|, but|CC|conj persists|VBZ|S[dcl]\NP at|IN|((S\NP)\(S\NP))/NP high|JJ|N/N levels|NNS|N in|IN|((S\NP)\(S\NP))/NP Ipr|NN|N/N CD4-8-T|NN|N/N cells|NNS|N .|.|.
These|DT|NP[nb]/N two|CD|N/N abnormalities|NNS|N at|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-AT|NN|N/N site|NN|N provide|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N potential|JJ|N/N mechanism|NN|N to|TO|(S[to]\NP)/(S[b]\NP) account|VB|(S[b]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N defect|NN|N in|IN|(NP\NP)/NP IL-2|NN|N/N production|NN|N from|IN|(NP\NP)/NP Ipr|NN|N/N CD4-8-T|NN|N/N cells|NNS|N .|.|.
CD30|NN|N ,|,|, a|DT|NP[nb]/N member|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N tumor|NN|N/N necrosis|NN|N/N factor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) TNF|NN|N/N )|RRB|RRB receptor|NN|N/N family|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP constitutively|RB|(S\NP)\(S\NP) on|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N surface|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N line|NN|N ACH-2|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) chronically|RB|(S\NP)\(S\NP) infected|VBN|(S[pss]\NP)/PP with|IN|PP/NP human|JJ|N/N immunodeficiency|NN|N/N virus|NN|N type-1|NN|N\N (|LRB|(N\N)/N HIV|NN|N )|RRB|RRB -1|CD|N\N .|.|.
We|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] cross-linking|JJ|(S[ng]\NP)/NP CD30|NN|N with|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N anti-CD30-specific|JJ|N/N monoclonal|JJ|N/N antibody|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) mimics|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N described|VBN|N/N biological|JJ|N/N activities|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N CD30|NN|N/N ligand|NN|N (|LRB|(NP\NP)/NP CD30L|NN|N )|RRB|RRB ,|,|, results|VBZ|(S[dcl]\(S[ng]\NP))/PP in|IN|PP/NP HIV|NN|N/N expression|NN|N .|.|.
CD30|NN|N/N cross-linking|NN|N does|VBZ|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) alter|VB|(S[b]\NP)/NP proliferation|NN|N of|IN|(NP\NP)/NP ACH-2|NN|N/N cells|NNS|N and|CC|conj the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP HIV|NN|N/N expression|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP endogenous|JJ|N/N TNF|NN|N/N alpha/beta|NN|N .|.|.
Furthermore|RB|S/S ,|,|, cross-linking|NN|N of|IN|(NP\NP)/NP CD30|NN|N leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N and|CC|conj enhanced|VBN|N/N HIV|NN|N/N transcription|NN|N .|.|.
Thus|RB|S/S ,|,|, CD30-CD30L|JJ|N/N interactions|NNS|N mediate|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP HIV|NN|N/N expression|NN|N by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N kappa|NN|(N/N)/(N/N) B-dependent|JJ|N/N pathway|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) independent|JJ|(S[adj]\NP)/PP of|IN|PP/NP TNF|NN|N .|.|.
This|DT|NP[nb]/N mechanism|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) important|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP HIV|NN|N/N expression|NN|N from|IN|(NP\NP)/NP latently|RB|(N/N)/(N/N) infected|JJ|N/N CD4+|JJ|N/N T|NN|N/N cells|NNS|N ,|,|, especially|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP lymphoid|JJ|N/N organs|NNS|N where|WRB|(NP\NP)/S[dcl] cell|NN|N/N to|TO|((N/N)\(N/N))/(N/N) cell|NN|N/N contact|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) conducive|JJ|(S[adj]\NP)/PP to|TO|PP/NP receptor-ligand|JJ|N/N interactions|NNS|N .|.|.
Type|NN|N/N II|CD|(N/N)\(N/N) major|JJ|N/N histocompatibility|NN|N/N complex|NN|N/N combined|JJ|N/N immune|JJ|N/N deficiency|NN|N (|LRB|(NP\NP)/NP type|NN|N/N II|CD|(N/N)\(N/N) MHC|NN|N/N CID|NN|N or|CC|conj bare|JJ|N/N lymphocyte|NN|N/N syndrome|NN|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N congenital|JJ|N/N immunodeficiency|NN|N/N disease|NN|N characterized|VBN|(S[pss]\NP)/PP by|IN|PP/NP absent|JJ|N/N MHC|NN|N/N class|NN|N/N II|CD|(N/N)\(N/N) expression|NN|N .|.|.
Four|CD|N/N distinct|JJ|N/N complementation|NN|N/N groups|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) identified|VBN|S[pss]\NP .|.|.
Recently|RB|S/S ,|,|, the|DT|NP[nb]/N defective|JJ|N/N gene|NN|N in|IN|(NP\NP)/NP group|NN|N/N II|CD|(N/N)\(N/N) type|NN|N/N II|CD|(N/N)\(N/N) MHC|NN|N/N CID|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) isolated|VBN|S[pss]\NP and|CC|conj termed|VBN|(S[pss]\NP)/NP CIITA|NN|N .|.|.
Here|RB|S/S ,|,|, we|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] CIITA|NN|N is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N MHC|NN|N/N class|NN|N/N II|CD|(N/N)\(N/N) gene-specific|JJ|N/N transcription|NN|N/N activator|NN|N .|.|.
The|DT|NP[nb]/N transcription|NN|N/N activation|NN|N/N function|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) provided|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N N-terminal|JJ|N/N acidic|JJ|N/N domain|NN|N (|LRB|(NP\NP)/NP amino|NN|N/N acids|NNS|N 26-137|CD|N )|RRB|RRB ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) experimentally|RB|(S[adj]\NP)/(S[adj]\NP) exchangeable|JJ|(S[adj]\NP)/PP with|IN|PP/NP a|DT|NP[nb]/N heterologous|JJ|N/N viral|JJ|N/N transcription-activating|JJ|N/N domain|NN|N .|.|.
The|DT|NP[nb]/N specificity|NN|N of|IN|(NP\NP)/NP CIITA|NN|N for|IN|(NP\NP)/NP three|CD|N/N major|JJ|N/N MHC|NN|N/N class|NN|N/N II|CD|(N/N)\(N/N) genes|NNS|N ,|,|, DR|NN|N ,|,|, DQ|NN|N and|CC|conj DP|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP its|PRP$|NP[nb]/N remaining|VBG|N/N C-terminal|JJ|N/N residues|NNS|N (|LRB|(NP\NP)/NP amino|NN|N/N acids|NNS|N 317-1130|CD|N )|RRB|RRB .|.|.
The|DT|NP[nb]/N transactivation|NN|N of|IN|(NP\NP)/NP multiple|JJ|N/N cis|JJ|N/N elements|NNS|N ,|,|, especially|RB|NP/NP S|NN|N and|CC|conj X2|NN|N ,|,|, of|IN|(NP\NP)/NP the|DT|NP[nb]/N DR|NN|N/N alpha|NN|N/N proximal|JJ|N/N promoter|NN|N in|IN|(NP\NP)/NP group|NN|N/N II|CD|(N/N)\(N/N) CID|NN|N/N cells|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) CIITA|NN|(S[adj]\NP)/(S[adj]\NP) dependent|JJ|S[adj]\NP .|.|.
Since|IN|(S/S)/S[dcl] CIITA|NN|N/N overexpression|NN|N in|IN|(NP\NP)/NP normal|JJ|N/N cells|NNS|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) increase|VB|(S[b]\NP)/NP class|NN|N/N II|CD|(N/N)\(N/N) expression|NN|N ,|,|, we|PRP|NP propose|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] initiation|NN|N of|IN|(NP\NP)/NP CIITA|NN|N/N expression|NN|N serves|VBZ|(S[dcl]\NP)/PP as|IN|PP/NP the|DT|NP[nb]/N on-off|JJ|N/N switch|NN|N ,|,|, while|IN|((S\NP)\(S\NP))/S[dcl] availability|NN|N of|IN|(NP\NP)/NP downstream|JJ|N/N interactor|NN|N (|LRB|(NP\NP)/NP s|NNS|N )|RRB|RRB limits|VBZ|(S[dcl]\NP)/NP transcription|NN|N .|.|.
Adhesion|NN|N/N molecules|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) tether|VBP|((S[dcl]\NP)/PP)/NP circulating|VBG|N/N leukocytes|NNS|N to|TO|PP/NP endothelial|JJ|N/N cells|NNS|N may|MD|(S[dcl]\NP)/(S[b]\NP) also|RB|(S\NP)\(S\NP) transduce|VB|(S[b]\NP)/NP or|CC|conj modulate|VB|(S[b]\NP)/NP outside-in|JJ|N/N signals|NNS|N for|IN|((S\NP)\(S\NP))/NP cellular|JJ|N/N activation|NN|N ,|,|, providing|VBG|(S[ng]\NP)/NP an|DT|NP[nb]/N initial|JJ|N/N regulatory|JJ|N/N point|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N inflammatory|JJ|N/N response|NN|N .|.|.
Adhesion|NN|N of|IN|(NP\NP)/NP human|JJ|N/N monocytes|NNS|N to|TO|(NP\NP)/NP P-selectin|NN|N ,|,|, the|DT|NP[nb]/N most|RBS|((N/N)/(N/N))/((N/N)/(N/N)) rapidly|RB|(N/N)/(N/N) expressed|VBN|N/N endothelial|JJ|N/N tethering|NN|N/N factor|NN|N ,|,|, increased|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N secretion|NN|N of|IN|(NP\NP)/NP monocyte|NN|N/N chemotactic|JJ|N/N protein-1|NN|N (|LRB|(N\N)/N MCP-1|NN|N )|RRB|RRB and|CC|conj tumor|NN|N/N necrosis|NN|N/N factor-alpha|NN|N (|LRB|(NP\NP)/NP TNF-alpha|NN|N )|RRB|RRB by|IN|(NP\NP)/NP the|DT|NP[nb]/N leukocytes|NNS|N when|WRB|((S\NP)\(S\NP))/S[dcl] they|PRP|NP were|VBD|(S[dcl]\NP)/(S[pss]\NP) stimulated|VBN|(S[pss]\NP)/PP with|IN|PP/NP platelet-activating|JJ|N/N factor|NN|N .|.|.
Increased|VBN|N/N cytokine|NN|N/N secretion|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) specifically|RB|(S\NP)\(S\NP) inhibited|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP G1|NN|N ,|,|, an|DT|NP[nb]/N anti-P-selectin|JJ|N/N mAb|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) prevents|VBZ|((S[dcl]\NP)/PP)/NP P-selectin|NN|N from|IN|PP/(S[ng]\NP) binding|VBG|(S[ng]\NP)/PP to|TO|PP/NP its|PRP$|NP[nb]/N ligand|NN|N (|LRB|(NP\NP)/NP P-selectin|NN|N/N glycoprotein|NN|N/N ligand-1|NN|N )|RRB|RRB on|IN|(NP\NP)/NP myeloid|JJ|N/N cells|NNS|N .|.|.
Moreover|RB|S/S ,|,|, tethering|NN|N by|IN|(NP\NP)/NP P-selectin|NN|N specifically|RB|(S\NP)/(S\NP) enhanced|VBD|(S[dcl]\NP)/NP nuclear|JJ|N/N translocation|NN|N of|IN|(NP\NP)/NP nuclear|JJ|N/N factor-kappa|NN|N/N B|NN|N (|LRB|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N )|RRB|RRB ,|,|, a|DT|NP[nb]/N transcription|NN|N/N factor|NN|N required|VBN|(S[pss]\NP)/PP for|IN|PP/NP expression|NN|N of|IN|(NP\NP)/NP MCP-1|NN|N ,|,|, TNF-alpha|NN|N ,|,|, and|CC|conj other|JJ|N/N immediate-early|JJ|N/N genes|NNS|N .|.|.
These|DT|NP[nb]/N results|NNS|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] P-selectin|NN|N ,|,|, through|IN|((S\NP)/(S\NP))/NP its|PRP$|NP[nb]/N ligands|NNS|N on|IN|(NP\NP)/NP monocytes|NNS|N ,|,|, may|MD|(S[dcl]\NP)/(S[b]\NP) locally|RB|(S\NP)\(S\NP) regulate|VB|(S[b]\NP)/NP cytokine|NN|N/N secretion|NN|N in|IN|(NP\NP)/NP inflamed|JJ|N/N tissues|NNS|N .|.|.
Transcriptional|JJ|N/N regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N alpha-like|JJ|N/N globin|NN|N/N genes|NNS|N ,|,|, embryonic|JJ|N/N zeta|NN|N 2|CD|N\N and|CC|conj adult|JJ|N/N alpha|NN|N ,|,|, during|IN|(NP\NP)/NP erythroid|JJ|N/N development|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N distal|JJ|N/N enhancer|NN|N ,|,|, HS-40|NN|N .|.|.
Previous|JJ|N/N protein-DNA|JJ|(N/N)/(N/N) binding|NN|N/N studies|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] HS-40|NN|N consists|VBZ|(S[dcl]\NP)/PP of|IN|PP/NP multiple|JJ|N/N nuclear|JJ|N/N factor|NN|N/N binding|NN|N/N motifs|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[pss]\NP) occupied|VBN|S[pss]\NP in|FW|((S\NP)\(S\NP))/NP vivo|FW|N in|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N erythroid|JJ|N/N lineage-|NN|N and|CC|conj developmental|JJ|N/N stage-specific|JJ|N/N manner|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) systematically|RB|(S\NP)\(S\NP) analyzed|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N functional|JJ|N/N roles|NNS|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N factor|NN|N/N binding|NN|N/N motifs|NNS|N of|IN|(NP\NP)/NP HS-40|NN|N by|IN|((S\NP)\(S\NP))/NP site-directed|JJ|N/N mutagenesis|NN|N and|CC|conj transient|JJ|(N/N)/(N/N) expression|NN|N/N assay|NN|N in|IN|(NP\NP)/NP erythroid|JJ|(N/N)/(N/N) cell|NN|N/N cultures|NNS|N .|.|.
Three|CD|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N HS-40|NN|N/N enhancer|NN|N/N motifs|NNS|N ,|,|, 5'NF-E2/AP1|NN|N ,|,|, GT|NN|N II|CD|N\N ,|,|, and|CC|conj GATA-1(c)|NN|N ,|,|, positively|RB|(S\NP)/(S\NP) regulate|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N zeta|NN|N/N 2-globin|NN|N/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP embryonic/fetal|JJ|N/N erythroid|JJ|N/N K562|NN|N/N cells|NNS|N and|CC|conj the|DT|NP[nb]/N adult|JJ|N/N alpha-globin|NN|N/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP adult|JJ|N/N erythroid|JJ|N/N MEL|NN|N/N cells|NNS|N .|.|.
On|IN|(S/S)/NP the|DT|NP[nb]/N other|JJ|N/N hand|NN|N ,|,|, the|DT|NP[nb]/N 3'NF-E2/AP1|NN|N/N motif|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) exert|VB|(S[b]\NP)/NP both|CC|(N/N)/(N/N) positive|JJ|N/N and|CC|conj negative|JJ|N/N regulatory|JJ|N/N effects|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N zeta|NN|N/N 2-globin|NN|N/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP K562|NN|N/N cells|NNS|N ,|,|, and|CC|conj this|DT|NP[nb]/N dual|JJ|N/N function|NN|N appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) modulated|VBN|S[pss]\NP through|IN|((S\NP)\(S\NP))/NP differential|JJ|N/N binding|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N ubiquitous|JJ|N/N AP1|NN|N/N factors|NNS|N and|CC|conj the|DT|NP[nb]/N erythroid-enriched|JJ|N/N NF-E2|NN|N/N factor|NN|N .|.|.
Mutation|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N GATA-1(d)|NN|N/N motif|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) exhibits|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N adult|JJ|N/N erythroid-specific|JJ|N/N genomic|JJ|N/N footprint|NN|N ,|,|, decreases|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N HS-40|NN|N/N enhancer|NN|N/N function|NN|N in|IN|((S\NP)\(S\NP))/NP dimethyl|JJ|N/N sulfoxide-induced|JJ|N/N MEL|NN|N/N cells|NNS|N but|CC|conj not|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP K562|NN|N/N cells|NNS|N .|.|.
These|DT|NP[nb]/N studies|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) defined|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N regulatory|JJ|N/N roles|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N different|JJ|N/N HS-40|NN|N/N motifs|NNS|N .|.|.
The|DT|NP[nb]/N remarkable|JJ|N/N correlation|NN|N between|IN|(NP\NP)/NP genomic|JJ|(N/N)/(N/N) footprinting|NN|N/N data|NNS|N and|CC|conj the|DT|NP[nb]/N mutagenesis|NN|N/N results|NNS|N also|RB|(S\NP)/(S\NP) suggests|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N erythroid|JJ|N/N lineage-|NN|N/N and|CC|conj developmental|JJ|N/N stage-specific|JJ|N/N regulation|NN|N of|IN|(NP\NP)/NP human|JJ|N/N alpha-like|JJ|N/N globin|NN|N/N promoters|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) indeed|RB|(S\NP)\(S\NP) modulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP stable|JJ|N/N binding|NN|N of|IN|(NP\NP)/NP specific|JJ|N/N nuclear|JJ|N/N factors|NNS|N in|FW|((S\NP)\(S\NP))/NP vivo|FW|N .|.|.
The|DT|NP[nb]/N protooncogene|NN|N p21ras|NN|N ,|,|, a|DT|NP[nb]/N monomeric|JJ|N/N G|NN|N/N protein|NN|N/N family|NN|N/N member|NN|N ,|,|, plays|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N critical|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/(S[ng]\NP) converting|VBG|((S[ng]\NP)/PP)/NP extracellular|JJ|N/N signals|NNS|N into|IN|PP/NP intracellular|JJ|N/N biochemical|JJ|N/N events|NNS|N .|.|.
Here|RB|S/S ,|,|, we|PRP|NP report|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] nitric|JJ|N/N oxide|NN|N (|LRB|(N\N)/N NO|NN|N )|RRB|RRB activates|VBZ|(S[dcl]\NP)/NP p21ras|NN|N in|IN|((S\NP)\(S\NP))/NP human|JJ|N/N T|NN|N/N cells|NNS|N as|IN|((S\NP)\(S\NP))/(S[pss]\NP) evidenced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N increase|NN|N in|IN|(NP\NP)/NP GTP-bound|JJ|N/N p21ras|NN|N .|.|.
In|FW|(N/N)/(N/N) vitro|FW|N/N studies|NNS|N using|VBG|(S[ng]\NP)/NP pure|JJ|N/N recombinant|JJ|N/N p21ras|NN|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N activation|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) direct|JJ|S[adj]\NP and|CC|conj reversible|JJ|S[adj]\NP .|.|.
Circular|JJ|N/N dichroism|NN|N/N analysis|NN|N reveals|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] NO|NN|N induces|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N profound|JJ|N/N conformational|JJ|N/N change|NN|N in|IN|(NP\NP)/NP p21ras|NN|N in|IN|((S\NP)\(S\NP))/NP association|NN|N with|IN|(NP\NP)/NP GDP/GTP|NN|N/N exchange|NN|N .|.|.
The|DT|NP[nb]/N mechanism|NN|N of|IN|(NP\NP)/NP activation|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) due|JJ|(S[adj]\NP)/PP to|TO|PP/NP S-nitrosylation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N critical|JJ|N/N cysteine|NN|N/N residue|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) stimulates|VBZ|(S[dcl]\NP)/NP guanine|NN|N/N nucleotide|NN|N/N exchange|NN|N .|.|.
Furthermore|RB|S/S ,|,|, we|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] p21ras|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) essential|JJ|S[adj]\NP for|IN|((S\NP)\(S\NP))/NP NO-induced|JJ|N/N downstream|JJ|N/N signaling|NN|N ,|,|, such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N ,|,|, and|CC|conj that|IN|S[em]/S[dcl] endogenous|JJ|N/N NO|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP p21ras|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N same|JJ|N/N cell|NN|N .|.|.
These|DT|NP[nb]/N studies|NNS|N identify|VBP|((S[dcl]\NP)/PP)/NP p21ras|NN|N as|IN|PP/NP a|DT|NP[nb]/N target|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N same|JJ|N/N cell|NN|N .|.|.
These|DT|NP[nb]/N studies|NNS|N identify|VBP|((S[dcl]\NP)/PP)/NP p21ras|NN|N as|IN|PP/NP a|DT|NP[nb]/N target|NN|N of|IN|(NP\NP)/NP NO|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N and|CC|conj suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] NO|NN|N activates|VBZ|(S[dcl]\NP)/NP p21ras|NN|N by|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N action|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) mimics|VBZ|(S[dcl]\NP)/NP that|DT|NP of|IN|(NP\NP)/NP guanine|NN|N/N nucleotide|NN|N/N exchange|NN|N/N factors|NNS|N .|.|.
The|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP interleukin|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL|NN|N/N )|RRB|RRB -2|CD|(N/N)\(N/N) gene|NN|N/N expression|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) investigated|VBN|S[pss]\NP mainly|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP T|NN|N/N lymphocytes|NNS|N ,|,|, the|DT|NP[nb]/N predominant|JJ|N/N producers|NNS|N of|IN|(NP\NP)/NP IL-2|NN|N .|.|.
However|RB|S/S ,|,|, B|NN|N/N cells|NNS|N can|MD|(S[dcl]\NP)/(S[b]\NP) also|RB|(S\NP)\(S\NP) synthesize|VB|(S[b]\NP)/NP IL-2|NN|N .|.|.
In|IN|(S/S)/NP the|DT|NP[nb]/N present|JJ|N/N study|NN|N we|PRP|NP analyzed|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N control|NN|N of|IN|(NP\NP)/NP IL-2|NN|N/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP Epstein-Barr|JJ|(N/N)/(N/N) virus|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) EBV|NN|N/N )|RRB|RRB -transformed|JJ|N/N B|NN|(N/N)/(N/N) cell|NN|N/N clones|NNS|N which|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[adj]\NP) capable|JJ|(S[adj]\NP)/PP of|IN|PP/(S[ng]\NP) secreting|VBG|(S[ng]\NP)/NP IL-2|NN|N at|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N low|JJ|N/N level|NN|N after|IN|((S\NP)\(S\NP))/NP stimulation|NN|N with|IN|(NP\NP)/NP phorbol|NN|N/N 12-myristate|NN|N/N 13-acetate|NN|N and|CC|conj the|DT|NP[nb]/N Ca2+|NN|N/N ionophore|NN|N/N ionomycin|NN|N .|.|.
Transient|JJ|N/N transfections|NNS|N using|VBG|(S[ng]\NP)/NP reporter|NN|N/N constructs|NNS|N with|IN|(NP\NP)/NP multiples|NNS|N of|IN|(NP\NP)/NP transcription|NN|N/N factor|NN|N/N binding|NN|N/N sites|NNS|N from|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N promoter|NN|N [|LRB|(NP\NP)/NP distal|JJ|N/N nuclear|JJ|N/N factor|NN|N (|LRB|(N\N)/N NF|NN|N )|RRB|RRB -AT|NN|N ,|,|, proximal|JJ|N/N NF-AT|NN|N ,|,|, AP-1/Octamer|NN|N (|LRB|(N\N)/N UPS|NN|N )|RRB|RRB or|CC|conj NF-chi|NN|N/N B|NN|N (|LRB|(N\N)/N TCEd|NN|N )|RRB|RRB sites|NNS|N ]|RRB|RRB were|VBD|(S[dcl]\NP)/(S[pss]\NP) performed|VBN|S[pss]\NP .|.|.
In|IN|(S/S)/NP EBV-transformed|JJ|N/N B|NN|N/N clones|NNS|N ,|,|, the|DT|NP[nb]/N chi|NN|N/N B|NN|N/N site|NN|N exerted|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N strongest|JJS|N/N inducible|JJ|N/N activity|NN|N ;|:|; the|DT|NP[nb]/N NF-AT|NN|N/N binding|NN|N/N sites|NNS|N showed|VBD|(S[dcl]\NP)/NP either|CC|NP/NP no|DT|N/N or|CC|conj only|RB|(N/N)/(N/N) weak|JJ|N/N activity|NN|N compared|VBN|((S\NP)\(S\NP))/PP to|TO|PP/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N .|.|.
An|DT|NP[nb]/N IL-2|NN|N/N promoter|NN|N bearing|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N defective|JJ|N/N NF-chi|NN|N/N B|NN|N/N site|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) completely|RB|(S[adj]\NP)/(S[adj]\NP) inactive|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP EBV-transformed|NN|N/N B|NN|N/N cells|NNS|N ,|,|, while|IN|((S\NP)\(S\NP))/S[dcl] it|PRP|NP still|RB|(S\NP)/(S\NP) had|VBD|(S[dcl]\NP)/NP activity|NN|N in|IN|(NP\NP)/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N .|.|.
In|IN|(S/S)/NP seven|CD|N/N EBV-B|NN|N/N cell|NN|N/N clones|NNS|N or|CC|conj lines|NNS|N differing|VBG|S[ng]\NP in|IN|((S\NP)\(S\NP))/NP their|PRP$|NP[nb]/N capacity|NN|N to|TO|(S[to]\NP)/(S[b]\NP) secrete|VB|(S[b]\NP)/NP IL-2|NN|N ,|,|, the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N promoter|NN|N correlated|VBD|(S[dcl]\NP)/PP well|RB|(S\NP)\(S\NP) with|IN|PP/NP the|DT|NP[nb]/N status|NN|N of|IN|(NP\NP)/NP IL-2|NN|N/N secretion|NN|N .|.|.
Similarly|RB|S/S ,|,|, a|DT|NP[nb]/N human|JJ|N/N immunodeficiency|NN|N/N virus|NN|N/N promoter|NN|N ,|,|, whose|WP$|((NP\NP)/(S[dcl]\NP))/N activity|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) controlled|VBN|S[pss]\NP through|IN|((S\NP)\(S\NP))/NP chi|NN|N/N B|NN|N/N factors|NNS|N ,|,|, was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) active|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N IL-2|NN|(N/N)/(N/N) producing|NN|N/N EBV-B|NN|N/N cells|NNS|N ,|,|, but|CC|conj inactive|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N non-IL-2-producing|JJ|N/N cells|NNS|N .|.|.
Electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N using|VBG|(S[ng]\NP)/NP protein|NN|N/N extracts|NNS|N from|IN|(NP\NP)/NP EBV-B|NN|N/N cells|NNS|N and|CC|conj the|DT|NP[nb]/N IL-2|NN|N/N NF-chi|NN|N/N B|NN|N/N probe|NN|N revealed|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N constitutive|JJ|N/N generation|NN|N of|IN|(NP\NP)/NP chi|NN|N/N B|NN|N/N complexes|NNS|N in|IN|(NP\NP)/NP IL-2-secreting|NN|N/N cells|NNS|N consisting|VBG|(S[ng]\NP)/PP mainly|RB|PP/PP of|IN|PP/NP heterodimeric|JJ|N/N p50/p65|NN|N/N complexes|NNS|N .|.|.
A|DT|NP[nb]/N weaker|JJR|N/N chi|NN|N/N B|NN|N/N complex|JJ|N/N formation|NN|N and|CC|conj faster-migrating|JJ|N/N complexes|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP non-IL-2-secreting|JJ|N/N cells|NNS|N .|.|.
These|DT|NP[nb]/N results|NNS|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N IL-2|NN|N/N NF-chi|NN|N/N B|NN|N/N site|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) indispensable|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N promoter|NN|N in|IN|(NP\NP)/NP EBV-transformed|JJ|N/N B|NN|N/N cells|NNS|N ,|,|, whereas|IN|((S\NP)\(S\NP))/S[dcl] other|JJ|N/N transcription|NN|N/N factors|NNS|N appear|VBP|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) less|RBR|(S[adj]\NP)/(S[adj]\NP) important|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP IL-2|NN|N/N expression|NN|N in|IN|(NP\NP)/NP these|DT|NP[nb]/N cells|NNS|N .|.|.
The|DT|NP[nb]/N normal|JJ|N/N cell|NN|N/N cycle|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) regulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP several|JJ|N/N molecules|NNS|N ,|,|, such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP the|DT|NP[nb]/N tumor-suppressor|JJ|N/N protein|NN|N pRb|NN|N ,|,|, the|DT|NP[nb]/N G1|NN|N/N cyclins|NNS|N ,|,|, the|DT|NP[nb]/N cyclin-dependent|JJ|N/N kinases|NNS|N ,|,|, and|CC|conj their|PRP$|NP[nb]/N inhibitors|NNS|N .|.|.
These|DT|NP[nb]/N regulators|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) targeted|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP negative|JJ|N/N growth|NN|N/N regulatory|JJ|N/N signals|NNS|N ,|,|, such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP that|DT|NP provided|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP TGF-beta|NN|N .|.|.
Here|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP either|CC|NP/NP wild-type|JJ|N/N EBV|NN|N or|CC|conj its|PRP$|NP[nb]/N transforming|VBG|N/N latent|JJ|N/N membrane|NN|N/N protein-1|NN|N (|LRB|(NP\NP)/NP LMP-1|NN|N )|RRB|RRB results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N loss|NN|N of|IN|(NP\NP)/NP TGF-beta|NN|N/N 1-mediated|JJ|N/N growth|NN|N/N inhibition|NN|N in|IN|(NP\NP)/NP human|JJ|N/N B|NN|N/N cells|NNS|N .|.|.
Chemical|JJ|N/N cross-linking|NN|N with|IN|(NP\NP)/NP 125I-labeled|JJ|N/N TGF-beta|NN|N 1|CD|N\N showed|VBD|(S[dcl]\NP)/NP an|DT|NP[nb]/N essentially|RB|(N/N)/(N/N) normal|JJ|N/N TGF-beta|NN|(N/N)/(N/N) receptor|NN|N/N profile|NN|N in|IN|(NP\NP)/NP EBV-positive|JJ|N/N and|CC|conj EBV-negative|JJ|N/N Burkitt|NN|N 's|POS|(NP[nb]/N)\NP lymphoma|NN|N cell|NN|N/N lines|NNS|N ,|,|, and|CC|conj these|DT|NP[nb]/N receptors|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) functional|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/(S[ng]\NP) transducing|VBG|(S[ng]\NP)/NP signals|NNS|N ,|,|, as|IN|((S\NP)\(S\NP))/(S[pss]\NP) evidenced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N TGF-beta|NN|N/N 1-mediated|JJ|N/N modulation|NN|N of|IN|(NP\NP)/NP junB|NN|N/N gene|NN|N/N expression|NN|N .|.|.
However|RB|S/S ,|,|, TGF-beta|NN|N 1|CD|N\N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) induce|VB|(S[b]\NP)/NP dephosphorylation|NN|N of|IN|(NP\NP)/NP pRb|NN|N in|IN|((S\NP)\(S\NP))/NP EBV|NN|N/N (|LRB|conj/conj or|CC|conj LMP-1|NN|N/N )|RRB|RRB -positive|JJ|N/N cells|NNS|N as|IN|(NP\NP)/(S[pss]\NP) opposed|VBN|(S[pss]\NP)/PP to|TO|PP/NP EBV|JJ|N/N -negative|JJ|N/N cells|NNS|N ,|,|, suggesting|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N dichotomy|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N TGF-beta|NN|N/N 1|CD|(N/N)\(N/N) signaling|NN|N/N pathway|NN|N leading|VBG|(S[ng]\NP)/PP to|TO|PP/NP separable|JJ|N/N gene|NN|(N/N)/(N/N) regulatory|JJ|N/N and|CC|conj growth|NN|(N/N)/(N/N) inhibitory|JJ|N/N responses|NNS|N .|.|.
Furthermore|RB|S/S ,|,|, LMP-1|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP cyclin|NN|N/N D2|NN|N ;|:|; normal|JJ|N/N B|NN|N/N cells|NNS|N or|CC|conj EBV-negative|JJ|N/N Burkitt|NN|N 's|POS|(NP[nb]/N)\NP lymphoma|NN|N/N cells|NNS|N do|VBP|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) express|VB|(S[b]\NP)/NP D-type|JJ|N/N cyclins|NNS|N .|.|.
Taken|VBN|S[pss]\NP together|RB|(S\NP)\(S\NP) ,|,|, these|DT|NP[nb]/N data|NNS|N point|VBP|(S[dcl]\NP)/PP to|TO|PP/NP a|DT|NP[nb]/N potential|JJ|N/N mechanism|NN|N underlying|VBG|(S[ng]\NP)/NP EBV-mediated|JJ|N/N B|NN|(N/N)/(N/N) cell|NN|N/N transformation|NN|N whereby|WRB|(NP\NP)/S[dcl] constitutive|JJ|N/N induction|NN|N of|IN|(NP\NP)/NP key|JJ|N/N cell|NN|(N/N)/(N/N) cycle|NN|N/N regulators|NNS|N by|IN|(NP\NP)/NP LMP-1|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) lead|VB|(S[b]\NP)/PP to|TO|PP/NP pRb|NN|N/N hyperphosphorylation|NN|N and|CC|conj uncontrolled|JJ|N/N cell|NN|N/N proliferation|NN|N .|.|.
The|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP treatment|NN|N on|IN|(NP\NP)/NP thyroid|NN|N/N antibody|NN|N/N production|NN|N and|CC|conj T|NN|(N/N)/(N/N) cell|NN|N/N reactivity|NN|N to|TO|(NP\NP)/NP thyroid|NN|N/N antigens|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) studied|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP 15|CD|N/N patients|NNS|N with|IN|(NP\NP)/NP Graves|NN|N '|POS|(NP[nb]/N)\NP disease|NN|N (|LRB|(NP\NP)/NP GD|NN|N )|RRB|RRB before|IN|(NP\NP)/NP and|CC|conj after|IN|(NP/NP)/NP thyroidectomy|NN|N ,|,|, 19|CD|N/N patients|NNS|N with|IN|(NP\NP)/NP GD|NN|N before|IN|(NP\NP)/NP and|CC|conj after|IN|(NP\NP)/NP radioactive|JJ|(N/N)/(N/N) iodine|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) RAI|NN|N/N )|RRB|RRB therapy|NN|N ,|,|, and|CC|conj 9|CD|N/N patients|NNS|N maintained|VBD|S[dcl]\NP euthyroid|JJ|(S\NP)\(S\NP) on|IN|((S\NP)\(S\NP))/NP antithyroid|JJ|N/N drugs|NNS|N (|LRB|(NP\NP)/NP ATD|NN|N )|RRB|RRB .|.|.
Twenty|CD|N/N subjects|NNS|N matched|JJ|(S[adj]\NP)/PP for|IN|PP/NP age|NN|N and|CC|conj sex|NN|N without|IN|(NP\NP)/NP known|JJ|N/N thyroid|NN|N/N disease|NN|N served|VBD|(S[dcl]\NP)/PP as|IN|PP/NP controls|NNS|N .|.|.
In|IN|(S/S)/NP GD|NN|N/N patients|NNS|N ,|,|, the|DT|NP[nb]/N responses|NNS|N of|IN|(NP\NP)/NP peripheral|JJ|N/N blood|NN|N/N mononuclear|JJ|N/N cells|NNS|N (|LRB|(NP\NP)/NP PBMC|NN|N )|RRB|RRB and|CC|conj TSH|NN|N/N receptor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) TSHR|NN|N/N )|RRB|RRB -specific|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N lines|NNS|N to|TO|(NP\NP)/NP recombinant|JJ|N/N human|JJ|N/N TSHR|NN|N/N extracellular|JJ|N/N domain|NN|N ,|,|, thyroglobulin|NN|N ,|,|, and|CC|conj TSHR|NN|N/N peptides|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) examined|VBN|S[pss]\NP on|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N day|NN|N of|IN|(NP\NP)/NP surgery|NN|N or|CC|conj RAI|NN|N/N therapy|NN|N (|LRB|(NP\NP)/NP day|NN|N 0|CD|N\N )|RRB|RRB and|CC|conj also|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) 6-8|CD|N/N weeks|NNS|N and|CC|conj 3-6|CD|N/N months|NNS|N thereafter|RB|((S\NP)\(S\NP))\NP .|.|.
Reactivity|NN|N to|TO|(NP\NP)/NP TSHR|NN|N/N peptides|NNS|N before|IN|(NP\NP)/NP surgery|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) heterogeneous|JJ|S[adj]\NP and|CC|conj spanned|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N entire|JJ|N/N extracellular|JJ|N/N domain|NN|N .|.|.
Six|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 8|CD|N/N weeks|NNS|N after|IN|(NP\NP)/NP subtotal|JJ|N/N thyroidectomy|NN|N ,|,|, the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP patients|NNS|N '|POS|(NP[nb]/N)\NP PBMC|NN|N responding|VBG|(S[ng]\NP)/PP to|TO|PP/NP any|DT|NP[nb]/N peptide|NN|N and|CC|conj the|DT|NP[nb]/N average|JJ|N/N number|NN|N of|IN|(NP\NP)/NP recognized|VBN|N/N peptides|NNS|N decreased|VBD|S[dcl]\NP .|.|.
A|DT|NP[nb]/N further|JJ|N/N decrease|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N T|NN|(N/N)/(N/N) cell|NN|N/N reactivity|NN|N to|TO|(NP\NP)/NP TSHR|NN|N/N peptides|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP 3-6|CD|((S\NP)\(S\NP))/((S\NP)\(S\NP)) months|NNS|(S\NP)\(S\NP) after|IN|((S\NP)\(S\NP))/NP surgery|NN|N .|.|.
The|DT|NP[nb]/N responses|NNS|N of|IN|(NP\NP)/NP PBMC|NN|N from|IN|(NP\NP)/NP Graves|NN|N '|POS|(NP[nb]/N)\NP patients|NNS|N before|IN|(NP\NP)/NP RAI|NN|N/N therapy|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) less|JJR|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP those|DT|NP in|IN|(NP\NP)/NP the|DT|NP[nb]/N presurgical|JJ|N/N group|NN|N .|.|.
Six|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 8|CD|N/N weeks|NNS|N after|IN|(NP\NP)/NP RAI|NN|N/N therapy|NN|N ,|,|, the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP patients|NNS|N responding|VBG|(S[ng]\NP)/PP to|TO|PP/NP any|DT|NP[nb]/N peptide|NN|N and|CC|conj the|DT|NP[nb]/N average|JJ|N/N number|NN|N of|IN|(NP\NP)/NP recognized|VBN|N/N peptides|NNS|N increased|VBD|S[dcl]\NP .|.|.
Three|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 6|CD|N/N months|NNS|N after|IN|(NP\NP)/NP RAI|NN|N ,|,|, T|NN|(N/N)/(N/N) cell|NN|N/N responses|NNS|N to|TO|(NP\NP)/NP TSHR|NN|N/N peptides|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) less|JJR|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP those|DT|NP[nb]/N 6-8|CD|N/N weeks|NNS|N after|IN|(NP\NP)/NP RAI|NN|N/N therapy|NN|N ,|,|, but|CC|conj still|RB|(S[adj]\NP)/(S[adj]\NP) higher|JJR|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N values|NNS|N on|IN|(NP\NP)/NP day|NN|N 0|CD|N\N .|.|.
Responses|NNS|N of|IN|(NP\NP)/NP PBMC|NN|N from|IN|(NP\NP)/NP patients|NNS|N with|IN|(NP\NP)/NP GD|NN|N ,|,|, maintained|VBD|S[dcl]\NP euthyroid|JJ|(S\NP)\(S\NP) on|IN|((S\NP)\(S\NP))/NP ATD|NN|N ,|,|, were|VBD|(S[dcl]\NP)/(S[adj]\NP) lower|JJR|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP those|DT|NP before|IN|(NP\NP)/NP surgery|NN|N or|CC|conj RAI|NN|N/N therapy|NN|N .|.|.
The|DT|NP[nb]/N reactivity|NN|N of|IN|(NP\NP)/NP T|NN|(N/N)/(N/N) cell|NN|N/N lines|NNS|N in|IN|(NP\NP)/NP different|JJ|N/N groups|NNS|N reflected|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N pattern|NN|N similar|JJ|(S[adj]\NP)/PP to|TO|PP/NP PBMC|NN|N after|IN|(NP\NP)/NP treatment|NN|N .|.|.
TSHR|NN|N/N antibody|NN|N and|CC|conj microsomal|JJ|N/N antibody|NN|N/N levels|NNS|N decreased|VBD|S[dcl]\NP after|IN|((S\NP)\(S\NP))/NP surgery|NN|N ,|,|, but|CC|conj increased|VBD|S[dcl]\NP after|IN|((S\NP)\(S\NP))/NP RAI|NN|N/N therapy|NN|N .|.|.
The|DT|NP[nb]/N difference|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP recognized|VBN|N/N peptides|NNS|N by|IN|(NP\NP)/NP patients|NNS|N '|POS|(NP[nb]/N)\NP PBMC|NN|N before|IN|(NP\NP)/NP RAI|NN|N and|CC|conj surgery|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) reflect|VB|(S[b]\NP)/NP the|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP long|JJ|(N/N)/(N/N) term|NN|N/N therapy|NN|N with|IN|(NP\NP)/NP ATD|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N patients|NNS|N before|IN|(NP\NP)/NP RAI|NN|N vs.|CC|conj the|DT|NP[nb]/N shorter|JJR|N/N period|NN|N in|IN|(NP\NP)/NP patients|NNS|N before|IN|(NP\NP)/NP surgery|NN|N .|.|.
The|DT|NP[nb]/N decreased|VBN|N/N T|NN|(N/N)/(N/N) cell|NN|N/N reactivity|NN|N to|TO|(NP\NP)/NP thyroid|NN|N/N antigens|NNS|N after|IN|(NP\NP)/NP thyroidectomy|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP the|DT|NP[nb]/N result|NN|N of|IN|(NP\NP)/NP removal|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N major|JJ|N/N part|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N thyroid|NN|N/N gland|NN|N or|CC|conj redistribution|NN|N of|IN|(NP\NP)/NP suppressor-inducer|JJ|N/N T|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N increased|VBN|N/N T|NN|(N/N)/(N/N) cell|NN|N/N response|NN|N after|IN|(NP\NP)/NP RAI|NN|N/N therapy|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) probably|RB|(S\NP)\(S\NP) epitope|NN|(S[adj]\NP)/(S[adj]\NP) specific|JJ|S[adj]\NP ,|,|, rather|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) than|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N response|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N whole|JJ|N/N TSHR|NN|N/N molecule|NN|N .|.|.
Synchronous|JJ|N/N recognition|NN|N of|IN|(NP\NP)/NP peptides|NNS|N/N 158-176|CD|N and|CC|conj 248-263|CD|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) important|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N development|NN|N of|IN|(NP\NP)/NP GD|NN|N ,|,|, and|CC|conj the|DT|NP[nb]/N loss|NN|N of|IN|(NP\NP)/NP recognition|NN|N of|IN|(NP\NP)/NP one|CD|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N epitopes|NNS|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP an|DT|NP[nb]/N early|JJ|N/N sign|NN|N of|IN|(NP\NP)/NP immune|JJ|N/N remission|NN|N and|CC|conj a|DT|NP[nb]/N predictor|NN|N of|IN|(NP\NP)/NP euthyroidism|NN|N .|.|.
Molecular|JJ|N/N events|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) underlie|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N well-defined|JJ|N/N phenotypic|JJ|N/N changes|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N differentiating|VBG|N/N thymocyte|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) poorly|RB|(S\NP)\(S\NP) understood|VBN|S[pss]\NP .|.|.
A|DT|NP[nb]/N candidate|NN|N/N gene|NN|N to|TO|(S[to]\NP)/(S[b]\NP) control|VB|(S[b]\NP)/NP thymocyte|NN|N/N differentiation|NN|N ,|,|, T|NN|(N/N)/(N/N) cell|NN|N/N factor-1|NN|N (|LRB|(NP\NP)/NP TCF-1|NN|N )|RRB|RRB *|SYM|NP\NP encodes|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N DNA-binding|JJ|N/N protein|NN|N .|.|.
Its|PRP$|NP[nb]/N mRNA|NN|N/N expression|NN|N/N pattern|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) complex|JJ|S[adj]\NP during|IN|((S\NP)\(S\NP))/NP embryogenesis|NN|N ,|,|, yet|RB|conj restricted|JJ|S[adj]\NP to|TO|((S[adj]\NP)\(S[adj]\NP))/NP lymphocytes|NNS|N postnatally|RB|(S[adj]\NP)\(S[adj]\NP) .|.|.
Expression|NN|N/N studies|NNS|N on|IN|(NP\NP)/NP TCF-1|NN|N/N protein|NN|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) hampered|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N difficulty|NN|N to|TO|(S[to]\NP)/(S[b]\NP) raise|VB|(S[b]\NP)/NP antibodies|NNS|N due|JJ|(NP\NP)/PP to|TO|PP/NP extreme|JJ|N/N evolutionary|JJ|N/N conservation|NN|N .|.|.
TCF-1|NN|N/N knock-out|JJ|N/N mice|NNS|N ,|,|, generated|VBN|S[pss]\NP recently|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP our|PRP$|NP[nb]/N laboratory|NN|N ,|,|, have|VBP|(S[dcl]\NP)/NP strongly|RB|(N/N)/(N/N) decreased|VBN|N/N numbers|NNS|N of|IN|(NP\NP)/NP thymocytes|NNS|N ,|,|, but|CC|conj are|VBP|(S[dcl]\NP)/(S[adj]\NP) otherwise|RB|(S[adj]\NP)/(S[adj]\NP) normal|JJ|S[adj]\NP .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) used|VBN|((S[pt]\NP)/(S[to]\NP))/NP these|DT|NP[nb]/N mice|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) generate|VB|(S[b]\NP)/NP anti-TCF-1|NN|N/N antibodies|NNS|N .|.|.
By|IN|(S/S)/NP immunization|NN|N with|IN|(NP\NP)/NP a|DT|NP[nb]/N recombinant|JJ|N/N fusion|NN|N/N protein|NN|N ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] TCF-1|NN|N/N knock-out|JJ|N/N mice|NNS|N readily|RB|(S\NP)/(S\NP) yield|VBP|(S[dcl]\NP)/NP antiserum|NN|N/N titers|NNS|N against|IN|(NP\NP)/NP human|JJ|N/N and|CC|conj mouse|NN|N/N TCF-1|NN|N/N protein|NN|N .|.|.
Wild-type|JJ|N/N littermates|NNS|N remain|VBP|(S[dcl]\NP)/(S[adj]\NP) unresponsive|JJ|(S[adj]\NP)/PP to|TO|PP/NP TCF-1|NN|N while|IN|((S\NP)\(S\NP))/S[dcl] they|PRP|NP mount|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N high-titer|JJ|N/N antibody|NN|N/N response|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N fusion|NN|N/N protein|NN|N ,|,|, Maltose|NN|N/N Binding|NN|N/N Protein|NN|N (|LRB|(NP\NP)/NP MBP|NN|N )|RRB|RRB .|.|.
Subsequently|RB|S/S ,|,|, TCF-1-specific|JJ|N/N hybridomas|NNS|N could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) prepared|VBN|S[pss]\NP from|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N spleens|NNS|N of|IN|(NP\NP)/NP immunized|VBN|N/N knock-out|JJ|N/N mice|NNS|N .|.|.
This|DT|NP[nb]/N study|NN|N illustrates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N almost|RB|(N/N)/(N/N) complete|JJ|N/N tolerance|NN|N of|IN|(NP\NP)/NP mice|NNS|N for|IN|(NP\NP)/NP human|JJ|N/N TCF-1|NN|N and|CC|conj demonstrates|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] this|DT|NP[nb]/N tolerance|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) readily|RB|(S\NP)\(S\NP) broken|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP gene|NN|N/N knock-out|NN|N .|.|.
Furthermore|RB|S/S ,|,|, the|DT|NP[nb]/N usefulness|NN|N of|IN|(NP\NP)/NP knock-out|JJ|N/N mice|NNS|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N generation|NN|N of|IN|(NP\NP)/NP monoclonal|JJ|N/N antibodies|NNS|N against|IN|(NP\NP)/NP the|DT|NP[nb]/N gene|NN|N/N product|NN|N of|IN|(NP\NP)/NP interest|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) underscored|VBN|S[pss]\NP .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) identified|VBN|(S[pt]\NP)/NP an|DT|NP[nb]/N in|FW|(N/N)/(N/N) vivo|FW|N/N footprint|NN|N over|IN|(NP\NP)/NP the|DT|NP[nb]/N PuF|NN|N/N site|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N translocated|VBN|N/N c-myc|NN|N/N allele|NN|N in|IN|(NP\NP)/NP Burkitt|NN|N 's|POS|((N/N)/(N/N))\NP lymphoma|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N PuF|NN|N/N site|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N silent|JJ|N/N normal|JJ|N/N c-myc|NN|N/N allele|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) unoccupied|JJ|S[adj]\NP .|.|.
We|PRP|NP demonstrated|VBD|(S[dcl]\NP)/S[em] by|IN|((S\NP)\(S\NP))/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N ,|,|, electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N with|IN|(NP\NP)/NP antibody|NN|N ,|,|, UV|NN|N/N cross-linking|NN|N followed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP SDS-gel|NN|N/N electrophoresis|NN|N ,|,|, and|CC|conj Western|NN|N/N analysis|NN|N that|IN|S[em]/S[dcl] Nm23H2|NN|N in|IN|(NP\NP)/NP B|NN|(N/N)/(N/N) cell|NN|N/N nuclear|JJ|N/N extracts|NNS|N bound|VBD|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N c-myc|NN|N/N PuF|NN|N/N site|NN|N .|.|.
Transfection|NN|N/N experiments|NNS|N with|IN|(NP\NP)/NP c-myc|NN|N/N promoter|NN|N/N constructs|NNS|N in|IN|(NP\NP)/NP both|CC|NP/NP DHL-9|NN|N/N and|CC|conj Raji|NN|N/N cells|NNS|N revealed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N PuF|NN|N/N site|NN|N functioned|VBD|(S[dcl]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N positive|JJ|N/N regulatory|JJ|N/N element|NN|N in|IN|(NP\NP)/NP B|NN|N/N cells|NNS|N with|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N drop|NN|N in|IN|(NP\NP)/NP activity|NN|N with|IN|(NP\NP)/NP mutation|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N site|NN|N .|.|.
Access|NN|N to|TO|(NP\NP)/NP this|DT|NP[nb]/N site|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) blocked|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N normal|JJ|N/N silent|JJ|N/N c-myc|NN|N/N allele|NN|N ;|:|; these|DT|NP[nb]/N data|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N Nm23H2|NN|N/N protein|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP deregulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N translocated|VBN|N/N c-myc|NN|N/N allele|NN|N in|IN|(NP\NP)/NP Burkitt|NN|N 's|POS|((N/N)/(N/N))\NP lymphoma|NN|N/N cells|NNS|N .|.|.
Interaction|NN|N between|IN|(NP\NP)/NP the|DT|NP[nb]/N stage|NN|(N/N)/(N/N) selector|NN|N/N element|NN|N (|LRB|(NP\NP)/NP SSE|NN|N )|RRB|RRB in|IN|(NP\NP)/NP the|DT|NP[nb]/N proximal|JJ|N/N gamma-globin|NN|N/N promoter|NN|N and|CC|conj hypersensitivity|NN|N/N site|NN|N 2|CD|N\N in|IN|(NP\NP)/NP the|DT|NP[nb]/N locus|NN|(N/N)/(N/N) control|NN|N/N region|NN|N partly|RB|(S\NP)/(S\NP) mediates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N competitive|JJ|N/N silencing|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N beta-globin|NN|N/N promoter|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N fetal|JJ|(N/N)/(N/N) developmental|JJ|N/N stage|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) now|RB|(S\NP)\(S\NP) demonstrated|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] a|DT|NP[nb]/N second|JJ|N/N SSE-like|JJ|N/N element|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N 5'-untranslated|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N gamma-gene|NN|N also|RB|(S\NP)/(S\NP) contributes|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP this|DT|NP[nb]/N competitive|JJ|N/N silencing|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N beta-gene|NN|N .|.|.
Utilizing|VBG|(S[ng]\NP)/NP transient|JJ|N/N transfection|NN|N/N assays|NNS|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N fetal|JJ|N/N erythroid|JJ|N/N cell|NN|N/N line|NN|N ,|,|, K562|NN|N ,|,|, we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N core|NN|N/N enhancer|NN|N of|IN|(NP\NP)/NP hypersensitivity|NN|N/N site|NN|N 2|CD|N\N can|MD|(S[dcl]\NP)/(S[b]\NP) preferentially|RB|(S\NP)\(S\NP) interact|VB|(S[b]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N proximal|JJ|N/N gamma-promoter|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N absence|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N SSE|NN|N ,|,|, completely|RB|(S\NP)/(S\NP) silencing|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N linked|VBN|N/N beta-promoter|NN|N .|.|.
Mutation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N 20-base|JJ|N/N pair|NN|N/N sequence|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N gamma-gene|NN|N/N 5'-untranslated|JJ|N/N region|NN|N (|LRB|(N\N)/N UTR|NN|N )|RRB|RRB led|VBD|(S[dcl]\NP)/PP to|TO|PP/NP derepression|NN|N of|IN|(NP\NP)/NP beta-promoter|NN|N/N activity|NN|N .|.|.
A|DT|NP[nb]/N marked|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP gamma-promoter|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) observed|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP this|DT|NP[nb]/N mutation|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N repressor|NN|N .|.|.
Fine|JJ|N/N mutagenesis|NN|N dissected|VBD|((S[dcl]\NP)/PP)/NP these|DT|NP[nb]/N activities|NNS|N to|TO|PP/NP different|JJ|N/N regions|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N 5'-UTR|NN|N .|.|.
The|DT|NP[nb]/N stage|NN|(N/N)/(N/N) selector|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) localized|VBN|(S[pss]\NP)/PP to|TO|PP/NP a|DT|NP[nb]/N region|NN|N centered|JJ|(S[pss]\NP)/PP on|IN|PP/NP nucleotides|NNS|N +13|CD|N to|TO|conj +15|CD|N .|.|.
Electromobility|NN|N/N shift|NN|N/N assays|NNS|N utilizing|VBG|(S[ng]\NP)/NP this|DT|NP[nb]/N sequence|NN|N demonstrated|VBD|(S[dcl]\NP)/NP binding|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N fetal|JJ|N/N and|CC|conj erythroid-specific|JJ|N/N protein|NN|N .|.|.
The|DT|NP[nb]/N repressor|NN|N/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N 5'-UTR|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) localized|VBN|(S[pss]\NP)/PP to|TO|PP/NP tandem|JJ|N/N GATA-like|JJ|N/N sites|NNS|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) appear|VBP|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/NP a|DT|NP[nb]/N complex|NN|N of|IN|(NP\NP)/NP two|CD|N/N proteins|NNS|N ,|,|, one|CD|NP of|IN|(NP\NP)/NP which|WDT|((NP\NP)/(S[dcl]\NP))\(NP/NP) is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N erythroid|JJ|N/N transcription|NN|N/N factor|NN|N GATA-1|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N 5'-UTR|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N gamma-gene|NN|N contains|VBZ|(S[dcl]\NP)/NP sequences|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) important|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP its|PRP$|NP[nb]/N transcriptional|JJ|N/N and|CC|conj developmental|JJ|N/N regulation|NN|N .|.|.
The|DT|NP[nb]/N eukaryotic|JJ|N/N transcription|NN|N/N factor|NN|N NF-kappa|NN|N/N B|NN|N plays|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N central|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N induced|VBN|N/N expression|NN|N of|IN|(NP\NP)/NP human|JJ|N/N immunodeficiency|NN|N/N virus|NN|N type|NN|N\N 1|CD|(N\N)\(N\N) and|CC|conj in|IN|((S\NP)\(S\NP))/NP many|JJ|N/N aspects|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N genetic|JJ|N/N program|NN|N mediating|VBG|(S[ng]\NP)/NP normal|JJ|N/N T-cell|NN|N/N activation|NN|N and|CC|conj growth|NN|N .|.|.
The|DT|NP[nb]/N nuclear|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) tightly|RB|(S[adj]\NP)/(S[adj]\NP) regulated|VBN|S[adj]\NP from|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cytoplasmic|JJ|N/N compartment|NN|N by|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N inhibitory|JJ|N/N subunit|NN|N called|VBN|(S[pss]\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N .|.|.
This|DT|NP[nb]/N cytoplasmic|JJ|N/N inhibitor|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) rapidly|RB|(S\NP)\(S\NP) phosphorylated|VBN|S[pss]\NP and|CC|conj degraded|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP a|DT|NP[nb]/N diverse|JJ|N/N set|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B-inducing|JJ|N/N agents|NNS|N ,|,|, including|VBG|(NP\NP)/NP T-cell|NN|N/N mitogens|NNS|N ,|,|, proinflammatory|JJ|N/N cytokines|NNS|N ,|,|, and|CC|conj viral|JJ|N/N transactivators|NNS|N such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP the|DT|NP[nb]/N Tax|NN|N/N protein|NN|N of|IN|(NP\NP)/NP human|JJ|N/N T-cell|NN|N/N leukemia|NN|N/N virus|NN|N type|NN|N\N 1|CD|(N\N)\(N\N) .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) explore|VB|(S[b]\NP)/NP these|DT|NP[nb]/N I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha-dependent|JJ|N/N mechanisms|NNS|N for|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N induction|NN|N ,|,|, we|PRP|NP identified|VBD|(S[dcl]\NP)/NP novel|JJ|N/N mutants|NNS|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) uncouple|VBP|(S[dcl]\NP)/NP its|PRP$|NP[nb]/N inhibitory|JJ|N/N and|CC|conj signal-transducing|JJ|N/N functions|NNS|N in|IN|(NP\NP)/NP human|JJ|N/N T|NN|N/N lymphocytes|NNS|N .|.|.
Specifically|RB|S/S ,|,|, removal|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N N-terminal|JJ|N/N 36|CD|N/N amino|NN|N/N acids|NNS|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N failed|VBD|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) disrupt|VB|(S[b]\NP)/NP its|PRP$|NP[nb]/N ability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) form|VB|(S[b]\NP)/NP latent|JJ|N/N complexes|NNS|N with|IN|((S\NP)\(S\NP))/NP NF-kappa|NN|N/N B|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cytoplasm|NN|N .|.|.
However|RB|S/S ,|,|, this|DT|NP[nb]/N deletion|NN|N/N mutation|NN|N prevented|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N induced|VBN|N/N phosphorylation|NN|N ,|,|, degradative|JJ|N/N loss|NN|N ,|,|, and|CC|conj functional|JJ|N/N release|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N from|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N in|IN|(NP\NP)/NP Tax-expressing|JJ|N/N cells|NNS|N .|.|.
Alanine|NN|N/N substitutions|NNS|N introduced|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP two|CD|N/N serine|NN|N/N residues|NNS|N positioned|JJ|S[adj]\NP within|IN|((S[adj]\NP)\(S[adj]\NP))/NP this|DT|NP[nb]/N N-terminal|JJ|N/N regulatory|JJ|N/N region|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N also|RB|(S\NP)/(S\NP) yielded|VBD|(S[dcl]\NP)/NP constitutive|JJ|N/N repressors|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) escaped|VBD|(S[dcl]\NP)/PP from|IN|PP/NP Tax-induced|JJ|N/N turnover|NN|N and|CC|conj that|WDT|(NP\NP)/(S[dcl]\NP) potently|RB|(S\NP)/(S\NP) inhibited|VBD|(S[dcl]\NP)/NP immune|JJ|N/N activation|NN|N/N pathways|NNS|N for|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N induction|NN|N ,|,|, including|VBG|(NP\NP)/NP those|DT|NP initiated|VBN|S[pss]\NP from|IN|((S\NP)\(S\NP))/NP antigen|NN|N/N and|CC|conj cytokine|NN|N/N receptors|NNS|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, introduction|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N phosphoserine|NN|N/N mimetic|JJ|N at|IN|(NP\NP)/NP these|DT|NP[nb]/N sites|NNS|N rectified|VBD|(S[dcl]\NP)/NP this|DT|NP[nb]/N functional|JJ|N/N defect|NN|N ,|,|, a|DT|NP[nb]/N finding|NN|N consistent|JJ|(S[adj]\NP)/PP with|IN|PP/NP a|DT|NP[nb]/N causal|JJ|N/N linkage|NN|N between|IN|(NP\NP)/NP the|DT|NP[nb]/N phosphorylation|NN|N/N status|NN|N and|CC|conj proteolytic|JJ|N/N stability|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N cytoplasmic|JJ|N/N inhibitor|NN|N .|.|.
Together|RB|S[adj]\NP ,|,|, these|DT|NP[nb]/N in|FW|(N/N)/(N/N) vivo|FW|N/N studies|NNS|N define|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N critical|JJ|N/N signal|NN|N/N response|NN|N/N domain|NN|N in|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) coordinately|RB|(S\NP)/(S\NP) controls|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N biologic|JJ|N/N activities|NNS|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N and|CC|conj NF-kappa|NN|N/N B|NN|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP viral|JJ|N/N and|CC|conj immune|JJ|N/N stimuli|NNS|N .|.|.
Human|JJ|N/N prostatic|JJ|N/N epithelial|JJ|N/N cells|NNS|N from|IN|(NP\NP)/NP an|DT|NP[nb]/N androgen-dependent|JJ|N/N LNCaP|NN|N/N cell|NN|N/N line|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) examined|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP conditioned|JJ|N/N medium|NN|N (|LRB|(NP\NP)/NP CM|NN|N )|RRB|RRB derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP phytohemagglutinin|NN|(N/N)/(N/N) (|LRB|(((N/N)/(N/N))\((N/N)/(N/N)))/((N/N)/(N/N)) PHA|NN|(N/N)/(N/N) )|RRB|RRB -stimulated|JJ|N/N lymphocytes|NNS|N .|.|.
Addition|NN|N of|IN|(NP\NP)/NP CM|NN|N caused|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N greater|JJR|S[adj]\NP than|IN|((N/N)/(N/N))\(S[adj]\NP) 70|CD|(N/N)/(N/N) %|NN|N/N reduction|NN|N of|IN|(NP\NP)/NP cell|NN|N/N proliferation|NN|N by|IN|(NP\NP)/NP cell|NN|N/N counting|NN|N and|CC|conj cell|NN|N/N cycle|NN|N .|.|.
These|DT|NP[nb]/N cells|NNS|N showed|VBD|(S[dcl]\NP)/NP G1|NN|N/N phase|NN|N/N arrest|NN|N and|CC|conj the|DT|NP[nb]/N clonogenicity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) reduced|VBN|S[pss]\NP .|.|.
The|DT|NP[nb]/N growth-modulating|JJ|N/N effect|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) dose-dependent|JJ|S[adj]\NP and|CC|conj not|RB|(S[adj]\NP)/(S[adj]\NP) due|JJ|(S[adj]\NP)/PP to|TO|PP/NP cell|NN|N/N lysis|NN|N or|CC|conj apoptosis|NN|N .|.|.
The|DT|NP[nb]/N binding|NN|N of|IN|(NP\NP)/NP androgen|NN|N to|TO|(NP\NP)/NP androgen|NN|N/N receptor|NN|N on|IN|(NP\NP)/NP these|DT|NP[nb]/N cells|NNS|N showed|VBD|(S[dcl]\NP)/NP approximately|RB|((N/N)/(N/N))/((N/N)/(N/N)) 50|CD|(N/N)/(N/N) %|NN|N/N reduction|NN|N ,|,|, underlining|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N proliferation|NN|(N/N)/(N/N) reduction|NN|N/N mechanism|NN|N .|.|.
The|DT|NP[nb]/N prostate-specific|JJ|N/N antigen|NN|N (|LRB|(N\N)/N PSA|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[pss]\NP) downregulated|VBN|S[pss]\NP to|TO|((S\NP)\(S\NP))/NP approximately|RB|(N/N)/(N/N) 75|CD|N/N %|NN|N during|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N process|NN|N .|.|.
Cell|NN|N/N morphology|NN|N showed|VBD|(S[dcl]\NP)/NP dendritic|JJ|N/N processes|NNS|N extending|VBG|(S[ng]\NP)/PP from|IN|PP/NP cytoplasm|NN|N and|CC|conj other|JJ|N/N neuroendocrine|JJ|N/N cell|NN|N/N characteristics|NNS|N .|.|.
The|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP several|JJ|N/N cytoskeleton|NN|N/N and|CC|conj intracellular|JJ|N/N proteins|NNS|N increased|VBD|S[dcl]\NP as|IN|((S\NP)\(S\NP))/(S[pss]\NP) determined|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP immunostaining|NN|N on|IN|(NP\NP)/NP slides|NNS|N and|CC|conj by|IN|((S\NP)\(S\NP))/NP ELISA|NN|N/N procedures|NNS|N .|.|.
These|DT|NP included|VBD|(S[dcl]\NP)/NP vimentin|NN|N ,|,|, correlating|VBG|(S[ng]\NP)/PP to|TO|PP/NP cell|NN|(N/N)/(N/N) shape|NN|N/N changes|NNS|N ,|,|, cytokeratins|NNS|N/N 8|CD|N and|CC|conj 18|CD|N ,|,|, associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP differentiated|VBN|N/N cell|NN|N/N types|NNS|N of|IN|(NP\NP)/NP prostate|NN|N/N epithelia|NN|N ,|,|, and|CC|conj neuron-specific|JJ|N/N enolase|NN|N and|CC|conj serotonin|NN|N ,|,|, associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP neuroendocrine|JJ|N/N cells|NNS|N .|.|.
From|IN|(S/S)/NP these|DT|NP[nb]/N cellular|JJ|N/N changes|NNS|N ,|,|, we|PRP|NP can|MD|(S[dcl]\NP)/(S[b]\NP) infer|VB|(S[b]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N cell|NN|N/N growth|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) modulated|VBN|S[pss]\NP along|IN|((S\NP)\(S\NP))/PP with|IN|PP/NP induction|NN|N of|IN|(NP\NP)/NP terminal|JJ|N/N differentiation|NN|N .|.|.
Activated|VBN|N/N T|NN|N/N cells|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) demonstrated|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) important|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/(S[ng]\NP) providing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N modulating|NN|N/N activity|NN|N .|.|.
This|DT|NP[nb]/N growth|NN|N/N modulator|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) semipurified|VBN|S[pss]\NP and|CC|conj had|VBD|(S[dcl]\NP)/NP an|DT|NP[nb]/N estimated|VBN|N/N molecular|JJ|N/N weight|NN|N 13,000|CD|N to|TO|(NP\NP)/NP 24,000|CD|N/N Da|NN|N .|.|.
The|DT|NP[nb]/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) determined|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) distinct|JJ|(S[adj]\NP)/PP from|IN|PP/NP TGF|NN|N ,|,|, TNF|NN|N ,|,|, and|CC|conj some|DT|NP[nb]/N commonly|RB|(N/N)/(N/N) known|JJ|N/N lymphokines|NNS|N .|.|.
The|DT|NP[nb]/N interaction|NN|N between|IN|(NP\NP)/NP lymphoid|JJ|N/N and|CC|conj prostatic|JJ|N/N cells|NNS|N in|IN|(NP\NP)/NP growth|NN|N and|CC|conj development|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) described|VBN|S[pss]\NP .|.|.
Human|JJ|N/N peripheral|JJ|N/N blood|NN|N/N monocytes|NNS|N responded|VBD|(S[dcl]\NP)/PP to|TO|PP/NP stimulation|NN|N of|IN|(NP\NP)/NP platelet-activating|JJ|N/N factor|NN|N (|LRB|(N\N)/N PAF|NN|N )|RRB|RRB with|IN|((S\NP)\(S\NP))/NP up-regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N transcript|NN|N for|IN|(NP\NP)/NP heparin-binding|JJ|N/N epidermal|JJ|N/N growth|NN|N/N factor-like|JJ|N/N growth|NN|N/N factor|NN|N (|LRB|(NP\NP)/NP HB-EGF|NN|N )|RRB|RRB ,|,|, a|DT|NP[nb]/N potent|JJ|N/N mitogen|NN|N for|IN|(NP\NP)/NP vascular|JJ|N/N smooth|JJ|N/N muscle|NN|N/N cells|NNS|N .|.|.
This|DT|NP[nb]/N function|NN|N of|IN|(NP\NP)/NP PAF|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP nanomolar|JJ|N/N concentrations|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N ligand|NN|N ,|,|, starting|VBG|(S[ng]\NP)/PP at|IN|PP/NP 30|CD|N/N min|NN|N after|IN|(NP\NP)/NP stimulation|NN|N .|.|.
The|DT|NP[nb]/N PAF-induced|JJ|N/N up-regulation|NN|N of|IN|(NP\NP)/NP HB-EGF|NN|N/N mRNA|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) accompanied|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N increase|NN|N in|IN|(NP\NP)/NP kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N activity|NN|N .|.|.
These|DT|NP[nb]/N functions|NNS|N of|IN|(NP\NP)/NP PAF|NN|N appeared|VBD|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP through|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cell|NN|N/N surface|NN|N/N PAF|NN|N/N receptors|NNS|N ,|,|, as|IN|((S\NP)\(S\NP))/S[dcl] two|CD|N/N PAF|NN|N/N receptor|NN|N/N antagonists|NNS|N ,|,|, WEB|NN|N 2086|CD|N\N and|CC|conj L-659|NN|N/N ,|,|, 989|CD|N ,|,|, blocked|VBD|(S[dcl]\NP)/NP both|CC|NP/NP the|DT|NP[nb]/N up-regulation|NN|N of|IN|(NP\NP)/NP HB-EGF|NN|N/N mRNA|NN|N and|CC|conj kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N activity|NN|N induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP PAF|NN|N .|.|.
The|DT|NP[nb]/N antagonists|NNS|N ,|,|, however|RB|(S\NP)/(S\NP) ,|,|, had|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N effect|NN|N on|IN|(NP\NP)/NP phorbol|NN|N/N ester-induced|JJ|N/N up-regulation|NN|N of|IN|(NP\NP)/NP HB-EGF|NN|N/N mRNA|NN|N and|CC|conj kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N activity|NN|N .|.|.
Pretreatment|NN|N of|IN|(NP\NP)/NP monocytes|NNS|N with|IN|(NP\NP)/NP pertussis|NN|N/N toxin|NN|N inhibited|VBD|(S[dcl]\NP)/NP these|DT|NP[nb]/N functions|NNS|N of|IN|(NP\NP)/NP PAF|NN|N ,|,|, whereas|IN|((S\NP)\(S\NP))/S[dcl] cholera|NN|N/N toxin|NN|N had|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N inhibitory|JJ|N/N effect|NN|N .|.|.
Pyrrolidine|NN|N/N dithiocarbamate|NN|N ,|,|, an|DT|NP[nb]/N inhibitor|NN|N for|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N ,|,|, markedly|RB|(S\NP)/(S\NP) reduced|VBD|(S[dcl]\NP)/NP PAF-stimulated|JJ|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N activity|NN|N as|RB|conj/conj well|RB|conj/conj as|IN|conj up-regulation|NN|N of|IN|(NP\NP)/NP HB-EGF|NN|N/N mRNA|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N potential|JJ|N/N role|NN|N of|IN|(NP\NP)/NP PAF|NN|N in|IN|(NP\NP)/NP HB-EGF|NN|N/N expression|NN|N and|CC|conj provide|VBP|(S[dcl]\NP)/NP evidence|NN|N/S[em] that|IN|S[em]/S[dcl] this|DT|NP[nb]/N stimulation|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) occur|VB|S[b]\NP through|IN|((S\NP)\(S\NP))/NP increased|VBN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N binding|NN|N/N activity|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/NP previously|RB|(S\NP)/(S\NP) described|VBN|S[pss]\NP a|DT|NP[nb]/N mutant|JJ|N/N B|NN|N/N lymphoblastoid|JJ|N/N cell|NN|N/N line|NN|N ,|,|, Clone-13|NN|N ,|,|, that|WDT|(NP\NP)/(S[dcl]\NP) expresses|VBZ|(S[dcl]\NP)/NP HLA-DQ|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N absence|NN|N of|IN|(NP\NP)/NP HLA-DR|NN|N and|CC|conj -DP|NN|N .|.|.
Several|JJ|N/N criteria|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N defect|NN|N in|IN|(NP\NP)/NP this|DT|NP[nb]/N cell|NN|N/N line|NN|N influences|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP an|DT|NP[nb]/N isotype-specific|JJ|N/N transcription|NN|N/N factor|NN|N .|.|.
Indeed|RB|S/S ,|,|, transient|JJ|N/N transfection|NN|N of|IN|(NP\NP)/NP HLA-DRA|NN|N/N and|CC|conj DQB|NN|N/N reporter|NN|N/N constructs|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N affected|VBN|N/N factor|NN|N operates|VBZ|S[dcl]\NP via|IN|((S\NP)\(S\NP))/NP cis-elements|NNS|N located|JJ|S[pss]\NP between|IN|((S\NP)\(S\NP))/NP -141|CD|N/N base|NN|N/N pairs|NNS|N and|CC|conj the|DT|NP[nb]/N transcription|NN|(N/N)/(N/N) initiation|NN|N/N site|NN|N .|.|.
A|DT|NP[nb]/N series|NN|N of|IN|(NP\NP)/NP hybrid|NN|N/N DRA/DQB|NN|N/N reporter|NN|N/N constructs|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) generated|VBN|S[pss]\NP to|TO|(S[to]\NP)/(S[b]\NP) further|JJ|(S\NP)/(S\NP) map|VB|(S[b]\NP)/NP the|DT|NP[nb]/N relevant|JJ|N/N cis-elements|NNS|N in|IN|(NP\NP)/NP this|DT|NP[nb]/N system|NN|N .|.|.
Insertion|NN|N of|IN|(NP\NP)/NP oligonucleotides|NNS|N spanning|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N DQB|NN|N/N X-box|NN|N (|LRB|conj/conj but|CC|conj not|RB|NP/NP the|DT|NP[nb]/N DQB-W|NN|N/N region|NN|N or|CC|conj the|DT|NP[nb]/N DQB|NN|N/N Y-box|NN|N )|RRB|RRB upstream|JJ|(S[adj]\NP)/PP of|IN|PP/NP -141|CD|N in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N DRA|NN|N/N reporter|NN|N/N plasmid|NN|N rescued|VBD|(S[dcl]\NP)/NP expression|NN|N to|TO|((S\NP)\(S\NP))/NP nearly|RB|(N/N)/(N/N) wild-type|JJ|N/N levels|NNS|N .|.|.
Substitution|NN|N/N promoters|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) then|RB|(S\NP)\(S\NP) generated|VBN|S[pss]\NP where|WRB|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N entire|JJ|N/N X-box|NN|N ,|,|, or|CC|conj only|RB|NP/NP the|DT|NP[nb]/N X1-|NN|N or|CC|conj X2-boxes|NNS|N of|IN|(NP\NP)/NP HLA-DRA|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) replaced|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N analogous|JJ|N/N regions|NNS|N of|IN|(NP\NP)/NP HLA-DQB|NN|N .|.|.
The|DT|NP[nb]/N DQB|NN|N/N X2-box|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) restore|VB|((S[b]\NP)/PP)/NP expression|NN|N to|TO|PP/NP the|DT|NP[nb]/N silent|JJ|N/N DRA|NN|N/N reporter|NN|N/N construct|NN|N .|.|.
Moreover|RB|S/S ,|,|, replacement|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DQB|NN|N/N X2-box|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N DRA|NN|N/N X2-box|NN|N markedly|RB|(S\NP)/(S\NP) diminished|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DQB|NN|N/N promoter|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N mutant|JJ|N/N cell|NN|N .|.|.
None|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N hybrid|NN|N/N reporter|NN|N/N constructs|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) defective|JJ|S[adj]\NP when|WRB|((S\NP)\(S\NP))/(S[pss]\NP) transfected|VBN|(S[pss]\NP)/PP into|IN|PP/NP the|DT|NP[nb]/N wild-type|JJ|N/N ,|,|, HLA-DR/-DQ|NN|N/N positive|JJ|N/N parental|JJ|N/N cell|NN|N/N line|NN|N ,|,|, Jijoye|NN|N .|.|.
These|DT|NP[nb]/N studies|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N divergent|JJ|N/N X2-box|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N class|NN|N/N II|CD|(N/N)\(N/N) major|JJ|N/N histocompatibility|NN|N/N complex|NN|N/N promoters|NNS|N plays|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/(S[ng]\NP) influencing|VBG|(S[ng]\NP)/NP differential|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N class|NN|N/N II|CD|(N/N)\(N/N) isotypes|NNS|N .|.|.
The|DT|NP[nb]/N ZEBRA|NN|N/N protein|NN|N has|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N unique|JJ|N/N biological|JJ|N/N function|NN|N among|IN|((S\NP)\(S\NP))/NP herpesviral|JJ|N/N proteins|NNS|N .|.|.
It|PRP|NP is|VBZ|(S[dcl]\NP)/(S[adj]\NP) responsible|JJ|(S[adj]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N disruption|NN|N of|IN|(NP\NP)/NP Epstein-Barr|JJ|(N/N)/(N/N) virus|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) EBV|NN|N/N )|RRB|RRB latency|NN|N and|CC|conj the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N lytic|JJ|N/N cycle|NN|N .|.|.
ZEBRA|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N bZIP|NN|N/N transcriptional|JJ|N/N activator|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) binds|VBZ|S[dcl]\NP as|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N dimer|NN|N to|TO|((S\NP)\(S\NP))/NP 7-bp|JJ|N/N response|NN|N/N elements|NNS|N within|IN|(NP\NP)/NP EBV|NN|N/N promoters|NNS|N and|CC|conj is|VBZ|(S[dcl]\NP)/(S[pss]\NP) directly|RB|(S\NP)\(S\NP) involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N stimulation|NN|N of|IN|(NP\NP)/NP virus|NN|N/N replication|NN|N at|IN|(NP\NP)/NP the|DT|NP[nb]/N EBV|NN|N/N lytic|JJ|N/N origin|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) employed|VBN|((S[pt]\NP)/(S[to]\NP))/NP the|DT|NP[nb]/N ZEBRA/EBV|NN|N/N biological|JJ|N/N system|NN|N to|TO|(S[to]\NP)/(S[b]\NP) test|VB|(S[b]\NP)/S[qem] whether|IN|S[qem]/S[dcl] a|DT|NP[nb]/N heterologous|JJ|N/N activation|NN|N/N domain|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) substitute|VB|(S[b]\NP)/PP for|IN|PP/NP another|DT|NP[nb]/N activation|NN|N/N domain|NN|N (|LRB|(NP\NP)/NP the|DT|NP[nb]/N ZEBRA|NN|N/N domain|NN|N )|RRB|RRB .|.|.
The|DT|NP[nb]/N ZEBRA|NN|N/N activation|NN|N/N region|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) replaced|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N potent|JJ|N/N acid|NN|N/N activation|NN|N/N region|NN|N from|IN|(NP\NP)/NP the|DT|NP[nb]/N herpes|NN|N/N simplex|JJ|N/N virus|NN|N/N VP16|NN|N/N protein|NN|N or|CC|conj with|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N activation|NN|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N EBV|NN|N/N R|NN|N/N protein|NN|N .|.|.
Both|DT|NP[nb]/N chimeras|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) transactivate|VB|(S[b]\NP)/NP model|NN|N/N and|CC|conj native|JJ|N/N promoters|NNS|N at|IN|((S\NP)\(S\NP))/NP equivalent|JJ|N/N or|CC|conj better|JJR|N/N levels|NNS|N than|IN|(NP\NP)/NP ZEBRA|NN|N itself|PRP|NP\NP .|.|.
Activation|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) target-|NN|(S[adj]\NP)/(S[adj]\NP) or|CC|conj cell-type|NN|(S[adj]\NP)/(S[adj]\NP) dependent|JJ|S[adj]\NP ,|,|, nor|CC|(S\S)/S[q] was|VBD|(S[q]/(S[adj]\NP))/NP it|PRP|NP dependent|JJ|(S[adj]\NP)/PP on|IN|PP/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP virus|NN|N .|.|.
These|DT|NP[nb]/N activation|NN|N/N domains|NNS|N restored|VBD|(S[dcl]\NP)/NP ZEBRA|NN|N 's|POS|(NP[nb]/N)\NP ability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP early|JJ|N/N antigen|NN|N and|CC|conj to|TO|(S[to]\NP)/(S[b]\NP) stimulate|VB|(S[b]\NP)/NP origin|NN|N/N replication|NN|N to|TO|((S\NP)\(S\NP))/NP levels|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) were|VBD|(S[dcl]\NP)/(S[adj]\NP) equal|JJ|S[adj]\NP to|TO|((S[adj]\NP)\(S[adj]\NP))/NP or|CC|conj greater|JJR|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP those|DT|NP of|IN|(NP\NP)/NP wild|JJ|N/N type|NN|N .|.|.
These|DT|NP[nb]/N studies|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N specificities|NNS|N of|IN|(NP\NP)/NP some|DT|NP of|IN|(NP\NP)/NP the|DT|NP[nb]/N known|JJ|N/N biological|JJ|N/N functions|NNS|N of|IN|(NP\NP)/NP ZEBRA|NN|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) dependent|JJ|S[adj]\NP upon|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N nature|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N activation|NN|N/N domain|NN|N present|JJ|S[adj]\NP within|IN|((S[adj]\NP)\(S[adj]\NP))/NP ZEBRA|NN|N .|.|.
Germ|NN|N/N line|NN|N/N C|NN|N/N transcripts|NNS|N can|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP IL-4|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N human|JJ|N/N B|NN|(N/N)/(N/N) cell|NN|N/N line|NN|N ,|,|, BL-2|NN|N .|.|.
Utilizing|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N IFN-gamma|NN|N/N activation|NN|N/N site-like|JJ|N/N DNA|NN|N/N sequence|NN|N/N element|NN|N located|JJ|S[pss]\NP upstream|RB|(S[adj]\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N I|NN|N/N epsilon|NN|N/N exon|NN|N ,|,|, we|PRP|NP demonstrated|VBD|(S[dcl]\NP)/S[em] by|IN|((S\NP)\(S\NP))/NP gel|NN|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N that|IN|S[em]/S[dcl] IL-4|NN|N induced|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N binding|NN|N/N activity|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cytosol|NN|N and|CC|conj nucleus|NN|N of|IN|(NP\NP)/NP BL-2|NN|N/N cells|NNS|N .|.|.
This|DT|NP[nb]/N factor|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) designated|VBN|(S[pss]\NP)/NP IL-4|NN|N/N NAF|NNS|N (|LRB|(NP\NP)/NP IL-4-induced|JJ|N/N nuclear-activating|JJ|N/N factors|NNS|N )|RRB|RRB and|CC|conj was|VBD|(S[dcl]\NP)/(S[pss]\NP) identified|VBN|(S[pss]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N tyrosine|NN|N/N phosphoprotein|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) translocates|VBZ|S[dcl]\NP from|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cytosol|NN|N to|TO|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N nucleus|NN|N upon|IN|((S\NP)\(S\NP))/NP IL-4|NN|N/N treatment|NN|N .|.|.
Because|IN|(S/S)/S[dcl] these|DT|NP are|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N characteristics|NNS|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N signal|NN|(N/N)/(N/N) transducer|NN|N/N and|CC|conj activator|NN|N/N of|IN|((N/N)\(N/N))/NP transcription|NN|N (|LRB|((N/N)\(N/N))/(N/N) Stat|NN|N/N )|RRB|RRB protein|NN|N ,|,|, we|PRP|NP determined|VBD|(S[dcl]\NP)/S[qem] whether|IN|S[qem]/S[dcl] antibodies|NNS|N to|TO|(NP\NP)/NP Stat|NN|N/N proteins|NNS|N will|MD|(S[dcl]\NP)/(S[b]\NP) interfere|VB|(S[b]\NP)/PP with|IN|PP/NP gel|NN|N/N mobility|NN|N/N shift|NN|N and|CC|conj found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] antibodies|NNS|N to|TO|(NP\NP)/NP IL-4|NN|N/N Stat|NN|N ,|,|, also|RB|(S\NP)/(S\NP) known|VBN|(S[pss]\NP)/PP as|IN|PP/NP Stat6|NN|N ,|,|, but|CC|conj not|RB|NP/NP antibodies|NNS|N to|TO|(NP\NP)/NP other|JJ|N/N Stat|NN|N/N proteins|NNS|N ,|,|, interfere|VBP|(S[dcl]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N formation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-4|NN|N/N NAF|NN|N/N complex|NN|N .|.|.
Congruous|JJ|(S/S)/PP with|IN|PP/NP the|DT|NP[nb]/N involvement|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N Stat|NN|N/N protein|NN|N ,|,|, IL-4|NN|N induced|VBD|(S[dcl]\NP)/NP robust|JJ|N/N Janus|NN|N/N kinase|NN|N/N 3|CD|(N/N)\(N/N) (|LRB|((N/N)\(N/N))/(N/N) JAK3|NN|N/N )|RRB|RRB activity|NN|N in|IN|(NP\NP)/NP BL-2|NN|N/N cells|NNS|N .|.|.
Cotransfection|NN|N of|IN|(NP\NP)/NP JAK3|NN|N with|IN|(NP\NP)/NP IL-4|NN|N/N Stat|NN|N into|IN|(NP\NP)/NP COS-7|NN|N/N cells|NNS|N produced|VBD|(S[dcl]\NP)/NP an|DT|NP[nb]/N intracellular|JJ|N/N activity|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) bound|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N same|JJ|N/N IFN-gamma|NN|N/N activation|NN|N/N site-like|JJ|N/N sequence|NN|N and|CC|conj comigrated|VBD|(S[dcl]\NP)/PP with|IN|PP/NP IL-4|NN|N/N NAF|NN|N in|IN|((S\NP)\(S\NP))/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-4|NN|N/N NAF|NN|N is|VBZ|(S[dcl]\NP)/NP IL-4|NN|N/N Stat|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) activated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP JAK3|NN|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP IL-4|NN|N/N receptor|NN|N/N engagement|NN|N .|.|.
Almost|RB|(N/N)/(N/N) 25|CD|N/N %|NN|N of|IN|(NP\NP)/NP patients|NNS|N with|IN|(NP\NP)/NP T-cell|NN|N/N acute|JJ|N/N lymphoblastic|JJ|N/N leukemia|NN|N (|LRB|(N\N)/N T-ALL|NN|N )|RRB|RRB have|VBP|(S[dcl]\NP)/NP tumor-specific|JJ|N/N rearrangements|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TAL1|NN|N/N gene|NN|N .|.|.
Although|IN|(S/S)/S[dcl] TAL1|NN|N/N expression|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) not|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N lymphocytes|NNS|N ,|,|, TAL1|NN|N/N gene|NN|N/N products|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) readily|RB|(S\NP)\(S\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP leukemic|JJ|N/N cells|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) harbor|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N rearranged|VBN|N/N TAL1|NN|N/N allele|NN|N .|.|.
Hence|RB|S/S ,|,|, it|PRP|NP[expl] has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) proposed|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] ectopic|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP TAL1|NN|N promotes|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N development|NN|N of|IN|(NP\NP)/NP T-ALL|NN|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N report|NN|N ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] TAL1|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N leukemic|JJ|N/N cells|NNS|N of|IN|(NP\NP)/NP most|JJS|N/N patients|NNS|N with|IN|(NP\NP)/NP T-ALL|NN|N ,|,|, including|VBG|(S[ng]\NP)/NP many|JJ|N that|WDT|(NP\NP)/(S[dcl]\NP) do|VBP|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) display|VB|(S[b]\NP)/NP an|DT|NP[nb]/N apparent|JJ|N/N TAL1|NN|(N/N)/(N/N) gene|NN|N/N alteration|NN|N .|.|.
A|DT|NP[nb]/N polymorphic|JJ|N/N dinucleotide|NN|N/N repeat|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N transcribed|VBN|N/N sequences|NNS|N of|IN|(NP\NP)/NP TAL1|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) determine|VB|(S[b]\NP)/NP the|DT|NP[nb]/N allele|NN|N/N specificity|NN|N of|IN|(NP\NP)/NP TAL1|NN|N/N transcription|NN|N in|IN|(NP\NP)/NP primary|JJ|N/N T-ALL|NN|N/N cells|NNS|N .|.|.
Monoallelic|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP TAL1|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N leukemic|JJ|N/N cells|NNS|N of|IN|(NP\NP)/NP all|DT|NP[nb]/N patients|NNS|N (|LRB|(NP\NP)/NP 8|CD|N of|IN|(NP\NP)/NP 8|CD|N )|RRB|RRB bearing|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N TAL1|NN|(N/N)/(N/N) gene|NN|N/N rearrangement|NN|N .|.|.
In|IN|(S/S)/NP the|DT|NP[nb]/N leukemic|JJ|N/N cells|NNS|N of|IN|(NP\NP)/NP patients|NNS|N without|IN|(NP\NP)/NP detectable|JJ|N/N TAL1|NN|N/N rearrangements|NNS|N ,|,|, TAL1|NN|N/N transcription|NN|N occurred|VBD|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP either|CC|NP/NP a|DT|NP[nb]/N monoallelic|JJ|N/N (|LRB|((N/N)\(N/N))/NP 3|CD|N of|IN|(NP\NP)/NP 7|CD|N/N patients|NNS|N )|RRB|RRB or|CC|conj a|DT|NP[nb]/N biallelic|JJ|N/N (|LRB|((N/N)\(N/N))/NP 4|CD|N of|IN|(NP\NP)/NP 7|CD|N/N patients|NNS|N )|RRB|RRB fashion|NN|N .|.|.
Thus|RB|S/S ,|,|, TAL1|NN|N/N activation|NN|N in|IN|(NP\NP)/NP these|DT|NP[nb]/N patients|NNS|N may|MD|(S[dcl]\NP)/(S[b]\NP) result|VB|(S[b]\NP)/PP from|IN|PP/NP subtle|JJ|N/N alterations|NNS|N in|IN|(NP\NP)/NP cis-acting|JJ|N/N regulatory|JJ|N/N sequences|NNS|N (|LRB|(S[ng]\NP)/(S[ng]\NP) affecting|VBG|(S[ng]\NP)/NP expression|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N single|JJ|N/N TAL1|NN|N/N allele|NN|N )|RRB|RRB or|CC|conj changes|NNS|N in|IN|(NP\NP)/NP trans-acting|JJ|N/N factors|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) control|VBP|(S[dcl]\NP)/NP TAL1|NN|N/N transcription|NN|N (|LRB|(S[ng]\NP)/(S[ng]\NP) affecting|VBG|(S[ng]\NP)/NP expression|NN|N of|IN|(NP\NP)/NP both|DT|NP[nb]/N TAL1|NN|N/N alleles|NNS|N )|RRB|RRB .|.|.
Acute|JJ|N/N megakaryoblastic|JJ|N/N leukaemia|NN|N (|LRB|(N\N)/N M7|NN|N )|RRB|RRB and|CC|conj transient|JJ|N/N myeloproliferative|JJ|N/N disorder|NN|N in|IN|(NP\NP)/NP Down|NN|N 's|POS|(NP[nb]/N)\NP syndrome|NN|N (|LRB|(NP\NP)/NP TMD|NN|N )|RRB|RRB are|VBP|(S[dcl]\NP)/(S[pss]\NP) characterized|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP rapid|JJ|N/N growth|NN|N of|IN|(NP\NP)/NP abnormal|JJ|N/N blast|NN|N/N cells|NNS|N which|WDT|(NP\NP)/(S[dcl]\NP) express|VBP|(S[dcl]\NP)/NP megakaryocytic|JJ|N/N markers|NNS|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) clarify|VB|(S[b]\NP)/NP properties|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N blast|NN|N/N cells|NNS|N in|IN|(NP\NP)/NP M7|NN|N/N and|CC|conj TMD|NN|N/N cases|NNS|N ,|,|, we|PRP|NP examined|VBD|(S[dcl]\NP)/NP erythroid|JJ|(N/N)/(N/N) markers|NNS|N/N expression|NN|N in|IN|(NP\NP)/NP blasts|NNS|N from|IN|(NP\NP)/NP six|CD|N/N cases|NNS|N with|IN|(NP\NP)/NP M7|NN|N and|CC|conj seven|CD|N/N cases|NNS|N with|IN|(NP\NP)/NP TMD|NN|N in|IN|((S\NP)\(S\NP))/NP this|DT|NP[nb]/N study|NN|N .|.|.
Erythroid-specific|JJ|N/N mRNAs|NNS|N encoding|VBG|(S[ng]\NP)/NP gamma-globin|NN|N and|CC|conj erythroid|JJ|N/N delta-aminolevulinate|JJ|N/N synthase|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP blasts|NNS|N from|IN|(NP\NP)/NP most|JJS|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N cases|NNS|N ,|,|, indicating|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] majorities|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N blasts|NNS|N in|IN|(NP\NP)/NP M7|NN|N/N and|CC|conj TMD|NN|N/N cases|NNS|N have|VBP|(S[dcl]\NP)/NP erythroid|JJ|N/N and|CC|conj megakaryocytic|JJ|N/N phenotypes|NNS|N .|.|.
We|PRP|NP also|RB|(S\NP)/(S\NP) found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] mRNAs|NNS|N encoding|VBG|(S[ng]\NP)/NP GATA-1|NN|N and|CC|conj GATA-2|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP all|DT|NP/NP these|DT|NP[nb]/N cases|NNS|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] M7|NN|N/N blasts|NNS|N and|CC|conj TMD|NN|N/N blasts|NNS|N correspond|VBP|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N erythroid/megakaryocytic|JJ|N/N bipotential|JJ|N/N progenitor|NN|N/N cells|NNS|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) previously|RB|(S\NP)\(S\NP) found|VBN|(S[pt]\NP)/NP a|DT|NP[nb]/N high|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP human|JJ|N/N Ah|NN|N/N receptor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) TCDD|NN|N/N receptor|NN|N/N )|RRB|RRB mRNA|NN|N in|IN|(NP\NP)/NP peripheral|JJ|N/N blood|NN|N/N cells|NNS|N of|IN|(NP\NP)/NP individuals|NNS|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N paper|NN|N ,|,|, the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N gene|NN|N in|IN|(NP\NP)/NP blood|NN|N/N cells|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) first|RB|(S\NP)\(S\NP) investigated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP fractions|NNS|N of|IN|(NP\NP)/NP nucleated|JJ|N/N cells|NNS|N ,|,|, revealing|VBG|(S[ng]\NP)/NP predominant|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Ah|NN|N/N receptor|NN|N/N gene|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N monocyte|NN|N/N fraction|NN|N .|.|.
Then|RB|S/S the|DT|NP[nb]/N expression|NN|N/N levels|NNS|N of|IN|(NP\NP)/NP AhR|NN|N/N mRNA|NN|N in|IN|(NP\NP)/NP various|JJ|N/N hematopoietic|JJ|(N/N)/(N/N) cell|NN|N/N lines|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) examined|VBN|S[pss]\NP together|RB|((S\NP)\(S\NP))/PP with|IN|PP/NP those|DT|NP of|IN|(NP\NP)/NP Arnt|NN|N and|CC|conj P450IA1|NN|N .|.|.
AhR|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP high|JJ|N/N levels|NNS|N in|IN|((S\NP)\(S\NP))/NP monocytoid|JJ|N/N U937|NN|N/N ,|,|, THP1|NN|N/N ,|,|, and|CC|conj HEL/S|NN|N/N cells|NNS|N ,|,|, and|CC|conj at|IN|((S\NP)\(S\NP))/NP moderate|JJ|N/N levels|NNS|N in|IN|((S\NP)\(S\NP))/NP promyelocytic|JJ|N/N HL60|NN|N/N cells|NNS|N and|CC|conj erythroblastic|JJ|N/N HEL|NN|N/N cells|NNS|N .|.|.
However|RB|S/S ,|,|, it|PRP|NP was|VBD|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP lymphoid|JJ|N/N cells|NNS|N MOLT4|NN|N (|LRB|(NP\NP)/NP T|NN|N/N cell|NN|N )|RRB|RRB and|CC|conj BALL1|NN|N (|LRB|(NP\NP)/NP B|NN|N/N cell|NN|N )|RRB|RRB ,|,|, nor|CC|conj in|IN|((S\NP)\(S\NP))/NP K562|NN|N/N erythroblasts|NNS|N .|.|.
Furthermore|RB|S/S ,|,|, a|DT|NP[nb]/N specific|JJ|N/N induction|NN|N of|IN|(NP\NP)/NP AhR|NN|N during|IN|(NP\NP)/NP monocytic|JJ|N/N differentiation|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) investigated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP HL60|NN|N/N and|CC|conj HEL|NN|N/N cells|NNS|N .|.|.
HL60|NN|N/N cells|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) induced|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) differentiate|VB|S[b]\NP toward|IN|((S\NP)\(S\NP))/NP monocytes-macrophages|NNS|N by|IN|((S\NP)\(S\NP))/NP incubation|NN|N with|IN|(NP\NP)/NP phorbol|NN|N/N ester|NN|N ,|,|, showing|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N 5-|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 2-fold|JJ|N/N increase|NN|N of|IN|(NP\NP)/NP AhR|NN|N/N mRNA|NN|N .|.|.
The|DT|NP[nb]/N incubation|NN|N with|IN|(NP\NP)/NP transforming|VBG|N/N growth|NN|N/N factor|NN|N/N beta|NN|N 1|CD|N\N and|CC|conj 1|CD|N/N alpha,25-dihydroxyvitamin|NN|N/N D3|NN|N resulted|VBD|(S[dcl]\NP)/PP in|IN|PP/NP a|DT|NP[nb]/N 5-|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 7-fold|JJ|N/N increase|NN|N of|IN|(NP\NP)/NP AhR|NN|N/N mRNA|NN|N .|.|.
The|DT|NP[nb]/N HEL|NN|N/N cells|NNS|N also|RB|(S\NP)/(S\NP) exhibited|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N similar|JJ|N/N elevation|NN|N of|IN|(NP\NP)/NP AhR|NN|(N/N)/(N/N) mRNA|NN|N/N level|NN|N ,|,|, when|WRB|((S\NP)\(S\NP))/S[dcl] they|PRP|NP had|VBD|(S[dcl]\NP)/(S[pt]\NP) differentiated|VBN|S[pt]\NP toward|IN|((S\NP)\(S\NP))/NP monocyte-macrophage|JJ|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/NP these|DT|NP[nb]/N combined|JJ|N/N inducers|NNS|N ,|,|, but|CC|conj little|JJ|N/N change|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N mRNA|NN|N/N level|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP when|WRB|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N cells|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) induced|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) differentiate|VB|(S[b]\NP)/PP into|IN|PP/NP other|JJ|N/N cell|NN|N/N types|NNS|N .|.|.
Treatment|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N differentiated|VBN|N/N HL60|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP 3-methylcholanthrene|NN|N ,|,|, a|DT|NP[nb]/N ligand|NN|N of|IN|(NP\NP)/NP AhR|NN|N ,|,|, induced|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N P450IA1|NN|N/N gene|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] expression|NN|N of|IN|(NP\NP)/NP AhR|NN|N/N mRNA|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) significantly|RB|(S\NP)\(S\NP) induced|VBN|S[pss]\NP during|IN|((S\NP)\(S\NP))/NP monocytic|JJ|N/N differentiation|NN|N and|CC|conj that|IN|S[em]/S[dcl] the|DT|NP[nb]/N differentiated|VBN|N/N cells|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) responsive|JJ|(S[adj]\NP)/PP to|TO|PP/NP xenobiotics|NNS|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] AhR|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) play|VB|(S[b]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N function|NN|N of|IN|(NP\NP)/NP monocytes|NNS|N and|CC|conj also|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N eventual|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP environmental|JJ|N/N carcinogens|NNS|N .|.|.
PU.1|NN|N (|LRB|(NP\NP)/NP the|DT|NP[nb]/N Spi-1|NN|N/N oncogene|NN|N )|RRB|RRB and|CC|conj Spi-B|NN|N are|VBP|(S[dcl]\NP)/NP closely|RB|(N/N)/(N/N) related|JJ|N/N members|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N ets|NN|N/N transcription|NN|N/N factor|NN|N/N family|NN|N ,|,|, sharing|VBG|(S[ng]\NP)/NP similar|JJ|N/N DNA|NN|(N/N)/(N/N) binding|NN|N/N specificities|NNS|N mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP similar|JJ|N/N DNA|NN|(N/N)/(N/N) binding|NN|N/N domains|NNS|N .|.|.
PU.1|NN|N and|CC|conj Spi-B|NN|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) previously|RB|(S\NP)\(S\NP) described|VBN|(S[pss]\NP)/PP as|IN|PP/(S[ng]\NP) being|VBG|(S[ng]\NP)/(S[pss]\NP) predominantly|RB|(S\NP)/(S\NP) expressed|VBN|S[pss]\NP coordinately|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP macrophages|NNS|N and|CC|conj B|NN|N/N cells|NNS|N ,|,|, but|CC|conj their|PRP$|NP[nb]/N expression|NN|N in|IN|(NP\NP)/NP early|JJ|N/N hematopoietic|JJ|N/N stages|NNS|N and|CC|conj during|IN|(NP\NP)/NP the|DT|NP[nb]/N course|NN|N of|IN|(NP\NP)/NP myeloid|JJ|N/N differentiation|NN|N to|TO|(NP\NP)/NP monocytes|NNS|N and|CC|conj macrophages|NNS|N or|CC|conj to|TO|(NP\NP)/NP neutrophils|NNS|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) not|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) extensively|RB|(S\NP)\(S\NP) investigated|VBN|S[pss]\NP .|.|.
Here|RB|S/S ,|,|, we|PRP|NP report|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] PU.1|NN|N/N mRNA|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) upregulated|VBN|S[pss]\NP during|IN|((S\NP)\(S\NP))/NP myeloid|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP human|JJ|N/N purified|VBN|N/N CD34+|JJ|N/N cells|NNS|N and|CC|conj murine|JJ|N/N multipotential|JJ|N/N FDCP-mix|NN|N/N A4|NN|N/N cells|NNS|N ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] PU.1|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) upregulated|VBN|S[pss]\NP as|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N early|JJ|N/N event|NN|N during|IN|((S\NP)\(S\NP))/NP differentiation|NN|N of|IN|(NP\NP)/NP multipotential|JJ|N/N progenitor|NN|N/N cells|NNS|N .|.|.
PU.1|NN|N/N expression|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) maintained|JJ|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP stable|JJ|N/N levels|NNS|N during|IN|((S\NP)\(S\NP))/NP differentiation|NN|N of|IN|(NP\NP)/NP myeloid|JJ|(N/N)/(N/N) cell|NN|N/N lines|NNS|N U937|NN|N and|CC|conj HL-60|NN|N to|TO|(NP\NP)/NP monocytic|JJ|N/N and|CC|conj neutrophilic|JJ|N/N cells|NNS|N .|.|.
PU.1|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP highest|JJS|N/N levels|NNS|N in|IN|((S\NP)\(S\NP))/NP mature|JJ|N/N human|JJ|N/N monocytes|NNS|N and|CC|conj human|JJ|N/N peripheral|JJ|N/N blood|NN|N/N neutrophils|NNS|N .|.|.
In|IN|(S/S)/NP contrast|NN|N to|TO|(NP\NP)/NP PU.1|NN|N ,|,|, significant|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP Spi-B|NN|N/N mRNA|NN|N and|CC|conj protein|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP only|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP some|DT|NP[nb]/N B-cell|NN|N/N lines|NNS|N and|CC|conj spleen|NN|N but|CC|conj are|VBP|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) found|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP myeloid|JJ|(N/N)/(N/N) cell|NN|N/N lines|NNS|N ,|,|, neutrophils|NNS|N ,|,|, or|CC|conj macrophages|NNS|N .|.|.
In|FW|(N/N)/(N/N) vitro|FW|N/N translated|VBN|N/N Spi-B|NN|N/N protein|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/PP to|TO|PP/NP PU.1|NN|N/N binding|NN|N/N sites|NNS|N in|IN|(NP\NP)/NP myeloid|JJ|N/N promoters|NNS|N and|CC|conj transactivate|VB|(S[b]\NP)/NP these|DT|NP[nb]/N promoters|NNS|N in|IN|((S\NP)\(S\NP))/NP nonmyeloid|JJ|N/N cells|NNS|N .|.|.
Therefore|RB|S/S ,|,|, although|IN|(S/S)/S[dcl] PU.1|NN|N and|CC|conj Spi-B|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/PP to|TO|PP/NP similar|JJ|N/N DNA|NN|N/N control|NN|N/N elements|NNS|N and|CC|conj have|VBP|(S[b]\NP)/NP redundancy|NN|N of|IN|(NP\NP)/NP transactivation|NN|N/N function|NN|N in|FW|(NP\NP)/NP vitro|FW|N ,|,|, the|DT|NP[nb]/N lack|NN|N of|IN|(NP\NP)/NP significant|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP Spi-B|NN|N in|IN|(NP\NP)/NP myeloid|JJ|N/N cells|NNS|N makes|VBZ|(((S[dcl]\NP)/S[em])/(S[adj]\NP))/NP[expl] it|PRP|NP[expl] unlikely|JJ|S[adj]\NP that|IN|S[em]/S[dcl] Spi-B|NN|N plays|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N significant|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP myeloid|JJ|N/N lineage|NN|N/N development|NN|N and|CC|conj gene|NN|N/N expression|NN|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, PU.1|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP high|JJ|N/N levels|NNS|N not|RB|((NP\NP)/(NP\NP))/((NP\NP)/(NP\NP)) only|RB|(NP\NP)/(NP\NP) in|IN|(NP\NP)/NP monocytes|NNS|N and|CC|conj macrophages|NNS|N but|CC|conj also|RB|(NP\NP)/(NP\NP) in|IN|(NP\NP)/NP neutrophils|NNS|N ,|,|, indicating|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] PU.1|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP gene|NN|N/N expression|NN|N in|IN|((S\NP)\(S\NP))/NP both|DT|NP[nb]/N major|JJ|N/N myeloid|JJ|N/N lineages|NNS|N .|.|.
The|DT|NP[nb]/N function|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N zeta-globin|NN|N/N promoter|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) studied|VBN|S[pss]\NP using|VBG|((S[ng]\NP)/(S[to]\NP))/NP a|DT|NP[nb]/N series|NN|N of|IN|(NP\NP)/NP zeta-globin|NN|N/N promoter|NN|N/N deletion|NN|N/N constructs|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) drive|VB|(S[b]\NP)/NP luciferase|NN|N/N expression|NN|N in|IN|((S\NP)\(S\NP))/NP transiently|RB|(N/N)/(N/N) transfected|VBN|N/N human|JJ|N/N erythroleukemia|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N promoters|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|S[pss]\NP without|IN|((S\NP)\(S\NP))/NP enhancers|NNS|N ,|,|, or|CC|conj with|IN|((S\NP)\(S\NP))/NP enhancers|NNS|N derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N beta-globin|NN|N/N locus|NN|N/N control|NN|N/N region|NN|N and|CC|conj the|DT|NP[nb]/N alpha-globin|NN|N/N HS-40|NN|N/N enhancer|NN|N .|.|.
When|WRB|(S/S)/(S[pss]\NP) transfected|VBN|(S[pss]\NP)/PP into|IN|PP/NP K562|NN|N/N cells|NNS|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) express|VBP|(S[dcl]\NP)/NP zeta-globin|NN|N ,|,|, comparable|JJ|N/N amounts|NNS|N of|IN|(NP\NP)/NP activity|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) obtained|VBN|(S[pss]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N -557|CD|N/N and|CC|conj -417|CD|N/N zeta-luciferase|NN|N/N constructs|NNS|N and|CC|conj the|DT|NP[nb]/N alpha-luciferase|NN|N/N constructs|NNS|N when|WRB|((S\NP)\(S\NP))/S[dcl] no|DT|NP[nb]/N enhancers|NNS|N or|CC|conj the|DT|NP[nb]/N alpha-globin|NN|N/N locus|NN|N/N enhancers|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|S[pss]\NP .|.|.
When|WRB|(S/S)/S[dcl] the|DT|NP[nb]/N constructs|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) transfected|VBN|(S[pss]\NP)/PP into|IN|PP/NP OCIM1|NN|N/N cells|NNS|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) do|VBP|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) express|VB|(S[b]\NP)/NP zeta-globin|NN|N ,|,|, the|DT|NP[nb]/N zeta-globin|NN|N/N promoters|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) at|IN|(NP/NP)/(S[asup]\NP) best|RB|S[asup]\NP 20|CD|N/N %|NN|N as|IN|((S[adj]\NP)/(S[adj]\NP))\NP active|JJ|S[adj]\NP as|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N alpha-globin|NN|N/N promoters|NNS|N .|.|.
When|WRB|(S/S)/S[dcl] sequences|NNS|N from|IN|(NP\NP)/NP -417|CD|N/N to|TO|((N/N)\(N/N))/(N/N) -207|CD|N/N 5'|JJ|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N zeta-globin|NN|N/N mRNA|NN|N/N cap|NN|N/N site|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) deleted|VBN|S[pss]\NP ,|,|, up|IN|((N/N)/(N/N))/((N/N)/(N/N)) to|TO|(N/N)/(N/N) 95|CD|N/N %|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N zeta-globin|NN|N/N promoter|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) lost|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP K562|NN|N/N cells|NNS|N .|.|.
Reinsertion|NN|N of|IN|(NP\NP)/NP these|DT|NP[nb]/N sequences|NNS|N into|IN|(NP\NP)/NP zeta-luciferase|NN|N/N constructs|NNS|N missing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N -417|CD|N/N to|TO|((N/N)\(N/N))/(N/N) -207|CD|N/N region|NN|N showed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N sequences|NNS|N lack|VBP|(S[dcl]\NP)/NP classical|JJ|N/N enhancer|NN|N/N activity|NN|N .|.|.
Point|NN|N/N mutation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N GATA-1|NN|N/N site|NN|N at|IN|(NP\NP)/NP -230|CD|N reduced|VBD|(S[dcl]\NP)/NP promoter|NN|N/N activity|NN|N by|IN|((S\NP)\(S\NP))/NP 37|CD|N/N %|NN|N .|.|.
Point|NN|N/N mutation|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N CCACC|NN|N/N site|NN|N at|IN|(NP\NP)/NP -240|CD|N had|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N effect|NN|N .|.|.
Electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N -230|CD|N/N GATA-1|NN|N/N site|NN|N has|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N relatively|RB|(N/N)/(N/N) low|JJ|N/N affinity|NN|N for|IN|(NP\NP)/NP GATA-1|NN|N .|.|.
These|DT|NP[nb]/N experiments|NNS|N show|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N strong|JJ|N/N positive-acting|JJ|N/N element|NN|N ,|,|, located|JJ|S[pss]\NP between|IN|((S\NP)\(S\NP))/NP -417|CD|(N/N)/(N/N) and|CC|conj -207|CD|(N/N)/(N/N) bp|NN|N/N 5'|JJ|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N zeta-globin|NN|N/N mRNA|NN|N/N cap|NN|N/N site|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[adj]\NP) necessary|JJ|(S[adj]\NP)/PP for|IN|PP/NP high-level|JJ|N/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP K562|NN|N/N cells|NNS|N .|.|.
This|DT|NP[nb]/N element|NN|N requires|VBZ|(S[dcl]\NP)/NP GATA-1|NN|N and|CC|conj additional|JJ|N/N unknown|JJ|N/N factors|NNS|N for|IN|((S\NP)\(S\NP))/NP maximal|JJ|N/N activity|NN|N .|.|.
T|NN|N/N cells|NNS|N express|VBP|(S[dcl]\NP)/NP multiple|JJ|N/N isotypes|NNS|N of|IN|(NP\NP)/NP protein|NN|N/N kinase|NN|N/N C|NN|N (|LRB|(NP\NP)/NP PKC|NN|N )|RRB|RRB and|CC|conj although|IN|(S/S)/S[dcl] it|PRP|NP[expl] is|VBZ|(S[dcl]\NP)/(S[pss]\NP) well|RB|(S\NP)\(S\NP) accepted|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] PKCs|NNS|N have|VBP|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N ,|,|, little|JJ|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) known|VBN|(S[pss]\NP)/PP about|IN|PP/NP the|DT|NP[nb]/N function|NN|N of|IN|(NP\NP)/NP individual|JJ|N/N PKC|NN|N/N isotypes|NNS|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) address|VB|(S[b]\NP)/NP this|DT|NP[nb]/N issue|NN|N ,|,|, mutationally|RB|(N/N)/(N/N) active|JJ|N/N PKC-alpha|NN|N ,|,|, -epsilon|NN|N ,|,|, or|CC|conj -zeta|NN|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) transfected|VBN|(S[pss]\NP)/PP into|IN|PP/NP T|NN|N/N cells|NNS|N and|CC|conj the|DT|NP[nb]/N consequences|NNS|N for|IN|(NP\NP)/NP T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N determined|VBN|S[pss]\NP .|.|.
p21ras|NN|N plays|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N essential|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N .|.|.
Accordingly|RB|S/S ,|,|, the|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N constitutively|RB|(N/N)/(N/N) active|JJ|N/N PKCs|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) compared|VBN|(S[pss]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP mutationally|RB|(N/N)/(N/N) activated|VBN|N/N p21ras|NN|N .|.|.
The|DT|NP[nb]/N data|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] PKC-epsilon|NN|N and|CC|conj ,|,|, to|TO|(NP/NP)/NP a|DT|NP[nb]/N lesser|JJR|N/N extent|NN|N PKC-alpha|NN|N but|CC|conj not|RB|NP/NP -zeta|NN|N ,|,|, can|MD|(S[dcl]\NP)/(S[b]\NP) regulate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N transcription|NN|(N/N)/(N/N) factors|NNS|N/N AP-1|NN|N and|CC|conj nuclear|JJ|N/N factor|NN|N of|IN|(NP\NP)/NP activated|VBN|N/N T|NN|N/N cells|NNS|N (|LRB|(NP\NP)/NP NF-AT-1|NN|N )|RRB|RRB .|.|.
The|DT|NP[nb]/N ability|NN|N of|IN|(NP\NP)/NP PKC-epsilon|NN|N to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP transactivation|NN|N of|IN|(NP\NP)/NP NF-AT-1|NN|N and|CC|conj AP-1|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) similar|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N stimulatory|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N constitutively|RB|(N/N)/(N/N) activated|VBN|N/N p21ras|NN|N .|.|.
PKC-epsilon|NN|N ,|,|, but|CC|conj not|RB|NP/NP PKC-alpha|NN|N nor|CC|conj activated|JJ|N/N p21ras|NN|N ,|,|, was|VBD|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP NF-KB|NN|N/N activity|NN|N .|.|.
Phorbol|NN|N/N esters|NNS|N induce|VBP|(S[dcl]\NP)/NP expression|NN|N of|IN|(NP\NP)/NP CD69|NN|N whereas|IN|((S\NP)\(S\NP))/NP none|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N activated|VBN|N/N PKC|NN|N/N isotypes|NNS|N tested|VBN|S[pss]\NP were|VBD|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) have|VB|(S[b]\NP)/NP this|DT|NP[nb]/N effect|NN|N .|.|.
Activated|VBN|N/N Src|NN|N and|CC|conj p21ras|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP CD69|NN|N/N expression|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N indicate|VBP|(S[dcl]\NP)/NP selective|JJ|N/N functions|NNS|N for|IN|(NP\NP)/NP different|JJ|N/N PKC|NN|N/N isotypes|NNS|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N .|.|.
Moreover|RB|S/S ,|,|, the|DT|NP[nb]/N data|NNS|N comparing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP activated|VBN|N/N Ras|NN|N/N and|CC|conj PKC|NN|N/N mutants|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] PKC-alpha|NN|N ,|,|, p21ras|NN|N ,|,|, and|CC|conj PKC-epsilon|NN|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S[adj]\NP)/(S[adj]\NP) positioned|JJ|S[adj]\NP linearly|RB|(S[adj]\NP)\(S[adj]\NP) on|IN|((S[adj]\NP)\(S[adj]\NP))/NP a|DT|NP[nb]/N single|JJ|N/N signal|NN|(N/N)/(N/N) transduction|NN|N/N pathway|NN|N .|.|.
Although|IN|(S/S)/S[dcl] glucocorticosteroids|NNS|N are|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N very|RB|(N/N)/(N/N) effective|JJ|N/N treatment|NN|N for|IN|(NP\NP)/NP asthma|NN|N and|CC|conj other|JJ|N/N chronic|JJ|N/N inflammatory|JJ|N/N diseases|NNS|N ,|,|, a|DT|NP[nb]/N small|JJ|N/N proportion|NN|N of|IN|(NP\NP)/NP patients|NNS|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) resistant|JJ|(S[adj]\NP)/PP to|TO|PP/NP their|PRP$|NP[nb]/N therapeutic|JJ|N/N effects|NNS|N .|.|.
The|DT|NP[nb]/N molecular|JJ|N/N mechanism|NN|N for|IN|(NP\NP)/NP this|DT|NP[nb]/N steroid|NN|N/N resistance|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) unclear|JJ|S[adj]\NP .|.|.
Steroid|NN|N/N resistance|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) be|VB|(S[b]\NP)/(S[pss]\NP) explained|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP pharmacokinetic|JJ|N/N mechanisms|NNS|N ,|,|, by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N defect|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N binding|NN|N of|IN|(NP\NP)/NP steroids|NNS|N to|TO|(NP\NP)/NP glucocorticoid|NN|N/N receptors|NNS|N ,|,|, nor|CC|conj by|IN|((S\NP)\(S\NP))/NP defective|JJ|N/N nuclear|JJ|N/N translocation|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N receptor|NN|N ,|,|, thereby|RB|(S\NP)/(S\NP) suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N molecular|JJ|N/N abnormality|NN|N lies|VBZ|S[dcl]\NP distal|JJ|((S\NP)\(S\NP))/PP to|TO|PP/NP nuclear|JJ|N/N translocation|NN|N .|.|.
We|PRP|NP examined|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N ability|NN|N of|IN|(NP\NP)/NP nuclear|JJ|N/N translocated|VBN|N/N glucocorticoid|NN|N/N receptors|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/PP to|TO|PP/NP their|PRP$|NP[nb]/N DNA|NN|N/N binding|NN|N/N sites|NNS|N (|LRB|(NP\NP)/NP GRE|NN|N )|RRB|RRB using|VBG|(S[ng]\NP)/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N in|IN|(NP\NP)/NP PBMC|NN|N from|IN|(NP\NP)/NP patients|NNS|N with|IN|(NP\NP)/NP steroid-sensitive|JJ|N/N and|CC|conj steroid-resistant|JJ|N/N asthma|NN|N .|.|.
The|DT|NP[nb]/N binding|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N to|TO|(NP\NP)/NP DNA|NN|N in|IN|(NP\NP)/NP these|DT|NP[nb]/N patients|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) studied|VBN|S[pss]\NP using|VBG|(S[ng]\NP)/NP Scatchard|NN|N/N analysis|NN|N .|.|.
Dexamethasone|NN|N induced|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N significant|JJ|N/N rapid|JJ|N/N and|CC|conj sustained|JJ|N/N twofold|JJ|N/N increase|NN|N in|IN|(NP\NP)/NP GRE|NN|N/N binding|NN|N in|IN|(NP\NP)/NP PBMCs|NNS|N from|IN|(NP\NP)/NP steroid-sensitive|JJ|N/N asthmatic|JJ|N/N patients|NNS|N and|CC|conj nonasthmatic|JJ|N/N individuals|NNS|N ,|,|, but|CC|conj this|DT|NP was|VBD|(S[dcl]\NP)/(S[pss]\NP) markedly|RB|(S\NP)\(S\NP) reduced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP steroid-resistant|JJ|N/N asthmatic|JJ|N/N patients|NNS|N .|.|.
Scatchard|NN|N/N analysis|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptor-GRE|NN|N/N binding|NN|N showed|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N change|NN|N in|IN|(NP\NP)/NP binding|NN|N/N affinity|NN|N but|CC|conj did|VBD|(S[dcl]\NP)/(S[b]\NP) show|VB|(S[b]\NP)/NP a|DT|NP[nb]/N reduced|VBN|N/N number|NN|N of|IN|(NP\NP)/NP receptors|NNS|N available|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP DNA|NN|N/N binding|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N steroid-resistant|JJ|N/N patients|NNS|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N ability|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/PP to|TO|PP/NP GRE|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) impaired|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP steroid-resistant|JJ|N/N patients|NNS|N because|IN|((S\NP)\(S\NP))/PP of|IN|PP/NP a|DT|NP[nb]/N reduced|VBN|N/N number|NN|N of|IN|(NP\NP)/NP receptors|NNS|N available|JJ|(S[adj]\NP)/PP for|IN|PP/(S[ng]\NP) binding|VBG|(S[ng]\NP)/PP to|TO|PP/NP DNA|NN|N .|.|.
Signaling|NN|N by|IN|(NP\NP)/NP a|DT|NP[nb]/N wide|JJ|N/N variety|NN|N of|IN|(NP\NP)/NP cytokines|NNS|N ,|,|, including|VBG|(S[ng]\NP)/NP interferons|NNS|N ,|,|, interleukins|NNS|N ,|,|, and|CC|conj growth|NN|N/N factors|NNS|N ,|,|, involves|VBZ|(S[dcl]\NP)/NP activation|NN|N of|IN|(NP\NP)/NP JAK|NN|N/N kinases|NNS|N and|CC|conj Stat|NNS|N/N (|LRB|((N/N)\(N/N))/(N/N) Signal|NN|N/N transducers|NNS|N and|CC|conj activators|NNS|N of|IN|(NP\NP)/NP transcription|NN|N )|RRB|RRB proteins|NNS|N .|.|.
At|IN|(S/S)/NP present|NN|N ,|,|, not|RB|NP/NP much|RB|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) known|VBN|S[pss]\NP about|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N molecular|JJ|N/N mechanisms|NNS|N by|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) interleukin-5|NN|N (|LRB|(N\N)/N IL-5|NN|N )|RRB|RRB exerts|VBZ|(S[dcl]\NP)/NP its|PRP$|NP[nb]/N diverse|JJ|N/N biologic|JJ|N/N effects|NNS|N .|.|.
Human|JJ|N/N eosinophils|NNS|N are|VBP|(S[dcl]\NP)/NP one|CD|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N most|RBS|(N/N)/(N/N) important|JJ|N/N target|NN|N/N cells|NNS|N for|IN|((S\NP)\(S\NP))/NP IL-5|NN|N and|CC|conj were|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|(S[pss]\NP)/(S[to]\NP) here|RB|(S\NP)\(S\NP) to|TO|(S[to]\NP)/(S[b]\NP) study|VB|(S[b]\NP)/NP IL-5|NN|N/N signaling|NN|N in|IN|(NP\NP)/NP a|DT|NP[nb]/N primary|JJ|N/N human|JJ|N/N cell|NN|N .|.|.
IL-5|NN|N induced|VBD|(S[dcl]\NP)/NP rapid|JJ|N/N and|CC|conj transient|JJ|N/N tyrosine|NN|N/N phosphorylation|NN|N of|IN|(NP\NP)/NP JAK2|NN|N .|.|.
Moreover|RB|S/S ,|,|, IL-5|NN|N induced|VBD|S[dcl]\NP at|IN|((N/N)/(N/N))/(S[asup]\NP) least|JJS|S[asup]\NP two|CD|N/N DNA-binding|JJ|N/N complexes|NNS|N ,|,|, using|VBG|(S[ng]\NP)/NP nuclear|JJ|N/N extracts|NNS|N from|IN|(NP\NP)/NP normal|JJ|N/N human|JJ|N/N eosinophils|NNS|N and|CC|conj the|DT|NP[nb]/N IL-6/interferon-gamma|NN|N/N response|NN|N/N element|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N ICAM-1|NN|N/N promoter|NN|N (|LRB|LRB ICAM-1|NN|N/N pIRE|NN|N )|RRB|RRB in|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N electromobility|NN|N/N shift|NN|N/N assay|NN|N .|.|.
From|IN|(S/S)/NP supershift|NN|N/N experiments|NNS|N it|PRP|NP[expl] was|VBD|(S[dcl]\NP[expl])/(S[pss]\NP) concluded|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] one|CD|N/N DNA-binding|JJ|N/N complex|NN|N contained|VBD|(S[dcl]\NP)/NP Stat1|NN|N/N alpha|NN|N ,|,|, probably|RB|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP a|DT|NP[nb]/N homodimer|NN|N .|.|.
Both|DT|NP[nb]/N DNA-binding|JJ|N/N complexes|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) inhibited|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N phosphotyrosine|NN|N/N antibody|NN|N (|LRB|(NP\NP)/NP 4G10|NN|N )|RRB|RRB ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] tyrosine|NN|N/N phosphorylation|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP complex|NN|N/N formation|NN|N .|.|.
IL-3|NN|N and|CC|conj granulocyte-macrophage|JJ|N/N colony-stimulating|JJ|N/N factor|NN|N induced|VBD|(S[dcl]\NP)/NP ,|,|, similar|JJ|(S[adj]\NP)/PP to|TO|PP/NP IL-5|NN|N ,|,|, two|CD|N/N DNA-binding|JJ|N/N complexes|NNS|N in|IN|(NP\NP)/NP human|JJ|N/N eosinophils|NNS|N ,|,|, including|VBG|(S[ng]\NP)/NP Stat1|NN|N/N alpha|NN|N .|.|.
These|DT|NP[nb]/N data|NNS|N show|VBP|(S[dcl]\NP)/S[em] for|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N first|JJ|N/N time|NN|N that|IN|S[em]/S[dcl] molecular|JJ|N/N mechanisms|NNS|N of|IN|(NP\NP)/NP IL-5|NN|N/N signaling|NN|N in|IN|(NP\NP)/NP human|JJ|N/N eosinophils|NNS|N involve|VBP|(S[dcl]\NP)/NP members|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N JAK|NN|(N/N)/(N/N) kinase|NN|N/N family|NN|N as|RB|conj/conj well|RB|conj/conj as|IN|conj members|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Stat|NN|N/N family|NN|N .|.|.
Tat|NN|N is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N essential|JJ|N/N regulatory|JJ|N/N protein|NN|N for|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N replication|NN|N of|IN|(NP\NP)/NP human|JJ|N/N immunodeficiency|NN|N/N virus|NN|N (|LRB|(NP\NP)/NP HIV|NN|N )|RRB|RRB .|.|.
Mutations|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N tat|NN|N/N gene|NN|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) block|VB|(S[b]\NP)/NP HIV|NN|N/N replication|NN|N in|IN|((S\NP)\(S\NP))/NP human|JJ|N/N T|NN|N/N cells|NNS|N .|.|.
Several|JJ|N/N studies|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) established|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] Tat|NN|N releases|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N elongation|NN|N/N block|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N transcription|NN|N of|IN|(NP\NP)/NP HIV|NN|N/N long|JJ|N/N terminal|JJ|N/N repeat|NN|N (|LRB|(NP\NP)/NP LTR|NN|N )|RRB|RRB ;|:|; however|RB|S/S ,|,|, it|PRP|NP[expl] is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) known|VBN|(S[pss]\NP)/S[qem] whether|IN|S[qem]/S[dcl] this|DT|NP[nb]/N mechanism|NN|N alone|RB|NP\NP is|VBZ|(S[dcl]\NP)/(S[adj]\NP) sufficient|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) explain|VB|(S[b]\NP)/NP the|DT|NP[nb]/N block|NN|N to|TO|(NP\NP)/NP HIV|NN|N/N replication|NN|N in|IN|(NP\NP)/NP human|JJ|N/N T|NN|N/N cells|NNS|N when|WRB|(NP\NP)/S[dcl] Tat|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) absent|JJ|S[adj]\NP .|.|.
It|PRP|NP[expl] is|VBZ|((S[dcl]\NP[expl])/S[em])/(S[adj]\NP) possible|JJ|S[adj]\NP that|IN|S[em]/S[dcl] Tat|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) needed|VBN|S[pss]\NP for|IN|((S\NP)\(S\NP))/NP other|JJ|N/N functions|NNS|N during|IN|((S\NP)\(S\NP))/NP HIV|NN|N/N replication|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) test|VB|(S[b]\NP)/NP these|DT|NP[nb]/N hypotheses|NNS|N ,|,|, we|PRP|NP studied|VBD|(S[dcl]\NP)/NP several|JJ|N/N tat|NN|N/N mutants|NNS|N ,|,|, including|VBG|(S[ng]\NP)/NP two|CD|N/N stop|NN|N/N codon|NN|N/N mutants|NNS|N and|CC|conj one|CD|N/N deletion|NN|N/N mutant|NN|N using|VBG|(S[ng]\NP)/NP replication-competent|JJ|N/N HIV-1|NN|N/N constructs|NNS|N carrying|VBG|(S[ng]\NP)/NP wild-type|JJ|N/N or|CC|conj mutant|JJ|N/N LTRs|NNS|N with|IN|(NP\NP)/NP modifications|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N and/or|CC|conj Sp1|NN|N/N binding|NN|N/N sites|NNS|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N study|NN|N ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] Tat-HIV-1|NN|N with|IN|(NP\NP)/NP wild-type|JJ|N/N LTRs|NNS|N can|MD|(S[dcl]\NP)/(S[b]\NP) replicate|VB|S[b]\NP in|IN|((S\NP)\(S\NP))/NP HeLa|NN|N/N cells|NNS|N ,|,|, and|CC|conj the|DT|NP[nb]/N virus|NN|N produced|VBN|S[pss]\NP from|IN|((S\NP)\(S\NP))/NP HeLa|NN|N/N cells|NNS|N can|MD|(S[dcl]\NP)/(S[b]\NP) infect|VB|(S[b]\NP)/NP primary|JJ|N/N peripheral|JJ|N/N blood|NN|N/N lymphocytes|NNS|N and|CC|conj macrophages|NNS|N .|.|.
It|PRP|NP[expl] was|VBD|(S[dcl]\NP[expl])/(S[pss]\NP) found|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N propagation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Tat|NN|N/N mutants|NNS|N containing|VBG|(S[ng]\NP)/NP wild-type|JJ|N/N LTRs|NNS|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) less|RBR|(S[adj]\NP)/(S[adj]\NP) efficient|JJ|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP that|DT|NP of|IN|(NP\NP)/NP the|DT|NP[nb]/N LTR-modified|JJ|N/N Tat|NN|N/N mutants|NNS|N .|.|.
Large|JJ|N/N amounts|NNS|N of|IN|(NP\NP)/NP viral|JJ|N/N RNA|NN|N and|CC|conj particles|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) synthesized|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP infections|NNS|N established|VBN|S[pss]\NP using|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N tat|NN|N/N mutants|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) contain|VBP|(S[dcl]\NP)/NP modified|VBN|NP/NP LTRs|NNS|N .|.|.
However|RB|S/S ,|,|, this|DT|NP[nb]/N efficient|JJ|N/N propagation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N LTR-modified|JJ|N/N tat|NN|N/N mutants|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) restricted|JJ|(S[pss]\NP)/PP to|TO|PP/NP some|DT|NP[nb]/N lymphoid|JJ|(N/N)/(N/N) cell|NN|N/N lines|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) transformed|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP other|JJ|N/N viruses|NNS|N .|.|.
Thus|RB|S/S ,|,|, despite|IN|(S/S)/NP its|PRP$|NP[nb]/N essential|JJ|N/N role|NN|N for|IN|(NP\NP)/(S[ng]\NP) releasing|VBG|(S[ng]\NP)/NP an|DT|NP[nb]/N elongation|NN|N/N block|NN|N ,|,|, Tat|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) otherwise|RB|(S\NP)\(S\NP) absolutely|RB|(S\NP)/(S\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP synthesis|NN|N of|IN|(NP\NP)/NP full-length|JJ|N/N HIV|NN|N/N transcripts|NNS|N and|CC|conj assembly|NN|N of|IN|(NP\NP)/NP virus|NN|N/N particles|NNS|N .|.|.
Direct|JJ|N/N sequencing|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N viral|JJ|N/N genomes|NNS|N and|CC|conj reinfection|NN|N/N kinetics|NNS|N showed|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N evidence|NN|N of|IN|(NP\NP)/NP wild-type|JJ|N/N reversion|NN|N even|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) after|IN|((S\NP)\(S\NP))/NP prolonged|JJ|N/N infection|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N Tat-virus|NN|N .|.|.
The|DT|NP[nb]/N implications|NNS|N for|IN|(NP\NP)/NP in|FW|(N/N)/(N/N) vivo|FW|N/N HIV-1|NN|N/N replication|NN|N and|CC|conj potential|JJ|N/N application|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N system|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N study|NN|N of|IN|(NP\NP)/NP alternative|JJ|N/N Tat|NN|N/N function|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) discussed|VBN|S[pss]\NP .|.|.
The|DT|NP[nb]/N class|NN|N/N II|CD|(N/N)\(N/N) major|JJ|N/N histocompatibility|NN|N/N complex|NN|N/N gene|NN|N HLA-DRA|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP B|NN|N/N cells|NNS|N ,|,|, activated|VBN|N/N T|NN|N/N lymphocytes|NNS|N ,|,|, and|CC|conj in|IN|((S\NP)\(S\NP))/NP antigen-presenting|JJ|N/N cells|NNS|N .|.|.
In|IN|(S/S)/NP addition|NN|N ,|,|, HLA-DRA|NN|N/N gene|NN|N/N expression|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) inducible|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP a|DT|NP[nb]/N variety|NN|N of|IN|(NP\NP)/NP cell|NN|N/N types|NNS|N by|IN|((S[adj]\NP)\(S[adj]\NP))/NP interferon-gamma|NN|N (|LRB|(N\N)/N IFN-gamma|NN|N )|RRB|RRB .|.|.
Here|RB|S/S we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N lymphoid-specific|JJ|N/N transcription|NN|N/N factor|NN|N Oct-2A|NN|N plays|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N critical|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP HLA-DRA|NN|N/N gene|NN|N/N expression|NN|N in|IN|(NP\NP)/NP class|NN|N/N II-positive|JJ|N/N B|NN|(N/N)/(N/N) cell|NN|N/N lines|NNS|N ,|,|, and|CC|conj that|IN|S[em]/S[dcl] the|DT|NP[nb]/N high|JJ|(N/N)/(N/N) mobility|NN|N/N group|NN|N/N protein|NN|N (|LRB|(NP\NP)/NP HMG|NN|N )|RRB|RRB I/Y|NN|N binds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP multiple|JJ|N/N sites|NNS|N within|IN|(NP\NP)/NP the|DT|NP[nb]/N DRA|NN|N/N promoter|NN|N ,|,|, including|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N Oct-2A|NN|N/N binding|NN|N/N site|NN|N .|.|.
Coexpression|NN|N of|IN|(NP\NP)/NP HMG|NN|N/N I/Y|NN|N and|CC|conj Oct-2|NN|N in|IN|(NP\NP)/NP cell|NN|N/N lines|NNS|N lacking|VBG|(S[ng]\NP)/NP Oct-2|NN|N results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP high|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP HLA-DRA|NN|N/N gene|NN|N/N expression|NN|N ,|,|, and|CC|conj in|FW|(N/N)/(N/N) vitro|FW|N/N DNA-binding|JJ|N/N studies|NNS|N reveal|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] HMG|NN|N/N I/Y|NN|N stimulates|VBZ|(S[dcl]\NP)/NP Oct-2A|NN|N/N binding|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N HLA-DRA|NN|N/N promoter|NN|N .|.|.
Thus|RB|S/S ,|,|, Oct-2A|NN|N and|CC|conj HMG|NN|N/N I/Y|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) synergize|VB|(S[b]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) activate|VB|(S[b]\NP)/NP HLA-DRA|NN|N/N expression|NN|N in|IN|(NP\NP)/NP B|NN|N/N cells|NNS|N .|.|.
By|IN|(S/S)/NP contrast|NN|N ,|,|, Oct-2A|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N IFN-gamma|NN|N/N induction|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N HLA-DRA|NN|N/N gene|NN|N in|IN|(NP\NP)/NP HeLa|NN|N/N cells|NNS|N ,|,|, but|CC|conj antisense|JJ|N/N HMG|NN|N/N I/Y|NN|N dramatically|RB|(S\NP)/(S\NP) decreases|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N level|NN|N of|IN|(NP\NP)/NP induction|NN|N .|.|.
We|PRP|NP conclude|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] distinct|JJ|N/N sets|NNS|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N two|CD|N/N modes|NNS|N of|IN|(NP\NP)/NP HLA-DRA|NN|N/N expression|NN|N ,|,|, and|CC|conj that|IN|S[em]/S[dcl] HMG|NN|N/N I/Y|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) important|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP B|NN|N/N cell-specific|JJ|N/N expression|NN|N ,|,|, and|CC|conj is|VBZ|(S[dcl]\NP)/(S[adj]\NP) essential|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP IFN-gamma|NN|N/N induction|NN|N .|.|.
Epstein-Barr|JJ|((N/N)/(N/N))/((N/N)/(N/N)) virus|NN|(N/N)/(N/N) (|LRB|(((N/N)/(N/N))\((N/N)/(N/N)))/((N/N)/(N/N)) EBV|NN|(N/N)/(N/N) )|RRB|RRB -infected|JJ|N/N cells|NNS|N may|MD|(S[dcl]\NP)/(S[b]\NP) sustain|VB|(S[b]\NP)/NP three|CD|N/N distinct|JJ|N/N forms|NNS|N of|IN|(NP\NP)/NP virus|NN|N/N latency|NN|N .|.|.
In|IN|(S/S)/NP lymphoblastoid|JJ|(N/N)/(N/N) cell|NN|N/N lines|NNS|N ,|,|, six|CD|N/N EBV-encoded|JJ|N/N nuclear|JJ|N/N antigens|NNS|N (|LRB|(NP\NP)/NP EBNA1|NN|N ,|,|, 2|CD|N ,|,|, 3A|NN|N ,|,|, 3B|NN|N ,|,|, 3C|NN|N ,|,|, -LP|NN|N )|RRB|RRB ,|,|, three|CD|N/N latent|JJ|N/N membrane|NN|N/N proteins|NNS|N (|LRB|(NP\NP)/NP LMP1|NN|N ,|,|, 2A|NN|N ,|,|, 2B|NN|N )|RRB|RRB ,|,|, and|CC|conj two|CD|N/N nuclear|JJ|N/N RNAs|NNS|N (|LRB|(NP\NP)/NP EBERs|NNS|N )|RRB|RRB are|VBP|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP .|.|.
This|DT|NP[nb]/N form|NN|N of|IN|(NP\NP)/NP latency|NN|N ,|,|, termed|VBN|(S[pss]\NP)/NP latency|NN|N III|CD|N\N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) encountered|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP some|DT|NP[nb]/N posttransplant|JJ|N/N lymphoproliferative|JJ|N/N disorders|NNS|N .|.|.
In|IN|(S/S)/NP EBV-positive|JJ|N/N cases|NNS|N of|IN|(NP\NP)/NP Hodgkin|NN|N 's|POS|(NP[nb]/N)\NP disease|NN|N ,|,|, the|DT|NP[nb]/N EBERs|NNS|N ,|,|, EBNA1|NN|N ,|,|, and|CC|conj the|DT|NP[nb]/N LMPs|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP (|LRB|((S\NP)\(S\NP))/NP latency|NN|N II|CD|N\N )|RRB|RRB ,|,|, whereas|IN|((S\NP)\(S\NP))/S[dcl] in|IN|(S/S)/NP Burkitt|NN|N 's|POS|(NP[nb]/N)\NP lymphoma|NN|N (|LRB|(NP\NP)/NP BL|NN|N )|RRB|RRB only|RB|NP/NP the|DT|NP[nb]/N EBERs|NNS|N and|CC|conj EBNA1|NN|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP (|LRB|((S\NP)\(S\NP))/NP latency|NN|N I|NN|N\N )|RRB|RRB .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) studied|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP EBV|NN|N/N proteins|NNS|N in|IN|((S\NP)\(S\NP))/NP 17|CD|N/N cases|NNS|N of|IN|(NP\NP)/NP EBV-positive|JJ|N/N endemic|JJ|N/N BL|NN|N by|IN|((S\NP)\(S\NP))/NP immunohistology|NN|N .|.|.
Expression|NN|N of|IN|(NP\NP)/NP LMP1|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) seen|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP variable|JJ|N/N proportions|NNS|N of|IN|(NP\NP)/NP tumor|NN|N/N cells|NNS|N in|IN|((S\NP)\(S\NP))/NP two|CD|N/N cases|NNS|N and|CC|conj EBNA2|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP some|DT|NP[nb]/N tumor|NN|N/N cells|NNS|N in|IN|((S\NP)\(S\NP))/NP three|CD|N/N other|JJ|N/N cases|NNS|N .|.|.
Also|RB|S/S ,|,|, the|DT|NP[nb]/N BZLF1|NN|N/N trans-activator|NN|N/N protein|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N few|JJ|N/N tumor|NN|N/N cells|NNS|N in|IN|((S\NP)\(S\NP))/NP 6|CD|N/N cases|NNS|N ,|,|, indicating|VBG|(S[ng]\NP)/NP entry|NN|N into|IN|(NP\NP)/NP the|DT|NP[nb]/N lytic|JJ|N/N cycle|NN|N .|.|.
A|DT|NP[nb]/N phenotypic|JJ|N/N drift|NN|N from|IN|(NP\NP)/NP latency|NN|N I|NN|N\N to|TO|(NP\NP)/NP latency|NN|N III|CD|N\N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP previously|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP some|DT|NP[nb]/N BL|NN|N/N cell|NN|N/N lines|NNS|N .|.|.
Our|PRP$|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] a|DT|NP[nb]/N similar|JJ|N/N phenomenon|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) occur|VB|S[b]\NP in|IN|((S\NP)\(S\NP))/NP BL|NN|N in|FW|(NP\NP)/NP vivo|FW|N and|CC|conj indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N operational|JJ|N/N definition|NN|N of|IN|(NP\NP)/NP EBV|NN|N/N latencies|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) easily|RB|(S\NP)/(S\NP) applied|VBN|(S[pss]\NP)/PP to|TO|PP/NP human|JJ|N/N tumors|NNS|N .|.|.
The|DT|NP[nb]/N intracellular|JJ|N/N signal|NN|N/N transduction|NN|N of|IN|(NP\NP)/NP IL-5|NN|N in|IN|(NP\NP)/NP eosinophils|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) unknown|JJ|S[adj]\NP .|.|.
The|DT|NP[nb]/N objective|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N study|NN|N was|VBD|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) investigate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N involvement|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N newly|RB|(N/N)/(N/N) discovered|VBN|N/N Jak-STAT|JJ|N/N pathway|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-5|NN|N/N signal|NN|N/N transduction|NN|N/N mechanism|NN|N .|.|.
Eosinophils|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) purified|VBN|S[pss]\NP from|IN|((S\NP)\(S\NP))/NP peripheral|JJ|N/N blood|NN|N by|IN|((S\NP)\(S\NP))/NP discontinuous|JJ|N/N Percoll|NN|N/N gradients|NNS|N and|CC|conj stimulated|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP IL-5|NN|N .|.|.
The|DT|NP[nb]/N involvement|NN|N of|IN|(NP\NP)/NP Jak|NN|N 2|CD|N\N was|VBD|(S[dcl]\NP)/(S[pss]\NP) investigated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP immunoprecipitation|NN|N followed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/(S[ng]\NP) immunoblotting|VBG|(S[ng]\NP)/PP for|IN|PP/NP tyrosine|NN|N/N phosphorylation|NN|N .|.|.
The|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP Jak|NN|N 2|CD|N\N was|VBD|(S[dcl]\NP)/(S[pss]\NP) studied|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP autophosphorylation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N immunoprecipitated|VBN|N/N kinase|NN|N .|.|.
Jak|NN|N 2|CD|N\N was|VBD|(S[dcl]\NP)/(S[pss]\NP) tyrosine|NN|(S\NP)/(S\NP) phosphorylated|JJ|S[pss]\NP within|IN|((S\NP)\(S\NP))/NP 1|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 3|CD|N/N min|NN|N after|IN|((S\NP)\(S\NP))/NP stimulation|NN|N of|IN|(NP\NP)/NP eosinophils|NNS|N with|IN|(NP\NP)/NP IL-5|NN|N .|.|.
Further|RB|S/S ,|,|, the|DT|NP[nb]/N immunoprecipitated|VBN|N/N Jak|NN|N 2|CD|N\N obtained|VBN|(S[pss]\NP)/PP from|IN|PP/NP IL-5-stimulated|JJ|N/N cells|NNS|N underwent|VBD|(S[dcl]\NP)/NP autophosphorylation|NN|N .|.|.
Jak|NN|N 2|CD|N\N coprecipitated|VBD|(S[dcl]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N beta-subunit|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-5|NN|N/N receptor|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N physical|JJ|N/N association|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N kinase|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N receptor|NN|N .|.|.
The|DT|NP[nb]/N nuclear|JJ|N/N factor|NN|N STAT-1|NN|N (|LRB|(NP\NP)/NP p91|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[pss]\NP) investigated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP immunoprecipitation|NN|N followed|VBN|(S[pss]\NP)/PP by|IN|PP/(S[ng]\NP) immunoblotting|VBG|(S[ng]\NP)/PP for|IN|PP/NP tyrosine|NN|N/N phosphorylation|NN|N .|.|.
STAT-1|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) tyrosine|NN|(S\NP)/(S\NP) phosphorylated|JJ|S[pss]\NP within|IN|((S\NP)\(S\NP))/NP 15|CD|N/N min|NN|N of|IN|(NP\NP)/NP IL-5|NN|N/N stimulation|NN|N .|.|.
The|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP STAT-1|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N nuclear|JJ|N/N extract|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) studied|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N .|.|.
IL-5|NN|N induced|VBD|(S[dcl]\NP)/NP two|CD|N/N proteins|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) bound|VBD|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N gamma-activating|JJ|N/N sequence|NN|N .|.|.
In|IN|(S/S)/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP an|DT|NP[nb]/N anti-STAT-1|JJ|N/N Ab|NN|N ,|,|, the|DT|NP[nb]/N band|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) supershifted|VBN|S[pss]\NP .|.|.
Thus|RB|S/S ,|,|, we|PRP|NP demonstrated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-5|NN|N activated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N Jak|NN|N/N 2-STAT|NN|N/N 1|CD|(N/N)\(N/N) signaling|NN|N/N pathway|NN|N in|IN|(NP\NP)/NP eosinophils|NNS|N .|.|.
We|PRP|NP speculate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N Jak|NN|N/N 2-STAT|NN|N/N 1|CD|(N/N)\(N/N) pathway|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP IL-5-inducible|JJ|N/N genes|NNS|N in|IN|(NP\NP)/NP eosinophils|NNS|N .|.|.
Immunosuppression|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) often|RB|(S\NP)\(S\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N course|NN|N of|IN|(NP\NP)/NP malignant|JJ|N/N diseases|NNS|N .|.|.
In|IN|(S/S)/NP the|DT|NP[nb]/N present|JJ|N/N study|NN|N ,|,|, the|DT|NP[nb]/N proliferation|NN|N of|IN|(NP\NP)/NP peripheral|JJ|N/N blood|NN|N/N mononuclear|JJ|N/N cells|NNS|N (|LRB|(NP\NP)/NP PBMCs|NNS|N )|RRB|RRB in|IN|(NP\NP)/NP response|NN|N to|TO|(NP\NP)/NP mitogenic|JJ|N/N stimulation|NN|N with|IN|(NP\NP)/NP phytohaemagglutinin|NN|N (|LRB|(NP\NP)/NP PHA|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[pss]\NP) assessed|VBN|S[pss]\NP prospectively|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP 90|CD|N/N patients|NNS|N with|IN|(NP\NP)/NP stage|NN|N/N I-III|CD|(N/N)\(N/N) breast|NN|N/N cancer|NN|N .|.|.
Whereas|IN|(S/S)/S[dcl] PHA-induced|JJ|N/N proliferation|NN|N of|IN|(NP\NP)/NP PBMCs|NNS|N derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP patients|NNS|N with|IN|(NP\NP)/NP breast|NN|N/N cancer|NN|N preoperatively|RB|(S\NP)\(S\NP) was|VBD|(S[dcl]\NP)/(S[pss]\NP) significantly|RB|(S\NP)\(S\NP) decreased|VBN|S[pss]\NP when|WRB|((S\NP)\(S\NP))/(S[pss]\NP) compared|VBN|(S[pss]\NP)/PP with|IN|PP/NP data|NNS|N obtained|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP healthy|JJ|N/N control|JJ|N/N individuals|NNS|N (|LRB|(NP\NP)/S[dcl] P|NN|N <|JJR|(S[dcl]\NP)/NP 0.001|CD|N )|RRB|RRB ,|,|, the|DT|NP[nb]/N degree|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N defect|NN|N in|IN|(NP\NP)/NP PHA-induced|JJ|N/N proliferation|NN|N of|IN|(NP\NP)/NP PBMCs|NNS|N depended|VBD|(S[dcl]\NP)/PP upon|IN|PP/NP the|DT|NP[nb]/N tumour|NN|N/N burden|NN|N as|IN|(NP\NP)/(S[pss]\NP) manifested|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP tumour|NN|N/N size|NN|N and|CC|conj axillary|NN|N/N lymph|NN|N/N node|NN|N/N involvement|NN|N (|LRB|(NP\NP)/S[dcl] P|NN|N <|JJR|(S[dcl]\NP)/NP 0.003|CD|N in|IN|((S\NP)\(S\NP))/NP each|DT|NP[nb]/N case|NN|N )|RRB|RRB .|.|.
PHA-induced|JJ|N/N proliferation|NN|N of|IN|(NP\NP)/NP PBMCs|NNS|N dropped|VBD|S[dcl]\NP significantly|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP patients|NNS|N who|WP|(NP\NP)/(S[dcl]\NP) received|VBD|(S[dcl]\NP)/NP adjuvant|JJ|N/N chemotherapy|NN|N consisting|VBG|(S[ng]\NP)/PP of|IN|PP/NP cyclophosphamide|NN|N ,|,|, methotrexate|NN|N and|CC|conj fluorouracil|NN|N (|LRB|(NP\NP)/NP CMF|NN|N )|RRB|RRB after|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N observation|NN|N/N period|NN|N of|IN|(NP\NP)/NP 6|CD|N/N months|NNS|N (|LRB|(NP\NP)/S[dcl] P|NN|N <|JJR|(S[dcl]\NP)/NP 0.01|CD|N )|RRB|RRB ,|,|, but|CC|conj not|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP patients|NNS|N under|IN|(NP\NP)/NP adjuvant|JJ|N/N treatment|NN|N with|IN|(NP\NP)/NP tamoxifen|NN|N only|RB|NP\NP .|.|.
After|IN|(S/S)/NP an|DT|NP[nb]/N additional|JJ|(N/N)/(N/N) 6|CD|N/N months|NNS|N (|LRB|(NP\NP)/NP i.e.|FW|N/N 12|CD|N/N months|NNS|N after|IN|(NP\NP)/NP surgery|NN|N )|RRB|RRB ,|,|, PHA-induced|JJ|N/N proliferation|NN|N of|IN|(NP\NP)/NP PBMCs|NNS|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) similar|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP patients|NNS|N after|IN|(NP\NP)/NP adjuvant|JJ|N/N chemotherapy|NN|N with|IN|(NP\NP)/NP CMF|NN|N and|CC|conj in|IN|((S[adj]\NP)\(S[adj]\NP))/NP those|DT|NP receiving|VBG|(S[ng]\NP)/NP continued|JJ|N/N adjuvant|JJ|N/N tamoxifen|NN|N/N treatment|NN|N (|LRB|(NP\NP)/S[dcl] P|NN|N >|JJR|(S[dcl]\NP)/NP 0.1|CD|N )|RRB|RRB ,|,|, but|CC|conj in|IN|((S\NP)/(S\NP))/NP all|DT|NP[nb]/N patients|NNS|N still|RB|(S\NP)/(S\NP) significantly|RB|(S\NP)/(S\NP) decreased|VBD|S[dcl]\NP as|IN|((S\NP)\(S\NP))/((S\NP)\(S\NP)) compared|VBN|((S\NP)\(S\NP))/PP with|IN|PP/NP healthy|JJ|N/N controls|NNS|N (|LRB|(NP\NP)/S[dcl] P|NN|N <|JJR|(S[dcl]\NP)/NP 0.001|CD|N )|RRB|RRB .|.|.
When|WRB|(S/S)/S[dcl] data|NNS|N obtained|VBN|S[pss]\NP preoperatively|RB|(S\NP)\(S\NP) and|CC|conj after|IN|((S\NP)\(S\NP))/NP 12|CD|N/N months|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) compared|VBN|S[pss]\NP ,|,|, it|PRP|NP[expl] was|VBD|(S[dcl]\NP[expl])/(S[pss]\NP) found|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] out|RB|((S\NP)/(S\NP))/PP of|IN|PP/NP 23|CD|N/N patients|NNS|N whose|WP$|((NP\NP)/(S[dcl]\NP))/N PBMCs|NNS|N had|VBD|(S[dcl]\NP)/(S[pt]\NP) experienced|VBN|(S[pt]\NP)/NP a|DT|NP[nb]/N drop|NN|N in|IN|(NP\NP)/NP their|PRP$|NP[nb]/N PHA-induced|JJ|N/N proliferation|NN|N ,|,|, 14|CD|N (|LRB|(NP\NP)/NP 61|CD|N/N %|NN|N )|RRB|RRB had|VBD|(S[dcl]\NP)/(S[pt]\NP) developed|VBN|(S[pt]\NP)/NP metastatic|JJ|N/N disease|NN|N within|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N subsequent|JJ|N/N 24|CD|N/N months|NNS|N (|LRB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) i.e.|FW|(((S\NP)\(S\NP))\((S\NP)\(S\NP)))/NP 36|CD|N/N months|NNS|N after|IN|(NP\NP)/NP surgery|NN|N )|RRB|RRB .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, out|RB|((S\NP)/(S\NP))/PP of|IN|PP/NP 59|CD|N/N patients|NNS|N whose|WP$|((NP\NP)/(S[dcl]\NP))/N PBMCs|NNS|N showed|VBD|(S[dcl]\NP)/NP an|DT|NP[nb]/N increase|NN|N in|IN|(NP\NP)/NP their|PRP$|NP[nb]/N PHA-induced|JJ|N/N proliferation|NN|N within|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N first|JJ|N/N 12|CD|N/N months|NNS|N after|IN|(((S\NP)\(S\NP))/NP)/NP surgery|NN|N ,|,|, only|RB|N/N one|CD|N (|LRB|(NP\NP)/NP 2|CD|N/N %|NN|N )|RRB|RRB presented|VBD|(S[dcl]\NP)/PP with|IN|PP/NP disease|NN|N/N progression|NN|N .|.|.
We|PRP|NP thus|RB|(S\NP)/(S\NP) conclude|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] PHA-induced|JJ|N/N proliferation|NN|N of|IN|(NP\NP)/NP PBMCs|NNS|N derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP patients|NNS|N with|IN|(NP\NP)/NP breast|NN|N/N cancer|NN|N depends|VBZ|(S[dcl]\NP)/PP upon|IN|PP/NP the|DT|NP[nb]/N tumour|NN|N/N load|NN|N and|CC|conj is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N good|JJ|N/N clinical|JJ|N/N predictor|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N further|JJ|N/N course|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N disease|NN|N .|.|.
A|DT|NP[nb]/N previously|RB|(N/N)/(N/N) unrecognized|JJ|N/N element|NN|N ,|,|, located|JJ|S[pss]\NP downstream|RB|((S\NP)\(S\NP))/PP of|IN|PP/NP the|DT|NP[nb]/N start|NN|N/N site|NN|N of|IN|(NP\NP)/NP transcription|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N first|JJ|N/N exon|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DR|NN|N/N alpha|NN|N/N gene|NN|N ,|,|, has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) defined|VBN|S[pss]\NP that|WDT|((S\NP)\(S\NP))/(S[dcl]\NP) enhances|VBZ|(S[dcl]\NP)/NP promoter|NN|N/N activity|NN|N up|IN|((S\NP)\(S\NP))/PP to|TO|PP/(S[adj]\NP) eightfold|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N position-dependent|JJ|N/N manner|NN|N .|.|.
Mutations|NNS|N in|IN|(NP\NP)/NP this|DT|NP[nb]/N DNA-binding|JJ|N/N site|NN|N abolished|VBD|(S[dcl]\NP)/NP binding|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N nuclear|JJ|N/N factor|NN|N in|IN|(NP\NP)/NP human|JJ|N/N B|NN|(N/N)/(N/N) cell|NN|N/N nuclear|JJ|N/N extract|NN|N and|CC|conj decreased|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DR|NN|N/N alpha|NN|N/N promoter|NN|N to|TO|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N basal|JJ|N/N level|NN|N .|.|.
Significant|JJ|N/N sequence|NN|N/N homology|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N element|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N DNA|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DR|NN|N/N beta|NN|N/N ,|,|, DP|NN|N/N alpha|NN|N/N and|CC|conj -beta|NN|N/N ,|,|, and|CC|conj DQ|NN|N/N alpha|NN|N/N genes|NNS|N ,|,|, always|RB|(S\NP)/(S\NP) located|JJ|S[pss]\NP downstream|RB|((S\NP)\(S\NP))/PP of|IN|PP/NP the|DT|NP[nb]/N transcriptional|JJ|N/N start|NN|N/N site|NN|N .|.|.
The|DT|NP[nb]/N nuclear|JJ|N/N factor|NN|N binds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N DR|NN|N/N alpha|NN|N/N and|CC|conj DP|NN|N/N alpha|NN|N/N element|NN|N but|CC|conj not|RB|PP/PP to|TO|PP/NP the|DT|NP[nb]/N element|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N DQ|NN|N/N alpha|NN|N/N gene|NN|N .|.|.
It|PRP|NP was|VBD|(S[dcl]\NP)/(S[pss]\NP) identified|VBN|(S[pss]\NP)/PP as|IN|PP/NP NF-E1|NN|N (|LRB|(N\N)/N YY1|NN|N )|RRB|RRB .|.|.
This|DT|NP[nb]/N protein|NN|N ,|,|, previously|RB|(S\NP)/(S\NP) identified|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP its|PRP$|NP[nb]/N binding|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N Ig|NN|N/N kappa|NN|N/N 3'|JJ|N/N enhancer|NN|N and|CC|conj the|DT|NP[nb]/N Ig|NN|N/N heavy|JJ|N/N chain|NN|N/N mu|NN|N/N E1|NN|N/N site|NN|N ,|,|, thus|RB|(S\NP)/(S\NP) also|RB|(S\NP)/(S\NP) appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) quite|RB|(S[adj]\NP)/(S[adj]\NP) important|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP MHC|NN|N/N class|NN|N/N II|CD|(N/N)\(N/N) gene|NN|N/N expression|NN|N .|.|.
Core|NN|N/N binding|NN|N/N factor|NN|N (|LRB|(NP\NP)/NP CBF|NN|N )|RRB|RRB ,|,|, also|RB|(S\NP)/(S\NP) known|VBN|(S[pss]\NP)/PP as|IN|PP/NP polyomavirus|NN|N/N enhancer-binding|JJ|N/N protein|NN|N 2|CD|N\N and|CC|conj SL3|NN|N/N enhancer|NN|N/N factor|NN|N 1|CD|N\N ,|,|, is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N mammalian|JJ|N/N transcription|NN|N/N factor|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) binds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP an|DT|NP[nb]/N element|NN|N termed|VBN|(S[pss]\NP)/NP the|DT|NP[nb]/N core|NN|N within|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N enhancers|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N murine|JJ|N/N leukemia|NN|N/N virus|NN|N/N family|NN|N of|IN|(NP\NP)/NP retroviruses|NNS|N .|.|.
The|DT|NP[nb]/N core|NN|N/N elements|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N SL3|NN|N/N virus|NN|N are|VBP|(S[dcl]\NP)/NP important|JJ|N/N genetic|JJ|N/N determinants|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N ability|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N virus|NN|N to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP T-cell|NN|N/N lymphomas|NNS|N and|CC|conj the|DT|NP[nb]/N transcriptional|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N viral|JJ|N/N long|JJ|N/N terminal|JJ|N/N repeat|NN|N in|IN|(NP\NP)/NP T|NN|N/N lymphocytes|NNS|N .|.|.
CBF|NN|N consists|VBZ|(S[dcl]\NP)/PP of|IN|PP/NP two|CD|N/N subunits|NNS|N ,|,|, a|DT|NP[nb]/N DNA|NN|(N/N)/(N/N) binding|NN|N/N subunit|NN|N ,|,|, CBF|NN|N/N alpha|NN|N ,|,|, and|CC|conj a|DT|NP[nb]/N second|JJ|N/N subunit|NN|N ,|,|, CBF|NN|N/N beta|NN|N ,|,|, that|WDT|(NP\NP)/(S[dcl]\NP) stimulates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N DNA|NN|(N/N)/(N/N) binding|NN|N/N activity|NN|N of|IN|(NP\NP)/NP CBF|NN|N/N alpha|NN|N .|.|.
One|CD|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N genes|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) encodes|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N CBF|NN|(N/N)/(N/N) alpha|NN|N/N subunit|NN|N is|VBZ|(S[dcl]\NP)/NP AML1|NN|N ,|,|, also|RB|(S\NP)/(S\NP) called|VBN|(S[pss]\NP)/NP Cbf|NN|N/N alpha|NN|N 2|CD|N\N .|.|.
This|DT|NP[nb]/N locus|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) rearranged|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP chromosomal|JJ|N/N translocations|NNS|N in|IN|((S\NP)\(S\NP))/NP human|JJ|N/N myeloproliferative|JJ|N/N disorders|NNS|N and|CC|conj leukemias|NNS|N .|.|.
An|DT|NP[nb]/N exogenously|RB|(N/N)/(N/N) expressed|VBN|N/N Cbf|NN|N/N alpha|NN|N/N 2-encoded|JJ|N/N subunit|NN|N (|LRB|(NP\NP)/NP CBF|NN|N/N alpha|NN|N 2-451|CD|N\N )|RRB|RRB stimulated|VBD|(S[dcl]\NP)/NP transcription|NN|N from|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N SL3|NN|N/N enhancer|NN|N in|IN|(NP\NP)/NP P19|NN|N/N and|CC|conj HeLa|NN|N/N cells|NNS|N .|.|.
Activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP through|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N core|NN|N/N elements|NNS|N .|.|.
Three|CD|N/N different|JJ|N/N isoforms|NNS|N of|IN|(NP\NP)/NP CBF|NN|N/N beta|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) tested|VBN|(S[pss]\NP)/PP for|IN|PP/NP transcriptional|JJ|N/N activity|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N SL3|NN|N/N enhancer|NN|N .|.|.
The|DT|NP[nb]/N longest|JJS|N/N form|NN|N ,|,|, CBF|NN|N/N beta-187|NN|N ,|,|, increased|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N transcriptional|JJ|N/N stimulation|NN|N by|IN|(NP\NP)/NP CBF|NN|N/N alpha|NN|N 2-451|CD|N\N twofold|JJ|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP HeLa|NN|N/N cells|NNS|N ,|,|, although|IN|((S\NP)\(S\NP))/S[dcl] it|PRP|NP had|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N effect|NN|N in|IN|((S\NP)\(S\NP))/NP P19|NN|N/N cells|NNS|N .|.|.
Transcriptional|JJ|N/N activation|NN|N by|IN|(NP\NP)/NP CBF|NN|N/N beta|NN|N required|VBD|(S[dcl]\NP)/NP binding|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N CBF|NN|(N/N)/(N/N) alpha|NN|N/N subunit|NN|N ,|,|, as|IN|((S\NP)\(S\NP))/S[dcl] a|DT|NP[nb]/N form|NN|N of|IN|(NP\NP)/NP CBF|NN|N/N beta|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) lacked|VBD|(S[dcl]\NP)/NP binding|NN|N/N ability|NN|N ,|,|, CBF|NN|N/N beta-148|NN|N ,|,|, failed|VBD|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) increase|VB|(S[b]\NP)/NP activity|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] at|IN|((S/S)/(S/S))/(S[asup]\NP) least|JJS|S[asup]\NP in|IN|(S/S)/NP certain|JJ|N/N cell|NN|N/N types|NNS|N ,|,|, the|DT|NP[nb]/N maximum|NN|N/N activity|NN|N of|IN|(NP\NP)/NP CBF|NN|N required|VBD|(S[dcl]\NP)/NP both|DT|NP[nb]/N subunits|NNS|N .|.|.
They|PRP|NP also|RB|(S\NP)/(S\NP) provided|VBD|(S[dcl]\NP)/NP support|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N hypothesis|NN|N/S[em] that|IN|S[em]/S[dcl] CBF|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N factor|NN|N in|IN|(NP\NP)/NP T|NN|N/N lymphocytes|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) responsible|JJ|(S[adj]\NP)/PP for|IN|PP/NP recognition|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N SL3|NN|N/N cores|NNS|N .|.|.
We|PRP|NP also|RB|(S\NP)/(S\NP) examined|VBD|(S[dcl]\NP)/S[qem] whether|IN|S[qem]/S[dcl] CBF|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) distinguish|VB|(S[b]\NP)/NP a|DT|NP[nb]/N 1-bp|JJ|N/N difference|NN|N between|IN|(NP\NP)/NP the|DT|NP[nb]/N enhancer|NN|N/N core|NN|N of|IN|(NP\NP)/NP SL3|NN|N and|CC|conj the|DT|NP[nb]/N core|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N nonleukemogenic|JJ|N/N virus|NN|N ,|,|, Akv|NN|N .|.|.
This|DT|NP[nb]/N difference|NN|N strongly|RB|(S\NP)/(S\NP) affects|VBZ|(S[dcl]\NP)/NP transcription|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N and|CC|conj leukemogenicity|NN|N of|IN|(NP\NP)/NP SL3|NN|N .|.|.
However|RB|S/S ,|,|, no|DT|NP[nb]/N combination|NN|N of|IN|(NP\NP)/NP CBF|NN|(N/N)/(N/N) alpha|NN|N/N and|CC|conj CBF|NN|(N/N)/(N/N) beta|NN|N/N subunits|NNS|N that|WDT|(NP\NP)/(S[dcl]/NP) we|PRP|NP tested|VBD|(S[dcl]\NP)/NP was|VBD|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) distinguish|VB|(S[b]\NP)/NP the|DT|NP[nb]/N 1-bp|JJ|N/N difference|NN|N in|IN|(NP\NP)/NP transcription|NN|N/N assays|NNS|N .|.|.
Thus|RB|S/S ,|,|, a|DT|NP[nb]/N complete|JJ|N/N understanding|NN|N of|IN|(NP\NP)/S[qem] how|WRB|S[qem]/S[dcl] T|NN|N/N cells|NNS|N recognize|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N SL3|NN|N/N core|NN|N remains|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) elucidated|VBN|S[pss]\NP .|.|.
Our|PRP$|NP[nb]/N previous|JJ|N/N studies|NNS|N in|IN|(NP\NP)/NP human|JJ|N/N monocytes|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) demonstrated|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] interleukin|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL|NN|N/N )|RRB|RRB -10|CD|N inhibits|VBZ|(S[dcl]\NP)/NP lipopolysaccharide|NN|(N/N)/(N/N) (|LRB|(((N/N)/(N/N))\((N/N)/(N/N)))/((N/N)/(N/N)) LPS|NN|(N/N)/(N/N) )|RRB|RRB -stimulated|JJ|N/N production|NN|N of|IN|(NP\NP)/NP inflammatory|JJ|N/N cytokines|NNS|N ,|,|, IL-1|NN|N/N beta|NN|N ,|,|, IL-6|NN|N ,|,|, IL-8|NN|N ,|,|, and|CC|conj tumor|NN|N/N necrosis|NN|N/N factor|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) TNF|NN|N/N )|RRB|RRB -alpha|NN|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) blocking|VBG|(S[ng]\NP)/NP gene|NN|N/N transcription|NN|N .|.|.
Using|VBG|(S[ng]\NP)/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N (|LRB|(NP\NP)/NP EMSA|NN|N )|RRB|RRB ,|,|, we|PRP|NP now|RB|(S\NP)/(S\NP) show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] ,|,|, in|IN|(S/S)/NP monocytes|NNS|N stimulated|VBN|(S[pss]\NP)/PP with|IN|PP/NP LPS|NN|N or|CC|conj TNF|NN|N/N alpha|NN|N ,|,|, IL-10|NN|N inhibits|VBZ|(S[dcl]\NP)/NP nuclear|JJ|N/N stimulation|NN|N of|IN|(NP\NP)/NP nuclear|JJ|N/N factor|NN|N kappa|NN|N/N B|NN|N (|LRB|(NP\NP)/NP NF|NN|N kappa|NN|N/N B|NN|N )|RRB|RRB ,|,|, a|DT|NP[nb]/N transcription|NN|N/N factor|NN|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP inflammatory|JJ|N/N cytokine|NN|N/N genes|NNS|N .|.|. Several|JJ|N/N other|JJ|N/N transcription|NN|N/N factors|NNS|N including|VBG|(S[ng]\NP)/NP NF-IL-6|NN|N ,|,|, AP-1|NN|N ,|,|, AP-2|NN|N ,|,|, GR|NN|N ,|,|, CREB|NN|N ,|,|, Oct-1|NN|N ,|,|, and|CC|conj Sp-1|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) affected|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP IL-10|NN|N .|.|.
This|DT|NP[nb]/N selective|JJ|N/N inhibition|NN|N by|IN|(NP\NP)/NP IL-10|NN|N of|IN|(NP\NP)/NP NF|NN|(N/N)/(N/N) kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N occurs|VBZ|S[dcl]\NP rapidly|RB|(S\NP)\(S\NP) and|CC|conj in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N dose-dependent|JJ|N/N manner|NN|N and|CC|conj correlates|VBZ|(S[dcl]\NP)/PP well|RB|(S\NP)\(S\NP) with|IN|PP/NP IL-10|NN|N 's|POS|(NP[nb]/N)\NP cytokine|NN|N/N synthesis|NN|N/N inhibitory|JJ|N/N activity|NN|N in|IN|((S\NP)\(S\NP))/NP terms|NNS|N of|IN|(NP\NP)/NP both|CC|NP/NP kinetics|NNS|N and|CC|conj dose|NN|N/N responsiveness|NN|N .|.|.
Furthermore|RB|S/S ,|,|, compounds|NNS|N such|JJ|(NP\NP)/(NP\NP) as|IN|(NP\NP)/NP tosylphenylalanyl|NN|N/N chloromethyl|NN|N/N ketone|NN|N and|CC|conj pyrrolidinedithiocarbamate|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[pss]\NP) known|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) selectively|RB|(S\NP)\(S\NP) inhibit|VB|(S[b]\NP)/NP NF|NN|(N/N)/(N/N) kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N block|VBP|(S[dcl]\NP)/NP cytokine|NN|N/N gene|NN|N/N transcription|NN|N in|IN|(NP\NP)/NP LPS-stimulated|JJ|N/N monocytes|NNS|N .|.|.
Taken|VBN|S[pss]\NP together|RB|(S\NP)\(S\NP) ,|,|, these|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] inhibition|NN|N of|IN|(NP\NP)/NP NF|NN|(N/N)/(N/N) kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N mechanism|NN|N for|IN|(NP\NP)/NP IL-10|NN|N/N suppression|NN|N of|IN|(NP\NP)/NP cytokine|NN|N/N gene|NN|N/N transcription|NN|N in|IN|(NP\NP)/NP human|JJ|N/N monocytes|NNS|N .|.|.
IL-4|NN|N ,|,|, another|DT|NP[nb]/N cytokine|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) inhibits|VBZ|(S[dcl]\NP)/NP cytokine|NN|(N/N)/(N/N) mRNA|NN|N/N accumulation|NN|N in|IN|(NP\NP)/NP monocytes|NNS|N ,|,|, shows|VBZ|(S[dcl]\NP)/NP little|JJ|N/N inhibitory|JJ|N/N effect|NN|N on|IN|(NP\NP)/NP LPS-induced|JJ|N/N NF|NN|(N/N)/(N/N) kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N .|.|.
Further|RB|N/N examination|NN|N reveals|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] ,|,|, unlike|IN|(S/S)/NP IL-10|NN|N ,|,|, IL-4|NN|N enhances|VBZ|(S[dcl]\NP)/NP mRNA|NN|N/N degradation|NN|N and|CC|conj does|VBZ|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) suppress|VB|(S[b]\NP)/NP cytokine|NN|N/N gene|NN|N/N transcription|NN|N .|.|.
These|DT|NP[nb]/N data|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-10|NN|N and|CC|conj IL-4|NN|N inhibit|VBP|(S[dcl]\NP)/NP cytokine|NN|N/N production|NN|N by|IN|((S\NP)\(S\NP))/NP different|JJ|N/N mechanisms|NNS|N .|.|.
LMP-1|NN|N ,|,|, an|DT|NP[nb]/N Epstein-Barr|JJ|(N/N)/(N/N) virus|NN|N/N membrane|NN|N/N protein|NN|N expressed|VBN|S[pss]\NP during|IN|((S\NP)\(S\NP))/NP latent|JJ|N/N infection|NN|N ,|,|, has|VBZ|(S[dcl]\NP)/NP oncogenic|JJ|N/N properties|NNS|N ,|,|, as|IN|((S\NP)\(S\NP))/(S[pss]\NP) judged|VBN|(S[pss]\NP)/PP from|IN|PP/NP its|PRP$|NP[nb]/N ability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) transform|VB|(S[b]\NP)/NP B|NN|N/N lymphocytes|NNS|N and|CC|conj rodent|JJ|N/N fibroblasts|NNS|N .|.|.
LMP-1|NN|N induces|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP bcl2|NN|N ,|,|, an|DT|NP[nb]/N oncogene|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) protects|VBZ|((S[dcl]\NP)/PP)/NP cells|NNS|N from|IN|PP/NP apoptosis|NN|N ,|,|, as|RB|conj/conj well|RB|conj/conj as|IN|conj of|IN|(NP\NP)/NP genes|NNS|N encoding|VBG|(S[ng]\NP)/NP other|JJ|N/N proteins|NNS|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP cell|NN|N/N regulation|NN|N and|CC|conj growth|NN|N/N control|NN|N .|.|.
The|DT|NP[nb]/N mechanisms|NNS|N by|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) LMP-1|NN|N upregulates|VBZ|(S[dcl]\NP)/NP these|DT|NP[nb]/N proteins|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) unknown|JJ|S[adj]\NP ,|,|, but|CC|conj it|PRP|NP[expl] is|VBZ|((S[dcl]\NP[expl])/S[em])/(S[adj]\NP) plausible|JJ|S[adj]\NP that|IN|S[em]/S[dcl] LMP-1|NN|N modifies|VBZ|(S[dcl]\NP)/NP signal|NN|(N/N)/(N/N) transduction|NN|N/N pathways|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) result|VBP|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP one|CD|N/N or|CC|conj more|JJR|N/N transcription|NN|N/N factors|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) ultimately|RB|(S\NP)/(S\NP) regulate|VBP|(S[dcl]\NP)/NP transcription|NN|N of|IN|(NP\NP)/NP oncogenic|JJ|N/N genes|NNS|N .|.|.
NF-kappa|NN|N/N B|NN|N ,|,|, a|DT|NP[nb]/N transcription|NN|N/N factor|NN|N controlling|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP genes|NNS|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP cell|NN|N/N activation|NN|N and|CC|conj growth|NN|N/N control|NN|N ,|,|, has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) activated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP LMP-1|NN|N .|.|.
The|DT|NP[nb]/N mechanism|NN|N (|LRB|(NP\NP)/NP s|NNS|N )|RRB|RRB regulating|VBG|(S[ng]\NP)/NP this|DT|NP[nb]/N activation|NN|N remains|VBZ|(S[dcl]\NP)/(S[adj]\NP) unknown|JJ|S[adj]\NP .|.|.
Our|PRP$|NP[nb]/N data|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] increased|VBN|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N DNA|NN|N/N binding|NN|N and|CC|conj functional|JJ|N/N activity|NN|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) present|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP B-lymphoid|JJ|N/N cells|NNS|N stably|RB|(S\NP)/(S\NP) or|CC|conj transiently|RB|(S\NP)/(S\NP) expressing|VBG|(S[ng]\NP)/NP LMP-1|NN|N .|.|.
I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) selectively|RB|(S\NP)\(S\NP) modified|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP LMP-1-expressing|JJ|N/N B|NN|N/N cells|NNS|N .|.|.
A|DT|NP[nb]/N phosphorylated|JJ|N/N form|NN|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N and|CC|conj increased|VBN|N/N protein|NN|N/N turnover-degradation|NN|N correlate|VBP|(S[dcl]\NP)/PP with|IN|PP/NP increased|VBN|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N nuclear|JJ|N/N translocation|NN|N .|.|.
This|DT|NP results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP increased|VBN|N/N transcription|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B-dependent-genes|NNS|N ,|,|, including|VBG|(S[ng]\NP)/NP those|DT|NP encoding|VBG|(S[ng]\NP)/NP p105|NN|N and|CC|conj I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N (|LRB|(NP\NP)/NP MAD3|NN|N )|RRB|RRB .|.|.
These|DT|NP[nb]/N results|NNS|N indicate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] LMP-1|NN|N activates|VBZ|(S[dcl]\NP)/NP NF-kappa|NN|N/N B|NN|N in|IN|((S\NP)\(S\NP))/NP B-cell|NN|N/N lines|NNS|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) targeting|VBG|(S[ng]\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N .|.|.
Identification|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N pathways|NNS|N activated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP LMP-1|NN|N to|TO|(S[to]\NP)/(S[b]\NP) result|VB|(S[b]\NP)/PP in|IN|PP/NP posttranslational|JJ|N/N modifications|NNS|N of|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N will|MD|(S[dcl]\NP)/(S[b]\NP) aid|VB|(S[b]\NP)/PP in|IN|PP/(S[ng]\NP) determining|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N role|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N virus-host|JJ|N/N cell|NN|N/N protein|NN|N/N interaction|NN|N in|IN|(NP\NP)/NP Epstein-Barr|JJ|N/N virus-mediated|JJ|N/N oncogenesis|NN|N .|.|.
A|DT|NP[nb]/N DNA|NN|N/N response|NN|N/N element|NN|N (|LRB|(NP\NP)/NP TR2RE-SV40|NN|N )|RRB|RRB for|IN|(NP\NP)/NP the|DT|NP[nb]/N TR2|NN|N/N orphan|NN|N/N receptor|NN|N ,|,|, a|DT|NP[nb]/N member|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N steroid-thyroid|JJ|N/N hormone|NN|N/N receptor|NN|N/N superfamily|NN|N ,|,|, has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) identified|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N simian|JJ|N/N virus|NN|N/N 40|CD|(N/N)\(N/N) (|LRB|((N/N)\(N/N))/(N/N) SV40|NN|N/N )|RRB|RRB +55|CD|N/N region|NN|N (|LRB|(NP\NP)/NP nucleotide|NN|N/N numbers|NNS|N/N 368-389|CD|N ,|,|, 5'-GTTAAGGTTCGTAGGTCATGGA-3'|NN|N )|RRB|RRB .|.|.
Electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N ,|,|, using|VBG|(S[ng]\NP)/NP in|FW|(N/N)/(N/N) vitro|FW|N/N translated|VBN|N/N TR2|NN|N/N orphan|NN|N/N receptor|NN|N with|IN|(NP\NP)/NP a|DT|NP[nb]/N molecular|JJ|N/N mass|NN|N of|IN|(NP\NP)/NP 67|CD|N/N kilodaltons|NNS|N ,|,|, showed|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N specific|JJ|N/N binding|NN|N with|IN|(NP\NP)/NP high|JJ|N/N affinity|NN|N (|LRB|(NP\NP)/S[dcl] dissociation|NN|N/N constant|NN|N =|JJ|(S[dcl]\NP)/NP 9|CD|N/N nM|NN|N )|RRB|RRB for|IN|(NP\NP)/NP this|DT|NP[nb]/N DNA|NN|N/N sequence|NN|N .|.|.
DNA-swap|NN|N/N experiments|NNS|N using|VBG|(S[ng]\NP)/NP chloramphenicol|NN|N/N acetyl-transferase|NN|N/N assay|NN|N demonstrated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] androgen|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) suppress|VB|(S[b]\NP)/NP the|DT|NP[nb]/N transcriptional|JJ|N/N activities|NNS|N of|IN|(NP\NP)/NP SV40|NN|N/N early|JJ|N/N promoter|NN|N via|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N interaction|NN|N between|IN|(NP\NP)/NP this|DT|NP[nb]/N TR2RE-SV40|NN|N and|CC|conj the|DT|NP[nb]/N chimeric|JJ|N/N receptor|NN|N AR/TR2/AR|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N DNA-binding|JJ|N/N domain|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TR2|NN|N/N orphan|NN|N/N receptor|NN|N flanked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N N-terminal|JJ|N/N and|CC|conj androgen-binding|JJ|N/N domains|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N androgen|NN|N/N receptor|NN|N .|.|.
In|IN|(S/S)/NP addition|NN|N ,|,|, this|DT|NP[nb]/N TR2RE-SV40|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) function|VB|(S[b]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N repressor|NN|N to|TO|(S[to]\NP)/(S[b]\NP) suppress|VB|(S[b]\NP)/NP the|DT|NP[nb]/N transcriptional|JJ|N/N activities|NNS|N of|IN|(NP\NP)/NP both|CC|NP[nb]/N SV40|NN|N/N early|JJ|N/N and|CC|conj late|JJ|N/N promoters|NNS|N .|.|.
Together|RB|S/S ,|,|, these|DT|NP[nb]/N data|NNS|N suggest|VBP|(S[dcl]\NP)/S[dcl] the|DT|NP[nb]/N TR2RE-SV40|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) represent|VB|(S[b]\NP)/NP the|DT|NP[nb]/N first|JJ|(N/N)/(N/N) identified|VBN|N/N natural|JJ|N/N DNA|NN|N/N response|NN|N/N element|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N TR2|NN|N/N orphan|NN|N/N receptor|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) may|MD|(S[dcl]\NP)/(S[b]\NP) function|VB|(S[b]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N repressor|NN|N for|IN|(NP\NP)/NP the|DT|NP[nb]/N SV40|NN|N/N gene|NN|N/N expression|NN|N .|.|.
Karyotypic|JJ|N/N detection|NN|N of|IN|(NP\NP)/NP chromosomal|JJ|N/N 16|CD|(N/N)\(N/N) abnormalities|NNS|N classically|RB|(S\NP)/(S\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP AML|NN|N/N M4Eo|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) difficult|JJ|S[adj]\NP .|.|.
Characterization|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N two|CD|N/N genes|NNS|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N inv(16)(p13q22)|NN|N ,|,|, CBF|NN|N/N beta|NN|N and|CC|conj MYH11|NN|N ,|,|, has|VBZ|(S[dcl]\NP)/(S[pt]\NP) allowed|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N detection|NN|N of|IN|(NP\NP)/NP fusion|NN|N/N transcripts|NNS|N by|IN|((S\NP)\(S\NP))/NP reverse-transcriptase|NN|N/N polymerase|NN|N/N chain|NN|N/N reaction|NN|N (|LRB|(NP\NP)/NP RT-PCR|NN|N )|RRB|RRB .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) analyzed|VBN|(S[pt]\NP)/NP CBF|NN|N/N beta-MYH11|NN|N/N fusion|NN|N/N transcripts|NNS|N by|IN|((S\NP)\(S\NP))/NP RT-PCR|NN|N in|IN|((S\NP)\(S\NP))/NP myelomonocytic|JJ|N/N leukemias|NNS|N ,|,|, with|IN|(NP\NP)/NP or|CC|conj without|IN|(NP\NP)/NP eosinophilia|NN|N ,|,|, to|TO|(S[to]\NP)/(S[b]\NP) determine|VB|(S[b]\NP)/S[qem] whether|IN|S[qem]/S[dcl] their|PRP$|NP[nb]/N presence|NN|N correlates|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP morphology|NN|N .|.|.
Fifty-three|CD|N/N cases|NNS|N (|LRB|(NP\NP)/NP 11|CD|N/N AML|NN|N/N M4Eo|NN|N ;|:|; 1|CD|N/N AML|NN|N/N M4|NN|N with|IN|(NP\NP)/NP atypical|JJ|N/N abnormal|JJ|N/N eosinophils|NNS|N (|LRB|(NP\NP)/NP AML|NN|N/N M4|NN|N "|LQU|LQU Eo|NN|N\N "|RQU|RQU )|RRB|RRB ;|:|; 29|CD|N/N AML|NN|N/N M4|NN|N ;|:|; 8|CD|N/N AML|NN|N/N M5|NN|N ;|:|; 3|CD|N/N CMML|NN|N ;|:|; and|CC|conj 1|CD|N/N AML|NN|N/N M2|NN|N with|IN|(NP\NP)/NP eosinophilia|NN|N )|RRB|RRB were|VBD|(S[dcl]\NP)/(S[pss]\NP) analyzed|VBN|S[pss]\NP .|.|.
All|DT|NP[nb]/N 11|CD|N/N typical|JJ|N/N AML|NN|N/N M4Eo|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) CBF|NN|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) beta-MYH11|NN|(S[adj]\NP)/(S[adj]\NP) positive|JJ|S[adj]\NP .|.|.
The|DT|NP[nb]/N single|JJ|N/N case|NN|N of|IN|(NP\NP)/NP AML|NN|N/N M4|NN|N with|IN|(NP\NP)/NP distinctive|JJ|N/N eosinophil|NN|N/N abnormalities|NNS|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) negative|JJ|S[adj]\NP by|IN|((S\NP)\(S\NP))/NP karyotype|NN|N ,|,|, RT-PCR|NN|N and|CC|conj fluorescent|JJ|N/N in|FW|(N/N)/(N/N) situ|FW|N/N hybridization|NN|N (|LRB|(N\N)/N FISH|NN|N )|RRB|RRB .|.|.
Three|CD|N/N of|IN|((N/N)\(N/N))/(N/N) 29|CD|N/N (|LRB|((N/N)\(N/N))/NP 10|CD|N/N %|NN|N )|RRB|RRB AML|NN|N/N M4|NN|N without|IN|(NP\NP)/NP abnormal|JJ|N/N eosinophils|NNS|N were|VBD|(S[dcl]\NP)/NP CBF|NN|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) beta-MYH11|NN|(S[adj]\NP)/(S[adj]\NP) positive|JJ|S[adj]\NP ,|,|, 1|CD|N of|IN|(NP\NP)/NP which|WDT|((NP\NP)/(S[dcl]\NP))\(NP/NP) did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) show|VB|(S[b]\NP)/NP any|DT|NP[nb]/N apparent|JJ|N/N chromosome|NN|N/N 16|CD|(N/N)\(N/N) abnormalities|NNS|N by|IN|((S\NP)\(S\NP))/NP classical|JJ|N/N metaphase|NN|N/N analysis|NN|N (|LRB|(NP\NP)/NP 2|CD|N not|RB|(S\NP)/(S\NP) tested|VBN|S[pss]\NP )|RRB|RRB .|.|.
Both|DT|NP[nb]/N cases|NNS|N tested|VBN|S[pss]\NP also|RB|(S\NP)/(S\NP) showed|VBD|(S[dcl]\NP)/NP MYH11|NN|N/N genomic|JJ|N/N rearrangement|NN|N .|.|.
None|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N other|JJ|N/N leukemias|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) RT-PCR|NN|(S[adj]\NP)/(S[adj]\NP) positive|JJ|S[adj]\NP .|.|.
Follow-up|NN|N of|IN|(NP\NP)/NP three|CD|N/N patient|NN|N showed|VBD|(S[dcl]\NP)/NP residual|JJ|N/N positivity|NN|N in|IN|((S\NP)\(S\NP))/NP apparent|JJ|N/N complete|JJ|N/N remission|NN|N .|.|.
These|DT|NP[nb]/N data|NNS|N show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] CBF|NN|N/N beta-MYH11|NN|N/N fusion|NN|N/N transcripts|NNS|N occur|VBP|S[dcl]\NP not|RB|(((S\NP)\(S\NP))/((S\NP)\(S\NP)))/(((S\NP)\(S\NP))/((S\NP)\(S\NP))) only|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N vast|JJ|N/N majority|NN|N of|IN|(NP\NP)/NP typical|JJ|N/N AML|NN|N/N M4Eo|NN|N ,|,|, but|CC|conj also|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP approximately|RB|(N/N)/(N/N) 10|CD|N/N %|NN|N of|IN|(NP\NP)/NP AML|NN|N/N M4|NN|N without|IN|(NP\NP)/NP eosinophilic|JJ|N/N abnormalities|NNS|N ,|,|, a|DT|NP[nb]/N much|RB|(N/N)/(N/N) higher|JJR|N/N incidence|NN|N than|IN|(NP\NP)/(S[dcl]/NP) the|DT|NP[nb]/N sporadic|JJ|N/N reports|NNS|N of|IN|(NP\NP)/NP chromosome|NN|N/N 16|CD|(N/N)\(N/N) abnormalities|NNS|N in|IN|(NP\NP)/NP AML|NN|N/N M4|NN|N would|MD|(S[dcl]\NP)/(S[b]\NP) suggest|VB|(S[b]\NP)/NP .|.|.
Taken|VBN|S[pss]\NP together|RB|((S\NP)\(S\NP))/PP with|IN|PP/NP the|DT|NP[nb]/N detection|NN|N of|IN|(NP\NP)/NP CBF|NN|N/N beta-MYH11transcripts|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N absence|NN|N of|IN|(NP\NP)/NP apparent|JJ|N/N chromosome|NN|N/N 16|CD|(N/N)\(N/N) abnormalities|NNS|N by|IN|(NP\NP)/NP classical|JJ|N/N banding|NN|N/N techniques|NNS|N ,|,|, these|DT|NP[nb]/N data|NNS|N show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] additional|JJ|N/N screening|NN|N by|IN|(NP\NP)/NP either|CC|NP/NP RT-PCR|NN|N or|CC|conj FISH|NN|N should|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) performed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP all|DT|NP[nb]/N AML|NN|N/N M4|NN|N ,|,|, regardless|RB|((S\NP)\(S\NP))/PP of|IN|PP/NP morphologic|JJ|N/N features|NNS|N ,|,|, to|TO|(S[to]\NP)/(S[b]\NP) allow|VB|(S[b]\NP)/NP accurate|JJ|N/N evaluation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N prognostic|JJ|N/N importance|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N fusion|NN|N/N transcript|NN|N .|.|.
This|DT|NP[nb]/N study|NN|N demonstrates|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] human|JJ|(N/N)/(N/N) immunodeficiency|NN|(N/N)/(N/N) virus|NN|N/N type|NN|(N/N)\(N/N) 1|CD|((N/N)\(N/N))\((N/N)\(N/N)) (|LRB|((N/N)\(N/N))/(N/N) HIV-1|NN|N/N )|RRB|RRB Tat|NN|N/N protein|NN|N amplifies|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N activity|NN|N of|IN|(NP\NP)/NP tumor|NN|N/N necrosis|NN|N/N factor|NN|N (|LRB|(NP\NP)/NP TNF|NN|N )|RRB|RRB ,|,|, a|DT|NP[nb]/N cytokine|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) stimulates|VBZ|(S[dcl]\NP)/NP HIV-1|NN|N/N replication|NN|N through|IN|((S\NP)\(S\NP))/NP activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N .|.|.
In|IN|(S/S)/NP HeLa|NN|N/N cells|NNS|N stably|RB|(S\NP)/(S\NP) transfected|VBN|(S[pss]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N HIV-1|NN|N/N tat|NN|N/N gene|NN|N (|LRB|(NP\NP)/NP HeLa-tat|JJ|N/N cells|NNS|N )|RRB|RRB ,|,|, expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Tat|NN|N/N protein|NN|N enhanced|VBD|(S[dcl]\NP)/NP both|CC|NP/NP TNF-induced|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N and|CC|conj TNF-mediated|JJ|N/N cytotoxicity|NN|N .|.|.
A|DT|NP[nb]/N similar|JJ|N/N potentiation|NN|N of|IN|(NP\NP)/NP TNF|NN|N/N effects|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N and|CC|conj HeLa|NN|N/N cells|NNS|N treated|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP soluble|JJ|N/N Tat|NN|N/N protein|NN|N .|.|.
TNF-mediated|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N and|CC|conj cytotoxicity|NN|N involves|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N intracellular|JJ|N/N formation|NN|N of|IN|(NP\NP)/NP reactive|JJ|N/N oxygen|NN|N/N intermediates|NNS|N .|.|.
Therefore|RB|S/S ,|,|, Tat-mediated|JJ|N/N effects|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N cellular|JJ|N/N redox|NN|N/N state|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) analyzed|VBN|S[pss]\NP .|.|.
In|IN|(S/S)/NP both|CC|NP/NP T|NN|N/N cells|NNS|N and|CC|conj HeLa|NN|N/N cells|NNS|N HIV-1|NN|N/N Tat|NN|N suppressed|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP Mn-dependent|JJ|N/N superoxide|NN|N/N dismutase|NN|N (|LRB|(NP\NP)/NP Mn-SOD|NN|N )|RRB|RRB ,|,|, a|DT|NP[nb]/N mitochondrial|JJ|N/N enzyme|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/NP part|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N cellular|JJ|N/N defense|NN|N/N system|NN|N against|IN|(NP\NP)/NP oxidative|JJ|N/N stress|NN|N .|.|.
Thus|RB|S/S ,|,|, Mn-SOD|NN|N/N RNA|NN|N/N protein|NN|N/N levels|NNS|N and|CC|conj activity|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) markedly|RB|(S\NP)\(S\NP) reduced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP Tat|NN|N .|.|.
Decreased|VBN|N/N Mn-SOD|NN|N/N expression|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP decreased|VBN|N/N levels|NNS|N of|IN|(NP\NP)/NP glutathione|NN|N and|CC|conj a|DT|NP[nb]/N lower|JJR|N/N ratio|NN|N of|IN|(NP\NP)/NP reduced|VBN|N/N :|:|conj oxidized|VBN|N/N glutathione|NN|N .|.|.
A|DT|NP[nb]/N truncated|VBN|N/N Tat|NN|N/N protein|NN|N (|LRB|(NP\NP)/NP Tat1-72|CD|N )|RRB|RRB ,|,|, known|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) transactivate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N HIV-1|NN|N/N long|JJ|N/N terminal|JJ|N/N repeat|NN|N (|LRB|(N\N)/N LTR|NN|N )|RRB|RRB ,|,|, no|RB|((S\NP)/(S\NP))/((S\NP)/(S\NP)) longer|RBR|(S\NP)/(S\NP) affected|VBD|(S[dcl]\NP)/NP Mn-SOD|NN|N/N expression|NN|N ,|,|, the|DT|NP[nb]/N cellular|JJ|N/N redox|NN|N/N state|NN|N or|CC|conj TNF-mediated|JJ|N/N cytotoxicity|NN|N .|.|.
Thus|RB|S/S ,|,|, our|PRP$|NP[nb]/N experiments|NNS|N demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N C-terminal|JJ|N/N region|NN|N of|IN|(NP\NP)/NP HIV-1|NN|N/N Tat|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) suppress|VB|(S[b]\NP)/NP Mn-SOD|NN|N/N expression|NN|N and|CC|conj to|TO|(S[to]\NP)/(S[b]\NP) induce|VB|(S[b]\NP)/NP pro-oxidative|JJ|N/N conditions|NNS|N reflected|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N drop|NN|N in|IN|(NP\NP)/NP reduced|VBN|N/N glutathione|NN|N (|LRB|(N\N)/N GSH|NN|N )|RRB|RRB and|CC|conj the|DT|NP[nb]/N GSH|NN|N/N :|:|: oxidized|VBN|(N/N)/(N/N) GSH|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) GSSG|NN|N )|RRB|RRB ratio|NN|N .|.|.
Glucocorticoids|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) included|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP almost|RB|NP/NP all|DT|NP[nb]/N treatment|NN|N/N regimens|NNS|N for|IN|(NP\NP)/NP childhood|NN|N/N acute|JJ|N/N lymphoblastic|JJ|N/N leukemia|NN|N for|IN|((S\NP)\(S\NP))/NP decades|NNS|N .|.|.
However|RB|S/S ,|,|, optimal|JJ|N/N agents|NNS|N ,|,|, doses|NNS|N ,|,|, and/or|CC|conj schedules|NNS|N have|VBP|(S[dcl]\NP)/(S[to]\NP) yet|RB|(S\NP)\(S\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) defined|VBN|S[pss]\NP despite|IN|((S\NP)\(S\NP))/NP extensive|JJ|N/N clinical|JJ|N/N application|NN|N .|.|.
New|JJ|N/N data|NNS|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N pharmacokinetics|NNS|N ,|,|, pharmacodynamics|NNS|N ,|,|, and|CC|conj molecular|JJ|N/N mechanisms|NNS|N of|IN|(NP\NP)/NP action|NN|N of|IN|(NP\NP)/NP glucocorticoids|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) suggested|VBN|(S[pt]\NP)/NP alternative|JJ|N/N approaches|NNS|N in|IN|(NP\NP)/NP ALL|NN|N .|.|.
These|DT|NP suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] prolonged|JJ|N/N ,|,|, i.e.|FW|N/N 28|CD|N/N day|NN|N ,|,|, glucocorticoid|NN|N/N therapy|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) unnecessary|JJ|S[adj]\NP as|IN|((S\NP)\(S\NP))/S[dcl] exposure|NN|N to|TO|(NP\NP)/NP glucocorticoid|NN|N induces|VBZ|(S[dcl]\NP)/NP down-regulation|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptors|NNS|N .|.|.
Dexamethasone|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) superior|JJ|(S[adj]\NP)/PP to|TO|PP/NP prednisone|NN|N in|IN|((S\NP)\(S\NP))/NP conventional|JJ|N/N equi-effective|JJ|N/N doses|NNS|N .|.|.
Blast|NN|N/N sensitivity|NN|N to|TO|(NP\NP)/NP glucocorticoids|NNS|N correlates|VBZ|(S[dcl]\NP)/PP closely|RB|(S\NP)\(S\NP) with|IN|PP/NP sensitivity|NN|N to|TO|(NP\NP)/NP other|JJ|N/N ,|,|, putatively|RB|(N/N)/(N/N) non-cross-resisting|JJ|N/N agents|NNS|N and|CC|conj with|IN|PP/NP outcome|NN|N after|IN|(NP\NP)/NP multi-agent|JJ|N/N therapy|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/NP overlapping|JJ|N/N mechanisms|NNS|N of|IN|(NP\NP)/NP action|NN|N ,|,|, and|CC|conj focusing|VBG|(S[ng]\NP)/NP attention|NN|N on|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N determinants|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N threshold|NN|N for|IN|(NP\NP)/NP apoptosis|NN|N .|.|.
Increasing|VBG|N/N success|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N treatment|NN|N of|IN|(NP\NP)/NP childhood|NN|N/N acute|JJ|N/N lymphoblastic|JJ|N/N leukemia|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) led|VBN|(S[pt]\NP)/PP to|TO|PP/NP increasing|VBG|N/N awareness|NN|N of|IN|(NP\NP)/NP avascular|JJ|N/N necrosis|NN|N of|IN|(NP\NP)/NP bone|NN|N as|IN|(NP\NP)/NP a|DT|NP[nb]/N potentially|RB|(N/N)/(N/N) disabling|JJ|N/N sequela|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N therapy|NN|N ,|,|, especially|RB|(NP\NP)/(NP\NP) in|IN|(NP\NP)/NP adolescent|JJ|N/N and|CC|conj young|JJ|(N/N)/(N/N) adult|JJ|N/N patients|NNS|N .|.|.
Expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Epstein-Barr|JJ|(N/N)/(N/N) virus|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) EBV|NN|N/N )|RRB|RRB latent|JJ|N/N membrane|NN|N/N protein|NN|N/N 1|CD|(N/N)\(N/N) (|LRB|((N/N)\(N/N))/(N/N) LMP-1|NN|N/N )|RRB|RRB oncogene|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) regulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N EBV|NN|N/N nuclear|JJ|N/N protein|NN|N/N 2|CD|(N/N)\(N/N) (|LRB|((N/N)\(N/N))/(N/N) EBNA-2|NN|N/N )|RRB|RRB transactivator|NN|N .|.|.
EBNA-2|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) known|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) interact|VB|(S[b]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N cellular|JJ|N/N DNA-binding|JJ|N/N protein|NN|N J|NN|N/N kappa|NN|N and|CC|conj is|VBZ|(S[dcl]\NP)/(S[pss]\NP) recruited|VBN|(S[pss]\NP)/PP to|TO|PP/NP promoters|NNS|N containing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N GTGGGAA|NN|N/N J|NN|N/N kappa|NN|N/N recognition|NN|N/N sequence|NN|N .|.|.
The|DT|NP[nb]/N minimal|JJ|N/N EBNA-2-responsive|JJ|N/N LMP-1|NN|N/N promoter|NN|N includes|VBZ|(S[dcl]\NP)/NP one|CD|N/N J|NN|N/N kappa-binding|JJ|N/N site|NN|N ,|,|, and|CC|conj we|PRP|NP now|RB|(S\NP)/(S\NP) show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] mutation|NN|N of|IN|(NP\NP)/NP that|DT|NP[nb]/N site|NN|N ,|,|, such|JJ|(NP\NP)/S[em] that|IN|S[em]/S[dcl] J|NN|N/N kappa|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) bind|VB|S[b]\NP ,|,|, reduces|VBZ|(S[dcl]\NP)/NP EBNA-2|NN|N/N responsiveness|NN|N by|IN|((S\NP)\(S\NP))/NP 60|CD|N/N %|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) identify|VB|(S[b]\NP)/NP other|JJ|N/N factors|NNS|N which|WDT|(NP\NP)/(S[dcl]\NP) interact|VBP|(S[dcl]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N LMP-1|NN|N/N EBNA-2|NN|N/N response|NN|N/N element|NN|N (|LRB|(NP\NP)/NP E2RE|NN|N )|RRB|RRB ,|,|, a|DT|NP[nb]/N -236/-145|JJ|N/N minimal|JJ|N/N E2RE|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) used|VBN|(S[pss]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N probe|NN|N in|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assay|NN|N .|.|.
The|DT|NP[nb]/N previously|RB|(N/N)/(N/N) characterized|VBN|N/N factors|NNS|N J|NN|N/N kappa|NN|N ,|,|, PU.1|NN|N ,|,|, and|CC|conj AML1|NN|N bind|VBP|(S[dcl]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N LMP-1|NN|N/N E2RE|NN|N ,|,|, along|IN|((S\NP)\(S\NP))/PP with|IN|PP/NP six|CD|N/N other|JJ|N/N unidentified|JJ|N/N factors|NNS|N (|LRB|(NP\NP)/NP LBF2|NN|N to|TO|(NP\NP)/NP LBF7|NN|N )|RRB|RRB .|.|.
Binding|VBG|N/N sites|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) mapped|VBN|S[pss]\NP for|IN|((S\NP)\(S\NP))/NP each|DT|NP[nb]/N factor|NN|N .|.|.
LBF4|NN|N is|VBZ|(S[dcl]\NP)/NP B-|NN|(S[adj]\NP)/(S[adj]\NP) and|CC|conj T-cell|NN|(S[adj]\NP)/(S[adj]\NP) specific|JJ|S[adj]\NP and|CC|conj recognizes|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N PU.1|NN|N/N GGAA|NN|N/N core|NN|N/N sequence|NN|N as|IN|((S\NP)\(S\NP))/(S[pss]\NP) shown|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP methylation|NN|N/N interference|NN|N .|.|.
LBF4|NN|N has|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N molecular|JJ|N/N mass|NN|N of|IN|(NP\NP)/NP 105|CD|N/N kDa|NN|N and|CC|conj is|VBZ|(S[dcl]\NP)/(S[adj]\NP) probably|RB|(S\NP)\(S\NP) unrelated|JJ|(S[adj]\NP)/PP to|TO|PP/NP PU.1|NN|N .|.|.
LBF2|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP only|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP epithelial|JJ|N/N cell|NN|N/N lines|NNS|N ,|,|, whereas|IN|((S\NP)\(S\NP))/NP LBF3|NN|N ,|,|, LBF5|NN|N ,|,|, LBF6|NN|N ,|,|, and|CC|conj LBF7|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) cell|NN|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) type|NN|(S[adj]\NP)/(S[adj]\NP) specific|JJ|S[adj]\NP .|.|.
Mutations|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N AML1-|NN|N/N or|CC|conj LBF4-binding|JJ|N/N sites|NNS|N had|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N effect|NN|N on|IN|(NP\NP)/NP EBNA-2|NN|N/N transactivation|NN|N ,|,|, whereas|IN|((S\NP)\(S\NP))/S[dcl] mutation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N PU.1-binding|JJ|N/N site|NN|N completely|RB|(S\NP)/(S\NP) eliminated|VBD|(S[dcl]\NP)/NP EBNA-2|NN|N/N responses|NNS|N .|.|.
A|DT|NP[nb]/N gst-EBNA-2|NN|N/N fusion|NN|N/N protein|NN|N specifically|RB|(S\NP)/(S\NP) depleted|VBD|((S[dcl]\NP)/PP)/NP PU.1|NN|N from|IN|PP/NP nuclear|JJ|N/N extracts|NNS|N and|CC|conj bound|VBD|(S[dcl]\NP)/NP in|FW|(N/N)/(N/N) vitro|FW|N/N translated|VBN|N/N PU.1|NN|N ,|,|, providing|VBG|(S[ng]\NP)/NP biochemical|JJ|N/N evidence|NN|N for|IN|(NP\NP)/NP a|DT|NP[nb]/N direct|JJ|N/N EBNA-2-PU.1|JJ|N/N interaction|NN|N .|.|.
Thus|RB|S/S ,|,|, EBNA-2|NN|N/N transactivation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N LMP-1|NN|N/N promoter|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) dependent|JJ|(S[adj]\NP)/PP on|IN|PP/NP interaction|NN|N with|IN|(NP\NP)/NP at|IN|((N/N)/(N/N))/(S[asup]\NP) least|JJS|S[asup]\NP two|CD|N/N distinct|JJ|N/N sequence-specific|JJ|N/N DNA-binding|JJ|N/N proteins|NNS|N ,|,|, J|NN|N/N kappa|NN|N and|CC|conj PU.1|NN|N .|.|.
LBF3|NN|N ,|,|, LBF5|NN|N ,|,|, LBF6|NN|N ,|,|, or|CC|conj LBF7|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) also|RB|(S\NP)\(S\NP) be|VB|(S[b]\NP)/(S[pss]\NP) involved|VBN|S[pss]\NP ,|,|, since|IN|((S\NP)\(S\NP))/S[dcl] their|PRP$|NP[nb]/N binding|VBG|N/N sites|NNS|N also|RB|(S\NP)/(S\NP) contribute|VBP|(S[dcl]\NP)/PP to|TO|PP/NP EBNA-2|NN|N/N responsiveness|NN|N .|.|.
Major|JJ|N/N depressive|JJ|N/N disorder|NN|N (|LRB|(N\N)/N MDD|NN|N )|RRB|RRB in|IN|(NP\NP)/NP adolescents|NNS|N demonstrates|VBZ|((S[dcl]\NP)/PP)/NP resistance|NN|N to|TO|PP/NP tricyclic|JJ|N/N antidepressants|NNS|N and|CC|conj absence|NN|N of|IN|(NP\NP)/NP hypercortisolemia|NN|N .|.|.
The|DT|NP[nb]/N efficacy|NN|N of|IN|(NP\NP)/NP serotonin|NN|(N/N)/(N/N) reuptake|NN|N/N inhibitors|NNS|N (|LRB|(NP\NP)/NP SRIs|NNS|N )|RRB|RRB is|VBZ|(S[dcl]\NP)/(S[adj]\NP) uncertain|JJ|S[adj]\NP ,|,|, and|CC|conj response|NN|N/N predictors|NNS|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) unavailable|JJ|S[adj]\NP .|.|.
Abnormal|JJ|N/N fast|JJ|N/N feedback|NN|N and|CC|conj negative|JJ|N/N feedback|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N hypothalamic-pituitary-adrenal|JJ|N/N axis|NN|N implicates|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N dampened|JJ|N/N limbic-hippocampal|JJ|N/N glucocorticoid|NN|N/N type|NN|N/N II|CD|(N/N)\(N/N) receptor|NN|N (|LRB|(N\N)/N GCII|NN|N )|RRB|RRB .|.|.
We|PRP|NP hypothesized|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] lymphocyte|NN|N/N GCII|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) altered|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP adolescent|JJ|N/N MDD|NN|N and|CC|conj could|MD|(S[dcl]\NP)/(S[b]\NP) serve|VB|(S[b]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N marker|NN|N for|IN|(NP\NP)/NP response|NN|N to|TO|(NP\NP)/NP SRIs|NNS|N .|.|.
In|IN|(S/S)/NP an|DT|NP[nb]/N open-label|JJ|N/N study|NN|N ,|,|, adolescents|NNS|N (|LRB|(NP\NP)/S[dcl] n|NN|N =|JJ|(S[dcl]\NP)/NP 20|CD|N )|RRB|RRB meeting|VBG|(S[ng]\NP)/NP DSM-III-R|NN|N/N criteria|NNS|N for|IN|(NP\NP)/NP MDD|NN|N showed|VBD|(S[dcl]\NP)/NP baseline|NN|N/N lymphocyte|NN|N/N GCII|NN|N/N sites|NNS|N per|IN|((N/N)\NP)/NP cell|NN|N (|LRB|((N/N)\(N/N))/(N/N) sites/cell|NNS|N/N )|RRB|RRB values|NNS|N of|IN|(NP\NP)/NP 793|CD|N +/-|CC|(NP\NP)/NP 106|CD|N versus|CC|conj 2|CD|N ,|,|, 563|CD|N +/-|CC|(NP\NP)/NP 499|CD|N (|LRB|(NP\NP)/(NP\NP) +/-|CC|(NP\NP)/NP SEM|NN|N )|RRB|RRB for|IN|(NP\NP)/NP matched|VBN|N/N controls|NNS|N (|LRB|(NP\NP)/S[dcl] n|NN|N =|JJ|(S[dcl]\NP)/NP 18|CD|N )|RRB|RRB (|LRB|(NP\NP)/S[dcl] t|NN|N =|JJ|(S[dcl]\NP)/NP 3.5|CD|N ;|:|; df|NN|N =|JJ|(S[dcl]\NP)/NP 36|CD|N ;|:|; p|NN|N <|JJR|(S[dcl]\NP)/NP .001|CD|N )|RRB|RRB .|.|.
GCII|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) bimodally|RB|(S\NP)\(S\NP) distributed|VBN|S[pss]\NP ,|,|, with|IN|(((S\NP)\(S\NP))/(S[ng]\NP))/NP SRI|NN|N/N responders|NNS|N differing|VBG|(S[ng]\NP)/PP from|IN|PP/NP nonresponders|NNS|N (|LRB|(NP\NP)/S[dcl] t|NN|N =|JJ|(S[dcl]\NP)/NP 3.9|CD|N ;|:|; df|NN|N =|JJ|(S[dcl]\NP)/NP 14|CD|N ;|:|; p|NN|N <|JJR|(S[dcl]\NP)/NP .001|CD|N )|RRB|RRB .|.|.
GCII|NN|N accurately|RB|(S\NP)/(S\NP) classified|VBD|(S[dcl]\NP)/NP 90|CD|N/N percent|NN|N of|IN|(NP\NP)/NP sertraline|NN|N/N responders|NNS|N and|CC|conj 80|CD|N/N percent|NN|N of|IN|(NP\NP)/NP nonresponders|NNS|N .|.|.
Only|RB|N/N SRI|NN|N/N responders|NNS|N showed|VBD|(S[dcl]\NP)/NP GCII|NN|N/N sites/cell|NNS|N upregulated|VBN|S[pss]\NP after|IN|((S\NP)\(S\NP))/NP 6|CD|N/N weeks|NNS|N of|IN|(NP\NP)/NP treatment|NN|N (|LRB|(NP\NP)/NP t|NN|N =|JJ|(S[dcl]\NP)/NP 2.1|CD|N ,|,|, df|NN|N =|JJ|(S[dcl]\NP)/NP 10|CD|N ;|:|; p|NN|N <|JJR|(S[dcl]\NP)/NP .05|CD|N )|RRB|RRB .|.|.
The|DT|NP[nb]/N tumor|NN|N/N necrosis|NN|N/N factor-alpha|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) TNF|NN|N/N alpha|NN|N/N )|RRB|RRB gene|NN|N is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N immediate|JJ|N/N early|JJ|N/N gene|NN|N in|IN|(NP\NP)/NP activated|VBN|N/N T|NN|N/N cells|NNS|N ,|,|, in|IN|((S\NP)\(S\NP))/S[em] that|IN|S[em]/S[dcl] it|PRP|NP is|VBZ|(S[dcl]\NP)/(S[pss]\NP) rapidly|RB|(S\NP)\(S\NP) induced|VBN|S[pss]\NP without|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N requirement|NN|N for|IN|(NP\NP)/NP protein|NN|N/N synthesis|NN|N .|.|.
Maximal|JJ|N/N induction|NN|N of|IN|(NP\NP)/NP TNF|NN|N/N alpha|NN|N/N mRNA|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP treatment|NN|N of|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP calcium|NN|N/N ionophores|NNS|N alone|RB|NP\NP ,|,|, via|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N calcineurin-dependent|JJ|N/N process|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) blocked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP cyclosporin|NN|N/N A|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) previously|RB|(S\NP)\(S\NP) identified|VBN|(S[pt]\NP)/NP a|DT|NP[nb]/N promoter|NN|N/N element|NN|N ,|,|, kappa|NN|N 3|CD|N\N ,|,|, that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|S[pss]\NP for|IN|((S\NP)\(S\NP))/NP calcium-stimulated|JJ|N/N ,|,|, cyclosporin|NN|(N/N)/(N/N) A-sensitive|JJ|N/N induction|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TNF|NN|N/N alpha|NN|N/N gene|NN|N in|IN|(NP\NP)/NP activated|VBN|N/N T|NN|N/N cells|NNS|N .|.|.
Here|RB|S/S ,|,|, we|PRP|NP demonstrate|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N kappa|NN|N/N 3|CD|(N/N)\(N/N) binding|NN|N/N factor|NN|N contains|VBZ|(S[dcl]\NP)/NP NFATp|NN|N ,|,|, a|DT|NP[nb]/N cyclosporin-sensitive|JJ|N/N DNA-binding|JJ|N/N protein|NN|N required|VBN|(S[pss]\NP)/PP for|IN|PP/NP interleukin-2|NN|N/N gene|NN|N/N transcription|NN|N .|.|.
NFATp|NN|N binds|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP two|CD|N/N sites|NNS|N within|IN|(NP\NP)/NP the|DT|NP[nb]/N kappa|NN|N/N 3|CD|(N/N)\(N/N) element|NN|N ,|,|, and|CC|conj occupancy|NN|N of|IN|(NP\NP)/NP both|DT|NP[nb]/N sites|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) required|VBN|(S[pss]\NP)/PP for|IN|PP/NP TNF|NN|N/N alpha|NN|N/N gene|NN|N/N induction|NN|N .|.|.
Thus|RB|S/S ,|,|, although|IN|(S/S)/S[dcl] the|DT|NP[nb]/N kappa|NN|N/N 3|CD|(N/N)\(N/N) element|NN|N has|VBZ|(S[dcl]\NP)/NP little|JJ|N/N sequence|NN|N/N similarity|NN|N to|TO|(NP\NP)/NP other|JJ|N/N NFATp-binding|JJ|N/N sites|NNS|N ,|,|, it|PRP|NP appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) function|VB|(S[b]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N cyclosporin-sensitive|JJ|N/N promoter|NN|N/N element|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/NP virtue|NN|N of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N ability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/NP NFATp|NN|N .|.|.
The|DT|NP[nb]/N involvement|NN|N of|IN|(NP\NP)/NP NFATp|NN|N in|IN|(NP\NP)/NP transcriptional|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP both|DT|NP/NP the|DT|NP[nb]/N interleukin-2|NN|N/N and|CC|conj TNF|NN|(N/N)/(N/N) alpha|NN|N/N genes|NNS|N suggests|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] this|DT|NP[nb]/N factor|NN|N plays|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N role|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N coordinate|JJ|N/N induction|NN|N of|IN|(NP\NP)/NP multiple|JJ|N/N cytokine|NN|N/N genes|NNS|N ,|,|, starting|VBG|((S\NP)\(S\NP))/PP at|IN|PP/NP the|DT|NP[nb]/N earliest|JJS|N/N stages|NNS|N of|IN|(NP\NP)/NP T|NN|(N/N)/(N/N) cell|NN|N/N activation|NN|N .|.|.
The|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N human|JJ|N/N myeloid|JJ|N/N cell|NN|N/N nuclear|JJ|N/N differentiation|NN|N/N antigen|NN|N (|LRB|(NP\NP)/NP MNDA|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP specifically|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP cells|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N granulocyte-macrophage|JJ|N/N lineage|NN|N in|IN|((S\NP)\(S\NP))/NP our|PRP$|NP[nb]/N earlier|JJR|N/N reports|NNS|N .|.|.
The|DT|NP[nb]/N specificity|NN|N of|IN|(NP\NP)/NP MNDA|NN|N/N expression|NN|N for|IN|(NP\NP)/NP cells|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N granulocyte-macrophage|NN|N/N lineage|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) reexamined|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP cell|NN|N/N lines|NNS|N established|VBN|(S[pss]\NP)/PP from|IN|PP/NP patients|NNS|N with|IN|(NP\NP)/NP Philadelphia|NN|N/N chromosome-positive|JJ|N/N chronic|JJ|N/N myeloid|JJ|N/N leukemia|NN|N .|.|.
Cell|NN|N/N lines|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) expressed|VBD|(S[dcl]\NP)/NP MNDA|NN|N exhibited|VBD|(S[dcl]\NP)/NP myeloid|JJ|(N/N)/(N/N) cell|NN|N/N features|NNS|N and|CC|conj granulocyte|NN|N/N or|CC|conj monocyte|NN|N/N differentiation|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP in|FW|((S\NP)\(S\NP))/NP vitro|FW|N ,|,|, while|IN|((S\NP)\(S\NP))/S[dcl] cell|NN|N/N lines|NNS|N exhibiting|VBG|(S[ng]\NP)/NP properties|NNS|N of|IN|(NP\NP)/NP very|RB|((N/N)/(N/N))/((N/N)/(N/N)) early|JJ|(N/N)/(N/N) stage|NN|N/N cells|NNS|N or|CC|conj multipotential|JJ|N/N cells|NNS|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) express|VB|(S[b]\NP)/NP MNDA|NN|N .|.|.
Cells|NNS|N originating|VBG|(S[ng]\NP)/PP from|IN|PP/NP cases|NNS|N of|IN|(NP\NP)/NP Burkitt|NN|N 's|POS|(NP[nb]/N)\NP lymphoma|NN|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) negative|JJ|S[adj]\NP .|.|.
By|IN|(S/S)/NP contrast|NN|N ,|,|, three|CD|N/N lymphoblastoid|JJ|N/N cell|NN|N/N lines|NNS|N (|LRB|(NP\NP)/(S[pss]\NP) immortalized|VBN|S[pss]\NP in|FW|((S\NP)\(S\NP))/NP vitro|FW|N with|IN|((S\NP)\(S\NP))/NP Epstein-Barr|JJ|N/N virus|NN|N )|RRB|RRB were|VBD|(S[dcl]\NP)/(S[adj]\NP) weakly|RB|(S[adj]\NP)/(S[adj]\NP) positive|JJ|S[adj]\NP and|CC|conj MNDA|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) up-regulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP interferon-alpha|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IFN-alpha|NN|N/N )|RRB|RRB treatment|NN|N .|.|.
As|IN|(S/S)/S[dcl] we|PRP|NP reported|VBD|S[dcl]\NP previously|RB|(S\NP)\(S\NP) ,|,|, MNDA|NN|N/N mRNA|NN|N/N level|NN|N in|IN|(NP\NP)/NP adherent|JJ|N/N monocytes|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) elevated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP IFN-alpha|NN|N ;|:|; in|IN|(S/S)/NP this|DT|NP[nb]/N study|NN|N ,|,|, we|PRP|NP further|RB|(S\NP)/(S\NP) assessed|VBD|(S[dcl]\NP)/NP MNDA|NN|N/N expression|NN|N in|IN|((S\NP)\(S\NP))/NP in|FW|(N/N)/(N/N) vitro|FW|N/N monocyte-derived|JJ|N/N macrophages|NNS|N .|.|.
Three|CD|N/N additional|JJ|N/N agents|NNS|N (|LRB|(NP\NP)/NP endotoxin|NN|N ,|,|, phytohemagglutinin|NN|N ,|,|, and|CC|conj phorbol|NN|N/N ester|NN|N )|RRB|RRB and|CC|conj other|JJ|N/N conditions|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) affect|VBP|(S[dcl]\NP)/NP function|NN|N ,|,|, cytokine|NN|N/N production|NN|N ,|,|, differentiation|NN|N ,|,|, and/or|CC|conj growth|NN|N of|IN|(NP\NP)/NP monocytes|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) examined|VBN|(S[pss]\NP)/PP for|IN|PP/NP their|PRP$|NP[nb]/N ability|NN|N to|TO|(S[to]\NP)/(S[b]\NP) alter|VB|(S[b]\NP)/NP MNDA|NN|N/N expression|NN|N .|.|.
The|DT|NP[nb]/N results|NNS|N varied|VBD|(S[dcl]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N agent|NN|N ,|,|, cell|NN|N/N type|NN|N ,|,|, and|CC|conj stage|NN|N of|IN|(NP\NP)/NP differentiation|NN|N .|.|.
Changes|NNS|N in|IN|(NP\NP)/NP MNDA|NN|N/N expression|NN|N occurred|VBD|S[dcl]\NP slowly|RB|(S\NP)\(S\NP) (|LRB|((S\NP)\(S\NP))/NP hours|NNS|N to|TO|(NP\NP)/NP days|NNS|N )|RRB|RRB ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] MNDA|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) mediate|VB|(S[b]\NP)/NP changes|NNS|N realized|VBN|S[pss]\NP over|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N long|JJ|N/N period|NN|N .|.|.
The|DT|NP[nb]/N results|NNS|N also|RB|(S\NP)/(S\NP) reveal|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N discordance|NN|N in|IN|(NP\NP)/NP certain|JJ|N/N MNDA|NN|(N/N)/(N/N) positive|JJ|N/N cells|NNS|N between|IN|(NP\NP)/NP steady-state|JJ|N/N levels|NNS|N or|CC|conj changes|NNS|N in|IN|(NP\NP)/NP levels|NNS|N of|IN|(NP\NP)/NP protein|NN|N and|CC|conj mRNA|NN|N indicating|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP MNDA|NN|N/N expression|NN|N occurs|VBZ|S[dcl]\NP at|IN|((S\NP)\(S\NP))/NP more|JJR|S[adj]\NP than|IN|((N/N)/(N/N))\(S[adj]\NP) one|CD|N/N point|NN|N .|.|.
Changes|NNS|N in|IN|(NP\NP)/NP MNDA|NN|N/N expression|NN|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) consistent|JJ|(S[adj]\NP)/PP with|IN|PP/NP a|DT|NP[nb]/N role|NN|N in|IN|(NP\NP)/(S[ng]\NP) opposing|VBG|(S[ng]\NP)/NP macrophage|NN|N/N differentiation|NN|N and|CC|conj activation|NN|N of|IN|(NP\NP)/NP monocytes/macrophages|NNS|N .|.|.
The|DT|NP[nb]/N Epstein-Barr|JJ|(N/N)/(N/N) virus|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) EBV|NN|N/N )|RRB|RRB nuclear|JJ|N/N antigen|NN|N/N 2|CD|(N/N)\(N/N) (|LRB|((N/N)\(N/N))/(N/N) EBNA-2|NN|N/N )|RRB|RRB protein|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) essential|JJ|S[adj]\NP for|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N immortalization|NN|N of|IN|(NP\NP)/NP human|JJ|N/N primary|JJ|N/N B|NN|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/NP EBV|NN|N .|.|.
EBNA-2|NN|N trans-activates|VBZ|(S[dcl]\NP)/NP cellular|JJ|N/N and|CC|conj viral|JJ|N/N genes|NNS|N like|IN|(NP\NP)/NP CD23|NN|N ,|,|, c-fgr|NN|N ,|,|, latent|JJ|N/N membrane|NN|N/N protein|NN|N 1|CD|N\N (|LRB|(N\N)/N LMP1|NN|N )|RRB|RRB and|CC|conj terminal|JJ|N/N protein|NN|N 1|CD|N\N (|LRB|(N\N)/N TP1|NN|N )|RRB|RRB .|.|.
Trans-activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TP1|NN|N/N promoter|NN|N and|CC|conj of|IN|(NP\NP)/NP the|DT|NP[nb]/N BamHI|NN|(N/N)/(N/N) C|NN|N/N promoter|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) already|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) investigated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP detail|NN|N and|CC|conj appears|VBZ|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP via|IN|((S\NP)\(S\NP))/NP protein-protein|JJ|N/N interactions|NNS|N and|CC|conj not|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) by|IN|((S\NP)\(S\NP))/NP direct|JJ|N/N binding|NN|N of|IN|(NP\NP)/NP EBNA-2|NN|N type|NN|N\N A|NN|(N\N)\(N\N) (|LRB|(NP\NP)/(NP\NP) of|IN|(NP\NP)/NP EBV|NN|N type|NN|N\N 1|CD|(N\N)\(N\N) )|RRB|RRB to|TO|(NP\NP)/NP the|DT|NP[nb]/N DNA|NN|N .|.|.
EBNA-2|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) trans-activate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N LMP|NN|N/N gene|NN|N in|IN|(NP\NP)/NP several|JJ|N/N cell|NN|N/N lines|NNS|N .|.|.
Various|JJ|N/N reports|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) delineated|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N cis-acting|JJ|N/N elements|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N LMP|NN|N/N promoter|NN|N through|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) EBNA-2|NN|N mediates|VBZ|(S[dcl]\NP)/NP trans-activation|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) determine|VB|(S[b]\NP)/S[qem] whether|IN|S[qem]/S[dcl] EBNA-2|NN|N also|RB|(S\NP)/(S\NP) trans-activates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N LMP|NN|N/N promoter|NN|N by|IN|((S\NP)\(S\NP))/NP protein-protein|JJ|N/N interactions|NNS|N ,|,|, we|PRP|NP performed|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N series|NN|N of|IN|(NP\NP)/NP gel|NN|N/N retardation|NN|N/N assays|NNS|N and|CC|conj competition|NN|N/N experiments|NNS|N with|IN|(NP\NP)/NP LMP|NN|N/N promoter|NN|N/N fragments|NNS|N of|IN|(NP\NP)/NP different|JJ|N/N sizes|NNS|N .|.|.
We|PRP|NP determined|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N protein-binding|JJ|N/N region|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N LMP|NN|N/N promoter|NN|N was|VBD|(S[dcl]\NP)/PP within|IN|PP/NP a|DT|NP[nb]/N 42|CD|(N/N)/(N/N) bp|NN|N/N fragment|NN|N encompassing|VBG|(S[ng]\NP)/NP nucleotides|NNS|N -135|CD|N to|TO|(NP\NP)/NP -176|CD|N relative|JJ|((S\NP)\(S\NP))/PP to|TO|PP/NP the|DT|NP[nb]/N LMP|NN|N/N transcriptional|JJ|N/N start|NN|N/N site|NN|N .|.|.
None|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DNA|NN|N/N fragments|NNS|N investigated|VBN|S[pss]\NP indicated|VBD|(S[dcl]\NP)/NP interaction|NN|N of|IN|(NP\NP)/NP EBNA-2|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N DNA|NN|N via|IN|(NP\NP)/NP protein-protein|JJ|N/N interactions|NNS|N .|.|.
No|DT|NP[nb]/N significant|JJ|N/N differences|NNS|N between|IN|(NP\NP)/NP EBNA-2-positive|JJ|N/N and|CC|conj EBNA-2-negative|JJ|N/N nuclear|JJ|N/N extracts|NNS|N could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) seen|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N gel|NN|N/N retardation|NN|N/N assay|NN|N under|IN|((S\NP)\(S\NP))/NP conditions|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) clearly|RB|(S\NP)/(S\NP) showed|VBD|(S[dcl]\NP)/NP binding|NN|N of|IN|(NP\NP)/NP EBNA-2A|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N TP1|NN|N/N promoter|NN|N .|.|.
However|RB|S/S ,|,|, analysis|NN|N of|IN|(NP\NP)/NP sucrose|NN|N/N gradient|NN|N/N fractions|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N gel|NN|N/N retardation|NN|N/N assay|NN|N provided|VBD|(S[dcl]\NP)/NP evidence|NN|N/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N LMP|NN|N/N promoter-binding|JJ|N/N proteins|NNS|N form|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N complex|NN|N of|IN|(NP\NP)/NP higher|JJR|N/N M(r)|NN|N in|IN|(NP\NP)/NP EBNA-2-positive|JJ|N/N cell|NN|N/N extracts|NNS|N .|.|.
These|DT|NP[nb]/N complexes|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) destroyed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP detergent|NN|N .|.|.
We|PRP|NP deduce|VBP|(S[dcl]\NP)/S[em] from|IN|((S\NP)\(S\NP))/NP these|DT|NP[nb]/N results|NNS|N that|IN|S[em]/S[dcl] EBNA-2-positive|JJ|N/N cells|NNS|N might|MD|(S[dcl]\NP)/(S[b]\NP) indeed|RB|(S\NP)\(S\NP) contain|VB|(S[b]\NP)/NP specific|JJ|N/N complexes|NNS|N bound|VBN|(S[pss]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N LMP|NN|N/N promoter|NN|N which|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[adj]\NP) ,|,|, however|RB|(S\NP)\(S\NP) ,|,|, too|RB|(S[adj]\NP)/(S[adj]\NP) labile|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N standard|JJ|N/N gel|NN|N/N retardation|NN|N/N assay|NN|N .|.|.
Terminal|JJ|N/N differentiation|NN|N of|IN|(NP\NP)/NP B|NN|N/N cells|NNS|N to|TO|(NP\NP)/NP plasma|NN|N/N cells|NNS|N in|FW|(NP\NP)/NP vivo|FW|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) characterized|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP secretion|NN|N of|IN|(NP\NP)/NP Ig|NN|N and|CC|conj extinction|NN|N of|IN|(NP\NP)/NP MHC|NN|N/N class|NN|N/N II|CD|(N/N)\(N/N) expression|NN|N on|IN|(NP\NP)/NP the|DT|NP[nb]/N cell|NN|N/N surface|NN|N .|.|.
We|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] IL-6|NN|N/N signaling|NN|N leads|VBZ|(S[dcl]\NP)/PP to|TO|PP/NP marked|JJ|N/N increases|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N synthesis|NN|N and|CC|conj secretion|NN|N of|IN|(NP\NP)/NP Ig|NN|N in|IN|(NP\NP)/NP clonal|JJ|N/N human|JJ|N/N B|NN|(N/N)/(N/N) cell|NN|N/N lines|NNS|N and|CC|conj newly|RB|(N/N)/(N/N) isolated|VBN|N/N polyclonal|JJ|N/N B|NN|N/N lymphocytes|NNS|N in|FW|(NP\NP)/NP vitro|FW|N .|.|.
The|DT|NP[nb]/N IL-6-induced|JJ|N/N cells|NNS|N resemble|VBP|(S[dcl]\NP)/NP plasma|NN|N/N cells|NNS|N in|IN|((S\NP)\(S\NP))/NP ultrastructure|NN|N and|CC|conj in|IN|((S\NP)\(S\NP))/NP reduced|VBN|N/N expression|NN|N of|IN|(NP\NP)/NP surface|NN|N/N MHC|NN|N class|NN|N\N II|CD|(N\N)\(N\N) .|.|.
Enhanced|VBN|N/N Ig|NN|N/N synthesis|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N result|NN|N of|IN|(NP\NP)/NP coordinated|VBN|N/N transcriptional|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP Ig|NN|N/N genes|NNS|N without|IN|(NP\NP)/NP promoter|NN|N/N or|CC|conj isotype|NN|N/N specificity|NN|N ,|,|, and|CC|conj differential|JJ|N/N accumulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N mRNA|NN|N encoding|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N secreted|VBN|N/N form|NN|N of|IN|(NP\NP)/NP Ig|NN|N/N heavy|JJ|N/N chain|NN|N .|.|.
It|PRP|NP is|VBZ|(S[dcl]\NP)/(S[adj]\NP) saturable|JJ|S[adj]\NP and|CC|conj subject|JJ|(S[adj]\NP)/PP to|TO|PP/NP negative|JJ|N/N control|NN|N when|WRB|((S\NP)\(S\NP))/S[dcl] IL-6|NN|N/N stimulation|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) prolonged|JJ|S[adj]\NP .|.|.
Coordinate|JJ|(S/S)/PP with|IN|PP/NP temporal|JJ|N/N changes|NNS|N in|IN|(NP\NP)/NP Ig|NN|N/N synthesis|NN|N ,|,|, the|DT|NP[nb]/N DNA-binding|JJ|N/N activity|NN|N and|CC|conj the|DT|NP[nb]/N synthesis|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N B|NN|N/N cell-enriched|JJ|N/N transcription|NN|N/N factor|NN|N Oct-2|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) regulated|VBN|S[pss]\NP .|.|.
Thus|RB|S/S ,|,|, differentiation|NN|N of|IN|(NP\NP)/NP B|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP IL-6|NN|N in|FW|(NP\NP)/NP vitro|FW|N recapitulates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N hallmarks|NNS|N of|IN|(NP\NP)/NP terminal|JJ|N/N B|NN|N/N differentiation|NN|N in|FW|(NP\NP)/NP vivo|FW|N ;|:|; Oct-2|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) have|VB|(S[b]\NP)/NP a|DT|NP[nb]/N role|NN|N in|IN|((S\NP)\(S\NP))/NP this|DT|NP[nb]/N process|NN|N .|.|.
The|DT|NP[nb]/N human|JJ|N/N interleukin-3|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL-3|NN|N/N )|RRB|RRB gene|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP almost|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) exclusively|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP activated|VBN|N/N T|NN|N/N cells|NNS|N .|.|.
Its|PRP$|NP[nb]/N expression|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) regulated|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP the|DT|NP[nb]/N transcriptional|JJ|N/N and|CC|conj post-transcriptional|JJ|N/N level|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) previously|RB|(S\NP)\(S\NP) shown|VBN|(S[pt]\NP)/S[em] that|IN|S[em]/S[dcl] treatment|NN|N of|IN|(NP\NP)/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N with|IN|(NP\NP)/NP phytohemaglutinin|NN|N (|LRB|(N\N)/N PHA|NN|N )|RRB|RRB and|CC|conj the|DT|NP[nb]/N phorbol|NN|N/N ester|NN|N ,|,|, PMA|NN|N ,|,|, activated|VBD|(S[dcl]\NP)/NP transcription|NN|N/N initiation|NN|N from|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-3|NN|N/N gene|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) define|VB|(S[b]\NP)/NP the|DT|NP[nb]/N regions|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N gene|NN|N required|VBN|(S[pss]\NP)/PP for|IN|PP/NP transcription|NN|N/N activation|NN|N ,|,|, we|PRP|NP generated|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N series|NN|N of|IN|(NP\NP)/NP reporter|NN|N/N constructs|NNS|N containing|VBG|(S[ng]\NP)/NP different|JJ|N/N regions|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-3|NN|N/N gene|NN|N/N 5'|JJ|N/N and|CC|conj 3'|JJ|N/N flanking|JJ|N/N sequences|NNS|N .|.|.
Both|CC|NP/NP positive|JJ|N/N and|CC|conj negative|JJ|N/N regulatory|JJ|N/N elements|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) identified|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N proximal|JJ|N/N 5'|JJ|N/N flanking|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-3|NN|N/N gene|NN|N .|.|.
The|DT|NP[nb]/N promoter|NN|N/N region|NN|N between|IN|(NP\NP)/NP -173|CD|N and|CC|conj -60|CD|N contained|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N strongest|JJS|N/N activating|VBG|N/N elements|NNS|N .|.|.
The|DT|NP[nb]/N transcription|NN|N/N factor|NN|N AP-1|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/PP to|TO|PP/NP this|DT|NP[nb]/N positive|JJ|N/N activator|NN|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N promoter|NN|N .|.|.
We|PRP|NP also|RB|(S\NP)/(S\NP) examined|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N function|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-3|NN|N/N CK-1/CK-2|NN|N/N elements|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) are|VBP|(S[dcl]\NP)/(S[adj]\NP) present|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP many|JJ|N/N cytokine|NN|N/N genes|NNS|N and|CC|conj found|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] they|PRP|NP acted|VBD|(S[dcl]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N repressor|NN|N of|IN|(NP\NP)/NP basal|JJ|N/N level|NN|N/N expression|NN|N when|WRB|((S\NP)\(S\NP))/(S[pss]\NP) cloned|VBN|S[pss]\NP upstream|RB|(S[adj]\NP)/PP of|IN|PP/NP a|DT|NP[nb]/N heterologous|JJ|N/N promoter|NN|N but|CC|conj were|VBD|(S[dcl]\NP)/(S[adj]\NP) also|RB|(S\NP)\(S\NP) inducible|JJ|S[adj]\NP by|IN|((S[adj]\NP)\(S[adj]\NP))/NP PMA/PHA|NN|N .|.|.
The|DT|NP[nb]/N PEBP2|NN|N/N alpha|NN|N/N A|NN|N/N and|CC|conj PEBP2|NN|N/N alpha|NN|N/N B|NN|N/N genes|NNS|N encode|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N DNA-binding|JJ|N/N subunit|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N murine|NN|N/N transcription|NN|N/N factor|NN|N ,|,|, PEBP2|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[pss]\NP) implicated|VBN|(S[pss]\NP)/PP as|IN|PP/NP a|DT|NP[nb]/N T-cell-specific|JJ|N/N transcriptional|JJ|N/N regulator|NN|N .|.|.
These|DT|NP[nb]/N two|CD|N/N related|JJ|N/N genes|NNS|N share|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N evolutionarily|RB|(N/N)/(N/N) conserved|VBN|N/N region|NN|N encoding|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N Runt|NN|N/N domain|NN|N .|.|.
PEBP2|NN|N/N alpha|NN|N/N B|NN|N is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N murine|NN|N/N counterpart|NN|N of|IN|(NP\NP)/NP human|JJ|N/N AML1|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) located|JJ|S[adj]\NP at|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N breakpoints|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N 8;21|NN|N/N and|CC|conj 3;21|NN|N/N chromosome|NN|N/N translocations|NNS|N associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP acute|JJ|N/N myeloid|JJ|N/N leukemia|NN|N .|.|.
Northern|NN|N/N (|LRB|LRB RNA|NN|N/N )|RRB|RRB blots|NNS|N of|IN|(NP\NP)/NP various|JJ|N/N adult|JJ|(N/N)/(N/N) mouse|NN|N/N tissues|NNS|N revealed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N levels|NNS|N of|IN|(NP\NP)/NP expression|NN|N of|IN|(NP\NP)/NP both|DT|NP[nb]/N genes|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) most|RBS|(S[adj]\NP)/(S[adj]\NP) prominent|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N thymus|NN|N .|.|.
Furthermore|RB|S/S ,|,|, transcripts|NNS|N of|IN|(NP\NP)/NP PEBP2|NN|N/N alpha|NN|N/N A|NN|N and|CC|conj mouse|NN|N/N AML1/PEBP2|NN|N/N alpha|NN|N/N B|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP T|NN|N/N lymphocytes|NNS|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N thymuses|NNS|N from|IN|(NP\NP)/NP day|NN|N/N 16|CD|(N/N)\(N/N) embryos|NNS|N and|CC|conj newborns|NNS|N ,|,|, as|RB|conj/conj well|RB|conj/conj as|IN|conj 4-week-old|JJ|N/N adult|JJ|N/N mice|NNS|N ,|,|, by|IN|((S\NP)\(S\NP))/NP in|FW|(N/N)/(N/N) situ|FW|N/N hybridization|NN|N .|.|.
The|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N genes|NNS|N persisted|VBD|S[dcl]\NP in|IN|((S\NP)\(S\NP))/NP peripheral|JJ|N/N lymph|NN|N/N nodes|NNS|N of|IN|(NP\NP)/NP adult|JJ|N/N mice|NNS|N .|.|.
The|DT|NP[nb]/N transcripts|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP all|PDT|NP/NP the|DT|NP[nb]/N CD4-|JJ|N/N CD8-|JJ|N/N ,|,|, CD4+|JJ|N/N CD8+|JJ|N/N ,|,|, CD4+|JJ|N/N CD8-|JJ|N/N ,|,|, and|CC|conj CD4-|JJ|N/N CD8+|JJ|N/N cell|NN|N/N populations|NNS|N .|.|.
The|DT|NP[nb]/N results|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] both|DT|NP[nb]/N genes|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP T|NN|N/N cells|NNS|N throughout|IN|((S\NP)\(S\NP))/NP their|PRP$|NP[nb]/N development|NN|N ,|,|, supporting|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N notion|NN|N/S[em] that|IN|S[em]/S[dcl] PEBP2|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N T-cell-specific|JJ|N/N transcription|NN|N/N factor|NN|N .|.|.
Transcripts|NNS|N of|IN|(NP\NP)/NP mouse|NN|N/N AML1/PEBP2|NN|N/N alpha|NN|N/N B|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP day|NN|N/N 12|CD|(N/N)\(N/N) fetal|JJ|N/N hematopoietic|JJ|N/N liver|NN|N and|CC|conj in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N bone|NN|(N/N)/(N/N) marrow|NN|N/N cells|NNS|N of|IN|(NP\NP)/NP newborn|JJ|N/N mice|NNS|N .|.|.
The|DT|NP[nb]/N implication|NN|N of|IN|(NP\NP)/NP mouse|NN|N/N AML1/PEBP2|NN|N/N alpha|NN|N/N B|NN|N/N expression|NN|N in|IN|(NP\NP)/NP hematopoietic|JJ|N/N cells|NNS|N other|JJ|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP those|DT|NP of|IN|(NP\NP)/NP T-cell|NN|N/N lineage|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) discussed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP relation|NN|N to|TO|(NP\NP)/NP myeloid|JJ|N/N leukemogenesis|NN|N .|.|.
Glucocorticoids|NNS|N have|VBP|(S[dcl]\NP)/NP an|DT|NP[nb]/N inhibitory|JJ|N/N effect|NN|N on|IN|(NP\NP)/NP inflammatory|JJ|N/N and|CC|conj immune|JJ|N/N responses|NNS|N ,|,|, and|CC|conj this|DT|NP may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/PP through|IN|PP/NP the|DT|NP[nb]/N modulation|NN|N of|IN|(NP\NP)/NP transcription|NN|N/N factor|NN|N/N binding|VBG|N to|TO|(NP\NP)/NP DNA|NN|N .|.|.
The|DT|NP[nb]/N interaction|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N factors|NNS|N ,|,|, activator|NN|N/N protein-1|NN|N (|LRB|(NP\NP)/NP AP-1|NN|N )|RRB|RRB ,|,|, nuclear|JJ|N/N factor|NN|N kappa|NN|N/N B|NN|N (|LRB|(NP\NP)/NP NF|NN|N/N kappa|NN|N/N B|NN|N )|RRB|RRB ,|,|, and|CC|conj cAMP-responsive|JJ|N/N element|NN|N/N binding|NN|N/N protein|NN|N (|LRB|(NP\NP)/NP CREB|NN|N )|RRB|RRB with|IN|(NP\NP)/NP DNA|NN|N/N and|CC|conj glucocorticoid|NN|N/N receptors|NNS|N (|LRB|(NP\NP)/NP GR|NN|N )|RRB|RRB was|VBD|(S[dcl]\NP)/(S[pss]\NP) analyzed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP human|JJ|N/N peripheral|JJ|N/N blood|NN|N/N mononuclear|JJ|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/NP gel|NN|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N .|.|.
TNF-alpha|NN|N/N ,|,|, IL-1|NN|N/N beta|NN|N/N and|CC|conj phorbol|NN|N/N myristate|NN|N/N acetate|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) PMA|NN|N/N )|RRB|RRB treatment|NN|N increased|VBD|(S[dcl]\NP)/NP AP-1|NN|N/N and|CC|conj NF|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N DNA|NN|N/N binding|NN|N by|IN|((S\NP)\(S\NP))/NP up|RB|((N/N)/(N/N))/((N/N)/(N/N)) to|TO|(N/N)/(N/N) 200|CD|N/N %|NN|N but|CC|conj decreased|VBD|(S[dcl]\NP)/NP CREB|NN|N/N binding|NN|N (|LRB|(NP\NP)/NP 38|CD|N/N %|NN|N )|RRB|RRB over|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N 60-min|JJ|N/N time|NN|N/N course|NN|N .|.|.
Dexamethasone|NN|N produced|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N rapid|JJ|N/N and|CC|conj sustained|JJ|N/N increase|NN|N in|IN|(NP\NP)/NP glucocorticoid|NN|N/N response|NN|N/N element|NN|N/N binding|NN|N and|CC|conj a|DT|NP[nb]/N concomitant|JJ|N/N 40-50|CD|(N/N)/(N/N) %|NN|N/N decrease|NN|N in|IN|(NP\NP)/NP AP-1|NN|N/N ,|,|, NF|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N ,|,|, and|CC|conj CREB|NN|N/N DNA|NN|N/N binding|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) was|VBD|(S[dcl]\NP)/(S[pss]\NP) blocked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP combined|JJ|N/N dexamethasone|NN|N/N and|CC|conj cytokine|NN|N/N or|CC|conj PMA|NN|N/N treatment|NN|N .|.|.
These|DT|NP[nb]/N latter|JJ|N/N effects|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) due|JJ|(S[adj]\NP)/PP to|TO|PP/NP increases|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N nuclear|JJ|N/N localization|NN|N of|IN|(NP\NP)/NP GR|NN|N ,|,|, not|RB|((S\NP)\(S\NP))/PP to|TO|PP/NP reduced|VBN|N/N amounts|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N other|JJ|N/N transcription|NN|N/N factors|NNS|N .|.|.
This|DT|NP suggests|VBZ|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] in|IN|(S/S)/NP these|DT|NP[nb]/N cells|NNS|N GR|NN|N within|IN|(NP\NP)/NP the|DT|NP[nb]/N nucleus|NN|N interacts|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP cytokine-stimulated|JJ|N/N transcription|NN|N/N factors|NNS|N by|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N process|NN|N of|IN|(NP\NP)/NP cross|JJ|N/N coupling|NN|N .|.|.
This|DT|NP may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/NP an|DT|NP[nb]/N important|JJ|N/N molecular|JJ|N/N site|NN|N of|IN|(NP\NP)/NP steroid|NN|N/N action|NN|N .|.|.
Stimulation|NN|N of|IN|(NP\NP)/NP human|JJ|N/N CD4+|JJ|N/N T-cell|NN|N/N clones|NNS|N through|IN|(NP\NP)/NP the|DT|NP[nb]/N T-cell|NN|N/N receptor|NN|N (|LRB|(NP\NP)/NP TcR|NN|N )|RRB|RRB by|IN|(NP\NP)/NP high|JJ|N/N doses|NNS|N of|IN|(NP\NP)/NP specific|JJ|N/N peptide|NN|N results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N long-lived|JJ|N/N state|NN|N of|IN|(NP\NP)/NP nonresponsiveness|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) called|VBN|(S[pss]\NP)/NP anergy|NN|N .|.|.
During|IN|(S/S)/NP the|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP anergy|NN|N ,|,|, T|NN|N/N cells|NNS|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) phenotypically|RB|(S[adj]\NP)/(S[adj]\NP) similar|JJ|(S[adj]\NP)/PP to|TO|PP/NP cells|NNS|N responding|VBG|(S[ng]\NP)/PP to|TO|PP/NP an|DT|NP[nb]/N immunogenic|JJ|N/N stimulus|NN|N .|.|.
The|DT|NP[nb]/N amount|NN|N of|IN|(NP\NP)/NP TcR|NN|N at|IN|(NP\NP)/NP the|DT|NP[nb]/N cell|NN|N/N surface|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) downmodulated|VBN|S[pss]\NP ,|,|, whereas|IN|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N CD2|NN|N/N and|CC|conj CD25|NN|N/N receptors|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) increased|VBN|S[pss]\NP .|.|.
When|WRB|(S/S)/(S[pss]\NP) restimulated|VBN|S[pss]\NP ,|,|, however|RB|S/S ,|,|, anergic|JJ|N/N T|NN|N/N cells|NNS|N fail|VBP|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) up-regulate|VB|(S[b]\NP)/NP transcription|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N gene|NN|N and|CC|conj in|IN|((S\NP)/(S\NP))/NP consequence|NN|N do|VBP|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) produce|VB|(S[b]\NP)/NP IL-2|NN|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N study|NN|N ,|,|, we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) compared|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N ability|NN|N of|IN|(NP\NP)/NP various|JJ|N/N transcription|NN|N/N factors|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) bind|VB|(S[b]\NP)/PP to|TO|PP/NP their|PRP$|NP[nb]/N appropriate|JJ|N/N site|NN|N on|IN|(NP\NP)/NP DNA|NN|N .|.|.
Factors|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) isolated|VBN|(S[pss]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N nuclei|NNS|N of|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) were|VBD|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N induction|NN|N/N phase|NN|N of|IN|(NP\NP)/NP anergy|NN|N or|CC|conj were|VBD|(S[dcl]\NP)/(S[ng]\NP) undergoing|VBG|(S[ng]\NP)/NP activation|NN|N .|.|.
The|DT|NP[nb]/N pattern|NN|N of|IN|(NP\NP)/NP binding|NN|N/N activity|NN|N in|IN|(NP\NP)/NP restimulated|VBN|N/N T|NN|N/N cells|NNS|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) consistent|JJ|(S[adj]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N pattern|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) has|VBZ|(S[dcl]\NP)/(S[pt]\NP) previously|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) regulate|VB|(S[b]\NP)/NP T-cell-specific|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N and|CC|conj the|DT|NP[nb]/N beta|NN|N/N chain|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N TcR|NN|N/N genes|NNS|N .|.|.
The|DT|NP[nb]/N measured|VBN|N/N binding|NN|N to|TO|(NP\NP)/NP a|DT|NP[nb]/N TCF-1|NN|N/N site|NN|N is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N same|JJ|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N nuclei|NNS|N of|IN|(NP\NP)/NP resting|VBG|N/N ,|,|, activated|VBN|N/N ,|,|, and|CC|conj anergized|VBN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N inducible|JJ|N/N factors|NNS|N NK-kappa|NN|N/N B|NN|N ,|,|, beta|NN|N/N E2|NN|N ,|,|, CD28RC|NN|N ,|,|, and|CC|conj AP-1|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP resting|VBG|N/N cells|NNS|N and|CC|conj are|VBP|(S[dcl]\NP)/(S[adj]\NP) twofold|RB|(S[adj]\NP)/(S[adj]\NP) lower|RBR|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP anergized|VBN|N/N as|IN|((N/N)\(N/N))/PP compared|VBN|PP/PP with|IN|PP/(N/N) activated|VBN|N/N cells|NNS|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, anergic|JJ|N/N T|NN|N/N cells|NNS|N express|VBP|(S[dcl]\NP)/NP approximately|RB|((N/N)/(N/N))/((N/N)/(N/N)) eightfold|RB|(N/N)/(N/N) lower|JJR|N/N amounts|NNS|N of|IN|(NP\NP)/NP NF-AT|NN|N ,|,|, a|DT|NP[nb]/N member|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N class|NN|N of|IN|(NP\NP)/NP inducible|JJ|N/N factors|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) regulates|VBZ|(S[dcl]\NP)/NP IL-2|NN|N/N gene|NN|N/N transcription|NN|N .|.|.
A|DT|NP[nb]/N trace|NN|(N/N)/(N/N) element|NN|N/N preparation|NN|N (|LRB|(NP\NP)/NP Beres|NN|N/N Drops|NN|N/N Plus|NN|N ,|,|, BDP|NN|N )|RRB|RRB elevates|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N number|NN|N of|IN|(NP\NP)/NP glucocorticoid|NN|N/N receptors|NNS|N (|LRB|(NP\NP)/NP gcR|NN|N )|RRB|RRB in|IN|(NP\NP)/NP peripheral|JJ|N/N lymphocytes|NNS|N isolated|VBN|S[pss]\NP both|CC|((S\NP)\(S\NP))/((S\NP)\(S\NP)) from|IN|((S\NP)\(S\NP))/NP healthy|JJ|N/N blood|NN|N/N donors|NNS|N and|CC|conj rheumatoid|JJ|(N/N)/(N/N) arthritis|NN|N/N patients|NNS|N .|.|.
This|DT|NP[nb]/N enhancement|NN|N by|IN|(NP\NP)/NP BDP|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP either|CC|((S\NP)\(S\NP))/((S\NP)\(S\NP)) for|IN|((S\NP)\(S\NP))/NP constitutive|JJ|N/N expression|NN|N of|IN|(NP\NP)/NP gcRs|NNS|N or|CC|conj in|IN|((S\NP)\(S\NP))/NP experiments|NNS|N when|WRB|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N lymphocytes|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) stimulated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP interleukin|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IL|NN|N/N )|RRB|RRB -6|CD|N .|.|.
There|EX|NP[thr] was|VBD|(S[dcl]\NP[thr])/NP no|DT|NP[nb]/N significant|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP BDP|NN|N on|IN|(NP\NP)/NP IL-1|NN|N and|CC|conj tumour|NN|N/N necrosis|NN|N/N factor|NN|N/N alpha|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) TNF|NN|N/N alpha|NN|N/N )|RRB|RRB -induced|JJ|N/N changes|NNS|N of|IN|(NP\NP)/NP gcRs|NNS|N .|.|.
The|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP BDP|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) greatly|RB|(S[adj]\NP)/(S[adj]\NP) dependent|JJ|(S[adj]\NP)/PP on|IN|PP/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP Zn++|NN|N/N ions|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N preparation|NN|N ,|,|, since|IN|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N augmenting|VBG|N/N effect|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) abolished|VBN|S[pss]\NP if|IN|((S\NP)\(S\NP))/S[dcl] BDP|NN|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) contain|VB|(S[b]\NP)/NP zinc|NN|N .|.|.
The|DT|NP[nb]/N aim|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N study|NN|N was|VBD|(S[dcl]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) investigate|VB|(S[b]\NP)/S[qem] whether|IN|S[qem]/S[dcl] mutations|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) account|VB|(S[b]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N increasing|VBG|N/N unresponsiveness|NN|N of|IN|(NP\NP)/NP patients|NNS|N with|IN|(NP\NP)/NP chronic|JJ|N/N lymphatic|JJ|N/N leukemia|NN|N (|LRB|(N\N)/N CLL|NN|N )|RRB|RRB to|TO|(NP\NP)/NP combination|NN|N/N chemotherapy|NN|N .|.|.
The|DT|NP[nb]/N receptor|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) tested|VBN|S[pss]\NP immunocytochemically|RB|(S\NP)\(S\NP) ,|,|, in|IN|((S\NP)\(S\NP))/NP steroid|NN|N/N binding|NN|N/N assays|NNS|N ,|,|, and|CC|conj by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N mutation|NN|N/N screening|NN|N (|LRB|(NP\NP)/NP denaturing|VBG|N/N gradient|NN|N/N gel|NN|N/N electrophoresis|NN|N )|RRB|RRB of|IN|(NP\NP)/NP the|DT|NP[nb]/N receptor-cDNA|NN|N .|.|.
The|DT|NP[nb]/N receptor|NN|N/N concentration|NN|N ,|,|, as|IN|((S\NP)/(S\NP))/(S[pss]\NP) measured|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP staining|VBG|N and|CC|conj steroid|NN|N/N binding|NN|N/N test|NN|N ,|,|, varied|VBD|S[dcl]\NP considerably|RB|(S\NP)\(S\NP) but|CC|conj showed|VBD|(S[dcl]\NP)/NP no|DT|NP[nb]/N clear|JJ|N/N correlation|NN|N to|TO|(NP\NP)/NP clinical|JJ|N/N response|NN|N .|.|.
Using|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N highly|RB|(N/N)/(N/N) sensitive|JJ|N/N mutation|NN|(N/N)/(N/N) screening|NN|N/N assay|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N DNA-|NN|N/N and|CC|conj the|DT|NP[nb]/N steroid-binding|JJ|N/N region|NN|N ,|,|, none|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N treated|VBN|N/N patients|NNS|N revealed|VBD|(S[dcl]\NP)/NP any|DT|NP[nb]/N mutation|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N CLL|NN|N/N patients|NNS|N tested|VBN|S[pss]\NP is|VBZ|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) altered|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP these|DT|NP[nb]/N domains|NNS|N .|.|.
In|IN|(S/S)/NP one|CD|N/N individual|NN|N who|WP|(NP\NP)/(S[dcl]\NP) had|VBD|(S[dcl]\NP)/(S[pt]\NP) not|RB|(S\NP)\(S\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) treated|VBN|S[pss]\NP before|IN|((S\NP)\(S\NP))/NP analysis|NN|N a|DT|NP[nb]/N silent|JJ|N/N mutation|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP one|CD|N/N receptor|NN|N/N allele|NN|N .|.|.
The|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] mechanisms|NNS|N other|JJ|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP altered|JJ|N/N ligand|NN|N/N or|CC|conj DNA|NN|N/N binding|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N receptor|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) responsible|JJ|(S[adj]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N lack|NN|N of|IN|(NP\NP)/NP response|NN|N to|TO|(NP\NP)/NP chemotherapy|NN|N .|.|.
This|DT|NP[nb]/N conclusion|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) discussed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP relation|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N mechanism|NN|N of|IN|(NP\NP)/NP corticoid|NN|N/N resistance|NN|N in|IN|(NP\NP)/NP mouse|NN|N/N and|CC|conj human|JJ|N/N lymphoma|NN|N/N cells|NNS|N in|IN|(NP\NP)/NP culture|NN|N .|.|.
Expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N kappa|NN|N/N immunoglobulin|NN|N/N light|JJ|N/N chain|NN|N/N gene|NN|N requires|VBZ|(S[dcl]\NP)/NP developmental-|JJ|N/N and|CC|conj tissue-specific|JJ|N/N regulation|NN|N by|IN|(NP\NP)/NP trans-acting|JJ|N/N factors|NNS|N which|WDT|(NP\NP)/(S[dcl]\NP) interact|VBP|(S[dcl]\NP)/PP with|IN|PP/NP two|CD|N/N distinct|JJ|N/N enhancer|NN|N/N elements|NNS|N .|.|.
A|DT|NP[nb]/N new|JJ|N/N protein-DNA|JJ|N/N interaction|NN|N has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) identified|VBN|S[pss]\NP upstream|RB|(S[adj]\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N intron|NN|N/N enhancer|NN|N ,|,|, within|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N matrix-associated|JJ|N/N region|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N J-C|JJ|N/N intron|NN|N .|.|.
The|DT|NP[nb]/N binding|NN|N/N activity|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) greatly|RB|(S[adj]\NP)/(S[adj]\NP) inducible|JJ|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP pre-B|JJ|N/N cells|NNS|N by|IN|((S[adj]\NP)\(S[adj]\NP))/NP bacterial|JJ|N/N lipopolysaccharide|NN|N and|CC|conj interleukin-1|NN|N but|CC|conj specific|JJ|N/N complexes|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP at|IN|((S\NP)\(S\NP))/NP all|DT|NP[nb]/N stages|NNS|N of|IN|(NP\NP)/NP B|NN|(N/N)/(N/N) cell|NN|N/N development|NN|N tested|VBN|S[pss]\NP .|.|.
The|DT|NP[nb]/N footprinted|VBN|N/N binding|VBG|N/N site|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) homologous|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N consensus|NN|N/N AP1|NN|N/N motif|NN|N .|.|.
The|DT|NP[nb]/N protein|NN|N/N components|NNS|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N complex|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) specifically|RB|(S\NP)\(S\NP) competed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP an|DT|NP[nb]/N AP1|NN|N/N consensus|NN|N/N motif|NN|N and|CC|conj were|VBD|(S[dcl]\NP)/(S[pss]\NP) shown|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP supershift|NN|N to|TO|(S[to]\NP)/(S[b]\NP) include|VB|(S[b]\NP)/NP c-Jun|NN|N and|CC|conj c-Fos|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] this|DT|NP[nb]/N binding|VBG|N/N site|NN|N is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N AP1|NN|N/N motif|NN|N and|CC|conj that|IN|S[em]/S[dcl] the|DT|NP[nb]/N Jun|NN|N/N and|CC|conj Fos|NN|N/N families|NNS|N of|IN|(NP\NP)/NP transcription|NN|N/N factors|NNS|N play|VBP|(S[dcl]\NP)/NP a|DT|NP[nb]/N role|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N kappa|NN|N/N light|JJ|N/N chain|NN|N/N gene|NN|N .|.|.
Mutation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N AP1|NN|N/N motif|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N context|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N intron|NN|N/N enhancer|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) decrease|VB|(S[b]\NP)/NP enhancer-mediated|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N promoter|NN|N in|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP pre-B|JJ|N/N cells|NNS|N induced|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP LPS|NN|N and|CC|conj constitutive|JJ|N/N expression|NN|N in|IN|((S\NP)\(S\NP))/NP mature|JJ|N/N B|NN|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N tal-1|NN|N/N gene|NN|N ,|,|, frequently|RB|(S\NP)/(S\NP) activated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP human|JJ|N/N T-cell|NN|N/N acute|JJ|N/N lymphoblastic|JJ|N/N leukemia|NN|N (|LRB|(N\N)/N T-ALL|NN|N )|RRB|RRB ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N erythroid|JJ|(N/N)/(N/N) ,|,|, megakaryocytic|JJ|(N/N)/(N/N) ,|,|, and|CC|conj mast|NN|(N/N)/(N/N) cell|NN|N/N lineages|NNS|N during|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N hematopoiesis|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) gain|VB|(S[b]\NP)/NP further|JJ|N/N insight|NN|N into|IN|(NP\NP)/NP the|DT|NP[nb]/N molecular|JJ|N/N mechanisms|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) control|VBP|(S[dcl]\NP)/NP tal-1|NN|N/N expression|NN|N ,|,|, we|PRP|NP investigated|VBD|(S[dcl]\NP)/NP tal-1|NN|N/N chromatin|NN|N/N structure|NN|N in|IN|((S\NP)\(S\NP))/NP erythroid/megakaryocytic|JJ|(N/N)/(N/N) cell|NN|N/N lines|NNS|N and|CC|conj in|IN|((S\NP)\(S\NP))/NP T-cell|NN|N/N lines|NNS|N either|CC|(NP\NP)/(NP\NP) with|IN|(NP\NP)/NP or|CC|conj without|IN|(NP\NP)/NP tal-1|NN|N/N rearrangements|NNS|N .|.|.
Tal-1|NN|N/N transcription|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) shown|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) monoallelic|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP Jurkat|NN|N ,|,|, a|DT|NP[nb]/N T-cell|NN|N/N line|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) expresses|VBZ|(S[dcl]\NP)/NP tal-1|NN|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N absence|NN|N of|IN|(NP\NP)/NP apparent|JJ|N/N genomic|JJ|N/N alteration|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N locus|NN|N .|.|.
Methylation|NN|N/N studies|NNS|N indicated|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N tal-15|NN|N/N '|POS|N/N GC-rich|JJ|N/N region|NN|N behaves|VBZ|S[dcl]\NP like|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N CpG|NN|N/N island|NN|N ,|,|, hypomethylated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP normal|JJ|N/N cells|NNS|N ,|,|, and|CC|conj methylated|VBN|S[pss]\NP de|FW|((S\NP)\(S\NP))/NP novo|FW|N on|IN|((S\NP)\(S\NP))/NP transcriptionally|RB|(N/N)/(N/N) inactive|JJ|N/N alleles|NNS|N in|IN|((S\NP)\(S\NP))/NP established|JJ|N/N cell|NN|N/N lines|NNS|N .|.|.
Five|CD|N/N major|JJ|N/N DNase-I|NN|N/N hypersensitive|JJ|N/N sites|NNS|N (|LRB|(NP\NP)/NP HS|NN|N )|RRB|RRB were|VBD|(S[dcl]\NP)/(S[pss]\NP) mapped|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N tal-1|NN|N/N locus|NN|N .|.|.
HS|NN|N I|CD|N\N ,|,|, IV|CD|N\N ,|,|, and|CC|conj V|CD|N\N were|VBD|(S[dcl]\NP)/(S[pss]\NP) exclusively|RB|(S\NP)/(S\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N erythroid/megakaryocytic|JJ|N/N cell|NN|N/N lines|NNS|N that|WDT|(NP\NP)/(S[dcl]\NP) express|VBP|(S[dcl]\NP)/NP tal-1|NN|N from|IN|(NP\NP)/NP the|DT|NP[nb]/N promoters|NNS|N 1a|NN|N and|CC|conj 1b|NN|N .|.|.
HS|NN|N II|CD|N\N was|VBD|(S[dcl]\NP)/(S[adj]\NP) weak|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP hematopoietic|JJ|N/N cell|NN|N/N lines|NNS|N ,|,|, absent|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP Hela|NN|N ,|,|, and|CC|conj greatly|RB|(S\NP)/(S\NP) enhanced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP Jurkat|NN|N ,|,|, suggesting|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] this|DT|NP[nb]/N region|NN|N might|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) implicated|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N cis-activation|NN|N of|IN|(NP\NP)/NP tal-1|NN|N/N promoter|NN|N/N 1b|NN|N in|IN|(NP\NP)/NP this|DT|NP[nb]/N cell|NN|N/N line|NN|N .|.|.
HS|NN|N III|CD|N\N was|VBD|(S[dcl]\NP)/(S[adj]\NP) weak|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP HEL|NN|N and|CC|conj Jurkat|NN|N ,|,|, and|CC|conj greatly|RB|(S\NP)/(S\NP) enhanced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP DU528|NN|N ,|,|, a|DT|NP[nb]/N T-cell|NN|N/N line|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) bears|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N t(1;14)|NN|N and|CC|conj initiates|VBZ|(S[dcl]\NP)/NP tal-1|NN|N/N transcription|NN|N within|IN|((S\NP)\(S\NP))/NP exon|NN|N 4|CD|N\N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] distinct|JJ|N/N regulatory|JJ|N/N elements|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N use|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N different|JJ|N/N tal-1|NN|N/N promoters|NNS|N .|.|.
M-TAT|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N cytokine-dependent|JJ|N/N cell|NN|N/N line|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N potential|NN|N to|TO|(S[to]\NP)/(S[b]\NP) differentiate|VB|S[b]\NP along|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N erythroid|JJ|N/N and|CC|conj megakaryocytic|JJ|N/N lineages|NNS|N .|.|.
We|PRP|NP cultured|VBD|(S[dcl]\NP)/NP M-TAT|NN|N/N cells|NNS|N long|JJ|((S\NP)\(S\NP))/((S\NP)\(S\NP)) term|NN|(S\NP)\(S\NP) (|LRB|((S\NP)\(S\NP))/NP >|JJR|(N/N)/(N/N) 1|CD|N/N year|NN|N )|RRB|RRB in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N continuous|JJ|N/N presence|NN|N of|IN|(NP\NP)/NP erythropoietin|NN|N (|LRB|(N\N)/N EPO|NN|N )|RRB|RRB ,|,|, granulocyte-macrophage|JJ|N/N colony-stimulating|JJ|N/N factor|NN|N (|LRB|(N\N)/N GM-CSF|NN|N )|RRB|RRB ,|,|, or|CC|conj stem|NN|(N/N)/(N/N) cell|NN|N/N factor|NN|N (|LRB|(N\N)/N SCF|NN|N )|RRB|RRB .|.|.
These|DT|NP[nb]/N long|JJ|(N/N)/(N/N) term|NN|N/N cultures|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) referred|VBN|((S[pss]\NP)/PP)/(PP/NP) to|TO|PP/NP as|IN|PP/NP M-TAT/EPO|NN|N/N ,|,|, M-TAT/GM-CSF|NN|N/N ,|,|, and|CC|conj M-TAT/SCF|NN|N/N cells|NNS|N ,|,|, respectively|RB|(S\NP)\(S\NP) .|.|.
Hemoglobin|NN|N/N concentration|NN|N and|CC|conj gamma-globin|NN|N/N and|CC|conj erythroid|JJ|N/N delta-aminolevulinate|JJ|N/N synthase|NN|N/N mRNA|NN|N/N levels|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) significantly|RB|(S[adj]\NP)/(S[adj]\NP) higher|JJR|S[adj]\NP in|IN|((S[adj]\NP)\(S[adj]\NP))/NP M-TAT/EPO|NN|N/N cells|NNS|N than|IN|((S[adj]\NP)\(S[adj]\NP))/PP in|IN|PP/NP M-TAT/GM-CSF|NN|N/N cells|NNS|N .|.|.
When|WRB|(S/S)/S[dcl] the|DT|NP[nb]/N supplemented|VBN|N/N cytokine|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) switched|VBN|S[pss]\NP from|IN|((S\NP)\(S\NP))/NP GM-CSF|NN|N to|TO|((S\NP)\(S\NP))/NP EPO|NN|N ,|,|, hemoglobin|NN|N/N synthesis|NN|N in|IN|(NP\NP)/NP M-TAT/GM-CSF|NN|N/N cells|NNS|N increased|VBD|S[dcl]\NP rapidly|RB|(S\NP)\(S\NP) (|LRB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) within|IN|((S\NP)\(S\NP))/NP 5|CD|N/N h|NN|N )|RRB|RRB ,|,|, and|CC|conj the|DT|NP[nb]/N level|NN|N of|IN|(NP\NP)/NP GATA-1|NN|N/N mRNA|NN|N increased|VBD|S[dcl]\NP .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, the|DT|NP[nb]/N addition|NN|N of|IN|(NP\NP)/NP GM-CSF|NN|N to|TO|(NP\NP)/NP the|DT|NP[nb]/N M-TAT/EPO|NN|(N/N)/(N/N) cell|NN|N/N culture|NN|N decreased|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N amount|NN|N of|IN|(NP\NP)/NP hemoglobin|NN|N ,|,|, even|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N presence|NN|N of|IN|(NP\NP)/NP EPO|NN|N ,|,|, indicating|VBG|(S[ng]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N EPO|NN|N/N signal|NN|N for|IN|(NP\NP)/NP erythroid|JJ|N/N differentiation|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) suppressed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP GM-CSF|NN|N .|.|.
Thus|RB|S/S ,|,|, erythroid|JJ|N/N development|NN|N of|IN|(NP\NP)/NP M-TAT|NN|N/N cells|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) promoted|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP EPO|NN|N and|CC|conj suppressed|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP GM-CSF|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N support|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N hypothesis|NN|N/S[em] that|IN|S[em]/S[dcl] EPO|NN|N actively|RB|(S\NP)/(S\NP) influences|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N programming|NN|N of|IN|(NP\NP)/NP gene|NN|N/N expression|NN|N required|VBN|(S[pss]\NP)/PP for|IN|PP/NP erythroid|JJ|N/N progenitor|NN|N/N cell|NN|N/N differentiation|NN|N .|.|.
cdc2|NN|N/N mRNA|NN|N/N transcripts|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP immature|JJ|N/N bone|NN|(N/N)/(N/N) marrow|NN|N/N cells|NNS|N and|CC|conj became|VBD|(S[dcl]\NP)/(S[adj]\NP) undetectable|JJ|S[adj]\NP along|IN|((S\NP)\(S\NP))/PP with|IN|PP/NP differentiation|NN|N .|.|.
Peripheral|JJ|N/N blood|NN|N/N resting|NN|N/N cells|NNS|N did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) express|VB|(S[b]\NP)/NP cdc2|NN|N/N mRNA|NN|N ,|,|, but|CC|conj it|PRP|NP was|VBD|(S[dcl]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP T-lymphocytes|NNS|N when|WRB|((S\NP)\(S\NP))/S[dcl] the|DT|NP[nb]/N cells|NNS|N reentered|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N cell|NN|N/N cycle|NN|N in|IN|((S\NP)\(S\NP))/NP response|NN|N to|TO|(NP\NP)/NP specific|JJ|N/N mitogens|NNS|N .|.|.
In|IN|(S/S)/NP contrast|NN|N ,|,|, cdc2|NN|N/N mRNA|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) be|VB|(S[b]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP granulocytes|NNS|N and|CC|conj monocytes|NNS|N even|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) after|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N culture|NN|N with|IN|(NP\NP)/NP the|DT|NP[nb]/N appropriate|JJ|N/N stimulants|NNS|N .|.|.
In|IN|(S/S)/NP order|NN|N to|TO|(S[to]\NP)/(S[b]\NP) investigate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N mechanism|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP cdc2|NN|N/N mRNA|NN|N/N expression|NN|N in|IN|(NP\NP)/NP hematopoietic|JJ|N/N cells|NNS|N ,|,|, we|PRP|NP isolated|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N 5'-flanking|JJ|N/N sequence|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N cdc2|NN|N/N gene|NN|N and|CC|conj found|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N putative|JJ|N/N E2F|NN|N/N binding|NN|N/N site|NN|N at|IN|(NP\NP)/NP the|DT|NP[nb]/N position|NN|N of|IN|(NP\NP)/NP nucleotides|NNS|N -124|CD|N to|TO|(NP\NP)/NP -117|CD|N .|.|.
The|DT|NP[nb]/N binding|NN|N of|IN|(NP\NP)/NP E2F|NN|N at|IN|(NP\NP)/NP this|DT|NP[nb]/N region|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N gel-retardation|NN|N/N assay|NN|N and|CC|conj DNaseI|NN|N/N footprinting|NN|N in|IN|(NP\NP)/NP phytohemagglutinin-stimulated|JJ|N/N T-lymphocytes|NNS|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) was|VBD|(S[dcl]\NP)/(S[adj]\NP) coincident|JJ|(S[adj]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N expression|NN|N of|IN|(NP\NP)/NP cdc2|NN|N/N mRNA|NN|N .|.|.
E2F|NN|N/N binding|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) observed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP both|CC|NP/NP granulocytes|NNS|N and|CC|conj monocytes|NNS|N .|.|.
Transient|JJ|N/N chloramphenicol|NN|N/N acetyltransferase|NN|N/N assay|NN|N revealed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] the|DT|NP[nb]/N region|NN|N containing|VBG|(S[ng]\NP)/NP E2F|NN|N/N binding|NN|N/N site|NN|N had|VBD|(S[dcl]\NP)/NP a|DT|NP[nb]/N strong|JJ|N/N promoter|NN|N/N activity|NN|N ,|,|, and|CC|conj introduction|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N mutation|NN|N at|IN|(NP\NP)/NP the|DT|NP[nb]/N E2F|NN|N/N binding|NN|N/N site|NN|N resulted|VBD|(S[dcl]\NP)/PP in|IN|PP/NP a|DT|NP[nb]/N significant|JJ|N/N loss|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N activity|NN|N .|.|.
E2F-1|NN|N/N and|CC|conj DP-1|NN|N/N mRNAs|NNS|N were|VBD|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) detectable|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP granulocytes|NNS|N ,|,|, monocytes|NNS|N and|CC|conj resting|VBG|N/N T-lymphocytes|NNS|N but|CC|conj were|VBD|(S[dcl]\NP)/(S[pss]\NP) induced|VBN|S[pss]\NP after|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N mitogenic|JJ|N/N stimulation|NN|N of|IN|(NP\NP)/NP T-lymphocytes|NNS|N .|.|.
The|DT|NP[nb]/N induction|NN|N of|IN|(NP\NP)/NP E2F|NN|N/N activity|NN|N preceded|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N appearance|NN|N of|IN|(NP\NP)/NP cdc2|NN|N/N mRNA|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/(S[adj]\NP) consistent|JJ|(S[adj]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N role|NN|N of|IN|(NP\NP)/NP E2F|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP cdc2|NN|N/N mRNA|NN|N/N expression|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] cdc2|NN|N/N mRNA|NN|N/N expression|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) related|JJ|(S[adj]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N cell|NN|N/N cycling|NN|N of|IN|(NP\NP)/NP normal|JJ|N/N human|JJ|N/N hematopoietic|JJ|N/N cells|NNS|N and|CC|conj that|IN|S[em]/S[dcl] E2F|NN|N plays|VBZ|(S[dcl]\NP)/NP some|DT|NP[nb]/N roles|NNS|N in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N expression|NN|N .|.|.
Human|JJ|(N/N)/(N/N) immunodeficiency|NN|(N/N)/(N/N) virus|NN|N/N type|NN|(N/N)\(N/N) 1|CD|((N/N)\(N/N))\((N/N)\(N/N)) (|LRB|((N/N)\(N/N))/(N/N) HIV-1|NN|N/N )|RRB|RRB replication|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) controlled|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N complex|JJ|N/N array|NN|N of|IN|(NP\NP)/NP virally|RB|(N/N)/(N/N) encoded|VBN|N/N and|CC|conj cellular|JJ|N/N proteins|NNS|N .|.|.
A|DT|NP[nb]/N wide|JJ|N/N spectrum|NN|N of|IN|(NP\NP)/NP levels|NNS|N of|IN|(NP\NP)/NP HIV-1|NN|N/N expression|NN|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) demonstrated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP various|JJ|N/N cells|NNS|N ,|,|, both|CC|((S\NP)\(S\NP))/((S\NP)\(S\NP)) in|IN|((S\NP)\(S\NP))/NP cell|NN|N/N culture|NN|N and|CC|conj in|FW|((S\NP)\(S\NP))/NP vivo|FW|N .|.|.
Molecular|JJ|N/N mechanisms|NNS|N leading|VBG|(S[ng]\NP)/PP to|TO|PP/NP restricted|JJ|N/N HIV-1|NN|N/N replication|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) differ|VB|S[b]\NP between|IN|((S\NP)\(S\NP))/NP certain|JJ|N/N cell|NN|N/N types|NNS|N .|.|.
It|PRP|NP[expl] is|VBZ|(S[dcl]\NP[expl])/(S[pss]\NP) now|RB|(S\NP)\(S\NP) demonstrated|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] HIV-1|NN|N/N proviral|JJ|N/N latency|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N monocytic|JJ|N/N cell|NN|N/N line|NN|N U1|NN|N ,|,|, in|IN|(NP\NP)/NP which|WDT|((NP\NP)/S[dcl])\((NP\NP)/NP) only|RB|(N/N)/(N/N) extremely|RB|(N/N)/(N/N) low|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP HIV-1|NN|N/N expression|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) detected|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N baseline|NN|N/N unstimulated|JJ|N/N state|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) associated|VBN|(S[pss]\NP)/PP with|IN|PP/NP alterations|NNS|N in|IN|(NP\NP)/NP nuclear|JJ|N/N factor-kappa|NN|N/N B|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) NF-kappa|NN|(N/N)/(N/N) B|NN|N/N )|RRB|RRB moieties|NNS|N demonstrated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP these|DT|NP[nb]/N cells|NNS|N by|IN|((S\NP)\(S\NP))/NP electrophoretic|JJ|N/N mobility|NN|N/N shift|NN|N/N assays|NNS|N (|LRB|(NP\NP)/NP EMSAs|NNS|N )|RRB|RRB and|CC|conj in|FW|(N/N)/(N/N) situ|FW|N/N UV|NN|N/N cross-linking|JJ|N/N studies|NNS|N .|.|.
A|DT|NP[nb]/N predominance|NN|N of|IN|(NP\NP)/NP p50|NN|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N moieties|NNS|N and|CC|conj possibly|RB|NP/NP p50|NN|N/N homodimers|NNS|N or|CC|conj closely|RB|(N/N)/(N/N) related|JJ|N/N species|NNS|N ,|,|, rather|RB|(NP\NP)/(NP\NP) than|IN|(NP\NP)/NP the|DT|NP[nb]/N p50-p56|NN|N/N heterodimer|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) is|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N predominant|JJ|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N species|NNS|N in|IN|(NP\NP)/NP most|JJS|N/N T|NN|N/N lymphocytic|JJ|N/N and|CC|conj monocytic|JJ|N/N cells|NNS|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) demonstrated|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N nuclei|NNS|N of|IN|(NP\NP)/NP U1|NN|N/N cells|NNS|N .|.|.
This|DT|NP[nb]/N pattern|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B-related|JJ|N/N moieties|NNS|N differs|VBZ|(S[dcl]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N latently|RB|(N/N)/(N/N) infected|JJ|N/N T|NN|N/N lymphocytic|JJ|N/N cell|NN|N/N line|NN|N ACH-2|NN|N ,|,|, and|CC|conj from|IN|PP/NP the|DT|NP[nb]/N U937|NN|N/N monocytic|JJ|N/N line|NN|N ,|,|, the|DT|NP[nb]/N parental|JJ|N/N cell|NN|N/N line|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N U1|NN|N/N cellular|JJ|N/N clone|NN|N .|.|.
As|IN|(S/S)/N such|JJ|N ,|,|, these|DT|NP[nb]/N data|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] different|JJ|N/N proximal|JJ|N/N mechanisms|NNS|N may|MD|(S[dcl]\NP)/(S[b]\NP) lead|VB|(S[b]\NP)/PP to|TO|PP/NP restricted|JJ|N/N HIV-1|NN|N/N replication|NN|N in|IN|(NP\NP)/NP various|JJ|N/N cell|NN|N/N types|NNS|N .|.|.
Since|IN|(S/S)/S[dcl] most|JJS|N/N B|NN|(N/N)/(N/N) cell|NN|N/N clones|NNS|N immortalized|VBN|S[pss]\NP with|IN|((S\NP)\(S\NP))/NP EBV|NN|N/N virus|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) induced|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) produce|VB|(S[b]\NP)/NP interleukin-2|NN|N ,|,|, a|DT|NP[nb]/N typical|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N cytokine|NN|N ,|,|, we|PRP|NP studied|VBD|(S[dcl]\NP)/NP the|DT|NP[nb]/N role|NN|N of|IN|(NP\NP)/NP different|JJ|N/N elements|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N promoter|NN|N in|IN|(NP\NP)/NP such|JJ|NP/NP clones|NNS|N by|IN|((S\NP)\(S\NP))/NP transfection|NN|N .|.|.
It|PRP|NP was|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|S[pss]\NP ,|,|, in|IN|((S\NP)\(S\NP))/(S[adj]\NP) particular|JJ|S[adj]\NP ,|,|, that|IN|S[em]/S[dcl] the|DT|NP[nb]/N element|NN|N TCEd|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) binds|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N factor|NN|N NF-kB|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[adj]\NP) very|RB|(S[adj]\NP)/(S[adj]\NP) active|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP all|DT|NP[nb]/N three|CD|N/N B|NN|N/N clones|NNS|N tested|VBN|S[pss]\NP .|.|.
This|DT|NP[nb]/N element|NN|N has|VBZ|(S[dcl]\NP)/NP no|DT|NP[nb]/N activity|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Jurkat|NN|N/N line|NN|N .|.|.
The|DT|NP[nb]/N NFATd|NN|N/N element|NN|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) binds|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N transcription|NN|N/N factor|NN|N NFAT-1|NN|N and|CC|conj is|VBZ|(S[dcl]\NP)/(S[adj]\NP) very|RB|(S[adj]\NP)/(S[adj]\NP) active|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP T|NN|N/N cells|NNS|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[adj]\NP) only|RB|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) weakly|RB|(S[adj]\NP)/(S[adj]\NP) active|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP one|CD|N/N B|NN|N/N clone|NN|N and|CC|conj not|RB|((S\NP)\(S\NP))/((S\NP)\(S\NP)) at|IN|((S\NP)\(S\NP))/NP all|DT|NP in|IN|((S\NP)\(S\NP))/NP another|DT|NP .|.|.
Different|JJ|N/N elements|NNS|N thus|RB|(S\NP)/(S\NP) contribute|VBP|(S[dcl]\NP)/PP to|TO|PP/NP IL-2|NN|N/N promoter|NN|N/N activity|NN|N in|IN|(NP\NP)/NP different|JJ|N/N cells|NNS|N .|.|.
The|DT|NP[nb]/N mechanisms|NNS|N regulating|VBG|(S[ng]\NP)/NP human|JJ|(N/N)/(N/N) immunodeficiency|NN|(N/N)/(N/N) virus|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) HIV|NN|N/N )|RRB|RRB persistence|NN|N in|IN|(NP\NP)/NP human|JJ|N/N monocytes/macrophages|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) partially|RB|(S\NP)/(S\NP) understood|VBN|S[pss]\NP .|.|.
Persistent|JJ|N/N HIV|NN|N/N infection|NN|N of|IN|(NP\NP)/NP U937|NN|N/N monocytic|JJ|N/N cells|NNS|N results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N .|.|.
Whether|IN|S[qem]/S[dcl] virus-induced|JJ|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N mechanism|NN|N that|WDT|(NP\NP)/(S[dcl]\NP) favors|VBZ|(S[dcl]\NP)/NP continuous|JJ|N/N viral|JJ|N/N replication|NN|N in|IN|(NP\NP)/NP macrophages|NNS|N remains|VBZ|(S[dcl]\NP)/(S[adj]\NP) unknown|JJ|S[adj]\NP .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) further|RB|(S\NP)/(S\NP) delineate|VB|(S[b]\NP)/NP the|DT|NP[nb]/N molecular|JJ|N/N mechanisms|NNS|N involved|VBN|(S[pss]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N in|IN|(NP\NP)/NP HIV-infected|JJ|N/N monocytes|NNS|N and|CC|conj macrophages|NNS|N ,|,|, we|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) focused|VBN|(S[pt]\NP)/PP on|IN|PP/NP the|DT|NP[nb]/N regulation|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N molecules|NNS|N .|.|.
First|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] persistent|JJ|N/N HIV|NN|N/N infection|NN|N results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP the|DT|NP[nb]/N activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N not|RB|((NP\NP)/(NP\NP))/((NP\NP)/(NP\NP)) only|RB|(NP\NP)/(NP\NP) in|IN|(NP\NP)/NP monocytic|JJ|N/N cells|NNS|N but|CC|conj also|RB|(NP\NP)/(NP\NP) in|IN|(NP\NP)/NP macrophages|NNS|N .|.|.
In|IN|(S/S)/NP HIV-infected|JJ|N/N cells|NNS|N ,|,|, I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N/N protein|NN|N/N levels|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) decreased|VBN|S[pss]\NP secondary|JJ|((S\NP)\(S\NP))/PP to|TO|PP/NP enhanced|VBN|N/N protein|NN|N/N degradation|NN|N .|.|.
This|DT|NP parallels|VBZ|(S[dcl]\NP)/NP the|DT|NP[nb]/N increased|VBN|N/N I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N/N synthesis|NN|N secondary|JJ|(NP\NP)/PP to|TO|PP/NP increased|VBN|N/N I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N alpha|NN|N/N gene|NN|N/N transcription|NN|N ,|,|, i.e.|FW|(NP\NP)/NP ,|,|, increased|VBN|N/N RNA|NN|N and|CC|conj transcriptional|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP its|PRP$|NP[nb]/N promoter-enhancer|NN|N .|.|.
Another|DT|NP[nb]/N protein|NN|N with|IN|(NP\NP)/NP I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N function|NN|N ,|,|, p105|NN|N ,|,|, is|VBZ|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) modified|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP HIV-infected|JJ|N/N cells|NNS|N :|:|(NP\NP)/NP p105|NN|N/N and|CC|conj p50|NN|N/N steady-state|JJ|N/N protein|NN|N/N levels|NNS|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) increased|VBN|S[pss]\NP as|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N result|NN|N of|IN|(NP\NP)/NP increased|VBN|N/N synthesis|NN|N and|CC|conj proteolytic|JJ|N/N processing|NN|N of|IN|(NP\NP)/NP p105|NN|N .|.|.
Transcriptional|JJ|N/N activity|NN|N of|IN|(NP\NP)/NP p105|NN|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) increased|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP infected|JJ|N/N cells|NNS|N and|CC|conj is|VBZ|(S[dcl]\NP)/(S[pss]\NP) also|RB|(S\NP)\(S\NP) mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP NF-kappa|NN|N/N B|NN|N through|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N specific|JJ|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N motif|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N demonstrate|VBP|(S[dcl]\NP)/NP the|DT|NP[nb]/N existence|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N triple|JJ|N/N autoregulatory|JJ|N/N loop|NN|N in|IN|(NP\NP)/NP monocytes|NNS|N and|CC|conj macrophages|NNS|N involving|VBG|(S[ng]\NP)/NP HIV|NN|N ,|,|, p105|NN|N and|CC|conj p50|NN|N ,|,|, and|CC|conj MAD3|NN|N ,|,|, with|IN|(NP\NP)/NP the|DT|NP[nb]/N end|NN|N/N result|NN|N of|IN|(NP\NP)/NP persistent|JJ|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activation|NN|N and|CC|conj viral|JJ|N/N persistence|NN|N .|.|.
Furthermore|RB|S/S ,|,|, persistent|JJ|N/N HIV|NN|N/N infection|NN|N of|IN|(NP\NP)/NP monocytes|NNS|N and|CC|conj macrophages|NNS|N provides|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N useful|JJ|N/N model|NN|N with|IN|(NP\NP)/NP which|WDT|((NP\NP)/(S[to]\NP))\((NP\NP)/NP) to|TO|(S[to]\NP)/(S[b]\NP) study|VB|(S[b]\NP)/NP concomitant|JJ|N/N modifications|NNS|N of|IN|(NP\NP)/NP different|JJ|N/N I|NN|N/N kappa|NN|(N/N)/(N/N) B|NN|N/N molecules|NNS|N .|.|.
Induction|NN|N of|IN|(NP\NP)/NP apoptosis|NN|N in|IN|(NP\NP)/NP lymphocytes|NNS|N ,|,|, which|WDT|(NP\NP)/(S[dcl]\NP) may|MD|(S[dcl]\NP)/(S[b]\NP) account|VB|(S[b]\NP)/PP for|IN|PP/NP the|DT|NP[nb]/N therapeutic|JJ|N/N effects|NNS|N of|IN|(NP\NP)/NP glucocorticoids|NNS|N in|IN|(NP\NP)/NP various|JJ|N/N diseases|NNS|N including|VBG|(S[ng]\NP)/NP leukemia|NN|N ,|,|, depends|VBZ|(S[dcl]\NP)/PP on|IN|PP/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N .|.|.
However|RB|S/S ,|,|, the|DT|NP[nb]/N events|NNS|N leading|VBG|((S[ng]\NP)/PP)/PP from|IN|PP/NP the|DT|NP[nb]/N activated|VBN|N/N receptor|NN|N to|TO|PP/NP cell|NN|N/N lysis|NN|N are|VBP|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) understood|VBN|S[pss]\NP .|.|.
A|DT|NP[nb]/N prevailing|VBG|N/N hypothesis|NN|N postulates|VBZ|(S[dcl]\NP)/NP induction|NN|N of|IN|(NP\NP)/NP so-called|JJ|N/N '|LQU|LQU lysis|NN|N/N genes|NNS|N '|RQU|RQU by|IN|(NP\NP)/NP the|DT|NP[nb]/N activated|VBN|N/N receptor|NN|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N study|NN|N ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] an|DT|NP[nb]/N activation-deficient|JJ|N/N glucocorticoid|NN|N/N receptor|NN|N/N mutant|NN|N is|VBZ|(S[dcl]\NP)/(S[adj]\NP) as|RB|(S[adj]\NP)/(S[adj]\NP) effective|JJ|S[adj]\NP as|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N wild-type|JJ|N/N receptor|NN|N in|IN|((S\NP)\(S\NP))/NP repression|NN|N of|IN|(NP\NP)/NP AP-1|NN|N/N activity|NN|N ,|,|, inhibition|NN|N of|IN|(NP\NP)/NP interleukin-2|NN|N/N production|NN|N ,|,|, inhibition|NN|N of|IN|(NP\NP)/NP c-myc|NN|N/N expression|NN|N and|CC|conj induction|NN|N of|IN|(NP\NP)/NP apoptosis|NN|N .|.|.
Furthermore|RB|S/S ,|,|, we|PRP|NP show|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] retinoic|JJ|N/N acid|NN|N can|MD|(S[dcl]\NP)/(S[b]\NP) also|RB|(S\NP)\(S\NP) induce|VB|(S[b]\NP)/NP apoptosis|NN|N in|IN|((S\NP)\(S\NP))/NP these|DT|NP[nb]/N cells|NNS|N through|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N retinoic|JJ|(N/N)/(N/N) acid|NN|N/N receptor|NN|N ,|,|, whose|WP$|((NP\NP)/(S[dcl]\NP))/N repressive|JJ|N/N functions|NNS|N but|CC|conj not|RB|N/N target|NN|(N/N)/(N/N) site|NN|N/N specificity|NN|N ,|,|, are|VBP|(S[dcl]\NP)/(S[adj]\NP) similar|JJ|(S[adj]\NP)/PP to|TO|PP/NP those|DT|NP of|IN|(NP\NP)/NP the|DT|NP[nb]/N glucocorticoid|NN|N/N receptor|NN|N .|.|.
Therefore|RB|S/S ,|,|, the|DT|NP[nb]/N primary|JJ|N/N effect|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N receptor|NN|N in|IN|(NP\NP)/NP glucocorticoid-mediated|JJ|N/N apoptosis|NN|N correlates|VBZ|(S[dcl]\NP)/PP with|IN|PP/NP transcriptional|JJ|N/N repression|NN|N rather|RB|(NP\NP)/(NP\NP) than|IN|(NP\NP)/NP activation|NN|N and|CC|conj could|MD|(S[dcl]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[pss]\NP) mediated|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP interference|NN|N with|IN|(NP\NP)/NP other|JJ|N/N transcription|NN|N/N factors|NNS|N required|VBN|(S[pss]\NP)/PP for|IN|PP/NP cell|NN|N/N survival|NN|N .|.|.
NF-kappa|NN|N/N B|NN|N is|VBZ|(S[dcl]\NP)/NP a|DT|NP[nb]/N nuclear|JJ|N/N protein|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N rel|NN|N/N oncogene|NN|N/N family|NN|N capable|JJ|(S[adj]\NP)/PP of|IN|PP/(S[ng]\NP) enhancing|VBG|(S[ng]\NP)/NP transcription|NN|N of|IN|(NP\NP)/NP several|JJ|N/N cellular|JJ|N/N genes|NNS|N ,|,|, including|VBG|(S[ng]\NP)/NP IL-2|NN|N and|CC|conj the|DT|NP[nb]/N IL-2|NN|N/N receptor|NN|N ,|,|, and|CC|conj viral|JJ|N/N genes|NNS|N transcribed|VBN|(S[pss]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N HIV-1|NN|N/N LTR|NN|N .|.|.
It|PRP|NP has|VBZ|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) reported|VBN|(S[pss]\NP)/S[em] that|IN|S[em]/S[dcl] HIV-1|NN|N/N protease|NN|N may|MD|(S[dcl]\NP)/(S[b]\NP) cleave|VB|(S[b]\NP)/NP the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N precursor|NN|N to|TO|(NP\NP)/NP its|PRP$|NP[nb]/N active|JJ|N/N form|NN|N in|FW|((S\NP)\(S\NP))/NP vitro|FW|N .|.|.
In|IN|(S/S)/NP this|DT|NP[nb]/N study|NN|N the|DT|NP[nb]/N effects|NNS|N of|IN|(NP\NP)/NP HIV|NN|N/N protease|NN|N on|IN|(NP\NP)/NP NF-kappa|NN|(N/N)/(N/N) B|NN|N/N precursor|NN|N/N activation|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) examined|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP Jurkat|NN|N/N T|NN|N/N cells|NNS|N by|IN|((S\NP)\(S\NP))/(S[ng]\NP) introducing|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N protease|NN|N/N expression|NN|N/N vector|NN|N into|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N cells|NNS|N .|.|.
Increased|VBN|N/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) observed|VBN|S[pss]\NP and|CC|conj this|DT|NP[nb]/N increased|VBN|N/N activity|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) blocked|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N specific|JJ|N/N inhibitor|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N viral|JJ|N/N protease|NN|N .|.|.
Viral|JJ|N/N transcription|NN|N ,|,|, as|IN|((S\NP)/(S\NP))/(S[pss]\NP) measured|VBN|S[pss]\NP using|VBG|(S[ng]\NP)/NP LTR-CAT|JJ|N/N assays|NNS|N ,|,|, was|VBD|(S[dcl]\NP)/(S[adj]\NP) only|RB|((S[adj]\NP)/(S[adj]\NP))/((S[adj]\NP)/(S[adj]\NP)) slightly|RB|(S[adj]\NP)/(S[adj]\NP) enhanced|VBN|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N HIV-protease|NN|N/N expressing|JJ|N/N cells|NNS|N ,|,|, while|IN|((S\NP)\(S\NP))/S[dcl] secretion|NN|N of|IN|(NP\NP)/NP IL-2|NN|N and|CC|conj expression|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N IL-2|NN|N/N receptor|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) not|RB|(S\NP)\(S\NP) affected|VBN|S[pss]\NP .|.|.
The|DT|NP[nb]/N limited|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP NF-kappa|NN|N/N B|NN|N by|IN|(NP\NP)/NP HIV|NN|N/N protease|NN|N appears|VBZ|(S[dcl]\NP)/(S[adj]\NP) unlikely|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) have|VB|(S[b]\NP)/NP a|DT|NP[nb]/N significant|JJ|N/N effect|NN|N on|IN|(NP\NP)/NP virus|NN|N/N expression|NN|N or|CC|conj T|NN|(N/N)/(N/N) cell|NN|N/N function|NN|N .|.|.
We|PRP|NP have|VBP|(S[dcl]\NP)/(S[pt]\NP) examined|VBN|(S[pt]\NP)/NP the|DT|NP[nb]/N feasibility|NN|N of|IN|(NP\NP)/(S[ng]\NP) using|VBG|(S[ng]\NP)/NP interferon|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) IFN|NN|N/N )|RRB|RRB gene|NN|N/N transfer|NN|N as|IN|(NP\NP)/NP a|DT|NP[nb]/N novel|JJ|N/N approach|NN|N to|TO|(NP\NP)/NP anti-human|JJ|(N/N)/(N/N) immunodeficiency|NN|(N/N)/(N/N) virus|NN|N/N type|NN|(N/N)\(N/N) 1|CD|((N/N)\(N/N))\((N/N)\(N/N)) (|LRB|((N/N)\(N/N))/(N/N) HIV-1|NN|N/N )|RRB|RRB therapy|NN|N in|IN|(NP\NP)/NP this|DT|NP[nb]/N study|NN|N .|.|.
To|TO|(S[to]\NP)/(S[b]\NP) limit|VB|(S[b]\NP)/NP expression|NN|N of|IN|(NP\NP)/NP a|DT|NP[nb]/N transduced|VBN|N/N HIV-1|NN|N/N long|JJ|N/N terminal|JJ|N/N repeat|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) LTR|NN|N/N )|RRB|RRB -IFNA2|NN|N/N (|LRB|((N/N)\(N/N))/S[dcl] the|DT|NP[nb]/N new|JJ|N/N approved|JJ|N/N nomenclature|NN|N for|IN|(NP\NP)/NP IFN|NN|N/N genes|NNS|N is|VBZ|(S[dcl]\NP)/(S[pss]\NP) used|VBN|S[pss]\NP throughout|IN|((S\NP)\(S\NP))/NP this|DT|NP[nb]/N article|NN|N )|RRB|RRB hybrid|NN|N/N gene|NN|N to|TO|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N HIV-1-infected|JJ|N/N cells|NNS|N ,|,|, HIV-1|NN|N/N LTR|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) modified|VBN|S[pss]\NP .|.|.
Deletion|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N elements|NNS|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV-1|NN|N/N LTR|NN|N significantly|RB|(S\NP)/(S\NP) inhibited|VBD|(S[dcl]\NP)/NP Tat-mediated|JJ|N/N transactivation|NN|N in|IN|(NP\NP)/NP T-cell|NN|N/N lines|NNS|N ,|,|, as|RB|conj/conj well|RB|conj/conj as|IN|conj in|IN|(NP\NP)/NP a|DT|NP[nb]/N monocyte|NN|N/N line|NN|N ,|,|, U937|NN|N .|.|.
Replacement|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N NF-kappa|NN|(N/N)/(N/N) B|NN|N/N elements|NNS|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N HIV-1|NN|N/N LTR|NN|N by|IN|(NP\NP)/NP a|DT|NP[nb]/N DNA|NN|N/N fragment|NN|N derived|VBN|(S[pss]\NP)/PP from|IN|PP/NP the|DT|NP[nb]/N 5'-flanking|JJ|N/N region|NN|N of|IN|(NP\NP)/NP IFN-stimulated|JJ|N/N gene|NN|N 15|CD|N\N (|LRB|(N\N)/N ISG15|NN|N )|RRB|RRB ,|,|, containing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N IFN-stimulated|JJ|N/N response|NN|N/N element|NN|N ,|,|, partially|RB|(S\NP)/(S\NP) restored|VBD|(S[dcl]\NP)/NP Tat-mediated|JJ|N/N activation|NN|N of|IN|(NP\NP)/NP LTR|NN|N in|IN|(NP\NP)/NP T|NN|N/N cells|NNS|N as|RB|conj/conj well|RB|conj/conj as|IN|conj in|IN|(NP\NP)/NP monocytes|NNS|N .|.|.
Insertion|NN|N of|IN|(NP\NP)/NP this|DT|NP[nb]/N chimeric|JJ|N/N promoter|NN|N (|LRB|(NP\NP)/NP ISG15|NN|N/N LTR|NN|N )|RRB|RRB upstream|JJ|(S[adj]\NP)/PP of|IN|PP/NP the|DT|NP[nb]/N human|JJ|N/N IFNA2|NN|N/N gene|NN|N directed|VBD|(S[dcl]\NP)/NP high|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP IFN|NN|N/N synthesis|NN|N in|IN|(NP\NP)/NP Tat-expressing|JJ|N/N cells|NNS|N ,|,|, while|IN|((S\NP)\(S\NP))/S[dcl] this|DT|NP[nb]/N promoter|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) not|RB|(S\NP)\(S\NP) responsive|JJ|(S[adj]\NP)/PP to|TO|PP/NP tumor|NN|N/N necrosis|NN|N/N factor|NN|N/N alpha-mediated|JJ|N/N activation|NN|N .|.|.
ISG15-LTR-IFN|JJ|N/N hybrid|NN|N/N gene|NN|N inserted|VBN|S[pss]\NP into|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N retrovirus|NN|N/N vector|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) transduced|VBN|(S[pss]\NP)/PP into|IN|PP/NP Jurkat|NN|N and|CC|conj U937|NN|N/N cells|NNS|N .|.|.
Selected|VBN|N/N transfected|VBN|N/N clones|NNS|N produced|VBD|(S[dcl]\NP)/NP low|JJ|N/N levels|NNS|N of|IN|(NP\NP)/NP IFN|NN|N/N A|NN|N (|LRB|(NP\NP)/NP IFNA|NN|N )|RRB|RRB constitutively|RB|(S\NP)\(S\NP) ,|,|, and|CC|conj their|PRP$|NP[nb]/N abilities|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) express|VB|(S[b]\NP)/NP interleukin-2|NN|N and|CC|conj interleukin-2|NN|N/N receptor|NN|N upon|IN|((S\NP)\(S\NP))/NP stimulation|NN|N with|IN|(NP\NP)/NP phytohemagglutinin|NN|N and|CC|conj phorbol|NN|N/N myristate|NN|N/N acetate|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) retained|VBN|S[pss]\NP .|.|.
Enhancement|NN|N of|IN|(NP\NP)/NP IFNA|NN|N/N synthesis|NN|N observed|VBN|S[pss]\NP upon|IN|((S\NP)\(S\NP))/NP HIV-1|NN|N/N infection|NN|N resulted|VBD|(S[dcl]\NP)/PP in|IN|PP/NP significant|JJ|N/N inhibition|NN|N of|IN|(NP\NP)/NP HIV-1|NN|N/N replication|NN|N for|IN|((S\NP)\(S\NP))/NP a|DT|NP[nb]/N period|NN|N of|IN|(NP\NP)/NP at|IN|((N/N)/(N/N))/(S[asup]\NP) least|JJS|S[asup]\NP 30|CD|N/N days|NNS|N .|.|.
Virus|NN|N isolated|VBN|(S[pss]\NP)/PP from|IN|PP/NP IFNA-producing|JJ|N/N cells|NNS|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) able|JJ|(S[adj]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) replicate|VB|S[b]\NP in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N U937|NN|N/N cells|NNS|N but|CC|conj did|VBD|(S[dcl]\NP)/(S[b]\NP) not|RB|(S\NP)\(S\NP) replicate|VB|S[b]\NP efficiently|RB|(S\NP)\(S\NP) in|IN|((S\NP)\(S\NP))/NP U937|NN|N/N cells|NNS|N transduced|VBN|(S[pss]\NP)/PP with|IN|PP/NP the|DT|NP[nb]/N IFNA|NN|N/N gene|NN|N .|.|.
These|DT|NP[nb]/N results|NNS|N suggest|VBP|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] targeting|VBG|(S[ng]\NP)/NP IFN|NN|N/N synthesis|NN|N to|TO|((S\NP)\(S\NP))/NP HIV-1-infected|JJ|N/N cells|NNS|N is|VBZ|(S[dcl]\NP)/NP an|DT|NP[nb]/N attainable|JJ|N/N goal|NN|N and|CC|conj that|IN|S[em]/S[dcl] autocrine|NN|N/N IFN|NN|N/N synthesis|NN|N results|VBZ|(S[dcl]\NP)/PP in|IN|PP/NP a|DT|NP[nb]/N long-lasting|JJ|N/N and|CC|conj permanent|JJ|N/N suppression|NN|N of|IN|(NP\NP)/NP HIV-1|NN|N/N replication|NN|N .|.|.
Human|JJ|N/N cDNAs|NNS|N encoding|VBG|(S[ng]\NP)/NP Kruppel-type|JJ|N/N zinc|NN|N/N finger|NN|N/N domains|NNS|N ,|,|, designated|VBN|(S[pss]\NP)/NP KOX|NN|N 1-32|CD|N\N ,|,|, have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[pss]\NP) cloned|VBN|S[pss]\NP from|IN|((S\NP)\(S\NP))/NP human|JJ|N/N T|NN|N/N lymphocyte|NN|N/N cell|NN|N/N line|NN|N/N libraries|NNS|N .|.|.
We|PRP|NP report|VBP|(S[dcl]\NP)/NP here|RB|(S\NP)\(S\NP) the|DT|NP[nb]/N regional|JJ|N/N localizations|NNS|N by|IN|(NP\NP)/NP in|FW|(N/N)/(N/N) situ|FW|N/N hybridization|NN|N of|IN|(NP\NP)/NP KOX|NN|N 18|CD|N\N and|CC|conj KOX|NN|N 25|CD|N\N on|IN|(N\N)/NP chromosome|NN|N/N bands|NNS|N 7q21q22|NN|N .|.|.
Pulse-field|JJ|N/N gel|NN|N/N electrophoresis|NN|N/N (|LRB|((N/N)\(N/N))/(N/N) PFGE|NN|N/N )|RRB|RRB analysis|NN|N showed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] these|DT|NP[nb]/N genes|NNS|N are|VBP|(S[dcl]\NP)/(S[adj]\NP) physically|RB|(S[adj]\NP)/(S[adj]\NP) located|JJ|S[adj]\NP within|IN|((S[adj]\NP)\(S[adj]\NP))/NP a|DT|NP[nb]/N DNA|NN|N/N fragment|NN|N of|IN|(NP\NP)/NP 250|CD|N/N kb|NN|N .|.|.
The|DT|NP[nb]/N genes|NNS|N KOX|NN|N 4|CD|N\N and|CC|conj KOX|NN|N 9|CD|N\N ,|,|, mapped|VBN|S[pss]\NP on|IN|((S\NP)\(S\NP))/NP chromosome|NN|N/N 8q24|NN|N ,|,|, were|VBD|(S[dcl]\NP)/(S[pss]\NP) found|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) be|VB|(S[b]\NP)/(S[adj]\NP) located|JJ|S[adj]\NP within|IN|((S[adj]\NP)\(S[adj]\NP))/NP a|DT|NP[nb]/N DNA|NN|N/N fragment|NN|N of|IN|(NP\NP)/NP 450|CD|N/N kb|NN|N .|.|.
From|IN|(S/S)/NP the|DT|NP[nb]/N present|JJ|N/N and|CC|conj previous|JJ|N/N data|NNS|N ,|,|, eighteen|CD|N/N different|JJ|N/N KOX|NN|N/N genes|NNS|N have|VBP|(S[dcl]\NP)/(S[pt]\NP) been|VBN|(S[pt]\NP)/(S[adj]\NP) located|JJ|S[adj]\NP at|IN|((((S\NP)\(S\NP))/((S\NP)\(S\NP)))/(((S\NP)\(S\NP))/((S\NP)\(S\NP))))/(S[asup]\NP) least|JJS|S[asup]\NP two|CD|((S\NP)\(S\NP))/((S\NP)\(S\NP)) by|IN|((S\NP)\(S\NP))/NP two|CD|N within|IN|((S\NP)\(S\NP))/NP nine|CD|N/N DNA|NN|N/N fragments|NNS|N of|IN|(NP\NP)/NP 200|CD|N/N to|TO|((N/N)\(N/N))/(N/N) 580|CD|N/N kb|NN|N .|.|.
This|DT|NP[nb]/N study|NN|N investigated|VBD|(S[dcl]\NP)/NP age-related|JJ|N/N T|NN|(N/N)/(N/N) cell|NN|N/N responses|NNS|N after|IN|((S\NP)\(S\NP))/NP in|FW|(N/N)/(N/N) vitro|FW|N/N exposure|NN|N to|TO|(NP\NP)/NP influenza|NN|(N/N)/(N/N) A|NN|N/N virus|NN|N .|.|.
Mononuclear|JJ|N/N leukocytes|NNS|N from|IN|(NP\NP)/NP young|JJ|N/N or|CC|conj elderly|JJ|N/N persons|NNS|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) sham-exposed|VBN|(S[pss]\NP)/PP or|CC|conj exposed|VBN|(S[pss]\NP)/PP to|TO|PP/NP influenza|NN|N/N virus|NN|N for|IN|(NP\NP)/NP 1|CD|N ,|,|, 24|CD|N ,|,|, and|CC|conj 72|CD|N/N h|NN|N .|.|.
Immunofluorescent|JJ|N/N staining|NN|N and|CC|conj flow|NN|N/N cytometric|JJ|N/N analysis|NN|N were|VBD|(S[dcl]\NP)/(S[pss]\NP) then|RB|(S\NP)\(S\NP) used|VBN|(S[pss]\NP)/(S[to]\NP) to|TO|(S[to]\NP)/(S[b]\NP) detect|VB|(S[b]\NP)/NP T|NN|N/N cells|NNS|N producing|VBG|(S[ng]\NP)/NP the|DT|NP[nb]/N transcriptional|JJ|N/N regulating|NN|N/N proteins|NNS|N Fos|NN|N and|CC|conj Jun|NN|N .|.|.
Fewer|JJR|N/N virus-exposed|JJ|N/N cells|NNS|N from|IN|(NP\NP)/NP elderly|JJ|N/N donors|NNS|N stained|VBN|(S[pss]\NP)/PP for|IN|PP/NP Fos|NN|N and|CC|conj Jun|NN|N at|IN|((S\NP)\(S\NP))/NP each|DT|NP[nb]/N data|NNS|N/N point|NN|N compared|VBD|(S[dcl]\NP)/PP with|IN|PP/NP cells|NNS|N from|IN|(NP\NP)/NP young|JJ|N/N donors|NNS|N .|.|.
Flow|NN|N/N cytometric|JJ|N/N analysis|NN|N also|RB|(S\NP)/(S\NP) showed|VBD|(S[dcl]\NP)/S[em] that|IN|S[em]/S[dcl] at|IN|(S/S)/NP 72|CD|N/N h|NN|N of|IN|(NP\NP)/NP virus|NN|N/N exposure|NN|N fewer|JJR|N/N T|NN|N/N cells|NNS|N from|IN|(NP\NP)/NP the|DT|NP[nb]/N elderly|JJ|N produced|VBD|(S[dcl]\NP)/NP interferon-gamma|NN|N (|LRB|(NP\NP)/NP IFN-gamma|NN|N )|RRB|RRB ,|,|, suggesting|VBG|(S[ng]\NP)/NP a|DT|NP[nb]/N link|NN|N between|IN|(NP\NP)/NP the|DT|NP[nb]/N magnitude|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N Fos|NN|N/N and|CC|conj Jun|NN|N/N and|CC|conj IFN-gamma|NN|N/N responses|NNS|N .|.|.
Thus|RB|S/S ,|,|, failure|NN|N of|IN|(NP\NP)/NP virus-exposed|JJ|N/N T|NN|N/N cells|NNS|N to|TO|(S[to]\NP)/(S[b]\NP) produce|VB|(S[b]\NP)/NP Fos|NN|N and|CC|conj Jun|NN|N could|MD|(S[dcl]\NP)/(S[b]\NP) contribute|VB|(S[b]\NP)/PP to|TO|PP/NP the|DT|NP[nb]/N increase|NN|N in|IN|(NP\NP)/NP illness|NN|N due|JJ|(NP\NP)/(NP\NP) to|TO|(NP\NP)/NP influenza|NN|N/N virus|NN|N in|IN|(NP\NP)/NP the|DT|NP[nb]/N elderly|JJ|N .|.|.
OBJECTIVES|NNS|N :|:|: To|TO|(S[to]\NP)/(S[b]\NP) analyze|VB|(S[b]\NP)/NP the|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP retinoic|JJ|N/N acids|NNS|N (|LRB|(NP\NP)/NP RA|NNS|N )|RRB|RRB on|IN|(NP\NP)/NP HIV-1|NN|N/N expression|NN|N and|CC|conj correlate|VB|(S[b]\NP)/NP this|DT|NP[nb]/N effect|NN|N with|IN|(NP\NP)/NP expression|NN|N/N levels|NNS|N of|IN|(NP\NP)/NP RA|NN|N/N receptors|NNS|N (|LRB|(NP\NP)/NP RARs|NNS|N )|RRB|RRB in|IN|(NP\NP)/NP T-lymphoid|JJ|N/N and|CC|conj monocytoid|JJ|N/N cell|NN|N/N lines|NNS|N .|.|.
DESIGN|NN|N AND|CC|conj METHODS|NNS|N :|:|: The|DT|NP[nb]/N effect|NN|N of|IN|(NP\NP)/NP all-trans|JJ|N/N and|CC|conj 9-cis|JJ|N/N RA|NN|N on|IN|(NP\NP)/NP HIV-1|NN|N/N production|NN|N in|IN|(NP\NP)/NP T-lymphoid|JJ|N/N (|LRB|((N/N)\(N/N))/(N/N) H9|NN|N/N ,|,|, CEM|NN|N/N )|RRB|RRB and|CC|conj monocytoid|JJ|N/N (|LRB|((N/N)\(N/N))/(N/N) U937|NN|N/N ,|,|, THP-1|NN|N/N )|RRB|RRB cell|NN|N/N lines|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) measured|VBN|S[pss]\NP during|IN|((S\NP)\(S\NP))/NP acute|JJ|N/N and|CC|conj chronic|JJ|N/N infection|NN|N .|.|.
The|DT|NP[nb]/N expression|NN|N/N levels|NNS|N of|IN|(NP\NP)/NP human|JJ|N/N RAR|NN|N/N alpha|NN|N (|LRB|(NP\NP)/NP hRAR|NN|N/N alpha|NN|N ,|,|, receptor|NN|N for|IN|(NP\NP)/NP all-trans|JJ|N/N RA|NN|N )|RRB|RRB and|CC|conj the|DT|NP[nb]/N human|JJ|N/N retinoid-X|NN|N/N receptor|NN|N/N alpha|NN|N (|LRB|(NP\NP)/NP hRXR|NN|N/N alpha|NN|N/N receptor|NN|N for|IN|(NP\NP)/NP 9-cis|JJ|N/N RA|NN|N )|RRB|RRB were|VBD|(S[dcl]\NP)/(S[pss]\NP) determined|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP Northern|NN|N/N blot|NN|N/N analysis|NN|N .|.|.
RESULTS|NNS|N :|:|: Both|CC|NP/NP all-trans|JJ|N/N and|CC|conj 9-cis|JJ|N/N RA|NN|N inhibited|VBD|(S[dcl]\NP)/NP virus|NN|N/N replication|NN|N in|IN|((S\NP)\(S\NP))/NP HIV-1|NN|N/N IIIB-infected|JJ|N/N monocytoid|JJ|N/N cells|NNS|N ,|,|, in|IN|((S\NP)\(S\NP))/NP the|DT|NP[nb]/N presence|NN|N and|CC|conj absence|NN|N of|IN|(NP\NP)/NP the|DT|NP[nb]/N co-stimulatory|JJ|N/N agent|NN|N phorbol|NN|N/N myristate|NN|N/N acetate|NN|N (|LRB|(NP\NP)/NP PMA|NN|N )|RRB|RRB .|.|.
The|DT|NP[nb]/N retinoids|NNS|N had|VBD|(S[dcl]\NP)/NP weak|JJ|N/N or|CC|conj no|DT|N/N stimulatory|JJ|N/N effects|NNS|N on|IN|(NP\NP)/NP HIV|NN|N/N production|NN|N by|IN|(NP\NP)/NP T-cell|NN|N/N lines|NNS|N .|.|.
HIV|NN|N/N production|NN|N by|IN|(NP\NP)/NP PMA-stimulated|JJ|N/N T-cell|NN|N/N lines|NNS|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) inhibited|VBN|S[pss]\NP by|IN|((S\NP)\(S\NP))/NP these|DT|NP[nb]/N retinoids|NNS|N .|.|.
The|DT|NP[nb]/N 9-cis|JJ|N/N RA|NN|N was|VBD|(S[dcl]\NP)/(S[adj]\NP) generally|RB|(S[adj]\NP)/(S[adj]\NP) more|RBR|(S[adj]\NP)/(S[adj]\NP) effective|JJ|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP all-trans|JJ|N/N RA|NN|N in|IN|((S[adj]\NP)\(S[adj]\NP))/(S[ng]\NP) inhibiting|VBG|(S[ng]\NP)/NP HIV|NN|N/N production|NN|N and|CC|conj in|IN|((S[adj]\NP)/(S[adj]\NP))/NP combination|NN|N generally|RB|(S[adj]\NP)/(S[adj]\NP) more|RBR|(S[adj]\NP)/(S[adj]\NP) effective|JJ|S[adj]\NP than|IN|((S[adj]\NP)\(S[adj]\NP))/NP the|DT|NP[nb]/N single|JJ|N/N agents|NNS|N alone|RB|NP\NP .|.|.
Human|JJ|N/N RAR|NN|N/N alpha|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP H9|NN|N/N ,|,|, U937|NN|N/N and|CC|conj THP-1|NN|N/N cells|NNS|N ,|,|, but|CC|conj almost|RB|(S[adj]\NP)/(S[adj]\NP) undetectable|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP CEM|NN|N/N cells|NNS|N .|.|.
Human|JJ|N/N RXR|NN|N/N alpha|NN|N was|VBD|(S[dcl]\NP)/(S[pss]\NP) significantly|RB|(S\NP)\(S\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP U937|NN|N/N and|CC|conj THP-1|NN|N/N cells|NNS|N ,|,|, weakly|RB|(S\NP)\(S\NP) expressed|VBN|S[pss]\NP in|IN|((S\NP)\(S\NP))/NP H9|NN|N/N cells|NNS|N and|CC|conj not|RB|(S[adj]\NP)/(S[adj]\NP) detectable|JJ|S[adj]\NP in|IN|((S\NP)\(S\NP))/NP CEM|NN|N/N cells|NNS|N .|.|.
